

OMB No. 7100-0341
Expiration Date: October 31, 2017

**Instructions for the
Capital Assessments and Stress Testing information collection**
(Reporting Form FR Y-14A)

This Report is required by law: section 165 of the Dodd-Frank Act (12 U.S.C. § 5365) and section 5 of the Bank Holding Company Act (12 U.S.C. § 1844). Public reporting burden for this information collection is estimated to vary from approximately 10 to 987 hours per response, with an average of 159 hours per response, including time to gather and maintain data in the required form and to review instructions and complete the information collection. Comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing the burden, may be sent to Secretary, Board of Governors of the Federal Reserve System, 20th and C Streets, NW, Washington, DC 20551, and to the Office of Management and Budget, Paperwork Reduction Project (7100-0341), Washington, DC 20503.

GENERAL INSTRUCTIONS.....	4
Schedule A—Summary.....	10
GENERAL INSTRUCTIONS.....	10
1. INCOME STATEMENT, BALANCE SHEET, AND CAPITAL.....	11
<i>A.1.a—Income Statement.....</i>	<i>11</i>
<i>A.1.b—Balance Sheet.....</i>	<i>26</i>
<i>A.1.c—Risk-Weighted Assets (RWA).....</i>	<i>40</i>
<i>A.1.c.1—General RWA.....</i>	<i>40</i>
<i>A.1.c.2—Standardized RWA.....</i>	<i>42</i>
<i>A.1.c.3—Advanced RWA.....</i>	<i>52</i>
<i>A.1.d—Capital.....</i>	<i>53</i>
2. RETAIL.....	81
<i>A.2.a—Retail Balance and Loss Projections.....</i>	<i>81</i>
<i>A.2.b—Retail Repurchase.....</i>	<i>86</i>
<i>A.2.c—ASC 310-30.....</i>	<i>92</i>
3. AFS/HTM SECURITIES.....	95
<i>A.3.a—Projected OTTI for AFS Securities and HTM by Security.....</i>	<i>97</i>
<i>A.3.b—High-Level OTTI Methodology and Assumptions for AFS and HTM Securities by Portfolio.....</i>	<i>97</i>
<i>A.3.c—Projected OTTI for AFS and HTM Securities by Portfolio.....</i>	<i>97</i>
<i>A.3.d—Projected OCI and Fair Value for AFS and Impaired HTM Securities.....</i>	<i>98</i>
<i>A.3.e—Actual AFS and HTM Fair Market Value Sources by Portfolio.....</i>	<i>98</i>
4. TRADING.....	99
5. COUNTERPARTY CREDIT RISK (CCR).....	101
6. BHC OPERATIONAL RISK SCENARIO INPUTS AND PROJECTIONS.....	102
7. PRE-PROVISION NET REVENUE (PPNR).....	104
<i>A.7.a—PPNR Projections Sub-schedule.....</i>	<i>107</i>
<i>A.7.b—PPNR Net Interest Income (NII) Sub-schedule.....</i>	<i>122</i>
<i>A.7.c—PPNR Metrics.....</i>	<i>131</i>
Schedule B—Scenario.....	145
B.1—SUPERVISORY BASELINE SCENARIO.....	146
B.2—SUPERVISORY ADVERSE SCENARIO.....	146
B.3—SUPERVISORY SEVERELY ADVERSE SCENARIO.....	146
B.4—BHC BASELINE SCENARIO.....	146
B.5—BHC ADVERSE SCENARIO.....	146
B.6+ —ADDITIONAL SCENARIO #1/#2/ETC.....	146
Schedule C—Regulatory Capital Instruments.....	148
Schedule D—Regulatory Capital Transitions.....	170
D.1—CAPITAL COMPOSITION.....	171
D.2—EXCEPTION BUCKET CALCULATOR.....	181
D.3—ADVANCED RISK-WEIGHTED ASSETS.....	184
D.4—STANDARDIZED RISK-WEIGHTED ASSETS.....	189
D.5—LEVERAGE EXPOSURE.....	196

D.6—PLANNED ACTIONS	201
Schedule E—Operational Risk.....	204
E.1—BHC OPERATIONAL RISK HISTORICAL CAPITAL (BHC BASELINE SCENARIO ONLY)	204
E.2—BHC LEGAL RESERVES REPORTING.....	204
Schedule F – Business Plan Changes.....	205
Appendix A: Supporting Documentation.....	205

**INSTRUCTIONS FOR PREPARATION OF
Capital Assessments and Stress Testing Report
FR Y-14A**

GENERAL INSTRUCTIONS

The Capital Assessments and Stress Testing Report (FR Y-14A report) collects detailed data on bank holding companies' (BHCs) quantitative projections of balance sheet assets and liabilities, income, losses, and capital across a range of macroeconomic scenarios and qualitative information on methodologies used to develop internal projections of capital across scenarios.

The FR Y-14A report is comprised of a Summary, Macro Scenario, Regulatory Capital Instruments, Regulatory Capital Transitions, Operational Risk and Counterparty Credit Risk (CCR) schedules, each with multiple supporting sub-schedules. The number of schedules a BHC must complete is subject to materiality thresholds and certain other criteria. BHCs report projections on the FR Y-14A schedules across supervisory scenarios provided by the Federal Reserve (supervisory baseline, adverse and severely adverse), as well as BHC defined scenarios (BHC baseline and BHC adverse). One or more of the macroeconomic scenarios includes a market risk shock that the BHCs will assume when making trading and counterparty loss projections. The Federal Reserve will provide details about the macroeconomic scenarios to the BHCs.

BHCs are also required to submit qualitative information supporting their projections, including descriptions of the methodologies used to develop the internal projections of capital across scenarios and other analyses that support their comprehensive capital plans. Further information regarding the qualitative and technical requirements of required supporting documentation is provided in individual schedules as appropriate, as well as in Appendix A: Supporting Documentation.

As noted, this document includes requirements and supervisory expectations related to supporting documentation for all BHCs subject to the Y-14 reporting requirements. That supporting documentation is intended to help to ensure that BHCs subject to Y-14 reporting requirements provide accurate and comprehensive information for their Y-14 reports. In certain cases, particularly as outlined in Appendix A, this document describes additional expectations for certain capital planning practices to help support BHCs' Y-14 reporting. However, this document is not intended to describe the full set of expectations for capital planning. The full set of capital planning expectations have been consolidated in two Federal Reserve two supervisory letters, SR Letters 15-18 and 15-19, issued in December 2015. Importantly, those two SR letters clarify that the capital planning expectations for LISCC and Large and Complex Firms (as defined in those letters) are higher than the expectations for Large and Noncomplex Firms (as defined in those letters).¹ A BHC

¹ SR Letter 15-18 sets forth capital planning expectations for BHCs that are subject to the Federal Reserve's Large Institution Supervisory Coordinating Committee (LISCC) framework and BHCs with total consolidated assets with total consolidated assets of \$250 billion or more or consolidated total on-balance sheet exposure of \$10 billion or more (defined as a Large and Complex Firm). SR Letter 15-19 sets forth capital planning expectations for BHCs that have total consolidated assets of at least \$50 billion but less than \$250 billion, have consolidated total on-balance sheet exposure of less than \$10 billion, and are not otherwise subject to the LISCC framework (defined as a Large and Noncomplex Firm).

should refer to SR Letter 15-18 or SR Letter 15-19, as applicable, for the capital planning expectations applicable to that BHC (depending on the BHC's size and complexity), as this document applies to all BHCs subject to Y-14 reporting and does not differentiate between Large and Complex vs Large and Noncomplex Firms. To the extent that this document references expectations that may not be applicable to a Large and Noncomplex Firm pursuant to SR Letter 15-19, a Large and Noncomplex will not be held to those expectations but should instead refer to the expectations in SR Letter 15-19.

Who Must Report

A. Reporting Criteria

BHCs with total consolidated assets of \$50 billion or more, as defined by the capital plan rule (12 CFR 225.8), are required to submit the Capital Assessment and Stress Testing report (FR Y-14A/Q/M) to the Federal Reserve. The capital plan rule defines total consolidated assets as the average of the company's total consolidated assets over the course of the previous four calendar quarters, as reflected on the BHC's Consolidated Financial Statement for Bank Holding Companies (FR Y-9C). Total assets shall be calculated based on the due date of the bank holding company's most recent FR Y-9C. If the BHC has not filed an FR Y-9C for each of the four most recent quarters, the average of the BHC's total consolidated assets in the most recent consecutive quarters as reported quarterly on the BHC's FR Y-9C should be used in the calculation.

Separate annual schedules must be reported for each scenario as required, unless otherwise specified in the schedule or sub-schedule instructions (for example for historical data collections on the Retail Repurchase sub-schedule, for which only the baseline scenario is required). Certain data elements within the annual schedules are subject to materiality thresholds. The instructions to these data schedules provide details on how to determine whether a BHC must submit a specific schedule, sub-schedule, or data element.

All annual schedules are required to be reported by all BHCs with the exception of the CCR schedule, and the Trading and CCR sub-schedules of the Summary schedule, which should be filed as described below:

CCR schedule and Trading and CCR sub-schedules (Summary Schedule): BHCs with greater than \$500 billion in total consolidated assets who are subject to the amended market risk rule (12 CFR Parts 208, Appendix E and 225 Appendix E) must submit this schedule and sub-schedules. Additionally, the Board or the Director of the Division of Banking Supervision and Regulation of the Federal Reserve Board, acting under delegated authority, may require any company to complete the CCR schedule and sub-schedule under 12 CFR 252.144(b)(2).must submit this schedule and sub-schedules.

B. Exemptions

BHCs that do not meet the reporting criteria listed above are exempt from reporting. The following institutions are also exempt:

BHCs, savings and loan holding companies (SLHCs) and state member banks (SMBs) with average total consolidated assets of greater than \$10 billion but less than \$50 billion subject to the final rule on annual company-run stress tests (12 CFR 252(h)) are not required to file this report. However, institutions meeting this threshold should review the reporting requirements and instructions for

the Annual Company-Run Stress Test Projections (FR Y-16) on the Board's public website.

SLHCs are currently not required to comply with FR Y-14A reporting requirements. Further information regarding reporting for SLHCs will be provided in the future.²

Where to Submit the Reports

All BHCs subject to these reporting requirements must submit completed reports electronically via the IntraLinks website. BHCs will be provided information on how to transmit data to the FR Y-14 IntraLinks Collaboration website. Requests for access to the IntraLinks site should be sent to ccar.support@ccar.frb.org.

For requirements regarding the submission of qualitative supporting information, please see Appendix A: Supporting Documentation, in addition to instructions associated with each schedule for which supporting documentation might be required.

When to Submit the Reports

BHCs must file the FR Y-14A schedules annually or semi-annually according to the appropriate time schedules described below. All schedules will be due on or before the end of the submission date (unless that day falls on a weekend (subject to timely filing provisions)). Early submission, including submission of schedules on a flow basis prior to the due date, aids the Federal Reserve in reviewing and processing data and is encouraged.

If the submission date falls on a weekend or holiday, the data must be received on the first business day after the weekend or holiday. No other extensions of time for submitting reports will be granted.

² SLHCs would not be subject to Dodd-Frank annual company-run stress testing requirements until the next calendar year after the SLHCs become subject to regulatory capital requirements.

Schedules and Sub-Sub-schedules	Data as-of-date	Submission Date to Federal Reserve
Semi-annual Schedules		
Summary, Macro Scenario	<ul style="list-style-type: none"> Data as-of December 31st. Data as-of June 30th. 	<ul style="list-style-type: none"> Data are due April 5th of the following year. Data are due October 5th of the same year.
Annual Schedules		
Regulatory Capital Instruments, Regulatory Capital Transitions, Operational Risk and Business Plan Changes schedules	<ul style="list-style-type: none"> Data as-of December 31st. 	<ul style="list-style-type: none"> Data are due April 5th of the following year.
<u>CCAR Market Shock exercise Summary schedule</u> <ul style="list-style-type: none"> Trading Risk Counterparty 	<ul style="list-style-type: none"> Data as-of a specified date in the first quarter. As-of-date would be communicated by Federal Reserve³ 	Data are due April 5th of the following year

How to Prepare the Reports:

A. Applicability of GAAP

BHCs are required to prepare and file the FR Y-14A schedules in accordance with U.S. generally accepted accounting principles (GAAP) and these instructions. The financial records of the BHCs should be maintained in such a manner and scope to ensure the FR Y-14A is prepared in accordance with these instructions and reflects a fair presentation of the BHCs' financial condition and assessment of performance under stressed scenarios.

B. Rules of Consolidation

Please reference the FR Y-9C General Instructions for a discussion regarding the rules of consolidation.

C. Projections

Many schedules collect data on a "projection horizon", which includes one quarter of actual data

³ As outlined in Sections 252.144 (Annual Stress Tests) of Regulation YY (12 CFR 252), the as-of date will be between January 1st and March 1st of that calendar year and will be communicated to the BHCs by March 1st of the calendar year. BHCs are permitted to submit the CCR schedule and the Trading and CCR sub-schedules of the Summary schedule as-of another recent reporting date prior to the supplied as-of date as appropriate.

followed by at least nine quarters of projected data. Where projections are required, the following applies:

- The “projection horizon” refers to the nine quarters starting with the first quarter of the reporting year (e.g., from the first quarter of 2013 through the first quarter of 2015).
- Column headings refer to PQ1 through PQ9. PQ stands for projected quarter. PQ1 through PQ9 are nine quarterly projections over which the planning horizon extends.
- In some cases, the projected quarters will extend beyond the nine-quarter planning horizon (as is the case of projected future losses charged to the repurchase reserve), necessitating PQ10 or more.

D. Technical Details

The following instructions apply generally to the FR Y-14A schedules, unless otherwise specified. For further information on the technical specifications for this report, please see the Technical Instructions.

- Do not enter any information in gray highlighted or shaded cells, including those with embedded formulas. Only non-shaded cells should be completed by institutions.
- Ensure that any internal consistency checks are complete prior to submission.
- Report dollar values in millions of US dollars (unless specified otherwise).
- Dates should be entered in an YYYYMMDD format (unless specified otherwise).
- Report negative numbers with a minus (-) sign.
- Report data as an integer (unless specified otherwise)
- An amount, zero or null should be entered for all items, except in those cases where other options such as “not available” or “other” are specified. If information is not available or not applicable and no such options are offered, the field should be left blank.
- Report income and loss data on a quarterly basis, and not on a cumulative or year-to-date basis.

E. Other Instructional Guidance

BHCs should review the following published documents (in the order listed below) when determining the precise definition to be used in completing the schedules. Where applicable, references to the FR Y-9C have been provided in the FR Y-14A instructions and templates noting associations between the reporting series.

- The FR Y-14A instructions;
- The FR Y-14 Q/M instructions;
- The latest available FR Y-9C instructions published on the Federal Reserve’s public web site: <http://www.federalreserve.gov/reportforms>

For purposes of completing certain FR Y-14A schedules, BHCs should also consult the following references for relevant guidance:

- The most recent CapPR Instructions
- The most recent CCAR Instructions

F. Confidentiality

As these data will be collected as part of the supervisory process, they are subject to confidential treatment under exemption 8 of the Freedom of Information Act (5 U.S.C. 552(b)(8)). In addition, commercial and financial information contained in these information collections may be exempt from disclosure under Exemption 4.5 (U.S.C. 552(b)(4)). Disclosure determinations would be made on a case-by-case basis.

G. Amended Reports

The Federal Reserve will require the filing of amended reports if previous submissions contain significant errors. In addition, a reporting institution must file an amended report when it or the Federal Reserve discovers significant errors or omissions subsequent to submission of a report. Failure to file amended reports on a timely basis may subject the institution to supervisory action.

If resubmissions are required, institutions should contact the appropriate Reserve Bank, as well as the FR Y-14 mailbox at info@ccar.frb.org, and resubmit data via the Intralinks website.

H. Questions and Requests for Interpretations

BHCs should submit any questions or requests for interpretations by e-mail to info@CCAR.frb.org.

Schedule A—Summary

General Instructions

This document contains instructions for the FR Y-14A Summary schedule. The schedule includes data collection sub-schedules related to the following:

1. Income Statement, Balance Sheet, and Capital Statements;
2. Retail;
3. Securities;
4. Trading;
5. Counterparty Credit Risk;
6. Operational Risk; and
7. Pre-Provision Net Revenue (PPNR).

The bank holding company (BHC) should submit a **separate** Summary schedule for **each** scenario.

A BHC that decides the supervisory baseline scenario is appropriate for its BHC baseline scenario should still submit an FR Y-14A for each scenario. The two submissions would differ in that the supervisory baseline FR Y-14A would contain a completed Capital - CCAR and Capital - DFAST; the BHC baseline submission would not contain a completed Capital - DFAST.

Under the BHC baseline, supervisory baseline, supervisory adverse, and supervisory severely adverse scenarios, BHCs should report the FR Y-14A summary schedule's worksheets, other than "Capital - DFAST" where applicable, assuming planned capital actions.

Under the BHC stress scenario, BHCs should report the FR Y-14A summary schedule's worksheets assuming alternative capital actions. The BHC stress scenario submission would not contain a completed Capital - DFAST.

Supporting Documentation

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

1. Income Statement, Balance Sheet, and Capital

A.1.a—Income Statement

The Income Statement sub-schedule collects projections for the main components of the income statement. Federal Reserve Micro Data Reference Manual (MDRM) codes are provided in the 'Notes' column for many of the line items.⁴ Where applicable, use the definitions for the FR Y-9C line items corresponding to the MDRM code. For each scenario used, input the loan loss projections for the various line items in this sub-schedule. The BHC should include losses tied to the relevant balances reported on the Balance Sheet sub-schedule. Losses associated with held for investment loans accounted for at amortized cost should be reported in the appropriate line items under the "Losses Associated With Loans Held for Investment Accounted for at Amortized Cost" section and any losses due to changes in the fair value of assets that are held for sale or held for investment under the fair value option should be reported in the appropriate line items under the "Losses Associated With Loans Held for Sale and Loans Accounted for Under the Fair Value Option" section.

For Corporate and CRE loans, if an MDRM number is not provided, use the same definitions as provided in the FR Y-14Q Corporate and Commercial Real Estate schedules. For credit card loans, use the same definitions as provided in the FR Y-14M Credit Card schedule. The Repurchase Reserve/Liability for Mortgage Reps and Warrants line items are included to provide information on the expected evolution of any reserve or accrued liability that has been established for losses related to sold or government- insured mortgage loans (first or second lien). Losses charged to this reserve can occur through contractual repurchases, settlement agreement, or litigation loss, including losses related to claims under securities law or fraud claims; it is likely that most losses charged to this reserve will come through contractual repurchases or settlements. Quarterly reserve/accrued liability levels and quarterly provisions and net charge-offs to the reserve/accrued liability should be reported as forecast under the applicable scenario. To ensure consistency across the sheets of each FR Y-14A summary workbook, the Provisions during the quarter line is linked to the PPNR Projections Sub-schedule rows where BHCs are expected to report any provisions to the Repurchase Reserve/Liability for Mortgage Reps and Warrants. For the same reason, the Net charges during the quarter line is linked to Table G.3 in the Retail Repurchase Sub-schedule.

Line items 1 through 43 LOSSES ASSOCIATED WITH LOANS HELD FOR INVESTMENT AT AMORTIZED COST:

Line item 1 Real estate loans (in domestic offices)

This item is a shaded cell and is derived from the sum of items 2, 5, 8 and 14.

Line item 2 First lien mortgages (including HELOANS)

⁴ Each MDRM code is associated with a specific line item (data cell) on the FR Y-9C report. See <http://www.federalreserve.gov/reportforms/mdrm/> for a list of MDRM codes and data descriptions.

This item is a shaded cell and is derived from the sum of items 3 and 4.

Line item 3 First lien mortgages

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, excluding closed-end first lien home equity loans (reported in item 4).

Line item 4 First lien home equity loans (HELOANS)

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end first lien home equity loans.

Line item 5 Second/junior lien mortgages

This item is a shaded cell and is derived from the sum of items 6 and 7.

Line item 6 Closed-end junior loans

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties.

Line item 7 Home equity lines of credit (HELOCS)

Report losses associated with loans held for investment accounted for at amortized cost on the amount outstanding under revolving, open-end lines of credit secured by 1 to 4 family residential properties.

Line item 8 Commercial real estate (CRE) loans

This item is a shaded cell and is derived from the sum of items 9, 10, and 11.

Line item 9 Construction

Report losses associated with loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2).

Line item 10 Multifamily

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d).

Line item 11 Nonfarm, nonresidential

This item is a shaded cell and is derived from the sum of items 12 and 13.

Line item 12 Owner-occupied

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1).

Line item 13 Non-owner-occupied

Report losses associated with loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential

properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2).

Line item 14 Loans secured by farmland

Report losses associated with loans held for investment accounted for at amortized cost on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

Line item 15 Real estate loans (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 16, 17, 18 and 24.

Line item 16 First lien mortgages (Not in domestic offices)

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, not held in domestic offices.

Line item 17 Second/junior lien mortgages (Not in domestic offices)

Report losses associated with loans held for investment accounted for at amortized cost on all loans secured by second/junior (i.e., other than first) liens on 1 to 4 family residential properties, not held in domestic offices.

Line item 18 Commercial real estate (CRE) loans (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 19, 20, and 21.

Line item 19 Construction (Not in domestic offices)

Report losses associated with loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), not held in domestic offices.

Line item 20 Multifamily (Not in domestic offices)

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), not held in domestic offices.

Line item 21 Nonfarm, nonresidential (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 22 and 23.

Line item 22 Owner-occupied (Not in domestic offices)

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1), not held in domestic offices.

Line item 23 Non-owner-occupied (Not in domestic offices)

Report losses associated with loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2), not held in domestic offices.

Line item 24 Loans secured by farmland (Not in domestic offices)

Report losses associated with loans held for investment accounted for at amortized cost on all loans

secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

Line item 25 C&I Loans

This item is a shaded cell and is derived from the sum of items 26, 27 and 28.

Line item 26 C&I Graded

Report losses associated with loans held for investment accounted for at amortized cost on all graded commercial and industrial (C&I) loans. Report only loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes losses associated with domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

Line item 27 Small Business (Scored/Delinquency Managed)

Report losses associated with loans held for investment accounted for at amortized cost on small business loans. Report all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

Line item 28 Business and Corporate Card

Report losses associated with loans held for investment accounted for at amortized cost on loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude losses associated with corporate card or charge card loans included in Line item 26 (C&I Graded Loans).

Line item 29 Credit Cards

Report losses associated with loans held for investment accounted for at amortized cost on loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

Line item 30 Other Consumer

This item is a shaded cell and is derived from the sum of items 31, 32, 33 and 34.

Line item 31 Auto Loans

Report losses associated with loans held for investment accounted for at amortized cost on auto loans, as defined in the FR Y-9C, Schedule HC-C, item 6(c).

Line item 32 Student Loans

Report losses associated with loans held for investment accounted for at amortized cost on student loans.

Line item 33 Other (consumer) loans backed by securities (non-purpose lending)

Report losses associated with loans held for investment accounted for at amortized cost on other consumer loans that are backed by securities (i.e., non-purpose lending).

Line item 34 Other (consumer)

Report losses associated with loans held for investment accounted for at amortized cost on all other consumer loans not reported in items 31, 32 or 33.

Line item 35 Other Loans

This item is a shaded cell and is derived from the sum of items 36, 37, 38, 39 and 40.

Line item 36 Loans to Foreign Governments

Report losses associated with loans held for investment accounted for at amortized cost on loans to foreign governments, as defined in the FR Y-9C, Schedule HC-C, item 7. Exclude losses associated with loans to foreign governments included in Line item 27 (Small Business Loans).

Line item 37 Agricultural Loans

Report losses associated with loans held for investment accounted for at amortized cost on agricultural loans, as defined in the FR Y-9C, Schedule HC-C, item 3. Exclude losses associated with agricultural loans included in Line item 27 (Small Business Loans).

Line item 38 Loans for Purchasing or Carrying Securities (secured or unsecured)

Report losses associated with loans held for investment accounted for at amortized cost on loans for purchasing or carrying securities (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(1). Exclude losses associated with loans for purchasing or carrying securities included in Line item 27 (Small Business Loans).

Line item 39 Loans to Depositories and Other Financial Institutions

Report losses associated with loans held for investment accounted for at amortized cost on loans to depositories and other financial Institutions (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, and 9.a. Exclude losses associated with loans to depositories and other financial institutions included in Line item 27 (Small Business Loans).

Line item 40 All Other Loans and Leases

This item is a shaded cell and is derived from the sum of items 41 and 42.

Line item 41 All Other Loans (exclude consumer loans)

Report losses associated with loans held for investment accounted for at amortized cost on all other loans (excluding consumer loans), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(2). Exclude losses associated with all other loans included in Line item 27 (Small Business Loans).

Line item 42 All Other Leases

Report losses associated with loans held for investment accounted for at amortized cost on all other leases (excluding consumer leases), as defined in the FR Y-9C, Schedule HC-C, item 10.b. Exclude

losses associated with all other leases included in Line item 27 (Small Business Loans).

Line item 43 Total Loans and Leases

Report the sum of items 1, 15, 25, 29, 30 and 35.

Line items 44 through 57 LOSSES ASSOCIATED WITH HELD FOR SALE LOANS AND LOANS ACCOUNTED FOR UNDER THE FAIR VALUE OPTION:

Report only the loans themselves (excluding hedges). Report hedges in the appropriate items of the income statement (e.g., hedges held in the trading book are reported in the trading book items).

Line item 44 Real estate loans (in domestic offices)

This item is a shaded cell and is derived from the sum of items 45, 46, 47 and 48.

Line item 45 First Lien Mortgages

Report losses associated with held for sale loans and loans accounted for under the fair value option on all closed-end loans secured by first liens on 1 to 4 family residential properties, including closed-end first lien home equity loans.

Line item 46 Second/Junior Lien Mortgages

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties.

Line item 47 Commercial real estate (CRE) loans

Report losses associated with held for sale loans and loans accounted for under the fair value option on all construction, multifamily, and nonfarm nonresidential loans, as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2).

Line item 48 Loans secured by farmland

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

Line item 49 Real estate loans (not in domestic offices)

This item is a shaded cell and is derived from the sum of items 50, 51 and 52.

Line item 50 Residential Mortgages (not in domestic offices)

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by 1 to 4 family residential properties, including both first lien and second/junior lien loans, not held in domestic offices.

Line item 51 Commercial real estate (CRE) loans (not in domestic offices)

Report losses associated with held for sale loans and loans accounted for under the fair value option on all construction, multifamily, and nonfarm nonresidential loans, as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2), not held in domestic offices.

Line item 52 Loans secured by farmland (not in domestic offices)

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

Line item 53 C&I Loans

Report losses associated with held for sale loans and loans accounted for under the fair value option on all commercial and industrial loans, as defined in items 26, 27 and 28.

Line item 54 Credit Cards

Report losses associated with held for sale loans and loans accounted for under the fair value option on loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

Line item 55 Other Consumer

Report losses associated with held for sale loans and loans accounted for under the fair value option on all other consumer loans, as defined in items 31, 32, 33 and 34.

Line item 56 All Other Loans and Leases

Report losses associated with held for sale loans and loans accounted for under the fair value option on all other loans and leases, as defined in items 36, 37, 38, 39, 41 and 42.

Line item 57 Total Loans and Leases

This item is a shaded cell and is derived from the sum of items 44, 49, 53, 54, 55 and 56.

Line items 58 through 63 TRADING ACCOUNT:

Line item 58 Trading Mark-to-market (MTM) Losses

Line item 58 must equal the sum of the totals reported in item 10 on the Trading Schedule, with the sign reversed.

Line item 59 Trading Issuer Default Losses

Line item 59 must equal item 1 on the Counterparty Risk Schedule.

Line item 60 Counterparty Credit MTM Losses (CVA losses)

Line item 60 must equal item 2 on the Counterparty Risk Schedule.

Line item 61 Counterparty Default losses

Line item 61 must equal item 3 on the Counterparty Risk Schedule.

Line item 62 Total Trading and Counterparty losses

This item is a shaded cell and is derived from the sum of items 58, 59, 60, and 61.

Line items 63 through 67 OTHER LOSSES:

Line item 63 Goodwill Impairment

Report losses associated with goodwill impairment, as defined in the FR Y-9C, Schedule HC, item 10(a). Under GAAP (ASC 350-20-35-30), "Goodwill of a reporting unit shall be tested for impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount." However, it is acceptable for purposes of this exercise to provide annual estimates as long as the resulting quarterly capital projections would not differ materially from those generated using quarterly impairment projections.

Line item 64 Valuation Adjustment for firm's own debt under fair value option (FVO)

Report losses associated with the valuation adjustment for the firm's own debt under the fair value option (FVO).

Line item 65 Other losses

Report all other losses not reported in items 1 through 65. Describe these losses in the supporting documentation.

Line item 66 Total Other Losses

Report the sum of all other losses included in items 63, 64, and 65.

Line item 67 Total Losses

Report the sum of items 43, 57, 62 and 66.

Line items 68 through 116 ALLOWANCE FOR LOAN AND LEASE LOSSES (ALL):

Line item 68 ALL prior quarter

Report the total allowance for loan and lease losses as of the end of the prior quarter.

Line item 69 Real Estate Loans (in Domestic Offices)

Report the sum of items 70, 74, and 78.

Line item 70 Residential Mortgages (in Domestic Offices)

Report the sum of the allowance for loan and lease losses included in items 71, 72, and 73.

Line item 71 First Lien Mortgages (in Domestic Offices)

Report the allowance for loan and lease losses for all loans secured by first liens on 1 to 4 family residential properties, including first lien home equity loans, held in domestic offices.

Line item 72 Closed-end Junior Liens (in Domestic Offices)

Report the allowance for loan and lease losses for all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties, held in domestic offices.

Line item 73 HELOCs (in Domestic Offices)

Report the allowance for loan and lease losses for revolving, open-end lines of credit secured by 1 to 4 family residential properties, held in domestic offices.

Line item 74 CRE Loans (in Domestic Offices)

Report the sum of the allowance for loan and lease losses included in items 76, 77 and 78.

Line item 75 Construction (in Domestic Offices)

Report the allowance for loan and lease losses for construction, land development, and other land loans (as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2)), held in domestic offices.

Line item 76 Multifamily (in Domestic Offices)

Report the allowance for loan and lease losses for loans secured by multifamily (5 or more) residential properties (as defined in the FR Y-9C, Schedule HC-C, item 1(d)), held in domestic offices.

Line item 77 Nonfarm, Non-residential (in Domestic Offices)

Report the allowance for loan and lease losses for loans secured by nonfarm nonresidential properties (as defined in the FR Y-9C, Schedule HC-C, items 1(e)(1) and 1(e)(2)), held in domestic offices.

Line item 78 Loans Secured by Farmland (in Domestic Offices)

Report the allowance for loan and lease losses for loans secured by farmland (as defined in the FR Y-9C, Schedule HC-C, item 1(b)), held in domestic offices.

Line item 79 Real Estate Loans (Not in Domestic Offices)

Report the sum of items 81, 82 and 83.

Line item 80 Residential Mortgages (Not in Domestic Offices)

Report the allowance for loan and lease losses for all loans secured by 1 to 4 family residential properties, including both first lien and second/junior lien loans, not held in domestic offices.

Line item 81 CRE Loans (Not in Domestic Offices)

Report the allowance for loan and lease losses for all construction, multifamily, and nonfarm nonresidential loans (as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2)), not held in domestic offices.

Line item 82 Farmland (Not in Domestic Offices)

Report the allowance for loan and lease losses for all loans secured by farmland (as defined in the FR Y-9C, Schedule HC-C, item 1(b)), not held in domestic offices.

Line item 83 C&I Loans

Report the sum of items 85, 86 and 87.

Line item 84 C&I Graded

Report the allowance for loan and lease losses for all graded commercial and industrial (C&I) loans. Report the associated allowance only for loans “graded” or “rated” using the reporting entity’s commercial credit rating system, as it is defined in the reporting entity’s normal course of business. This includes the allowance for loan and lease losses for all domestic and international business and

corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

Line item 85 Small Business (Scored/Delinquency Managed)

Report the allowance for loan and lease losses for small business loans. Report the associated allowance for all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

Line item 86 Business and Corporate Card

Report the allowance for loan and lease losses for loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude the allowance for loan and lease losses related to corporate card or charge card loans included in Line item 85 (C&I Graded Loans).

Line item 87 Credit Cards

Report the allowance for loan and lease losses for loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

Line item 88 Other Consumer

Report the allowance for loan and lease losses for all other consumer loans, as defined in items 31, 32, 33 and 34.

Line item 89 All Other Loans and Leases

Report the allowance for loan and lease losses for all other loans and leases, as defined in items 36, 37, 38, 39, 41 and 42.

Line item 90 Unallocated

Report any unallocated portion of the allowance for loan and lease losses.

Line item 91 Provisions during the quarter

Report the provision for loan and lease losses during the quarter, as defined in the FR Y-9C, Schedule HI, item 4.

Line item 92 Real Estate Loans (in Domestic Offices)

Report the sum of items 93, 97, and 101.

Line item 93 Residential Mortgages (in Domestic Offices)

Report the sum of the provision for loan and lease losses included in items 94, 95, and 96.

Line item 94 First Lien Mortgages (in Domestic Offices)

Report the provision for loan and lease losses for all loans secured by first liens on 1 to 4 family residential properties, including first lien home equity loans, held in domestic offices.

Line item 95 Closed-end Junior Liens (in Domestic Offices)

Report the provision for loan and lease losses for all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties, held in domestic offices.

Line item 96 HELOCs (in Domestic Offices)

Report the provision for loan and lease losses for revolving, open-end lines of credit secured by 1 to 4 family residential properties, held in domestic offices.

Line item 97 CRE Loans (in Domestic Offices)

Report the sum of the provision for loan and lease losses included in items 98, 99, and 100.

Line item 98 Construction (in Domestic Offices)

Report the provision for loan and lease losses for construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), held in domestic offices.

Line item 99 Multifamily (in Domestic Offices)

Report the provision for loan and lease losses for loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), held in domestic offices.

Line item 100 Nonfarm, Non-residential (in Domestic Offices)

Report the provision for loan and lease losses for loans secured by nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, items 1(e)(1) and 1(e)(2), held in domestic offices.

Line item 101 Loans Secured by Farmland (in Domestic Offices)

Report the provision for loan and lease losses for loans secured by farmland as defined in the FR Y-9C, Schedule HC-C, item 1(b), held in domestic offices.

Line item 102 Real Estate Loans (Not in Domestic Offices)

Report the sum of items 104, 105 and 106.

Line item 103 Residential Mortgages (Not in Domestic Offices)

Report the provision for loan and lease losses for all loans secured by 1 to 4 family residential properties, including both first lien and second/junior lien loans, not held in domestic offices.

Line item 104 CRE Loans (Not in Domestic Offices)

Report the provision for loan and lease losses for all construction, multifamily, and nonfarm nonresidential loans, as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2), not held in domestic offices.

Line item 105 Farmland (Not in Domestic Offices)

Report the provision for loan and lease losses for all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

Line item 106 C&I Loans

Report the sum of items 107, 108, and 109.

Line item 107 C&I Graded

Report the provision for loan and lease losses for all graded commercial and industrial (C&I) loans. Report the associated provision only for loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes the provision for loan and lease losses for all domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

Line item 108 Small Business (Scored/Delinquency Managed)

Report the provision for loan and lease losses for small business loans. Report the associated provision for all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b of schedule HC-C of the FR Y-9C excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

Line item 109 Business and Corporate Cards

Report the provision for loan and lease losses for loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude the provision for loan and lease losses related to corporate card or charge card loans included in Line item 107 (C&I Graded Loans).

Line item 110 Credit Cards

Report the provision for loan and lease losses for loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

Line item 111 Other Consumer

Report the provision for loan and lease losses for all other consumer loans, as defined in items 31, 32, 33 and 34.

Line item 112 All Other Loans and Leases

Report the provision for loan and lease losses for all other loans and leases, as defined in items 36, 37, 38, 39, 41 and 42.

Line item 113 Unallocated

Report any unallocated portion of the provision for loan and lease losses.

Line item 114 Net charge-offs during the quarter

Report charge-offs net of recoveries during the quarter, as defined in the FR Y-9C, Schedule HI-B, Part I, item 9, Column A minus Column B.

Line item 115 Other ALLL Changes

Report other changes to the allowance for loan and lease losses, as defined in the FR Y-9C, Schedule HI-B, Part II, item 6, minus Schedule HI-B, Part II, item 4.

Line item 116 ALLL, current quarter

Report the sum of items 69, 92 and 116, minus item 115.

Line items 117 through 120 PRE-PROVISION NET REVENUE (PPNR):

Line item 117 Net interest income

Line item 117 must equal item 13 on the PPNR Submission Sub-schedule.

Line item 118 Noninterest income

Line item 118 must equal item 26 on the PPNR Submission Sub-schedule.

Line item 119 Noninterest expense

Line item 119 must equal item 38 on the PPNR Submission Sub-schedule.

Line item 120 Pre-provision Net Revenue

Report the sum of items 117 and 118, minus item 119.

Line items 121 through 135 CONDENSED INCOME STATEMENT:

Line item 121 Pre-provision Net Revenue

Report the value for item 120.

Line item 122 Provisions during the quarter

Report the value for item 91.

Line item 123 Total Trading and Counterparty Losses

Report the value for item 62.

Line item 124 Total Other Losses

Report the value for item 66.

Line item 125 Other Income Statement (I/S) Items

Report other income statement items that the institution chooses to disclose. Describe these items

in the supporting documentation.

Line item 126 Realized Gains (Losses) on available-for-sale securities, including OTTI

Report realized gains (losses) on available-for-sale securities, as defined in the FR Y-9C, Schedule HI, item 6.b. For the projected quarters, this amount represents projected other-than-temporary impairment losses on available-for-sale securities and realized gains and losses on available-for-sale securities. Gains and losses from sales of available-for-sale securities, other than OTTI, should not be allowed unless there is an existing contractual or legal obligation to sell a security or a security has already been sold.

Line item 127 Realized Gains (Losses) on held-to-maturity securities, including OTTI

Report realized gains (losses) on held-to-maturity securities, as defined in the FR Y-9C, Schedule HI, item 6.a. For the projected quarters, this amount represents projected other-than-temporary impairment losses on held-to-maturity securities and realized gains and losses on held-to-maturity securities. Gains and losses from sales of held-to-maturity securities, other than OTTI, should not be allowed unless there is an existing contractual or legal obligation to sell a security or a security has already been sold.

Line item 128 Income (loss) before taxes and extraordinary items

Report the sum of items 121, 125, 126, and 127, minus items 122, 123, and 124.

Line item 129 Applicable income taxes (foreign and domestic)

Report all applicable income taxes, both foreign and domestic, as defined in the FR Y-9C, Schedule HI, item 9.

Line item 130 Income (loss) before extraordinary items and other adjustments

Report the amount of item 128 minus item 129.

Line item 131 Extraordinary items and other adjustments, net of income taxes

Report all extraordinary items and other adjustments, net of income taxes, as defined in the FR Y-9C, Schedule HI, item 11.

Line item 132 Net income (loss) attributable to BHC and minority interests

Report the sum of item 130 and item 131.

Line item 133 Net income (loss) attributable to minority interests

Report net income (loss) attributable to minority interests, as defined in the FR Y-9C, Schedule HI, item 13.

Line item 134 Net income (loss) attributable to BHC

Report the amount of item 133 minus item 134.

Line item 135 Effective Tax Rate (%)

Report the amount of item 132 divided by item 133, multiplied by 100.

Line items 136 through 139 REPURCHASE RESERVE/LIABILITY FOR MORTGAGE REPS AND

WARRANTIES:

Line item 136 Reserve, prior quarter

Report the amount of any reserve or accrued liability that was established in the prior quarter for losses related to sold or government-insured mortgage loans (first or second lien).

Line item 137 Provisions during the quarter

Report the amount of provisions during the quarter to the repurchase reserve/liability for mortgage representations and warranties.

Line item 138 Net charges during the quarter

Report the amount of net charges (charges less recoveries) during the quarter to the repurchase reserve/liability for mortgage representations and warranties. Losses charged to this reserve can occur through contractual repurchases, settlement agreement, or litigation loss, including losses related to claims under securities law or fraud claims.

Line item 139 Reserve, current quarter

Report the sum of items 136 and 137 minus item 138.

A.1.b—Balance Sheet

For each scenario used, input the loan balance projections in the various line items in this sub-schedule. Balance projections for loans held in the loans held for investment portfolio should be reported in the appropriate line items in the “Loans Held for Investment at Amortized Cost” and balances for held for sale or held for investment under the fair value option should be reported in the appropriate line items in the “Loans Held for Sale and Loans Accounted for Under the Fair Value Option” section. MDRM codes are provided within the ‘Notes’ column for many of the line items. When applicable, the definition of the BHC’s projections should correlate to the definitions outlined by the corresponding MDRM code within the FR Y-9C report. Domestic refers to portfolios in the domestic US offices (as defined in the FR Y-9C report), and International refers to portfolios outside of the domestic US offices.

Explain any M&A and divestitures included and how they are funded (liabilities, asset sales, etc.)

Line items 1 through 3 SECURITIES

Line item 1 Held to Maturity (HTM)

Report the amount of held-to-maturity securities, as defined in the FR Y-9C, Schedule HC, item 2.a.

Line item 2 Available for Sale (AFS)

Report the amount of available-for-sale securities, as defined in the FR Y-9C, Schedule HC, item 2.b.

Line item 3 Total Securities

This item is a shaded cell and is derived from the sum of items 1 and 2.

Line item 4 Securitizations (investment grade)

Investment grade means that the entity to which the Board-regulated institution is exposed through a loan or security, or the reference entity with respect to a credit derivative, has adequate capacity to meet financial commitments for the projected life of the asset or exposure. Such an entity or reference entity has adequate capacity to meet financial commitments if the risk of its default is low and the full and timely repayment of principal and interest is expected.

Line item 5 Securitizations (non-investment grade)

Securitizations that do not meet the investment grade definition above.

Line items 6 through 51 TOTAL LOANS AND LEASES

Line item 6 Real estate loans (in domestic offices)

This item is a shaded cell and is derived from the sum of items 7, 10, 13 and 19.

Line item 7 First lien mortgages (including HELOANS)

This item is a shaded cell and is derived from the sum of items 8 and 9.

Line item 8 First lien mortgages

Report loans secured by first liens on 1 to 4 family residential properties, excluding closed-end first lien home equity loans (reported in item 7).

Line item 9 First lien home equity loans (HELOANS)

Report all closed-end first lien home equity loans.

Line item 10 Second/junior lien mortgages

This item is a shaded cell and is derived from the sum of items 11 and 12.

Line item 11 Closed-end junior loans

Report all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b).

Line item 12 Home equity lines of credit (HELOCS)

Report the amount outstanding under revolving, open-end lines of credit secured by 1 to 4 family residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1).

Line item 13 Commercial real estate (CRE) loans

This item is a shaded cell and is derived from the sum of items 14, 15, and 16.

Line item 14 Construction

Report construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2).

Line item 15 Multifamily

Report loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d).

Line item 16 Nonfarm, nonresidential

This item is a shaded cell and is derived from the sum of items 17 and 18.

Line item 17 Owner-occupied

Report loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1).

Line item 18 Non-owner-occupied

Report nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2).

Line item 19 Loans secured by farmland

Report all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

Line item 20 Real estate loans (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 21, 22, 23 and 29.

Line item 21 First lien mortgages (Not in domestic offices)

Report all closed-end loans secured by first liens on 1 to 4 family residential properties, not held in domestic offices.

Line item 22 Second/junior lien mortgages (Not in domestic offices)

Report all loans secured by second/junior (i.e., other than first) liens on 1 to 4 family residential properties, not held in domestic offices.

Line item 23 Commercial real estate (CRE) loans (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 24, 25, and 26.

Line item 24 Construction (Not in domestic offices)

Report construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), not held in domestic offices.

Line item 25 Multifamily (Not in domestic offices)

Report loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), not held in domestic offices.

Line item 26 Nonfarm, nonresidential (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 27 and 28.

Line item 27 Owner-occupied (Not in domestic offices)

Report loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1), not held in domestic offices.

Line item 28 Non-owner-occupied (Not in domestic offices)

Report nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2), not held in domestic offices.

Line item 29 Loans secured by farmland (Not in domestic offices)

Report all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

Line item 30 C&I Loans

This item is a shaded cell and is derived from the sum of items 31, 32, 33 and 34.

Line item 31 C&I Graded

Report all graded commercial and industrial (C&I) loans. Report only loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

Line item 32 Small Business (Scored/Delinquency Managed)

Report all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in

the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

Line item 33 Corporate Card

Report loans extended under corporate credit cards. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude corporate card loans included in Line item 31 (C&I Graded Loans).

Line item 34 Business Card

Report loans extended under business credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level).

Line item 35 Credit Cards

This item is a shaded cell and is derived from the sum of items 36 and 37.

Line item 36 Charge Cards

Report loans extended under consumer general purpose or private label credit cards that have terms and conditions associated with a charge card. Instead of having a stated interest rate, charge cards have an annual fee and an interchange fee. Also customers must pay off the loan within the billing cycle, which is typically one month. General purpose charge cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and students card if applicable. Private label charge cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

Line item 37 Bank Cards

Report loans extended under consumer general purpose or private label credit cards that have terms and conditions associated with a bank card. A bank card will have a stated interest rate and a minimum payment amount due within the billing cycle. General purpose bank cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label bank cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

Line item 38 Other Consumer

This item is a shaded cell and is derived from the sum of items 39, 40, 41 and 42.

Line item 39 Auto Loans

Report all auto loans, as defined in the FR Y-9C, Schedule HC-C, item 6(c).

Line item 40 Student Loans

Report all student loans.

Line item 41 Other (consumer) loans backed by securities (non-purpose lending)

Report other consumer loans that are backed by securities (i.e., non-purpose lending).

Line item 42 Other (consumer)

Report all other consumer loans not reported in items 39, 40 or 41.

Line item 43 Other Loans

This item is a shaded cell and is derived from the sum of items 44, 45, 46, 47 and 48.

Line item 44 Loans to Foreign Governments

Report all loans to foreign governments, as defined in the FR Y-9C, Schedule HC-C, item 7. Exclude loans to foreign governments included in Line item 32 (Small Business Loans).

Line item 45 Agricultural Loans

Report all agricultural loans, as defined in the FR Y-9C, Schedule HC-C, item 3. Exclude agricultural loans included in Line item 32 (Small Business Loans).

Line item 46 Loans for Purchasing or Carrying Securities (secured or unsecured)

Report all loans for purchasing or carrying securities (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(1). Exclude loans for purchasing or carrying securities included in Line item 32 (Small Business Loans).

Line item 47 Loans to Depositories and Other Financial Institutions

Report all loans to depositories and other financial Institutions (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, and 9.a. Exclude loans to depositories and other financial institutions included in Line item 32 (Small Business Loans).

Line item 48 All Other Loans and Leases

This item is a shaded cell and is derived from the sum of items 49 and 50.

Line item 49 All Other Loans (exclude consumer loans)

Report all other loans (excluding consumer loans), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(2). Exclude all other loans included in Line item 32 (Small Business Loans).

Line item 50 All Other Leases

Report all other leases (excluding consumer leases), as defined in the FR Y-9C, Schedule HC-C, item 10.b. Exclude all other leases included in Line item 32 (Small Business Loans).

Line item 51 Total Loans and Leases

Report the sum of items 6, 20, 30, 35, 38 and 43.

Line items 52 through 94 LOANS HELD FOR INVESTMENT AT AMORTIZED COST:

Line item 52 Real estate loans (in domestic offices)

This item is a shaded cell and is derived from the sum of items 53, 56, 59 and 65.

Line item 53 First lien mortgages (including HELOANS)

This item is a shaded cell and is derived from the sum of items 54 and 55.

Line item 54 First lien mortgages

Report loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, excluding closed-end first lien home equity loans (reported in item 53).

Line item 55 First lien home equity loans (HELOANS)

Report loans held for investment accounted for at amortized cost on all closed-end first lien home equity loans.

Line item 56 Second/junior lien mortgages

This item is a shaded cell and is derived from the sum of items 57 and 58.

Line item 57 Closed-end junior loans

Report loans held for investment accounted for at amortized cost on all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties.

Line item 58 Home equity lines of credit (HELOCS)

Report loans held for investment accounted for at amortized cost on the amount outstanding under revolving, open-end lines of credit secured by 1 to 4 family residential properties.

Line item 59 Commercial real estate (CRE) loans

This item is a shaded cell and is derived from the sum of items 60, 61, and 62.

Line item 60 Construction

Report loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2).

Line item 61 Multifamily

Report loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d).

Line item 62 Nonfarm, nonresidential

This item is a shaded cell and is derived from the sum of items 61 and 62.

Line item 63 Owner-occupied

Report loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1).

Line item 64 Non-owner-occupied

Report loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2).

Line item 65 Loans secured by farmland

Report loans held for investment accounted for at amortized cost on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

Line item 66 Real estate loans (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 67, 68, 69 and 75.

Line item 67 First lien mortgages (Not in domestic offices)

Report loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, not held in domestic offices.

Line item 68 Second/junior lien mortgages (Not in domestic offices)

Report loans held for investment accounted for at amortized cost on all loans secured by second/junior (i.e., other than first) liens on 1 to 4 family residential properties, not held in domestic offices.

Line item 69 Commercial real estate (CRE) loans (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 70, 71, and 72.

Line item 70 Construction (Not in domestic offices)

Report loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), not held in domestic offices.

Line item 71 Multifamily (Not in domestic offices)

Report loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), not held in domestic offices.

Line item 72 Nonfarm, nonresidential (Not in domestic offices)

This item is a shaded cell and is derived from the sum of items 73 and 74.

Line item 73 Owner-occupied (Not in domestic offices)

Report loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1), not held in domestic offices.

Line item 74 Non-owner-occupied (Not in domestic offices)

Report loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2), not held in domestic offices.

Line item 75 Loans secured by farmland (Not in domestic offices)

Report loans held for investment accounted for at amortized cost on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

Line item 76 C&I Loans

This item is a shaded cell and is derived from the sum of items 77, 78 and 79.

Line item 77 C&I Graded

Report loans held for investment accounted for at amortized cost on all graded commercial and industrial (C&I) loans. Report only loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

Line item 78 Small Business (Scored/Delinquency Managed)

Report loans held for investment accounted for at amortized cost on small business loans. Report all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

Line item 79 Business and Corporate Card

Report loans held for investment accounted for at amortized cost on loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude corporate card or charge card loans included in Line item 77 (C&I Graded Loans).

Line item 80 Credit Cards

Report loans held for investment accounted for at amortized cost on loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

Line item 81 Other Consumer

This item is a shaded cell and is derived from the sum of items 82, 83, 84 and 85.

Line item 82 Auto Loans

Report loans held for investment accounted for at amortized cost on auto loans, as defined in the FR Y-9C, Schedule HC-C, item 6(c).

Line item 83 Student Loans

Report loans held for investment accounted for at amortized cost on student loans.

Line item 84 Other (consumer) loans backed by securities (non-purpose lending)

Report loans held for investment accounted for at amortized cost on other consumer loans that are backed by securities (i.e., non-purpose lending).

Line item 85 Other (consumer)

Report loans held for investment accounted for at amortized cost on all other consumer loans not reported in items 82, 83 or 84.

Line item 86 Other Loans and Leases

This item is a shaded cell and is derived from the sum of items 87, 88, 89, 90 and 91.

Line item 87 Loans to Foreign Governments

Report loans held for investment accounted for at amortized cost on loans to foreign governments, as defined in the FR Y-9C, Schedule HC-C, item 7. Exclude loans to foreign governments included in Line item 78 (Small Business Loans).

Line item 88 Agricultural Loans

Report loans held for investment accounted for at amortized cost on agricultural loans, as defined in the FR Y-9C, Schedule HC-C, item 3. Exclude agricultural loans included in Line item 78 (Small Business Loans).

Line item 89 Loans for Purchasing or Carrying Securities (secured or unsecured)

Report loans held for investment accounted for at amortized cost on loans for purchasing or carrying securities (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(1). Exclude loans for purchasing or carrying securities included in Line item 78 (Small Business Loans).

Line item 90 Loans to Depositories and Other Financial Institutions

Report loans held for investment accounted for at amortized cost on loans to depositories and other financial Institutions (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, and 9.a. Exclude loans to depositories and other financial institutions included in Line item 78 (Small Business Loans).

Line item 91 All Other Loans and Leases

This item is a shaded cell and is derived from the sum of items 92 and 93.

Line item 92 All Other Loans (exclude consumer loans)

Report loans held for investment accounted for at amortized cost on all other loans (excluding consumer loans), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(2). Exclude all other loans included in Line item 78 (Small Business Loans).

Line item 93 All Other Leases

Report loans held for investment accounted for at amortized cost on all other leases (excluding consumer leases), as defined in the FR Y-9C, Schedule HC-C, item 10.b. Exclude all other leases included in Line item 78 (Small Business Loans).

Line item 94 Total Loans and Leases

Report the sum of items 52, 66, 76, 80, 81 and 86.

Line items 95 through 111 HELD FOR SALE LOANS AND LOANS ACCOUNTED FOR UNDER THE FAIR VALUE OPTION:

Line item 95 Real estate loans (in domestic offices)

This item is a shaded cell and is derived from the sum of items 96, 97, 98 and 99.

Line item 96 First Lien Mortgages

This item is a shaded cell and is derived as item 7 minus item 53.

Line item 97 Second/Junior Lien Mortgages

This item is a shaded cell and is derived as item 10 minus item 56.

Line item 98 Commercial real estate (CRE) loans

This item is a shaded cell and is derived as item 13 minus item 59.

Line item 99 Loans secured by farmland

This item is a shaded cell and is derived as item 19 minus item 65.

Line item 100 Real estate loans (not in domestic offices)

This item is a shaded cell and is derived from the sum of items 101, 102 and 103.

Line item 101 Residential Mortgages (not in domestic offices)

This item is a shaded cell and is derived as the sum of items 21 and 22 minus items 67 and 68.

Line item 102 Commercial real estate (CRE) loans (not in domestic offices)

This item is a shaded cell and is derived as item 23 minus item 69.

Line item 103 Loans secured by farmland (not in domestic offices)

This item is a shaded cell and is derived as item 29 minus item 75.

Line item 104 C&I Loans

This item is a shaded cell and is derived as item 30 minus item 76.

Line item 105 Credit Cards

This item is a shaded cell and is derived as item 35 minus item 80.

Line item 106 Other Consumer

This item is a shaded cell and is derived as item 38 minus item 81.

Line item 107 All Other Loans and Leases

This item is a shaded cell and is derived as item 41 minus item 84.

Line item 108 Total Loans and Leases Held for Sale and Loans and Leases Accounted for under the Fair Value Option

This item is a shaded cell and is derived from the sum of items 95, 100, 104, 105, 106 and 107.

Line item 109 Unearned Income on Loans

Report all unearned income on loans, as defined in the FR Y-9C, Schedule HC-C, item 11, Column A.

Line item 110 Allowance for Loan and Lease Losses

This item is a shaded cell and is carried over from item 117 of the Income Statement Sub-schedule.

Line item 111 Loans and Leases (Held for Investment and Held for Sale) Net of Unearned Income and Allowance for Loan and Lease Losses

This item is a shaded cell and is derived as item 51 minus items 109 and 110.

TRADING

Line item 112 Trading Assets

Report trading assets, as defined in the FR Y-9C, Schedule HC, item 5.

Line items 113 through 117 INTANGIBLES:

Line item 113 Goodwill

Report goodwill, as defined in the FR Y-9C, Schedule HC, item 10.a.

Line item 114 Mortgage Servicing Rights

Report all mortgage servicing rights, as defined in the FR Y-9C, Schedule HC-M, item 12.a.

Line item 115 Purchased Credit Card Relationships and Nonmortgage Servicing Rights

Report all purchased credit card relationships and nonmortgage servicing rights, as defined in the FR Y-9C, Schedule HC-M, item 12.b.

Line item 116 All Other Identifiable Intangible Assets

Report all other identifiable intangible assets, as defined in the FR Y-9C, Schedule HC-M, item 12.c.

Line item 117 Total Intangible Assets

This item is a shaded cell and is derived from the sum of items 113, 114, 115 and 116.

Line items 118 through 131 OTHER (Assets):

Line item 118 Cash and cash equivalent

Report cash and cash equivalent, as defined in the FR Y-9C, Schedule HC, items 1.a., 1.b.(1), 1.b.(2).

Line item 119 Federal Funds Sold

Report federal funds sold in domestic offices, as defined in the FR Y-9C, Schedule HC, item 3.a.

Line item 120 Securities Purchased under Agreements to Resell

Report securities purchased under agreements to resell, as defined in the FR Y-9C, Schedule HC,

item 3.b.

Line item 121 Premises and Fixed Assets

Report all premises and fixed assets, as defined in the FR Y-9C, Schedule HC, item 6.

Line item 122 Other Real Estate Owned (OREO)

This item is a shaded cell and is derived from the sum of items 123, 124 and 125.

Line item 123 Commercial

Report the net book value of all other real estate owned in the form of, or for which the underlying real estate consists of, commercial real estate.

Line item 124 Residential

Report the net book value of all other real estate owned in the form of, or for which the underlying real estate consists of, residential real estate.

Line item 125 Farmland

Report the net book value of all other real estate owned in the form of, or for which the underlying real estate consists of, farmland.

Line item 126 Collateral Underlying Operating Leases for Which the Bank is the Lessor

This item is a shaded cell and is derived from the sum of items 127 and 128.

Line item 127 Autos

Report the carrying amount of automobiles rented to others under operating leases, net of accumulated depreciation. The amount reported should only reflect collateral rented under operating leases and should not include collateral subject to capital/financing type leases.

Line item 128 Other

Report the carrying amount of any equipment or other assets (other than automobiles) rented to others under operating leases, net of accumulated depreciation. The amount reported should only reflect collateral rented under operating leases and should not include collateral subject to capital/financing type leases.

Line item 129 Other assets

Report all other assets, as defined in the FR Y-9C, Schedule HC, sum of items 1.a, 1.b.(1), 1.b.(2), 3.a, 3.b, 8, 9 and 11, minus item 126 (above).

Line item 130 Total Other (assets)

This item is a shaded cell and is derived from the sum of items 121 and 129.

Line item 131 Total Assets

This item is a shaded cell and is derived from the sum of items 3, 111, 112, 117 and 130.

Line items 132 through 142 LIABILITIES:

Line item 132 Deposits in Domestic Offices

Report all deposits in domestic offices, as defined in the FR Y-9C, Schedule HC, items 13.a.(1) and 13.a.(2).

Line item 133 Deposits in Foreign Offices

Report all deposits in foreign offices, as defined in the FR Y-9C, Schedule HC, items 13.b.(1) and 13.b.(2).

Line item 134 Deposits

This item is a shaded cell and derived from the sum of items 132 and 133.

Line item 135 Federal Funds Purchased and Repurchase Agreements

Report all federal funds purchased and repurchase agreements, as defined in the FR Y-9C, Schedule HC, items 14.a and 14.b.

Line item 136 Trading Liabilities

Report all trading liabilities, as defined in the FR Y-9C, Schedule HC, item 15.

Line item 137 Other Borrowed Money

Report other borrowed money, as defined in the FR Y-9C, Schedule HC, item 16.

Line item 138 Subordinated Notes and Debentures

Report subordinated notes and debentures, as defined in the FR Y-9C, Schedule HC, item 19.a.

Line item 139 Subordinated Notes Payable to Unconsolidated Trusts Issuing TruPS and TruPS Issued by Consolidated Special Purpose Entities

Report all subordinated notes payable to unconsolidated trusts issuing trust preferred securities, and trust preferred securities issued by consolidated special purpose entities, as defined in the FR Y-9C, Schedule HC, item 19.b.

Line item 140 Other liabilities

Report other liabilities, as defined in the FR Y-9C, Schedule HC, item 20.

Line item 141 Memo: Allowance for off-balance sheet credit exposures

Report the allowance for off-balance sheet credit exposures, as defined in the FR Y-9C, Schedule HC-G, item 3.

Line item 142 Total Liabilities

Report the sum of items 134 through 140.

Line items 143 through 151 EQUITY CAPITAL:

Line item 143 Perpetual Preferred Stock and Related Surplus

Report all perpetual preferred stock and related surplus, as defined in the FR Y-9C, Schedule HC, item 23.

Line item 144 Common Stock (Par Value)

Report the par value of common stock, as defined in the FR Y-9C, Schedule HC, item 24.

Line item 145 Surplus (Exclude All Surplus Related to Preferred Stock)

Report surplus (excluding surplus related to preferred stock), as defined in the FR Y-9C, Schedule HC, item 25.

Line item 146 Retained Earnings

Report all retained earnings, as defined in the FR Y-9C, Schedule HC, item 26.a.

Line item 147 Accumulated Other Comprehensive Income (AOCI)

Report accumulated other comprehensive income (AOCI), as defined in the FR Y-9C, Schedule HC, item 26.b.

Line item 148 Other Equity Capital Components

Report other equity capital components, as defined in the FR Y-9C, Schedule HC, item 26.c.

Line item 149 Total BHC Equity Capital

Report the sum of items 143 through 148.

Line item 150 Noncontrolling (Minority) Interests in Consolidated Subsidiaries

Report all noncontrolling (minority) interests in consolidated subsidiaries, as defined in the FR Y-9C, Schedule HC, item 27.b.

Line item 151 Total Equity Capital

Report the sum of items 149 and 150.

Line item 152 Unused Commercial Lending Commitments and Letters of Credit

Report all unused commercial lending commitments and letters of credit, as defined in the FR Y-9C, Schedule HC-L, items 1.c.(1), 1.c.(2), 1.e.(1), 1.e.(2), 1.e.(3), 2, 3, and 4.

A.1.c—Risk-Weighted Assets (RWA)

All BHCs, including advanced approaches BHCs and non-advanced approaches BHCs, must complete the “General RWA” sub-schedule.

A.1.c.1—General RWA

Please note that for purposes of CCAR 2016, respondents are NOT required to fill out the “General RWA” worksheet, as indicated in the specific line item instructions below.

General Credit Risk (Including counterparty credit risk and non-trading credit risk) Report credit risk-weighted assets using the methodologies per the current general risk-based capital rules.

Line items 1 through 10

Definition of the BHC’s projections should correlate to the definitions outlined by the corresponding MDRM code (shown in column C) of the FR Y-9C report multiplied by the applicable credit conversion factor and/or risk-weight. **Do not report this item for CCAR 2016.**

Line item 11 General Credit RWA

This item is a shaded cell and is derived from the sum of items 1 through 10. **Do not report this item for CCAR 2016.**

Market Risk

If a BHC does not have a particular portfolio or no trading book at all, risk-weighted assets should be reported as 0. **Do not report this item for CCAR 2016.**

Line item 12 Value-at-risk (VaR)-based capital requirement

Report the greater of previous day’s VaR-based measure or average of daily VaR-based measure for each of the preceding 60 business days with applicable multiplication factor. VaR-based measure should be inclusive of all sources of risks that are included in the VaR calculation. **Do not report this item for CCAR 2016.**

Line item 13 Stressed VaR-based capital requirement

Report the greater of most recent stressed VaR-based measure or average of weekly stressed VaR-based measures for the preceding 12 weeks with applicable multiplication factor. Stressed VaR-based measure should be inclusive of all sources of risks that are included in the stressed VaR calculation. **Do not report this item for CCAR 2016.**

Line item 14 Incremental risk capital requirement

Report the greater of most recent increment risk measure or average of daily incremental risk measures for the preceding 12 weeks. **Do not report this item for CCAR 2016.**

Line item 15 Comprehensive risk capital requirement

Report the greater of most recent comprehensive risk measure or average of daily comprehensive risk measures for the preceding 12 weeks. RWA equivalent for exposures in the correlation trading portfolio which are subject to the comprehensive risk measurement, inclusive of the application of

the 8% surcharge based on the standardized measurement method. **Do not report this item for CCAR 2016.**

Line item 16 Non-modeled Securitization

This item is a shaded cell and is derived from the maximum of items 17 and 18. The capital charge (or RWA equivalent) for non-modeled traded securitization, including securitization positions that are not correlation trading positions and non-modeled correlation trading positions, is the larger of the net long and net short positions. For purposes of CCAR submission, traded securitization exposures subject to a 1250% risk weight or the equivalent of a deduction should be captured here by including values in lines 17 and 18. **Do not report this item for CCAR 2016.**

Line item 17 Net Long

Report the RWA equivalent according to the standardized measurement method for net long non-modeled securitization exposures including nth-to-default credit derivatives. For purposes of CCAR submission, traded securitization exposures subject to a 1250% risk weight or the equivalent of a deduction should be included here. **Do not report this item for CCAR 2016.**

Line item 18 Net Short

Report the RWA equivalent according to the standardized measurement method for net short non-modeled securitization exposures including nth-to-default credit derivatives. For purposes of CCAR submission, traded securitization exposures subject to a 1250% risk weight or the equivalent of a deduction should be included here. **Do not report this item for CCAR 2016.**

Line item 19 Specific risk add-on (excluding securitization and correlation)

This item is a shaded cell and is derived from sum of items 20 through 25. RWA equivalent for specific risk based on the standardized measurement method as applicable. This should not include RWA according to the standardized measurement method for exposures included in the correlation trading portfolio or the standardized approach for other non-correlation related traded securitization exposures. **Do not report this item for CCAR 2016.**

Line item 20 Sovereign debt positions

Report specific risk add-ons for sovereign debt positions for which the BHC's VaR-based measure does not capture all material aspects of specific risk. **Do not report this item for CCAR 2016.**

Line item 21 Government sponsored entity (GSE) debt positions

Report specific risk add-ons for GSE debt positions for which the BHC's VaR-based measure does not capture all material aspects of specific risk. **Do not report this item for CCAR 2016.**

Line item 22 Depository institution, foreign bank, and credit union debt positions

Report specific risk add-ons for depository institutions, foreign banking organization, and credit union debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk. **Do not report this item for CCAR 2016.**

Line item 23 Public sector entity (PSE) debt positions

Report total specific risk add-on for PSE debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk. **Do not report this item for CCAR 2016.**

Line item 24 Corporate debt positions

Report Specific risk add-on for corporate debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk. **Do not report this item for CCAR 2016.**

Line item 25 Equity

Report specific risk add-on for equity positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk. **Do not report this item for CCAR 2016.**

Line item 26 Capital requirement for de minimis exposures

Report the RWA equivalent for de minimis positions that are not captured in the VaR-based measure. **Do not report this item for CCAR 2016.**

Line item 27 Market Risk Equivalent Assets

This item is automatically calculated. **Do not report this item for CCAR 2016.**

Line item 28 Excess allowance for loan and lease losses (General risk-based capital rules)

Definition of the BHC's projections should correlate to the definitions outlined by the corresponding MDRM code (shown in column C) of the FR Y-9C report where applicable. **Do not report this item for CCAR 2016.**

Line item 29 Allocated transfer risk reserve

Definition of the BHC's projections should correlate to the definitions outlined by the corresponding MDRM code (shown in column C) of the FR Y-9C report where applicable. **Do not report this item for CCAR 2016.**

Line item 30 Total RWA (General risk-based capital rules)

This item is automatically calculated. **Do not report this item for CCAR 2016.**

Memoranda for Derivative Contracts

Provide balances (and not in terms of RWA) consistent with FR Y-9C instructions for each MDRM code.

Line items 31 through 39

Definition of the BHC's projections should correlate to the definitions outlined by the corresponding MDRM code (shown in column C) of the FR Y-9C report. **Do not report these items for CCAR 2016.**

A.1.c.2—Standardized RWA

All BHCs are required to complete the "Standardized RWA" sub-schedule for all reporting quarters starting January 1, 2015.

BHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. However, if a BHC projects to meet the trading activity threshold that would require it to be subject to the market risk capital

requirements during the forecast period, then the BHC should complete the market risk-weighted asset section within the sub-schedule. Please refer to 78 Federal Register 62250, October 11, 2013 and 78 Federal Register 76521, December 18, 2013 for details of the requirements.

Balance Sheet Asset Categories

Line item 1 Cash and balances due from depository institutions

Report the total risk-weighted amount of cash and balances due from depository institutions.

Line item 2 Federal funds sold and securities purchased under agreements to resell

Report the total risk-weighted amount of federal funds sold and securities purchased under agreements to resell, including reverse repurchase agreements.

Line item 3a Securities (excluding securitizations): Held-to-maturity

Report the total risk-weighted amortized cost of held-to-maturity (HTM) securities excluding those securities that qualify as securitization exposures as defined in 12 CFR 217.2 of the regulatory capital rules.

Line item 3b Securities (excluding securitizations): Available-for-sale

Report the total risk-weighted fair value of available-for-sale (AFS) securities, excluding those securities that qualify as securitization exposures as defined in 12 CFR 217.2 of the regulatory capital rules.

Loans and leases on held for sale

Line item 4a Residential mortgage exposures

Report the total risk-weighted portion of the carrying value of loans and leases held for sale (HFS) composed of items related to residential mortgage exposures.

Line item 4b High Volatility Commercial Real Estate

Report the total risk-weighted portion of the carrying value of loans and leases held for sale (HFS) related to high volatility commercial real estate exposures (HVCRE), as defined in 12 CFR 217.2 of the regulatory capital rules, including HVCRE exposures that are 90 days or more past due or on non-accrual status.

Line item 4c Exposures past due 90 days or more or on nonaccrual

Report the total risk-weighted portion of the carrying value of loans and leases held for sale (HFS) that are 90 days or more past due or on non-accrual status according to the requirements set forth in 12 CFR 217.32(k) of the regulatory capital rules. Do not include exposures to sovereigns or residential real estate, as described in 12 CFR 217.32(a) and 12 CFR 217.32(g) respectively, that are past due or on non-accrual status. Also do not include HVCRE exposures that are past due or on non-accrual status.

Line item 4d All other exposures

Report the total risk-weighted portion of the carrying value of loans and leases held for sale (HFS) that are not reported in items 4a through 4c.

Loans and leases, net of unearned income

Line item 5a Residential mortgage exposures

Report the total risk-weighted portion of the amount of loans and leases, net of unearned income, composed of items related to residential mortgage exposures, including the carrying value of the guaranteed portion of FHA and VA mortgage loans, loans secured by 1-4 family residential properties and by multifamily residential properties, as well as loans that meet the definition of statutory multifamily mortgage according to 12 CFR 217.2 of the regulatory capital rules.

Line item 5b High Volatility Commercial Real Estate

Report the total risk-weighted portion of the amount of loans and leases, net of unearned income that are related to high volatility commercial real estate exposures (HVCRE), including HVCRE exposures that are 90 days or more past due or on non-accrual status.

Line item 5c Exposures past due exposures 90 days or more or on nonaccrual

Report the total risk-weighted portion of the amount of loans and leases, net of unearned income, that are 90 days or more past due or on non-accrual status according to the requirements set forth in 12 CFR 217.32(k) of the regulatory capital rules. Do not include exposures to sovereigns or residential real estate, as described in 12 CFR 217.32(a) and 12 CFR 217.32(g) respectively, that are past due or on non-accrual status. Also do not include HVCRE exposures that are past due or on non-accrual status.

Line item 5d All other exposures

Report the total risk-weighted portion of the amount of loans and leases, net of unearned income that are not reported in items 5a through 5c.

Line item 6 Trading assets (excluding securitizations that receive standardized charges)

If the BHC is subject to the market risk capital rules, report the total risk-weighted fair value of trading assets that do not meet the definition of a covered position per the market risk capital rules, excluding those trading assets that do not meet the definition of a covered position per the market risk capital that are securitization exposures as defined in 12 CFR 217.2 of the regulatory capital rules.

If the BHC is not subject to the market risk capital rules, report the total risk-weighted fair value of trading assets, excluding those trading assets that are securitization exposures as defined in 12 CFR 217.2 of the regulatory capital rules.

Line item 7 All other assets

Include total risk-weighted amounts of items such as "Premises and fixed assets," "Other real estate owned," "Investments in unconsolidated subsidiaries and associated companies," "Direct and indirect investments in real estate ventures," "Goodwill," "Other intangible assets," and "Other assets," excluding those trading assets that are securitization exposures as defined in 12 CFR 217.2 of the regulatory capital rules. Also include the total risk-weighted amount of default fund contributions made by the banking organization to central counterparties (CCP) and collateral provided by the banking organization to CCPs that is not bankruptcy remote as described in 12 CFR 217.35 of the regulatory capital rules.

Line item 8a On-balance sheet securitization exposures: Held-to-maturity

Report the total risk-weighted portion of amortized cost of held-to-maturity (HTM) securities that are securitization exposures.

Line item 8b On-balance sheet securitization exposures: Available-for-sale

Report the total risk-weighted portion of the fair value of available-for-sale (AFS) securities that are securitization exposures.

Line item 8c On-balance sheet securitization exposures: Trading assets that are securitization exposures that receive standardized charges

If the BHC is subject to the market risk capital rules, report the total risk-weighted fair value of the portion of trading assets that are securitization exposures that do not meet the definition of a covered position per the market risk capital rules.

If the BHC is not subject to the market risk capital rules, report the total risk-weighted fair value of trading assets that are securitization exposures.

Line item 8d On-balance sheet securitization exposures: All other on-balance sheet

Report the total risk-weighted amount of any qualifying on-balance sheet securitization exposures which are not included above.

Line item 9 Off-balance sheet securitization exposures

Consistent with the HC-R, part II instructions, report the total risk-weighted amount of all off-balance sheet items included in Schedule HC-L or HC-S that qualify as securitization exposures.

Line item 10 RWA for Balance Sheet Asset Categories

This item is a shaded cell and is derived from the sum of items 1 through 8d.

Derivatives and Off-Balance Sheet Asset Categories (Excluding Securitization Exposures)

Line item 11 Financial standby letters of credit

Report the total risk-weighted amount of all financial standby letters of credit that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules.

Line item 12 Performance standby letters of credit and transaction related contingent items

Report the total risk-weighted amount of transaction related contingent items, which includes the face amount of performance standby letters of credit and any other transaction related contingent items that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules.

Line item 13 Commercial and similar letters of credit with an original maturity of one year or less

Report the the total risk-weighted amounts of commercial and similar letters of credit, including self-liquidating, trade-related contingent items that arise from the movement of goods, with an original maturity of one year or less that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules.

Line item 14 Retained recourse on small business obligations sold with recourse

Report the total risk-weighted amount of retained recourse on small business obligations that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules. Under Section 208 of the Riegle Community Development and Regulatory Improvement Act of 1994, a "qualifying institution"⁵ that transfers small business loans and leases on personal property (small business obligations) with recourse in a transaction that qualifies as a sale under generally accepted accounting principles (GAAP) must maintain risk-based capital only against the amount of recourse retained, provided the institution establishes a recourse liability account that is sufficient under GAAP. Only loans and leases to businesses that meet the criteria for a small business concern established by the Small Business Administration under Section 3(c) of the Small Business Act (12 U.S.C. 631) are eligible for this favorable risk-based capital treatment.

Line item 15 Repo-style transactions (excluding reverse repos)

Report the total risk-weighted amount of repo-style transactions, which is composed of the sum of the amount of securities lent, the amount of securities borrowed, and the amount of securities sold under agreements to repurchase that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules. Exclude the amount of securities purchased under agreements to resell (i.e., reverse repos).

Line item 16 All other off-balance sheet liabilities

Report the total risk-weighted amount of all other off-balance sheet liabilities that are covered by the regulatory capital rules as well as the amount of those credit derivatives that are covered by the regulatory capital rules, but do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules, and have not been included in any of the preceding items in the Derivatives and Off-Balance Sheet Items section.

Line item 17a Unused commitments: Original maturity of one year or less, excluding ABCP conduits

Report the total risk-weighted amount of the unused portion of an eligible liquidity facility with an original maturity of one year or less, excluding ABCP facilities that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules. The unused portion of commitments (facilities) that are unconditionally cancelable (without cause) at any time by the holding company have a zero percent credit conversion factor. The unused portion of such commitments should be excluded from this item and included in line item 18.

Note that "original maturity" is defined as the length of time between the date a commitment is issued and the date of maturity, or the earliest date on which the banking organization: (1) is scheduled to, and as a normal practice actually does, review the facility to determine whether or not it should be extended and; (2) can unconditionally cancel the commitment.

⁵ In general, a "qualifying institution" is one that is well capitalized without regard to the Section 208 provisions. If a bank ceases to be a qualifying institution or exceeds the retained recourse limit set forth in banking agency regulations implementing Section 208, all new transfers of small business obligations with recourse would not be treated as sales. However, the reporting and risk-based capital treatment described above will continue to apply to any transfers of small business obligations with recourse that were consummated during the time the bank was a "qualifying institution" and did not exceed the limit.

Line item 17b Unused commitments: Original maturity of one year or less to ABCP conduits

Report the total risk-weighted amount of the unused portion of an eligible liquidity facility with an original maturity of one year or less to ABCP facilities that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules. Under the regulatory capital rules, the unused portion of commitments (facilities) which are unconditionally cancelable (without cause) at any time by the banking organization have a zero percent conversion factor. The unused portion of such commitments should be excluded from this item and included in line item 18.

Line item 17c Unused commitments: Original maturity exceeding one year

Report the total risk-weighted amount of the unused portion of the eligible liquidity facility with an original maturity exceeding one year that are subject to the risk-based capital rules, and do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules. Under the regulatory capital rules, the unused portion of commitments (facilities) which are unconditionally cancelable (without cause) at any time by the banking organization have a zero percent conversion factor. The unused portion of such commitments should be excluded from this item and included in line item 18.

Line item 18 Unconditionally cancelable commitment

Report the total risk-weighted amount unconditionally cancelable commitments that are subject to the regulatory capital rules that do not meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules. The unused portion of commitments (facilities) that are unconditionally cancelable (without cause) at any time by the banking organization have a zero percent conversion factor. The unused portion of such commitments should be reported in this item.

Line item 19 Over-the-counter derivatives

Report the total risk-weighted credit equivalent amount of over-the-counter derivative contracts covered by the regulatory capital rules. Include over-the-counter credit derivative contracts held for trading purposes and subject to the market risk capital rules. Do not include centrally cleared derivative contracts. Do not include over-the-counter credit derivative contracts that meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules.

Line item 20 Centrally cleared derivatives

Report the total risk-weighted credit equivalent amount of centrally cleared derivative contracts covered by the regulatory capital rules. Include centrally cleared credit derivative contracts held for trading purposes and subject to the market risk capital rules. Do not include over-the-counter derivative contracts. Do not include centrally cleared derivative contracts that meet the definition of a securitization exposure as described in 12 CFR 217.2 of the regulatory capital rules.

Line item 21 RWA for Assets, Derivatives and Off-Balance-Sheet Asset Categories

This item is a shaded cell and is derived from the sum of items 9 through 20.

Line item 22 RWA for purposes of calculating the allowance for loan and lease losses (ALLL) 1.25 percent threshold

For this item, follow the instructions of the FR Y-9C, Schedule HC-R, Part II, line 26.

Market Risk

Line items 23 through 38 are applicable only to BHCs that are subject to the market risk capital rule. If a BHC does not have a particular portfolio or no trading book at all, risk-weighted assets should be reported as 0.

Line item 23 Value-at-risk (VaR)-based capital requirement

Report the greater of previous day's VaR-based measure or average of daily VaR-based measure for each of the preceding 60 business days with applicable multiplication factor. VaR-based measure should be inclusive of all sources of risks that are included in the VaR calculation.

Line item 24 Stressed VaR-based capital requirement

Report the greater of most recent stressed VaR-based measure or average of weekly stressed VaR-based measures for the preceding 12 weeks with applicable multiplication factor. Stressed VaR-based measure should be inclusive of all sources of risks that are included in the stressed VaR calculation.

Line item 25 Incremental risk capital requirement

Report the greater of most recent increment risk measure or average of daily incremental risk measures for the preceding 12 weeks.

Line item 26 Comprehensive risk capital requirement

Report the greater of most recent comprehensive risk measure or average of daily comprehensive risk measures for the preceding 12 weeks. RWA equivalent for exposures in the correlation trading portfolio which are subject to the comprehensive risk measurement, inclusive of the application of the 8% surcharge based on the standardized measurement method.

Line item 27 Non-modeled securitization

This item is a shaded cell and is derived from the maximum of items 28 and 29. The capital charge (or RWA equivalent) for non-modeled traded securitization, including securitization positions that are not correlation trading positions and non-modeled correlation trading positions, is the larger of the next long and next short positions. For purposes of CCAR submissions, traded securitization exposures subject to a 1250% risk weight or the equivalent of a deduction should be captured here by including values in line 28 and 29.

Line item 28 Net Long

Report the RWA equivalent according to the standardized measurement method for net long non-modeled securitization exposures including nth-to-default credit derivatives. For purposes of CCAR submission, traded securitization exposures subject to a 1250% risk weight or the equivalent of a deduction should be included here.

Line item 29 Net Short

Report the RWA equivalent according to the standardized measurement method for net short non-modeled securitization exposures including nth-to-default credit derivatives. For purposes of CCAR submission, traded securitization exposures subject to a 1250% risk weight or the equivalent of a deduction should be included here.

Line item 30 Specific risk add-on (excluding securitization and correlation)

This item is a shaded cell and is derived from sum of items 31 through 36. RWA equivalent for specific risk based on the standardized measurement method as applicable. This should not include RWA according to the standardized measurement method for exposures included in the correlation trading portfolio or the standardized approach for other non-correlation related traded securitization exposures.

Line item 31 Sovereign debt positions

Report specific risk add-ons for sovereign debt positions for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 32 Government sponsored entity (GSE) debt positions

Report specific risk add-ons for GSE debt positions for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 33 Depository institution, foreign bank, and credit union debt positions

Report specific risk add-ons for depository institutions, foreign banking organization, and credit union debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 34 Public sector entity (PSE) debt positions

Report total specific risk add-on for PSE debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 35 Corporate debt positions

Report Specific risk add-on for corporate debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 36 Equity

Report specific risk add-on for equity positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 37 Capital requirement for de minimis exposures

Report the RWA equivalent for de minimis positions that are not captured in the VaR-based measure.

Line item 38 Market risk equivalent assets

This item is a shaded cell and is derived from the sum of items 23 through 27, 30 and 37.

Line item 39 Risk-weighted assets before deductions for excess allowance of loan and lease losses and allocated risk transfer risk reserve

This item is a shaded cell and is derived from the sum of items 21 and 38.

Line item 40 Less: Excess allowance for loan and lease losses

Report the amount, if any, by which the banking organization's allowance for loan and lease losses exceeds 1.25% of the banking organization's gross risk-weighted assets.

Line item 41 Less: Allocated transfer risk reserve

Report the entire amount of any allocated transfer risk reserve (ATRR) the reporting banking organization is required to establish and maintain as specified in Section 905(a) of the International Lending Supervision Act of 1983, in the agency regulations implementing the Act (Subpart D of Federal Reserve Regulation K, Part 347 of the FDIC's Rules and Regulations, and 12 CFR Part 28, Subpart C (OCC)), and in any guidelines, letters, or instructions issued by the agencies. The entire amount of the ATRR equals the ATRR related to loans and leases held for investment (which is reported in Schedule RI-B, part II, Memorandum item 1) plus the ATRR for assets other than loans and leases held for investment.

Line item 42 Total risk-weighted assets

This item is a shaded cell and is derived from item 39 minus the sum of items 40 and 41.

Line item 43 Memoranda Items – Derivatives

Report all memoranda items lines 44 through 48g.

Line item 44 Current credit exposure across all derivative contracts covered by the regulatory capital rules

Report the total current credit exposure amount for all interest rate, foreign exchange rate and gold, credit (investment grade reference assets), credit (non-investment grade reference assets), equity, precious metals (except gold), and other derivative contracts covered by the regulatory capital rules after considering applicable legally enforceable bilateral netting agreements. Banking organizations that are subject to Subpart F of the regulatory capital rules should exclude all covered positions subject to these guidelines, except for foreign exchange derivatives that are outside of the trading account. Foreign exchange derivatives that are outside of the trading account and all OTC derivatives continue to have a counterparty credit risk capital charge and, therefore, a current credit exposure amount for these derivatives should be reported in this item.

Line item 45 Notional principal amounts of over-the-counter derivative contracts

This item is a shaded cell and is derived from the sum of lines 46a through 46g.

Report in the appropriate sub-item the notional amount or par value of all OTC derivative contracts, including credit derivatives that are subject to the regulatory capital rules. Such contracts include swaps, forwards, and purchased options.

Line item 46a Interest rate

Report interest rate contracts that are subject to the regulatory capital rules.

Line item 46b Foreign exchange rate and gold

Report foreign exchange contracts and the remaining maturities of gold contracts that are subject to the regulatory capital rules.

Line item 46c Credit (investment grade reference asset)

Report credit derivative contracts where the reference entity meets the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

Line item 46d Credit (non-investment grade reference asset)

Report credit derivative contracts where the reference entity does not meet the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

Line item 46e Equity

Report equity derivative contracts that are subject to the regulatory capital rules.

Line item 46f Precious metals (except gold)

Report other precious metals contracts that are subject to the regulatory capital rules. Report all silver, platinum, and palladium contracts.

Line item 46g Other

Report other contracts that are subject to the regulatory capital rules. For contracts with multiple exchanges of principal, notional amount is determined by multiplying the contractual amount by the number of remaining payments (e.g., changes of principal) in the derivative contract.

Line item 47 Notional principal amounts of centrally cleared derivative contracts

This item is a shaded cell and is derived from the sum of lines 48a through 48g.

Report in the appropriate sub-item the notional amount or par value of all centrally cleared derivative contracts, including credit derivatives that are subject to the regulatory capital rules. Such contracts include swaps, forwards, and purchased options.

Line item 48a Interest rate

Report interest rate contracts that are subject to the regulatory capital rules.

Line item 48b Foreign exchange rate and gold

Report foreign exchange contracts and the remaining maturities of gold contracts that are subject to the regulatory capital rules.

Line item 48c Credit (investment grade reference asset)

Report credit derivative contracts where the reference entity meets the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

Line item 48d Credit (non-investment grade reference asset)

Report credit derivative contracts where the reference entity does not meet the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

Line item 48e Equity

Report equity derivative contracts that are subject to the regulatory capital rules.

Line item 48f Precious metals (except gold)

Report other precious metals contracts that are subject to the regulatory capital rules. Report all silver, platinum, and palladium contracts.

Line item 48g Other

Report other contracts that are subject to the regulatory capital rules. For contracts with multiple exchanges of principal, notional amount is determined by multiplying the contractual amount by the number of remaining payments (e.g., changes of principal) in the derivative contract.

A.1.c.3—Advanced RWA

Please note that for purposes of CCAR 2016, BHCs are NOT required to fill out the “Advanced RWA” sub-schedule.

BHCs subject to subpart E of the revised regulatory capital rule that have exited the parallel run process and that have received notification from its primary Federal supervisor under section 121(d) of the advanced approaches rule are required to complete the “Advanced RWA” sub-schedule.

MDRM codes have been included in the sub-schedule (column C) and correspond to the definitions for the FFIEC 101 line items where applicable.

BHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. However, if a BHC projects to meet the trading activity threshold that would require it to be subject to the market risk capital requirements during the forecast period, then the BHC should complete the market risk-weighted asset section within the sub-schedule. Please refer to the final market risk capital rule released by the U.S. banking agencies (77 Federal Register 53060, August 30, 2012) for details of the requirements of the rule.

Advanced Approaches Credit Risk (Including CCR and non-trading credit risk), with 1.06 scaling factor and Operational Risk

Line items 1 through 57: Advanced Approaches Credit Risk (Including CCR and non-trading credit risk), with 1.06 scaling factor and Operational Risk

Line item 1 Advanced Approaches Credit RWA

This item is a shaded cell and is derived from sum of items 2, 13, 20, 32 or 33, 47, 49, 50, and 55.

Line items 2 through 57 Various

Definition of the BHC’s projections should correlate to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report per the current advanced approaches capital rules (72 Federal Register 69288, December 7, 2007) .

Market Risk

If a BHC does not have a particular portfolio or no trading book at all, risk-weighted assets should be reported as 0.

For items 58 through 73, refer to instructions for items 12 through 30, respectively, for market risk under the “General RWA” sub-schedule.

Line item 74 Other RWA

If the BHC is unable to assign RWA to one of the above categories, even on a best-efforts basis, they should be reported in this line.

Line item 75 Excess eligible credit reserves not included in tier 2 capital

Include excess eligible credit reserves not included in tier 2 capital, consistent with the current

advanced approaches capital rules (72 Federal Register 69288, December 7, 2007).

Line item 76 Total RWA

This item is a shaded cell and is derived from sum of items 6, 61, 63, and 79 less item 80.

A.1.d—Capital

The Capital sub-schedules collect projections of the main drivers of equity capital and the key components of the regulatory capital schedule. MDRM codes are provided in the 'Notes' column for many of the line items.

All data collected in the Capital sub-schedule should be reported on a quarterly basis and not on a year-to-date, cumulative basis. Note that item 142, Total number of bank holding company common shares outstanding, and item 157, Common shares outstanding, should be reported in millions of shares.

All BHCs are required to provide projections of common equity tier 1 capital, tier 1 capital, and total capital based on the revised regulatory capital rule for all quarters.

Under the Board's capital plan and stress test rules, a BHC's calculations of pro forma regulatory capital ratios over the planning horizon shall not include estimates using the advanced approaches (See 12 CFR 225.8.(b)(3)(i), 12 CFR 252.43(d)(1), and 12 CFR 252.53(d)(1)). Accordingly, for actual and projected items on the FR Y-14A Summary Schedule Capital – CCAR and Capital – DFAST sub-schedules, BHCs should not use the advanced approaches. For example, in line 58, "All other deductions from (additions to) common equity tier 1 capital before threshold-based deductions," an advanced approaches BHC should not include expected credit losses that exceed the eligible credit reserves.

The projections should clearly show any proposed capital distributions or other scenario-dependent actions that would affect the BHC's regulatory capital, including any assumptions required under the Board's regulations.

SCHEDULE HI-A—CHANGES IN BANK HOLDING COMPANY EQUITY CAPITAL

Line items 1 through 17: ITEMS RELATED TO SCHEDULE HI-A—CHANGES IN BANK HOLDING COMPANY EQUITY CAPITAL

Line item 1 Total bank holding company equity capital most recently reported for the end of previous QUARTER

Report total bank holding company equity capital most recently reported for the end of previous quarter, as defined in the FR Y-9C, Schedule HI-A, item 1 (except FR Y-9C, Schedule HI-A, item 1, is reported for the end of the previous calendar year).

Line item 2 Effect of changes in accounting principles and corrections of material accounting errors

Report the effect of changes in accounting principles and corrections of material accounting errors, as defined in the FR Y-9C, Schedule HI-A, item 2.

Line item 3 Balance end of previous QUARTER as restated

Report the sum of items 1 and 2.

Line item 4 Net Income (loss) attributable to bank holding company

Report net income (loss) attributable to bank holding company, as defined in the FR Y-9C, Schedule HI-A, item 4.

Line item 5 Sale of perpetual preferred stock, gross

Report the sale of perpetual preferred stock, gross, as defined in the FR Y-9C, Schedule HI-A, item 5.a.

Line item 6 Conversion or retirement of perpetual preferred stock

Report the conversion or retirement of perpetual preferred stock, as defined in the FR Y-9C, Schedule HI-A, item 5.b.

Line item 7 Sale of common stock, gross

Report the sale of common stock, gross, as defined in the FR Y-9C, Schedule HI-A, item 6.a.

Line item 8 Conversion or retirement of common stock

Report the conversion or retirement of common stock, as defined in the FR Y-9C, Schedule HI-A, item 6.b. Note: increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, or common stock as a result of the actual issuance of common stock for the employee stock compensation should be captured in this line item.

Line item 9 Sale of treasury stock

Report the sale of treasury stock, as defined in the FR Y-9C, Schedule HI-A, item 7.

Line item 10 Purchase of treasury stock

Report the purchase of treasury stock, as defined in the FR Y-9C, Schedule HI-A, item 8.

Line item 11 Changes incident to business combinations, net

Report the changes incident to business combinations, net, as defined in the FR Y-9C, Schedule HI-A, item 9.

Line item 12 Cash dividends declared on preferred stock

Report cash dividends declared on preferred stock, as defined in the FR Y-9C, Schedule HI-A, item 10.

Line item 13 Cash dividends declared on common stock

Report cash dividends declared on common stock, as defined in the FR Y-9C, Schedule HI-A, item 11.

Line item 14 Other comprehensive income

Report other comprehensive income, as defined in the FR Y-9C, Schedule HI-A, item 12.

Line item 15 Change in the offsetting debit to the liability for Employee Stock Ownership Plan (ESOP) debt guaranteed by the bank holding company

Report the change in the offsetting debit to the liability for Employee Stock Ownership Plan (ESOP) debt guaranteed by the bank holding company, as defined in the FR Y-9C, Schedule HI-A, item 13.

Line item 16 Other adjustments to equity capital (not included above)

Report other adjustments to equity capital, not included above, as defined in the FR Y-9C, Schedule HI-A, item 14. Report amounts separately and provide a text explanation of each type of adjustment to equity capital included in this item in item Memoranda 1 (line 167) at the end of this sub-schedule. Note: increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation should not be captured in this line item, instead the impact should be captured in line items 7, 8, 9, and/or 10 as appropriate.

Line item 17 Total bank holding company equity capital end of current period

This item is a shaded cell and is derived from the sum of items 3, 4, 5, 6, 7, 8, 9, 11, 14, 15 and 16, less items 10, 12 and 13. Note that this item must equal FR Y-9C, Schedule HC, item 27a.

Please note that for purposes of CCAR 2016, respondents are NOT required to fill out the "General risk-based capital rules" items, as indicated in the line item instructions below.
SCHEDULE HC-R Part 1.A. Per General Risk-based Capital Rules (12 CFR 225, Appendix A)
Line items 18 through 41: **Respondents should not report items 18-41 for CCAR 2016.**

Tier 1 Capital

Line item 18 Total bank holding company equity capital Report the amount from item 17, above. **Do not report this item for CCAR 2016.**

Line item 19 Net unrealized gains (losses) on available-for-sale securities (if a gain, report as a positive value; if a loss, report as a negative value)

Report net unrealized gains (losses) on available-for-sale securities, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 2. If a gain, report as a positive value; if a loss, report as a negative value. **Do not report this item for CCAR 2016.**

Line item 20 Net unrealized loss on available-for-sale equity securities (report loss as a positive value)

Report net unrealized loss on available-for-sale equity securities, as defined in the FR Y-9C, Schedule HC-R, item 3, as well as the FFIEC 101 (Schedule A), item 3. Report the loss as a positive value. **Do not report this item for CCAR 2016.**

Line item 21 Accumulated net gains (losses) on cash flow hedges and amounts recorded in AOCI resulting from the initial and subsequent application of FASB ASC 715-20 (former FASB statement No. 158) to defined benefit postretirement plans (if a gain, report as a positive value; if a loss, report as a negative value)

Report accumulated net gains (losses) on cash flow hedges, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 4. Include amounts recorded in accumulated other comprehensive income (AOCI) resulting from the initial and subsequent application of FASB ASC 715-20 (former FASB statement No. 158) to defined benefit postretirement plans. If a gain, report as a positive value; if a loss, report

as a negative value. **Do not report this item for CCAR 2016.**

Line item 22 Nonqualifying perpetual preferred stock

Report nonqualifying perpetual preferred stock, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 5. **Do not report this item for CCAR 2016.**

Line item 23 Qualifying Class A noncontrolling (minority) interests in consolidated subsidiaries

Report qualifying Class A noncontrolling (minority) interests in consolidated subsidiaries, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 6.a. **Do not report this item for CCAR 2016.**

Line item 24 Qualifying restricted core capital elements (other than cumulative perpetual preferred stock)

Report qualifying restricted core capital elements (other than cumulative perpetual preferred stock), as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 6.b. **Do not report this item for CCAR 2016.**

Line item 25 Qualifying mandatory convertible preferred securities of internationally active bank holding companies

Report qualifying mandatory convertible preferred securities of internationally active bank holding companies, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 6.c. **Do not report this item for CCAR 2016.**

Line item 26 Disallowed goodwill and other disallowed intangible assets

Report disallowed goodwill and other disallowed intangible assets, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 7.a. **Do not report this item for CCAR 2016.**

Line item 27 Cumulative change in fair value of all financial liabilities accounted for under a fair value option that is included in retained earnings and is attributable to changes in the bank holding company's own creditworthiness (if a net gain, report as a positive value; if a net loss, report as a negative value)

Report the cumulative change in fair value of all financial liabilities accounted for under a fair value option that is included in retained earnings and is attributable to changes in the bank holding company's own creditworthiness, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 7.b. If a net gain, report as a positive value; if a net loss, report as a negative value. **Do not report this item for CCAR 2016.**

Line item 28 Subtotal

Report the sum of items 18, 23, 24 and 25, less items 19, 20, 21, 22, 26 and 27. **Do not report this item for CCAR 2016.**

Line item 29 Disallowed servicing assets and purchased credit card relationships

Report disallowed servicing assets and purchased credit card relationships, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 9.a. **Do not report this item for CCAR 2016.**

Line item 30 Disallowed deferred tax assets

Report disallowed deferred tax assets, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 9.b.

Do not report this item for CCAR 2016.

Line item 31 Other additions to (deductions from) tier 1 capital

Report other additions to (deductions from) tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 10. Report amounts separately and provide a text explanation of each type of addition to (deduction from) tier 1 capital included in this item in item Memoranda .2 (line 168) at the end of this sub-schedule. **Do not report this item for CCAR 2016.**

Line item 32 Tier 1 capital

Report the sum of items 28 and 31, less items 29 through 30. **Do not report this item for CCAR 2016.**

Tier 2 Capital

Line item 33 Qualifying subordinated debt, redeemable preferred stock, and restricted core capital elements (except Class B noncontrolling (minority) interest) not includable in items 24 or 25

Report the restricted core capital elements, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 12. **Do not report this item for CCAR 2016.**

Line item 34 Cumulative perpetual preferred stock included in item 22 and Class B noncontrolling (minority) interest not included in item 24, but includable in tier 2 capital

Report the appropriate tier 2 capital items as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 13. **Do not report this item for CCAR 2016.**

Line item 35 Allowance for loan and lease losses includable in tier 2 capital

Report the allowance for loan and lease losses includable in tier 2 capital as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 14. **Do not report this item for CCAR 2016.**

Line item 36 Unrealized gains on available-for-sale equity securities includable in tier 2 capital

Report the Unrealized gains on available-for-sale equity securities includable in tier 2 capital as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 15. **Do not report this item for CCAR 2016.**

Line item 37 Other Tier 2 capital components

Report the amount of any items that qualify for inclusion in Tier 2 capital, as defined in the FR Y-9C, Schedule HC-R, item 16. **Do not report this item for CCAR 2016.**

Line item 38 Tier 2 capital

This is a shaded cell that is the sum of items 33 through 37. **Do not report this item for CCAR 2016.**

Line item 39 Allowable tier 2 capital

This is a shaded cell that equals the lesser of item 32 or 38. **Do not report this item for CCAR 2016.**

Line item 40 Deductions for total risk-based capital

Report deductions for total risk based capital, as defined in the FR Y-9C, Schedule HC-R, Part I.A., item 20. **Do not report this item for CCAR 2016.**

Line item 41 Total risk-based capital

This is a shaded cell that is the sum of items 32 and 39, less item 40. **Do not report this item for CCAR 2016.**

Regulatory Capital per Revised Regulatory Capital Rule (July 2013)

All advanced approaches BHCs and opt-in BHCs must complete the following section. Where applicable, please reflect the transition provisions for the appropriate line item, per the 2013 revised regulatory capital rule.

Line item 42 AOCI opt-out election

A holding company that is not an advanced approaches holding company may make a one-time election to opt-out of the requirement to include most components of AOCI in common equity tier 1 capital (with the exception of accumulated net gains and losses on cash flow hedges related to items that are not recognized at fair value on the balance sheet). A holding company that makes an AOCI opt-out election must enter "1" for "Yes" in item 42. There are no transition provisions applicable to reporting line item 45, if a holding company makes an AOCI opt-out election.

A holding company (except an advanced approaches holding company) must make its AOCI opt-out election on the holding company's March 31, 2015 FR Y-9C report. For a holding company that comes into existence after March 31, 2015, the holding company must make its AOCI opt-out election on the holding company's first FR Y-9C report. After a holding company initially makes its AOCI opt-out election, the holding company must report its election in each Y-14A report thereafter. With prior notice to the Federal Reserve, a holding company resulting from a merger, acquisition, or purchase transaction may make a new AOCI opt-out election, as described in section 22(b)(2) of the revised regulatory capital rules.

Common Equity Tier 1**Line item 43 Common stock and related surplus, net of treasury stock and unearned employee stock ownership plan (ESOP) shares**

(1) Common stock: report the amount of common stock reported in FR Y-9C Schedule HC-R,, item 1, provided it meets the criteria for common equity tier 1 capital based on the revised regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital.

(2) PLUS: related surplus: adjust the amount reported in FR Y-9C Schedule HC-R, item 1 as follows: include the net amount formally transferred to the surplus account, including capital contributions, and any amount received for common stock in excess of its par or stated value on or before the report date; exclude adjustments arising from treasury stock transactions.

(3) LESS: treasury stock, unearned ESOP shares, and any other contra-equity components.

Line item 44 Retained earnings

Report the amount of the holding company's retained earnings as reported in FR Y-9C Schedule HC-R, item 2.

Line item 45 Accumulated other comprehensive income (AOCI)

Report the amount of AOCI as reported under generally accepted accounting principles (GAAP) in the U.S. that is included in FR Y-9C Schedule HC-R, item 3.

Line item 46 Common equity tier 1 minority interest includable in common equity tier 1 capital.

Report the aggregate amount of common equity tier 1 minority interest consistent with 12 CFR 217.21 of the revised regulatory capital rules. Common equity tier 1 minority interest means the common equity tier 1 capital of a depository institution or foreign bank that is a consolidated subsidiary of the holding company and that is not owned by the holding company. In addition, the capital instruments issued by the subsidiary must meet all of the criteria for common equity tier 1 capital (qualifying common equity tier 1 capital).

The minority interest limitations apply only to the consolidated subsidiaries that have common equity tier 1 capital in excess of capital necessary to meet the minimum capital requirements plus the capital conservation buffer. For example, a subsidiary with a common equity tier 1 capital ratio of 8 percent that needs to maintain a common equity tier 1 capital ratio of more than 7 percent to avoid limitations on capital distributions and discretionary bonus payments is considered to have "surplus" common equity tier 1 capital. Thus, at the consolidated level, the holding company may not include the portion of such surplus common equity tier 1 capital and is required to phase out this surplus minority interest.

Line item 47 Common equity tier 1 capital before adjustments and deductions

This item is a shaded cell and is derived from the sum of items 43 through 46.

Common equity tier 1 capital: adjustments and deductions(when applicable, report all items reflective of transition provisions)

Line item 48 Goodwill net of associated deferred tax liabilities (DTLs)

Report the amount of goodwill included in FR Y-9C Schedule HC-R, item 6.

However, if the holding company has a DTL that is specifically related to goodwill acquired in a taxable purchase business combination that it chooses to net against the goodwill, the amount of

disallowed goodwill to be reported in this item should be reduced by the amount of the associated DTL.

If a holding company has significant investments in the capital of unconsolidated financial institutions in the form of common stock, the holding company should report in this item goodwill embedded in the valuation of a significant investment in the capital of an unconsolidated financial institution in the form of common stock (embedded goodwill). Such deduction of embedded goodwill would apply to investments accounted for under the equity method. Under GAAP, if there is a difference between the initial cost basis of the investment and the amount of underlying equity in the net assets of the investee, the resulting difference should be accounted for as if the investee were a consolidated subsidiary (which may include imputed goodwill).

There are no transition provisions for this item.

Line item 49 Intangible assets (other than goodwill and mortgage servicing assets (MSAs)), net of associated DTLs

Report the amount included in FR Y-9C Schedule HC-R, item 7. Report all intangible assets (other than goodwill and MSAs) net of associated DTLs, included in FR Y-9C Schedule HC-M, items 12.b and 12.c, that do not qualify for inclusion in common equity tier 1 capital under the regulatory capital rules. Generally, all purchased credit card relationships (PCCRs) and non-mortgage servicing rights, reported in FR Y-9C Schedule HC-M, item 12.b, and all other identifiable intangibles, reported in FR Y-9C Schedule HC-M, item 12.c, do not qualify for inclusion in common equity tier 1 capital and should be included in this item.

Further, if the holding company has a DTL that is specifically related to an intangible asset (other than servicing assets and PCCRs) acquired in a nontaxable purchase business combination that it chooses to net against the intangible asset for regulatory capital purposes, the amount of disallowed intangibles to be reported in this item should be reduced by the amount of the associated DTL. However, a DTL that the holding company chooses to net against the related intangible reported in this item may not also be netted against DTAs when the holding company determines the amount of DTAs that are dependent upon future taxable income and calculates the maximum allowable amount of such DTAs for regulatory capital purposes.

If the amount reported for other identifiable intangible assets in FR Y-9C Schedule HC-M, item 12.c, includes intangible assets that were recorded on the reporting holding company's balance sheet on or before February 19, 1992, the remaining book value as of the report date of these intangible assets may be excluded from this item.

Line item 50 Deferred Tax Assets (DTAs) that arise from net operating loss and tax credit carryforwards, net of any related valuation allowances and net of DTLs

Report the amount of DTAs included in FR Y-9C Schedule HC-R, item 8, that arise from net operating loss and tax credit carryforwards, net of any related valuation allowances and net of DTLs.

AOCI-related adjustments

If Item 42 is “1” for “Yes”, complete items 51 through 55 only for AOCI related adjustments.

Line item 51: AOCI related adjustments: Net unrealized gains (losses) on available-for-sale securities

Report the amount of net unrealized holding gains (losses) on available-for-sale securities, net of applicable taxes, that is included in FR Y-9C Schedule HC-R, item 9a, “Accumulated other comprehensive income.” If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

Line item 52: AOCI related adjustments: Net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures

Report as a positive value net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures that is included in FR Y-9C Schedule HC-R, item 9b, “Accumulated other comprehensive income.”

Line item 53: AOCI related adjustments: Accumulated net gains (losses) on cash flow hedges

Report the amount of accumulated net gains (losses) on cash flow hedges that is included in FR Y-9C Schedule HC-R, item 9c, “Accumulated other comprehensive income.” If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

Line item 54: AOCI related adjustments: Amounts recorded in AOCI attributed to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans

Report the amounts recorded in AOCI and included in FR Y-9C Schedule HC-R, item 9d, “Accumulated other comprehensive income,” resulting from the initial and subsequent application of ASC Subtopic 715-20 (formerly FASB Statement No. 158, “Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans”) to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans. A holding company may exclude this portion related to pension assets deducted in the line item above. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

Line item 55: AOCI related adjustments: Net unrealized gains (losses) on held-to-maturity securities that are included in AOCI

Report the amount of net unrealized gains (losses) that are not credit-related on held-to-maturity securities and are included in AOCI as reported in FR Y-9C Schedule HC-R, item 9e, “Accumulated other comprehensive income.” If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

Include (i) the unamortized balance of the unrealized holding gain (loss) that existed at the date of transfer of a debt security transferred into the held-to-maturity category from the available-for-sale category and (ii) the unaccreted portion of other-than-temporary impairment losses on available-for-sale and held-to-maturity debt securities that was not recognized in earnings in accordance with ASC Topic 320, Investments-Debt and Equity Securities (formerly FASB Statement No. 115, “Accounting for Certain Investments in Debt and Equity Securities”).

If Item 42 is “0” for “No”, complete item 56 only for AOCI related adjustments.

Line item 56 Accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects, that relate to the hedging of items that are not recognized at fair value on the balance sheet

Report the amount of accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects that relate to the hedging of items not recognized at fair value on the balance sheet, as reported in FR Y-9C Schedule HC-R, item 9f. If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

Line item 57 Other deductions from (additions to) common equity tier 1 capital before threshold-based deductions: Unrealized net gain (loss) related to changes in the fair value of liabilities that are due to changes in own credit risk

Report the amount of unrealized net gain (loss) as reported in FR Y-9C Schedule HC-R, item 10a, prior to the 10% and 15% threshold deductions, related to changes in the fair value of liabilities that are due to changes in the holding company’s own credit risk. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item. Advanced approaches holding companies only: include the credit spread premium over the risk free rate for derivatives that are liabilities.

Line item 58 Other deductions from (additions to) common equity tier 1 capital before threshold-based deductions: All other deductions from (additions to) common equity tier 1 capital before threshold-based deductions

Report the amount of other deductions from (additions to) common equity tier 1 capital as reported in FR Y-9C Schedule HC-R, item 10b, that are not included in items above, as described below.

(1) After-tax gain-on-sale in connection with a securitization exposure.

Report the same amount as reported in the subcomponent of the FR Y-9C Schedule HC-R, item 10b. Include any after-tax gain-on-sale in connection with a securitization exposure. Gain-on-sale means an increase in the equity capital of a holding company resulting from a securitization (other than an increase in equity capital resulting from the holding company’s receipt of cash in connection with the securitization or reporting of a mortgage servicing asset on FR Y-9C Schedule HC).

(2) Defined benefit pension fund assets, net of associated DTLs.

Report the same amount as reported in the subcomponent of the FR Y-9C Schedule HC-R, item 10b. A holding company must deduct defined benefit pension fund assets, net of associated DTLs, held by a holding company. With the prior approval of the Federal Reserve, this deduction is not required for any defined benefit pension fund net asset to the extent the holding company has unrestricted and unfettered access to the assets in that fund. For an insured depository institution, no deduction is required.

A holding company must risk weight any portion of the defined benefit pension fund asset

that is not deducted as if the holding company directly holds a proportional ownership share of each exposure in the defined benefit pension fund.

(3) Investments in the holding company's own shares to the extent not excluded as part of treasury stock.

Report the same amount as reported in the subcomponent of the FR Y-9C Schedule HC-R, item 10b. Include the holding company's investments in (including any contractual obligation to purchase) its own common stock instruments, including direct, indirect, and synthetic exposures to such instruments (as defined in the revised regulatory capital rules), to the extent such instruments are not excluded as part of treasury stock. If a holding company already deducts its investment in its own shares (for example, treasury stock) from its common equity tier 1 capital elements, it does not need to make such deduction twice.

A holding company may deduct gross long positions net of short positions in the same underlying instrument only if the short positions involve no counterparty credit risk. The holding company must look through any holdings of index securities to deduct investments in its own capital instruments.

In addition:

- (i) Gross long positions in investments in a holding company's own regulatory capital instruments resulting from holdings of index securities may be netted against short positions in the same underlying index;
- (ii) Short positions in index securities that are hedging long cash or synthetic positions may be decomposed to recognize the hedge; and
- (iii) The portion of the index that is composed of the same underlying exposure that is being hedged may be used to offset the long position if both the exposure being hedged and the short position in the index are covered positions under the market risk capital rule, and the hedge is deemed effective by the holding company's internal control processes which would have been assessed by the Federal Reserve.

(4) Reciprocal cross-holdings in the capital of financial institutions in the form of common stock.

Report the same amount as reported in the subcomponent of the FR Y-9C Schedule HC-R, item 10b. Include investments in the capital of other financial institutions (in the form of common stock) that the holding company holds reciprocally (this is the corresponding deduction approach). Such reciprocal crossholdings may result from a formal or informal arrangement to swap, exchange, or otherwise intend to hold each other's capital instruments.

(5) Advanced approaches holding companies only that exit parallel run.⁷

⁷ An advanced approaches holding company that exit the parallel run is an advanced approaches holding company that has completed the parallel run process and received notification from the Federal Reserve pursuant to section 121(d) of subpart E of the revised regulatory capital rules.

Report the same amount as reported in the subcomponent of the FR Y-9C Schedule HC-R, item 10b. Include the amount of expected credit loss that exceeds the eligible credit reserves.

Line item 59 Non-significant investments in the capital of unconsolidated financial institutions in the form of common stock that exceed the 10 percent threshold for non-significant investments

Report the same amount as reported in the FR Y-9C Schedule HC-R, Part I.B., item 11. A holding company has a non-significant investment in the capital of an unconsolidated financial institution (as defined in section 217.2 of the revised regulatory capital rules) if it owns 10 percent or less of the issued and outstanding common shares of that institution.

Report the amount of non-significant investments in the capital of unconsolidated financial institutions in the form of common stock that, in the aggregate, exceed the 10 percent threshold for non-significant investments, calculated as described below. The holding company may apply associated DTLs to this deduction.

Line item 60 Subtotal (item 47 minus items 48 through 59)

This item is a shaded cell and is derived from item 47 minus items 48 through 59.

Line item 61 Significant investments in the capital of unconsolidated financial institutions in the form of common stock, net of associated DTLs, that exceed 10 percent common equity tier 1 capital deduction threshold

This item should be derived from line item 92, reflective of any applicable transition provisions, and should correspond to what is reported in FR Y-9C Schedule HC-R, item 13..

A holding company has a significant investment in the capital of an unconsolidated financial institution when it owns more than 10 percent of the issued and outstanding common shares of that institution.

Report the amount of significant investments in the capital of unconsolidated financial institutions in the form of common stock that exceed the 10 percent common equity tier 1 capital deduction threshold, calculated as follows:

- (1) Determine the amount of significant investments in the capital of unconsolidated financial institutions in the form of common stock.
- (2) If the amount in (1) is greater than 10 percent of the amount of the subtotal in item 60, report the difference as this line item.
- (3) If the amount in (2) is less than 10 percent of the amount of the subtotal in item 60, report zero.

If the holding company included embedded goodwill in item 48, to avoid double counting, the holding company may net such embedded goodwill already deducted against the exposure amount of the significant investment. For example, if a holding company has deducted \$10 of goodwill embedded in a \$100 significant investment in the capital of an unconsolidated financial institution in the form of common stock, the holding company is allowed to net such embedded goodwill against the exposure amount of such significant investment (that is, the value of the investment is

\$90 for purposes of the calculation of the amount that is subject to deduction).

Line item 62 MSAs, net of associated DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold

This item should be derived from line item 97, reflective of any applicable transition provisions, and should correspond to what is reported in FR Y-9C Schedule HC-R, Part I.B., item 14.

Report the amount of MSAs included in FR Y-9C Schedule HC-M, item 12(a), net of associated DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold as follows:

- (1) Take the amount of MSAs as reported in FR Y-9C Schedule HC-M, item 12(a), net of associated DTLs.
- (2) If the amount in (1) is higher than 10 percent of the amount of the subtotal in item 60, report the difference as this line item.
- (3) If the amount in (1) is lower than 10 percent of the amount of the subtotal in item 60, enter zero.

Line item 63 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold

This item should be derived from line item 100, reflective of any applicable transition provisions, and should correspond to what is reported in FR Y-9C Schedule HC-R, item 15.

- (1) Report the amount of DTAs arising from temporary differences that the holding company could not realize through net operating loss carrybacks net of any related valuation allowances and net of associated DTLs (for example, DTAs resulting from the holding company's ALLL).
- (2) If the amount in (1) is higher than 10 percent of the amount the subtotal in item 60, report the difference as this line item.
- (3) If the amount in (1) is lower than 10 percent of the amount of the subtotal in item 60, enter zero.

DTAs arising from temporary differences that could be realized through net operating loss carrybacks are not subject to deduction, and instead must be assigned a 100 percent risk weight.

Line item 64 Amount of significant investments in the capital of unconsolidated financial institutions in the form of common stock; MSAs, net of associated DTLs; and DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs; that exceeds the 15 percent common equity tier 1 capital deduction threshold

This item should be derived from line item 105, reflective of any applicable transition provisions, and should correspond to what is reported in FR Y-9C Schedule HC-R, item 16.

The aggregate amount of the threshold items (that is, significant investments in the capital of unconsolidated financial institutions in the form of common stock; MSAs, net of associated DTLs; and DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs) may not exceed 15 percent of the

holding company's common equity tier 1 capital, net of applicable adjustments and deductions (the 15 percent common equity tier 1 capital deduction threshold).

Line item 65 Deductions applied to common equity tier 1 capital due to insufficient amount of additional tier 1 capital and tier 2 capital to cover deductions

Report the total amount of deductions as reported in FR Y-9C Schedule HC-R, item 17, related to reciprocal cross holdings, non-significant investments in the capital of unconsolidated financial institutions, and non-common stock significant investments in the capital of unconsolidated financial institutions if the holding company does not have a sufficient amount of additional tier 1 capital and tier 2 capital to cover these corresponding additional tier 1 and tier 2 deductions in items 72 and 83.

Line item 66 Total adjustments and deductions for common equity tier 1 capital

This item is a shaded cell that is derived from the sum of items 61 through 65.

Line item 67 Common equity tier 1 capital

This item is the numerator of the holding company's common equity tier 1 risk-based capital ratio, which should align with HC-R, item 19. It is an embedded formula.

Additional tier 1 capital

Line item 68 Additional tier 1 capital instruments plus related surplus

Report this item as consistent with the FR Y-9C Schedule HC-R, item 20. Starting on January 1, 2014 for advanced approaches holding companies and on January 1, 2015 for non-advanced holding companies, report the portion of noncumulative perpetual preferred stock and related surplus included in FR Y-9C Schedule HC, item 23, that satisfy all the criteria for additional tier 1 capital in the revised regulatory capital rules of the Federal Reserve.

Include instruments that were (i) issued under the Small Business Job's Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 1 capital under the Federal Reserve's general risk-based capital rules (12 CFR part 225, appendix A, and, if applicable, appendix E) (for example, tier 1 instruments issued under the TARP program that are grandfathered permanently). Also include additional tier 1 capital instruments issued as part of an ESOP, provided that the repurchase of such instruments is required solely by virtue of ERISA for a banking organization that is not publicly-traded.

Line item 69 Non-qualifying capital instruments subject to phase out from additional tier 1 capital

Report this item as consistent with the FR Y-9C Schedule HC-R, item 21, subject to the applicable phase-out schedule as described within the Y-9C. Starting on January 1, 2014 for advanced approaches holding companies and on January 1, 2015 for non-advanced holding companies, report the total amount of non-qualifying capital instruments that were included in tier 1 capital and outstanding as of January 1, 2014 according to the following criteria:

Depository institution holding companies with total consolidated assets of \$15 billion or more as of December 31, 2009 that are not 2010 MHCs must phase out non-qualifying capital instruments (that

is, debt or equity instruments that do not meet the criteria for additional tier 1 or tier 2 capital instruments in section 217.20 of the revised regulatory capital rules, but that were issued and included in tier 1 or tier 2 capital, respectively, prior to May 19, 2010).

If non-advanced approaches holding companies have non-qualifying capital instruments that are excluded from tier 1 capital, such non-qualifying capital instruments can be included in tier 2 capital, without limitation, provided the instruments meet the criteria for tier 2 capital set forth in section 217.20(d) of the revised regulatory capital rules.

For the case of advanced approaches holding companies, non-qualifying capital instruments that are phased out of tier 1 capital are fully includable in tier 2 capital until December 31, 2015. From January 1, 2016, until December 31, 2021, these holding companies are required to phase out such non-qualifying capital instruments from tier 2 capital.

Line item 70 Tier 1 minority interest not included in common equity tier 1 capital

Report this item as consistent with the FR Y-9C Schedule HC-R, item 22 – include the amount of tier 1 minority interest that is applicable at the consolidated level, as described below.

For each consolidated subsidiary, perform the calculations in steps (1) through (10) as laid out in the HC-R. Sum up the results from step 10 for each consolidated subsidiary and report the aggregate number in this item.

For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to tier 1 minority interest must meet all the criteria for either common equity tier 1 capital or additional tier 1 capital instrument.

Line item 71 Additional tier 1 capital before deductions

This captures the total of items 68 through 70.

Line item 72 Additional tier 1 capital deductions

Report this item as consistent with the FR Y-9C Schedule HC-R, item 24, including all applicable transition provisions. Report additional tier 1 capital deductions as the sum of the following elements:

a. Investments in own additional tier 1 capital instruments

Report the holding company's investments in (including any contractual obligation to purchase) its own additional tier 1 instruments, whether held directly or indirectly.

A holding company may deduct gross long positions net of short positions in the same underlying instrument only if the short positions involve no counterparty risk.

The holding company must look through any holdings of index securities to deduct investments in its own capital instruments. In addition:

- (i) Gross long positions in investments in a holding company's own regulatory capital instruments resulting from holdings of index securities may be netted against short

- positions in the same index;
- (ii) Short positions in index securities that are hedging long cash or synthetic positions can be decomposed to recognize the hedge; and
 - (iii) The portion of the index that is composed of the same underlying exposure that is being hedged may be used to offset the long position if both the exposure being hedged and the short position in the index are covered positions under the market risk capital rule, and the hedge is deemed effective by the holding company's internal control processes.

b. Reciprocal cross-holdings in the capital of financial institutions

Include investments in the additional tier 1 capital instruments of other financial institutions that the holding company holds reciprocally, where such reciprocal crossholdings result from a formal or informal arrangement to swap, exchange, or otherwise intend to hold each other's capital instruments. If the holding company does not have a sufficient amount of a specific component of capital to effect the required deduction, the shortfall must be deducted from the next higher (that is, more subordinated) component of regulatory capital.

For example, if a holding company is required to deduct a certain amount from additional tier 1 capital and it does not have additional tier 1 capital, then the deduction should be from common equity tier 1 capital.

c. Non-significant investments in additional tier 1 capital of unconsolidated financial institutions that exceed the 10 percent threshold for non-significant investments

An institution has a non-significant investment in the capital of an unconsolidated financial institution if it owns 10 percent or less of the issued and outstanding common shares of that institution.

Calculate this amount as follows:

- (1) Determine the aggregate amount of non-significant investments in the capital of unconsolidated financial institutions in the form of common stock, additional tier 1, and tier 2 capital.
- (2) Determine the amount of non-significant investments in the capital of unconsolidated financial institutions in the form of additional tier 1 capital.
- (3) If the amount in (1) is greater than the 10 percent threshold for non-significant investments, then multiply the difference by the ratio of (2) over (1). Report this product in this line item.
- (4) If the amount in (1) is less than the 10 percent threshold for non-significant investments, report zero.

d. Significant investments in the capital of unconsolidated financial institutions not in the form of common stock to be deducted from additional tier 1 capital

Report the total amount of significant investments in the capital of unconsolidated financial institutions in the form of additional tier 1 capital.

e. Other adjustments and deductions

Include adjustments and deductions applied to additional tier 1 capital due to insufficient tier 2 capital to cover deductions (related to reciprocal cross holdings, non-significant investments in the tier 2 capital of unconsolidated financial institutions, and significant investments in the tier 2 capital of unconsolidated financial institutions). Also include adjustments and deductions related to the calculation of DTAs, gain-on-sale, defined benefit pension fund assets, changes in fair value of liabilities due to changes in own credit risk, and expected credit losses during the transition period as applicable.

Line item 73 Additional tier 1 capital

Report this item as consistent with the FR Y-9C Schedule HC-R, Part I.B., item 25.

Tier 1 capital

Line item 74 Tier 1 capital (sum of items 67 and 73)

Item 74 is a shaded cell and is derived from the sum of items 67 and 73 and should be consistent with the FR Y-9C Schedule HC-R, item 26.T

Tier 2 capital

Line item 75 Tier 2 capital instruments plus related surplus

Report the amount consistent with the FR Y-9C Schedule HC-R, item 27. Starting on January 1, 2014 for advanced approaches holding companies and on January 1, 2015 for non-advanced holding companies, report tier 2 capital instruments that satisfy all eligibility criteria under the revised regulatory capital rules and related surplus.

Include instruments that were (i) issued under the Small Business Job's Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital under the Federal Reserve's general risk-based capital rules.

Line item 76 Non-qualifying capital instruments subject to phase out from tier 2 capital

Report the total amount of non-qualifying capital instruments that were included in tier 2 capital and outstanding as of January 1, 2014, and will be subject to phaseout, consistent with the FR Y-9C Schedule HC-R, item 28.

Line item 77 Total Capital minority interest that is now included in tier 1 capital

Report the amount of total capital minority interest that is includable at the consolidated level, as described below, consistent with the FR Y-9C Schedule HC-R, item 29. For each consolidated subsidiary, perform the calculations in steps (1) through (10) outlined within the Y-9C. Sum up the results for each consolidated subsidiary and report the aggregate number in this item.D

Line item 78 Allowance for loan and lease losses includable in tier 2 capital

Report the portion of the holding company's allowance for loan and lease losses that are includable in tier 2 capital, consistent with the FR Y-9C Schedule HC-R, item 30a. None of the holding company's allocated transfer risk reserve, if any, is includable in tier 2 capital.

Line item 79 (Advanced approaches holding companies that exit parallel run only): eligible credit reserves includable in tier 2 capital

BHCs do not have to report this field.

Line item 80 Unrealized gains on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures includable in tier 2 capital

(i) Holding companies that entered "1" for "Yes" in item 42:

Report the pretax net unrealized holding gain (i.e., the excess of fair value as reported in FR Y-9C Schedule HC-B, item 7, column D, over historical cost as reported in FR Y-9C Schedule HC-B, item 7, column C), if any, on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures includable in tier 2 capital, subject to the limits specified in the revised regulatory capital rules. The amount reported in this item cannot exceed 45 percent of the holding company's pretax net unrealized gain on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures.

(ii) Holding companies that entered "0" for "No" in item 42:

Do not apply any transition provision multiplier for this item.

Line item 81 Tier 2 capital before deductions

This item is a shaded cell that is derived from the sum of items 75, 76, 77, 78 and 80.

Line item 82 (Advanced approaches holding companies that exit parallel run only): Tier 2 capital before deductions, reflective of transition procedures

BHCs do not have to report this field.

Line item 83 Tier 2 capital deductions

Report total tier 2 capital deductions from FR Y-9C Schedule HC-R, item 33, as the sum of the following elements:

If a holding company does not have a sufficient amount of tier 2 capital to reflect these deductions, then the holding company must deduct the shortfall from additional tier 1 capital or, if there is not enough additional tier 1 capital, from common equity tier 1 capital.

In addition, advanced approaches holding companies with insufficient tier 2 capital for deductions will make the following adjustments: an advanced approaches holding company will make deductions on this schedule under the generally applicable rules that apply to all banking organizations. It will use FFIEC 101, Schedule A, to calculate its capital requirements under the advanced approaches. Therefore, in the case of an advanced approaches holding company with insufficient tier 2 capital to make tier 2 deductions, it will use the corresponding deduction approach and the generally applicable rules to take excess tier 2 deductions from additional tier 1 capital, and if necessary from common equity tier 1. It will use the advanced approaches rules to take deductions on the FFIEC 101 form.

a. Investments in own additional tier 2 capital instruments.

Report the holding company's investments in (including any contractual obligation to purchase) its own tier 2 instruments, whether held directly or indirectly.

A holding company may deduct gross long positions net of short positions in the same underlying instrument only if the short positions involve no counterparty risk.

The holding company must look through any holdings of index securities to deduct investments in its own capital instruments. In addition:

- (i) Gross long positions in investments in a holding company's own regulatory capital instruments resulting from holdings of index securities may be netted against short positions in the same index;
- (ii) Short positions in index securities that are hedging long cash or synthetic positions can be decomposed to recognize the hedge; and
- (iii) The portion of the index that is composed of the same underlying exposure that is being hedged may be used to offset the long position if both the exposure being hedged and the short position in the index are covered positions under the market risk capital rule, and the hedge is deemed effective by the holding company's internal control processes.

b. Reciprocal cross-holdings in the capital of financial institutions.

Include investments in the tier 2 capital instruments of other financial institutions that the holding company holds reciprocally, where such reciprocal crossholdings result from a formal or informal arrangement to swap, exchange, or otherwise intend to hold each other's capital instruments.

c. Non-significant investments in tier 2 capital of unconsolidated financial institutions that exceed the 10 percent threshold for non-significant investments.

Calculate this amount as follows:

- (1) Determine the aggregate amount of non-significant investments in the capital of unconsolidated financial institutions in the form of common stock, additional tier 1, and tier 2 capital.
- (2) Determine the amount of non-significant investments in the capital of unconsolidated financial institutions in the form of tier 2 capital.
- (3) If (1) is greater than the 10 percent threshold for non-significant investments, then, multiply the difference by the ratio of (2) over (1). Report this product in this line item.
- (4) If (1) is less than the 10 percent threshold for non-significant investments, enter zero.

d. Significant investments in the capital of unconsolidated financial institutions not in the form of common stock to be deducted from tier 2 capital.

Report the total amount of significant investments in the capital of unconsolidated financial institutions in the form of tier 2 capital.

e. Other adjustments and deductions.

Include any other applicable adjustments and deductions applied to tier 2 capital in accordance with the revised regulatory capital rules.

Line item 84 Tier 2 capital

This item is a shaded cell that is derived from item 81 minus item 83.

Line item 85 (Advanced approaches holding companies that exit parallel run): Tier 2 capital,

reflective of transition provisions

BHCs are not required to complete this field.

Total Capital

Line item 86 Total capital

This item is a shaded cell that is derived from the sum of items 74 and 84.

Line item 87 (Advanced approaches holding companies that exit parallel run only): Total capital, reflective of transition provisions (sum of items 74 and 85)

BHCs are not required to complete this field.

10%/15% Threshold Deductions Calculations

Significant Investments in the capital of unconsolidated financial institutions in the form of common stock, net of associated DTLs

Line item 88 Gross significant investments in the capital of unconsolidated financial institutions in the form of common stock

Aggregate holdings of capital instruments relevant to significant investments in the capital of unconsolidated financial entities, including direct, indirect and synthetic holdings in both the banking book and trading book.

Line item 89 Permitted offsetting short positions in relation to the specific gross holdings included above

Offsetting positions in the same underlying exposure where the maturity of the short position either matches the maturity of the long position or has a residual maturity of at least one year.

Line item 90 Significant investments in the capital of unconsolidated financial institutions in the form of common stock net of short positions

This item is a shaded cell and is the greater of item 88 minus item 89 or zero.

Line item 91 10 percent common equity tier 1 deduction threshold

This item is a shaded cell and is derived from item 60

Line item 92 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold

This item is a shaded cell and is the greater of item 90 minus item 91 or zero.

MSAs, net of associated DTLs

Line item 93 Total mortgage servicing assets classified as intangible

Report the amount of MSAs included in Schedule HC-M, item 12(a), prior to any netting of associated DTLs.

Line item 94 Associated deferred tax liabilities which would be extinguished if the

intangible becomes impaired or derecognized under the relevant accounting standards

The amount of mortgage servicing assets to be deducted from common equity tier 1 is to be offset by any associated deferred tax liabilities, with recognition capped at 10% of the bank's common equity tier 1 (after the application of all regulatory adjustments). If the bank chooses to net its deferred tax liabilities associated with mortgage servicing assets against deferred tax assets (in Line 17 of the Capital Composition sub-schedule), those deferred tax liabilities should not be deducted again here.

Line item 95 Mortgage servicing assets net of related deferred tax liabilities

This item is a shaded cell and is derived from items 93 and 94.

Line item 96 10 percent common equity tier 1 deduction threshold

This item is a shaded cell and is derived from item 60.

Line item 97 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold

This item is a shaded cell and is derived from items 95 and 96.

DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs

Line item 98 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs

The amount of DTAs arising from temporary differences that the holding company could not realize through net operating loss carrybacks net of any related valuation allowances and net of associated DTLs.

Line item 99 10 percent common equity tier 1 deduction threshold

This item is a shaded cell and is derived from item 160.

Line item 100 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold

This item is a shaded cell and is derived from items 98 and 99.

Aggregate of items subject to the 15% limit (significant investments, mortgage servicing assets and deferred tax assets arising from temporary differences)

Line item 101 Sum of items 90, 95, and 98

This item is a shaded cell and is derived from items 90, 95, and 98.

Line item 102 15 percent common equity tier 1 deduction threshold

This item is a shaded cell and is derived from item 60.

Line item 103 Sum of items 92, 97, and 100

This item is a shaded cell and is derived from items 92, 97, and 100.

Line item 104 Item 101 minus item 103

This item is a shaded cell and is derived from items 101 minus item 103.

Line item 105 Amount to be deducted from common equity tier 1 due to 15 percent deduction threshold, prior to transition provision (greater of item 104 minus item 102 or zero)

This item is a shaded cell and is derived from items 102 and 104.

Total Assets for the Leverage Ratio (12 CFR 217)

Line item 106 Average total consolidated assets

Report the amount of average total consolidated assets as reported in FR Y-9C, HC-R item 36.

Line item 107 Deductions from common equity tier 1 capital and additional tier 1 capital

This corresponds to the FR Y-9C Schedule HC-R item 37.

Line item 108 Other deductions from (additions to) assets for leverage ratio purposes

Based on the revised regulatory capital rules, report the amount of any deductions from (additions to) total assets for leverage capital purposes that are not included in Item 107. If the amount is a net deduction, report it as a positive value in this item. If the amount is a net addition, report it as a negative value in this item.

Line item 109 Total assets for the leverage ratio (item 106 minus items 107 and 108)

This item captures FR Y-9C HC-R item 39.

REGULATORY CAPITAL AND RATIOS

Line item 110 Tier 1 Common Capital For all quarters, BHCs are required to provide projections of tier 1 common capital, which is defined as tier 1 capital less non-common elements⁸, including perpetual preferred stock and related surplus, minority interest in subsidiaries, trust preferred securities, and mandatory convertible preferred securities **Do not report for CCAR 2016.**

Line item 111 Common Equity Tier 1

This item is a shaded cell and is derived from item 67.

Line item 112 Tier 1 Capital

This item is a shaded cell and is derived from item 32. **Do not report for CCAR 2016.**

Line item 113 Tier 1 Capital

This item is a shaded cell and is derived from item 74.

⁸ Non-common elements should include the following items captured in the September 30, 2013 FR Y-9C: Schedule HC, line item 23 net of Schedule HC-R, line item 5; and Schedule HC-R, line items 6a, 6b, and 6c.

Line item 114 Total Capital

This item is a shaded cell and is derived from item 41. **Do not report for CCAR 2016.**

Line item 115 Total Capital

This item is a shaded cell and is derived from item 86.

Line item 116 Total Capital (advanced approaches institutions that exit parallel run only)

Respondents are not required to complete this field.

Line item 117 Total risk-weighted assets using general risk-based capital rules; reflective of Tier 1 common capital deductions and adjustments

This item should equal the amount of total RWA, reflective of Tier 1 common capital adjustments, that is reported under the FR Y-14A, General RWA worksheet, for all BHCs for all quarters. **Do not report for CCAR 2016.**

Line item 118 Total risk-weighted assets using standardized approach

For all BHCs from 1Q15 onwards, please report the total amount of Standardized RWA, as reported under the Standardized RWA worksheet of the FR Y-14A Summary.

Line item 119 (Advanced approaches holding companies that exit parallel run only): total risk-weighted assets using advanced approaches rules

BHCs are not required to fill out this item.

Line item 120 Total Assets for the Leverage Ratio per revised regulatory capital rule

This is derived from line 109 and corresponds to the FR Y-9C, Schedule HC-R, item 39.

Line item 121 Tier 1 Common Ratio (%) (based upon generally applicable risk weighted assets)

This item is derived from item 110 divided by 117. **Do not report for CCAR 2016.**

Line item 122 Common Equity Tier 1 Ratio (%)

This item is derived from item 111 divided by 117 or 118.

Line item 123 Common Equity Tier 1 Ratio (%) (advanced approaches institutions that exit parallel run only)

BHCs are not required to fill out this item.

Line item 124 Tier 1 Capital Ratio (%)

This item is derived from item 112 or 113 divided by 117 or 118.

Line item 125 Tier 1 Capital Ratio (%) (advanced approaches institutions that exit parallel run only)

BHCs are not required to fill out this item.

Line item 126 Total risk-based capital ratio (%)

This item is derived from item 114 or 115 divided by 117 or 118.

Line item 127 Total risk-based capital ratio (%) (advanced approaches institutions that exit parallel run only)

BHCs are not required to fill out this item.

Line item 128 Tier 1 Leverage Ratio (%)

This item is derived from item 112 or 113 divided by 120.

Please note that for purposes of CCAR 2016, respondents are NOT required to fill out the "general risk-based capital rules" items, as indicated below.

Schedule HC-R — Memoranda (Section only applicable under the general risk-based capital rules)

Preferred stock (including related surplus) eligible for inclusion in Tier 1 capital:

Line item 129 Noncumulative perpetual preferred stock

Report noncumulative perpetual preferred stock, as defined in the FR Y-9C, Schedule HC-R, Memoranda item 3.a. **Do not report for CCAR 2016.**

Line item 130 Other noncumulative preferred stock eligible for inclusion in tier 1 capital (e.g., REIT preferred securities)

Report other noncumulative preferred stock eligible for inclusion in tier 1 capital (e.g., REIT preferred securities), as defined in the FR Y-9C, Schedule HC-R, Memoranda item 3.c. **Do not report for CCAR 2016.**

Line item 131 Other cumulative preferred stock eligible for inclusion in tier 1 capital (excluding TruPS)

Report other cumulative preferred stock eligible for inclusion in tier 1 capital (excluding trust preferred securities (TruPS)), as defined in the FR Y-9C, Schedule HC-R, Memoranda item 3.d. **Do not report for CCAR 2016.**

Treasury stock (including offsetting debit to the liability for ESOP debt):

Line item 132 In the form of perpetual preferred stock

Report Treasury stock in the form of perpetual preferred stock (including the offsetting debit to the liability for ESOP debt), as defined in the FR Y-9C, Schedule HC-R, Memoranda item 5.a. **Do not report for CCAR 2016.**

Line item 133 In the form of common stock

Report Treasury stock in the form of common stock (including the offsetting debit to the liability for ESOP debt), as defined in the FR Y-9C, Schedule HC-R, Memoranda item 5.b. **Do not report for CCAR 2016.**

Restricted core capital elements included in Tier 1 capital:

Line item 134 Qualifying Class B noncontrolling (minority) interest

Report all qualifying Class B noncontrolling (minority) interest, as defined in the FR Y-9C, Schedule HC-R, Memoranda item 8.a. **Do not report for CCAR 2016.**

Line item 135 Qualifying Class C noncontrolling (minority) interest

Report all qualifying Class C noncontrolling (minority) interest, as defined in the FR Y-9C, Schedule HC-R, Memoranda item 8.b. **Do not report for CCAR 2016.**

Line item 136 Qualifying cumulative perpetual preferred stock

Report all qualifying cumulative perpetual preferred stock, as defined in the FR Y-9C, Schedule HC-R, Memoranda item 8.c. **Do not report for CCAR 2016.**

Line item 137 Qualifying TruPS

Report all qualifying trust preferred securities (TruPS), as defined in the FR Y-9C, Schedule HC-R, Memoranda item 8.d. **Do not report for CCAR 2016.**

Line item 138 Goodwill net of any associated deferred tax liability

Report goodwill net of any associated deferred tax liability, as defined in the FR Y-9C, Schedule HC-R, Memoranda item 9. **Do not report for CCAR 2016.**

Line item 139 Is the bank holding company internationally active for purposes of the qualifying restricted core capital limit tests?

Report "Yes" or "No". An internationally active BHC is a BHC that (1) as of the most recent year-end estimates total consolidated assets equal to \$250 billion or more or (2) on a consolidated basis, as of the most recent year-end estimates total on-balance-sheet foreign exposure of \$10 billion or more. **Do not report for CCAR 2016.**

Schedule HC-F—Other Assets

Line item 140 Net deferred tax assets

Report net deferred tax assets, as defined in the FR Y-9C, Schedule HC-F, item 2.

Schedule HC-G—Other Liabilities

Line item 141 Net deferred tax liabilities

Report net deferred tax liabilities, as defined in the FR Y-9C, Schedule HC-G, item 2.

Schedule HC-M—Memoranda

Line item 142 Total number of bank holding company common shares outstanding

Report the total number (in millions) of bank holding company common shares outstanding, as defined in the FR Y-9C, Schedule HC-M, item 1.

Issuances associated with the U.S. Department of Treasury Capital Purchase Program

Line item 143 Senior perpetual preferred stock or similar items

Report issuances of senior perpetual preferred stock or similar items associated with the U.S. Department of Treasury capital purchase program, as defined in the FR Y-9C, Schedule HC-M, item 24.a.

Line item 144 Warrants to purchase common stock or similar items

Report issuances of warrants to purchase common stock or similar items associated with the U.S. Department of Treasury capital purchase program, as defined in the FR Y-9C, Schedule HC-M, item 24.b.

Deferred Tax Asset Information

Line item 145 Enter the tier 1 subtotal

Report the amount from item 28 above. **Do not report this item for CCAR 2016.**

Line item 146 Enter 10% of the tier 1 subtotal

Report the amount from item 145 above multiplied by 0.10. **Do not report this item for CCAR 2016.**

Line item 147 Enter the amount of deferred tax assets to be used when calculating the regulatory capital limit

Report the amount of deferred tax assets to be used when calculating the regulatory capital limit. **Do not report this item for CCAR 2016.**

Line item 148 Enter any optional adjustment made to item 141 in item 148 as allowed in the FR Y-9C instructions

This is an embedded formula and should be auto-populated. **Do not report this item for CCAR 2016.**

Line item 149 Enter the amount of taxes previously paid that the bank holding company could recover through loss carrybacks if the bank holding company's temporary differences (both deductible and taxable) fully reverse at the report date.

Report the amount of taxes previously paid that the bank holding company could recover through loss carrybacks if the bank holding company's temporary differences (both deductible and taxable) fully reverse at the report date. The carryback period is the prior two calendar tax years plus any current taxes paid in the year-to-date period. Report disaggregated data for taxes paid in memorandum items at the end of this sub-schedule.

Line item 150 Enter the amount of deferred tax assets that is dependent upon future taxable income

Report the amount of deferred tax assets that is dependent upon future taxable income. **Do not report this item for CCAR 2016.**

Line item 151 Enter the portion of (e) that the bank holding company could realize within the next 12 months based on its projected future taxable income.

Report the portion that the bank holding company could realize within the next 12 months based on its projected future taxable income. Future taxable income should not include net operating loss carryforwards to be used during the next 12 months or existing temporary differences that are expected to reverse over the next 12 months. **Do not report this item for CCAR 2016.**

**Line item 152 (g) Enter the minimum of (f) and (b)
Do not report this item for CCAR 2016.**

**Line item 153 Subtract (g) from (e), but cannot be less than 0
Do not report this item for CCAR 2016.**

**Line item 154 Future taxes paid (used to determine item 152)
Do not report this item for CCAR 2016.**

**Line item 155 Future taxable income (consistent with item 152)
Do not report this item for CCAR 2016.**

Supplemental Capital Action Information

Line item 156 Cash dividends declared on common stock

Line item 157 Common shares outstanding (Millions)

Line item 158 Common dividends per share (\$)

Line item 159 Issuance of common stock for employee compensation

Report the amount (in \$millions) of the issuance of common stock for employee compensation. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation.

Line item 160 Other issuance of common stock

Report the amount (in \$millions) of other issuance of common stock (other than for employee compensation).

Line item 161 Total issuance of common stock

Line item 162 Share repurchases to offset issuance for employee compensation

Report the amount (in \$millions) of share repurchases to offset the issuance of stock for employee compensation.

Line item 163 Other share repurchases

Report the amount (in \$millions) of all other share repurchases.

Line item 164 Total share repurchases

Supplemental Information on Trust Preferred Securities Subject to Phase-Out from Tier 1 Capital

Line item 165 Outstanding trust preferred securities

Report the outstanding notional balance of trust preferred securities as defined in the FR Y-9C, Schedule HC, item 19b.

Line item 166 Trust preferred securities included in item 24

Report trust preferred securities qualifying for tier 1 capital and included in item 24 above.

MEMORANDA:

Memoranda Line item 167 Itemized other adjustments to equity capital

Report amounts separately of other adjustments to equity capital included in item 16, and provide a text explanation of each type of adjustment. **Do not report this item for CCAR 2016.**

Memoranda Line item 168 Itemized other additions to (deductions from) tier 1 capital

Report amounts separately of other additions to (deductions from) tier 1 capital included in item 31, and provide a text explanation of each type of addition or deduction. **Do not report this item for CCAR 2016.**

Itemized historical data related to taxes paid:

Memoranda Line item 169 Taxes paid during fiscal year ended two years ago

Report the amount of taxes paid during fiscal year ended two years ago.

Memoranda Line item 170 Taxes paid during fiscal year ended one year ago

Report the amount of taxes paid during fiscal year ended one year ago.

Memoranda Line item 171 Taxes paid through the as-of date of the current fiscal year

Report the amount of taxes paid during the current fiscal year through the as-of date.

Memoranda Line item 172 Reconcile the Supplemental Capital Action and HI-A projections

In this item, reconcile the supplemental capital actions reported with HI-A projections reported in items 1 through 15; that is, allocate the capital actions among the HI-A buckets.

Supporting Documentation

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

2. Retail

Loans on the retail schedules should be reported based on the loan's classification on the FR Y-9C, Schedule HC-C (i.e. based on the loans collateral, counterparty, or purpose). Refer to the FR Y-9C instructions for Schedule HC-C for guidance on loan classification. All loans should be reported net of charge-offs.

Throughout the retail-related sub-schedules, Domestic refers to portfolios held in domestic US offices (as defined in the FR Y-9C glossary), and International refers to portfolios outside of the domestic US offices.

A.2.a—Retail Balance and Loss Projections

The Retail Balance and Loss Projections sub-schedule collects projections of business-line level balances and losses on BHCs' held for investment loans accounted for at amortized cost (accrual loans). Loans held for sale and loans held for investment under the fair value option should not be included.

Retail Loan Categories

A. First Lien Mortgages (in Domestic Offices)

The loan population includes all domestic first lien mortgage loans directly held on the BHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.2.(a).

B. First Lien HELOANs (in Domestic Offices)

The Loan population includes all domestic first lien home equity loans directly held on the BHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a).

C. Closed-End Junior Liens (in Domestic Offices)

The loan population includes all domestic loans directly held on the BHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC- C, item 1.c.(2)(b).

D. HELOCs (in Domestic Offices)

The loan population includes all first and junior lien domestic lines directly held on the BHC's portfolio. Portfolio lines are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1).

E. First Lien Mortgages and HELOANs (International)

The loan population includes all non-domestic loans directly held on the BHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a).

F. Closed-End Junior Liens and Home Equity Lines Of Credit (International)

The loan population includes all non-domestic loans/lines directly held on the BHC's portfolio. Portfolio loans are all loans/lines as defined in the FR Y-9C, Schedule HC -C, item 1.c.(2)(b), and item 1.c.(1).

G. Corporate Card (Domestic)

Employer-sponsored domestic credit cards for use by a company's employees. This includes US corporate credit card loans as defined in the FR Y-9C, Schedule HC-C, item 4.a, and US corporate card loans reported in other FR Y-9C lines.

Only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

Loans for which a commercially-graded corporation is ultimately responsible for repayment of credit losses incurred should not be reported in this Sub-schedule.

H. Business Card (Domestic)

Small business domestic credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as an applicant. Report at the control account level or the individual pay level (not at the sub-account level). This includes SME credit card loans as defined in the FR Y-9C, Schedule HC-C, item 4.a, and US corporate card loans reported in other FR Y-9C lines.

Only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

Loans for which a commercially-graded corporation is ultimately responsible for repayment of credit losses incurred should not be reported in this Sub-schedule.

I. Charge Card (Domestic)

Domestic credit cards for which the balance is repaid in full each billing cycle as defined in the FR Y-9C, Schedule HC-C item 6.a or 9.b.

Exclude charge cards to corporations and small businesses (report in Corporate Card or Business Card, as appropriate).

J. Bank Card (Domestic)

Regular general purpose domestic credit cards as defined in the FR Y-9C, Schedule HC-C, item 6.a or 9.b.

Bank cards include products that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity and co-brand cards in this category, and student cards, if applicable. This product type also includes private label or proprietary credit cards, which are tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil and gas cards in this loan type.

Exclude bank cards to corporations and small businesses (report in Corporate Card or Business Card, as appropriate).

K. Business and Corporate Card (International)

Report employer-sponsored non-domestic credit cards for use by a company's employees and small business non-domestic credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as an applicant. Such loans as defined in the FR Y-9C, Schedule HC-C, item 4.b, and International corporate and business card loans reported in other FR Y-9C lines.

For corporate cards, only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

For bank cards, only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

Loans for which a commercially-graded corporation is ultimately responsible for repayment of credit losses incurred should not be reported in this Sub-schedule.

L. Bank and Charge Card (International)

Include both non-domestic credit cards for which the balance is repaid in full each billing cycle and regular general purpose non-domestic credit cards as defined in the in FR Y-9C, Schedule HC-C item 6.a or 9.b.

Bank cards include products that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity and co-brand cards in this category, and student cards, if applicable. This product type also includes private label or proprietary credit cards, which are tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil and gas cards in this loan type.

Exclude bank cards to corporations and small businesses (report in Corporate Card or Business Card, as appropriate).

M. Auto Loans (Domestic)

Include all domestic as defined in the FR Y-9C, Schedule HC-C, item 6.c and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

N. Auto Loans (International)

Include all non-domestic as defined in the FR Y-9C, Schedule HC-C, item 6.c and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

O. Auto Leases (Domestic)

Include domestic auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

P. Auto Leases (International)

Include non-domestic auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

Q. Student Loan

Include student loans as defined in the FR Y-9C, Schedule HC-C, items 6.b and 6.d.

R. Small Business Loan - Scored (Domestic)

The loan population of domestic small business loans is dependent on two factors: 1) the classification of the loan as defined in the FR Y-9C, Schedule HC-C (i.e. based on the collateral, counterparty, or purpose of the loan); and (2) whether the method to measure credit risk for the loan is different than that used for ordinary corporate loans.

- a. Reportable loans may include those small business loans that are included in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a and 4.b (excluding SME credit card loans included on Item 4.a) 7, 9.b.(1), 9.b.(2) and 10.b.
- b. To be classified as a small business loan, the method to measure credit risk must be different than the method used for other corporate loans. Commercial internal risk ratings or grades tend to not be used to assess credit risk for ordinary corporate loans. Meanwhile, small business loans tend to be scored or delinquency managed. Additionally, loans that are nevertheless internally risk weighted but that use a scale different from that used for ordinary corporate loans may also be considered small business loans.

S. Small Business Loan - Scored (International)

The population of international small business loans includes all non-domestic loans that fit the definition of small business loans (see above).

T. Other Consumer Loans and Leases (Domestic)

- a. Include all domestic loans as defined in the FR Y-9C, Schedule HC-C, items 6.b and 6.d excluding student loans and non-purpose based securities loans. Non-purpose based securities loans are loans secured by a portfolio of securities that are used for the purpose of something other than purchasing securities.
- b. Include domestic non-auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a.

U. Other Consumer Loans and Leases (International)

- a. Include all non-domestic loans as defined in the FR Y-9C, Schedule HC-C, items 6.b and 6.d excluding student loans and non-purpose securities based loans. Non-purpose securities based loans are loans secured by a portfolio of securities that are used for the purpose of something other than purchasing securities.
- b. Include non-domestic non-auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a.

For Sections A through U: Report line items 1 through 8 for the current quarter and nine subsequent projected quarters (PQ1 through PQ9). Reporting of projections for credit cards should be based on all open accounts (active and inactive), but not charged-off accounts

Line item 1 Balances

Report according to FR Y-9C definitions (end of quarter levels). Report end of quarter levels for each Section. Where requested, please segment the total balances reported by age. For those lines, balances should be classified according to the origination date of the account with which the balance is associated.

Line item 2 New Originations

Report the total dollar amount of new originations net of sales to Agencies. Report only originations for those loans and leases that the bank holding company has the intent and ability to hold for the foreseeable future or until maturity or payoff.

Line item 3 Paydowns

Report the total dollar of repayments received in the given quarter.

Line item 4 Asset Purchases

Report the total dollar of assets purchased in the given quarter. Include mortgages repurchased from GNMA, GSEs, and private securitizations that are put back into the accrual book.

Line item 5 Asset Sales

Report the total dollar of assets sold in the given quarter, net of sales to Agencies.

Line item 6 Loan Losses

Report the total dollar of net charge-offs recognized in the given quarter.

Line item 7 Cumulative Interim Loan Losses – Non-PCI

Report the total unpaid principal balance that has been charged-off on loans in the segment through quarter-end of the reporting period on non-Purchased Credit-Impaired (PCI) loans. Interim charge-offs include all cumulative partial charge-offs/write-downs for loan that have not been fully charged-off or otherwise liquidated.

Line item 8 Cumulative Interim Loan Losses – PCI

Report the total interim losses through quarter-end of the reporting period that have been or are expected to be covered by the non-accretable mark or the reserve set up post-mark (ALLL) to cover additional shortfalls in expected cash flows on Purchased Credit-Impaired (PCI) loans. . This measure should not include liquidated loans. The amounts reported in this line should be consistent with the Non-Accretable Difference Remaining and other information reported on the ASC 310-30 sub-schedule.

For more information on purchased credit-impaired loans, refer to the FR Y-9C, Schedule HC-N, Memorandum item 9.

A.2.b—Retail Repurchase

The Retail Repurchase sub-schedule collects data on loans sold by the BHC that may be subject to repurchase risk due to breaches of representations and warranties made during the sale of the loans, as defined in the FR Y-9C, Schedule HC-P, item 6. It also collects data on loans insured by the US Government for which the insurance coverage could be denied or indemnification required if loan defects are identified.

This Schedule has three sections for information on loans sold by the BHC that may be subject to repurchase risk. Section 1 collects loans for which the outstanding unpaid principal balance (UPB) and delinquency information requested is available. Section 2 collects loans for which the outstanding UPB or delinquency information is incomplete or not available. Due to the missing data associated with loans reported in Section 2, loans in this population will be treated with conservative assumptions. Data collected in Sections 1 and 2 should be mutually exclusive. Section 3 collects the projected future lifetime losses that would be charged-off through the repurchase reserve under each scenario, as defined in Section 3 of these instructions.

Table Information:

Information reported in this schedule will be collected in Tables A through G. Please report information aggregated by Vintage for each table and corresponding data fields below. The Vintage of each column refers to the calendar year that the loan was sold (i.e., 2004 through the current year).

In cases where the data may not be available by Vintage, report the data in the Unallocated column. Loans sold prior to 2004 should be excluded from all data fields with the exception of *Projected Future Losses to BHC Charged to Repurchase Reserve*. *Projected Future Losses to BHC Charged to Repurchase Reserve* associated with Vintages prior to 2004 should be included in the Unallocated column. It is expected that use of the Unallocated column will be very limited. Any loans sold data reported in the Unallocated column will be treated with conservative assumptions by the Federal Reserve.

If Outstanding Balance and Delinquency information is available but Realized Net Credit Losses is not known, the BHC should report in tables A.1 through G.1 the available information and provide an explanation as to why credit loss information is not known.

If no information or incomplete information on the credit performance of the loans sold with repurchase agreements and warranties, the BHC should report in tables A.2 through G.2 “BHC Unable to Report Outstanding UPB or Delinquency Information” to report Original UPB and Projected Losses information. Report in tables A.2 through G.2 the Original UPB and Projected Future Losses of assets sold with servicing released where the BHC is unable to report Outstanding UPB and Credit.

Loans that have been sold, repurchased and then sold again should be reported in the most recent year of sale.

Row Variable Information:

For row variables described in Sections 1 through 3 with the note Excluding Exempt Population, the data submitted should exclude any loans for which the BHC has no risk of repurchase liability because of settlement or previous repurchase. Only finalized settlements should be considered Exempt; any loans subject to a pending settlement should be included on this sub-schedule. Loans for which a repurchase request has been made and subsequently rescinded should also be considered Exempt. Loans paid in full are not part of the exempt population unless they satisfy the defined exemption criteria. When addressing exclusions that may exist in any settlement agreement, BHCs should first make an effort to isolate the population of loans for which material exclusions exist and report these as 'loans with remaining liability'. In the event that a settlement has eliminated the vast majority (but not all) of the contractual representation and warrant liability for certain loans, these should be categorized as 'loans with no remaining liability'. However, BHCs should provide details on any limited settlement exclusions that may exist for those settled populations in the supporting documentation (i.e. settlement, previously repurchased), and specifics of any finalized settlements (including exposures and timeframes covered by these settlements and the date the settlements were finalized). BHCs should also explain any material changes in historical vintage exposure compared to prior year.

Tables A through F: For Tables A through F, data will be represented in three sections.

Section 1: BHC ABLE TO REPORT OUTSTANDING UPB AND DELINQUENCY INFORMATION REQUESTED

The row variables for Section 1 identified in Tables A through F should be completed using the following categories:

Original UPB:

Report the original UPB of all of the loans, including closed loans.

Original UPB (Excluding Exempt Population):

Report the original UPB of the loans, including closed loans but excluding the exempt population.

Outstanding UPB (Excluding Exempt Population):

Report the outstanding UPB as of the reporting date, excluding the exempt population.

Delinquency Status as of the reporting date (Excluding Exempt Population):

Report the data as of the reporting date, excluding the exempt population as defined above. The table collects delinquency categories as defined above. The sum of the four delinquency categories listed below should equal the outstanding UPB reported for that age.

As part of Section 1 for Tables A through F, when reporting the row variable for this item, the following delinquency categories will be utilized:

- Current: The UPB of loans less than 30 days past due
- Past due 30 to 89 days: The UPB of loans 30-89 days past due
- Past due 90 to 179 days: The UPB of loans 90-179 days past due

- Past due 180+ days: The UPB of all loans that are 180 days or more past due and have not yet been fully charged-off

Net Credit Loss Realized to-date (Excluding Exempt Population):

Report cumulative net credit losses realized by investors in the loans through the as-of date, excluding the exempt population as defined above. Cumulative net credit losses are defined as cumulative collateral loss incurred to date. Refer to the FR Y-9C, Schedule HC-P, item 6 for a further definition of "credit loss".

Repurchase Requests Outstanding (Excluding Exempt Population):

Report Repurchase Requests Outstanding, which is the total UPB of the loans which the investor has requested a repurchase of the loan or indemnification for any losses but a resolution had not been reached as-of the reporting date. Note that this variable is by definition exclusive of the exempt population as defined above.

Loss to-date Due to Denied Insurance and/or Indemnification (applicable to Table C.1 only):

Report losses realized through the reporting date due to insurance claims denied by the US Government due to an identified defect on the loan in question. Also include any losses incurred due to indemnification agreements that were established with the US Government on loans with identified defects.

Estimated Lifetime Net Credit Losses (Excluding Exempt Population):

Report the firm's estimate of lifetime net credit losses by investors in the loans (inclusive of net credit losses realized-to-date) under the scenario in question, excluding from the estimate losses on the exempt population as defined above.

Projected Future Losses to BHC Charged to Repurchase Reserve (Excluding Exempt Population):

Report lifetime future losses related to sold or government-insured loans under the scenario in question that the BHC expects to charge through its repurchase reserve. Refer to the FR Y-9C, Schedule HC-P, item 7 for a further definition of "repurchase reserve". Any amount of projected future losses associated with Vintages prior to 2004 should be highlighted in the supporting documentation and included in the Unallocated column. Planned future originations with the intent to sell where there are expected losses/reserves associated with new vintages should not be included on the Retail Repurchase sub-schedule.

Section 2: BHC UNABLE TO REPORT OUTSTANDING UPB OR DELINQUENCY INFORMATION REQUESTED

The row variables for Section 2 identified in Tables A through F should be completed using the following categories:

Original UPB:

Report the original UPB of all of the loans, including closed loans.

Original UPB (Excluding Exempt Population):

Report the original UPB of the loans, including closed loans but excluding the exempt population.

Outstanding UPB (Excluding Exempt Population):

Report the outstanding UPB as of the reporting date, excluding the exempt population.

For row variables described with the note *Excluding Exempt Population*, the data submitted should exclude:

- Any loans for which the BHC has no risk of repurchase liability because of final settlement, final judgment, or previous repurchase. Note: Only exclude loans for which a final judgment has been entered or final settlement has been reached⁹; any loans subject to a pending litigation (including appeals) or ongoing settlement negotiations should be included on this worksheet. Loans recorded in Table H with no remaining liability should be excluded from the worksheet; loans recorded in Table H with remaining liability should be included on the worksheet.
- Loans for which a repurchase request has been made and subsequently rescinded. Note: Loans paid in full are not part of the exempt population unless they satisfy the exemption criteria defined above.

Projected Future Losses to BHC Charged to Repurchase Reserve (Excluding Exempt Population):

Report lifetime future losses related to sold or government-insured loans under the scenario in question that the BHC expects to charge through its repurchase reserve.

Data collected in Sections 1 and 2 should be mutually exclusive.

Section 3: LOSS PROJECTIONS

The row variable for Section 3 identified in Tables A through F should be completed using the following category:

Projected Future Losses to BHC Charged to Repurchase Reserve:

Lifetime future losses related to sold or government-insured loans under the scenario in question that the BHC expects to charge through its repurchase reserve.

As part of Section 3 for Tables A through F, please distribute the projected future lifetime losses that would be charged-off through the repurchase reserve under each scenario, as defined in Table Instructions below, over the quarters displayed defined in each column header (i.e., PQ1 through PQ9, and PQ10 or later).

For Tables A through F, the sum of the projected future losses in Sections A.3 – F.3 expected to be charged off to the repurchase reserve should equal the sum of the projected future losses expected to be charged off through the repurchase reserve in Sections A.1 – F.1 and A.2 – F.2.

⁹ For these purposes, a judgment is final when the court of competent jurisdiction has entered judgment and any available appellate rights have been exhausted or waived. A settlement is final when any required payment has been made and any associated litigation claims have been withdrawn.

The Projection Validity Check cells will read “TRUE” when these projected losses are filled out correctly.

Further, the sum of the projected future losses reported in Sections A.3 - F.3 is calculated in Section G.3. The sum of losses expected to be charged to the repurchase reserve is linked to the net charge-off lines in the Repurchase Reserve on the Income Statement to ensure consistency across the sheets of the FR Y-14A summary workbook.

Table Instructions

Tables A—Loans Sold to Fannie Mae (FNMA)

Tables B—Loans Sold to Freddie Mac (FHLMC)

Tables C—Loans Insured by the US Government

Loans insured by the US Government include loans insured by the Federal Housing Administration (FHA) or the Farmers Home Administration (FmHA) or guaranteed by the Veterans Administration (VA) that back Government National Mortgage Association (GNMA) securities, i.e., “GNMA loans.” Include all loans insured by the US Government including those on balance sheet (including any GNMA buyouts or on-balance sheet FHA exposures) or sold into a GNMA security.

Tables D—Loans Securitized with Monoline Insurance

Include loans packaged into a securitization and wrapped with monoline insurance. If it cannot be identified whether a given loan is monoline insured, include the loan in this category.

Tables E—Loans Securitized without Monoline Insurance

Include loans packaged into a securitization but not wrapped with monoline insurance;

Tables F—Whole Loans Sold

Include loans sold as whole loans to parties other than Fannie Mae or Freddie Mac, even if the whole loans were subsequently sold to Fannie Mae or Freddie Mac.

Table G—Total Loss Projections

This item is a shaded cell and is derived from the sum of Tables A3, B3, C3, D3, E3, and F3.

Table H—Sold Loans Subject to Completed Settlements¹⁰

Include original UPB of loans subject to completed settlements, by vintage and investor. Only include loans subject to settlements finalized on or before the ‘as of’ date. Loans reported in Table H should not be included in the non-Exempt populations reported in Tables A-F as they are considered part of the Exempt population. Any loans subject to a pending settlement or a settlement occurring after the ‘as of’ date should not be included in Table H and should be included in the general sub-schedule. Please bifurcate the Original UPB of settlement exposures into loans with no remaining

¹⁰ Completed Settlements are defined as settlements for which final judgment has been entered or final settlement has been reached. A judgment is final when the court of competent jurisdiction has entered judgment and any available appellate rights have been exhausted or waived. A settlement is final when any required payment has been made and any associated litigation claims have been withdrawn.

contractual representation and warranty (R&W) liability and loans with remaining R&W liability. Please also indicate the total settlement dollars paid by investor type, as well as the subset of total settlement dollars paid that is directly related to contractual R&W claims (excluding any penalties, fees, damages, etc).

A.2.c—ASC 310-30

The Retail ASC 310-30 sub-schedule (Accounting Standards Codification (ASC) Subtopic 310-30, Receivables—Loans and Debt Securities Acquired with Deteriorated Credit Quality, formerly AICPA Statement of Position 03-3, “Accounting for Certain Loans or Debt Securities Acquired in a Transfer”) collects information and projections on the BHCs’ retail purchased credit impaired (PCI) portfolio reported as held for investment on the FR Y-9C, Schedule HC-C, Items 1 through 9. Do not report PCI loans that are either (1) loans held for sale; or (2) loans held for investment accounted for under the fair value option. Commercial loans should be excluded from this schedule. Provide actual information (required only in the baseline scenarios) for the fourth quarter of the reporting period and projected information for the future quarters (where applicable).

Submit the information requested by product loan type, as segregated on the sub-schedule. In the event that a firm has ASC 310-30 pools that include more than one of the products provided on the sub-schedule, please allocate the data between the products in question and provide documentation for the methodology you used for the allocation.

The FR Y-9C Glossary entry for “Purchased Impaired Loans and Debt Securities” contains further information on the carrying value, the nonaccretable difference, and the accretable yield.

For Sections A through, E, report line items 1 through 14 for the current quarter and nine subsequent projected quarters (PQ1 through PQ9). Information reported on this schedule will be collected in Sections A through E, as follows:

A. First Lien Mortgages

The term “first lien mortgages” is defined as all loans meeting the definition of FR Y-9C, Schedule HC-C, item 1.c.(2)(a). The loan population includes all loans directly held in the BHC’s portfolio.

B. Junior Lien HELOANS

The term “junior lien HELOANS” is defined as all loans meeting the definition of FR Y-9C, Schedule HC-C, Item 1.c.(2)(b). The loan population includes all loans directly held in the BHC’s portfolio.

C. HELOCs

The term “HELOCs” (home equity line of credit) is defined as all loans meeting the definition of FR Y-9C, Schedule HC-C, Item 1.c.(1). The active loan population includes all loans directly held in the BHC’s portfolio

D. Other (specify in documentation)

Provide information on all other PCI retail loans that do not meet the definition of first lien mortgages, junior lien HELOANS, or HELOCs (see above for definitions). Categorize “other loans” according to their classification on the Retail Balance and Loss Projections sub-schedule. Specify the applicable loan category(s), and report items 1 through 14 (e.g. Carry Value, Allowance, Net Carry Value, etc.) for the current quarter and nine subsequent projected quarters for each loan category. Combine all “Other” loans into a single portfolio and report the items for that aggregated portfolio.

E. Portfolio to be Acquired (specify in documentation)

Provide information on all PCI loans that are to be acquired. Classify PCI loans to be acquired according to the ASC 310-30 loan categories provided in Sections A through D (e.g. first lien mortgages, junior lien HELOANS, HELOCs, corporate cards, etc.). Specify the applicable loan category(s), and report items 1 through 14 (e.g. Carry Value, Allowance, Net Carry Value, etc.) for the current quarter and nine subsequent projected quarters for each loan category on the sub-schedule. In supporting documentation, provide details on the composition of the portfolio(s) of PCI loans to be acquired and on the deals related to the acquisition of these PCI loans.

Line item 1 Carry Value

Report the carrying value of the ASC 310-30 PCI loans held for investment as they are reported on the balance sheet. Carrying value does not reflect any allowance for loan losses, but includes purchase accounting adjustments (including the nonaccretable difference and the accretable yield). The reported amount should be consistent with the amount reported on the FR Y-9C, Schedule HC-C, Memoranda Item M.5(b).

Line item 2 Allowance

Report the amount of any allowance for loan losses that has been established for the PCI loans. The FR Y-9C, Glossary entries for "Allowance for Loan and Lease Losses" and "Purchase Impaired Loans and Debt Securities" contain further information.

Line item 3 Net Carry Value

Report the carry value less any allowance. This field is automatically calculated.

Line item 4 Unpaid Principal Balance

Report the total contractual unpaid principal balance of ASC 310-30 (SOP 03-3) PCI loans as of quarter-end.

Line item 5 Initial Day 1 Nonaccretable Difference to Absorb Cash Flow Shortfalls on PCI Loans

Report the initial Day 1 nonaccretable difference, which is the estimate at the date of acquisition of contractual cash flows not expected to be collected. Specify whether this includes principal only or principal plus interest. On the reporting form, this field only needs to be completed with data from the fourth quarter of the current year (i.e. the first column). In Supporting Documentation, specify whether this includes principal only or principal plus interest.

Line item 6 Quarter Ending Non Accretable Difference (NAD)

Report the amount of the Day 1 NAD remaining (see Item 5, above), net of (1) the amount allocated to offset 'Charge Offs to Date' (provided in Item 7) and (2) any amounts reclassified to accretable yield under ASC 310-30.

Line items 7 and 8 Cumulative "Charge-Offs" to Date

Report the amount of cumulative charge-offs that would have been recognized through the quarter to date based upon contractual amounts due from the borrower under the firm's charge-off policy. In other words, for these items, charge-offs should be calculated based upon the contractual amount due from the borrower rather than the carrying amount recorded on the balance sheet, considering

the firm's charge-off policy. Report the cumulative amount of charge-offs to date, if any, that have been charged against the nonaccretable difference (Item 7) and/or the allowance (Item 8). In supporting documentation, Report the amount of cumulative charge-offs to date that have been charged against the nonaccretable difference and/or the allowance. Refer to the Supporting Documentation Instructions for guidance on providing supporting documentation.

Line item 9 Provisions to Allowance

Report the amount of provisions to the allowance recognized in the income statement in the quarter due to changes in expected cash flows for PCI loans. Provide increases to the allowance as a positive number and reversals of the allowance as a negative number.

Line items 10 and 11 Quarterly "Charge-Offs"

Report the amount of charge-offs for the quarter to date that would have been recognized based upon contractual amounts due from the borrower under the firm's charge-off policy. In other words, for these items, charge-offs should be calculated based upon the contractual amount due from the borrower rather than the carrying amount recorded on the balance sheet, considering the firm's charge-off policy. In Supporting Documentation, report the amount of charge-offs for the quarter, if any, that have been charged against the nonaccretable difference and/or the allowance.

Line item 12 Accretable Yield Remaining

Report the accretable yield remaining as of the quarter-end.

Line item 13 Accretable Yield Accreted to Income

Report the amount of accretable yield recognized as income in the quarter.

Line item 14 Effective Yield (%)

Report the effective interest rate at which income is recognized in the quarter. Enter a numeral in decimal format with up to 4 decimal places.

Supporting Documentation

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

3. AFS/HTM Securities

General Instructions

High-Level OTTI Methodology and Assumptions for AFS and HTM Securities by Portfolio, Projected OTTI for AFS and HTM Securities by Portfolio, Projected OCI and Fair Value for AFS and Impaired HTM Securities, and Actual AFS and HTM Fair Market Value Sources by Portfolio collect data on the following types of securities:

- 1) *government agency mortgage-backed securities (MBS)*: MBS issued or guaranteed by U.S. Government agencies;
- 2) *auction rate securities*: auction-rate securities are variable rate securities with long-term maturities whose interest rates are periodically reset through auctions occurring at predetermined short-term intervals (generally 7, 14, 28, or 35 days);
- 3) *collateralized debt obligations (CDOs)*: CDOs are asset-backed securities collateralized by a discrete portfolio of fixed income assets and that make payments based on the performance of those assets;
- 4) *collateralized loan obligations (CLOs)*: CLOs are securitizations of portfolios of loans through a bankruptcy-remote special-purpose vehicle (SPV) that issues asset-backed securities in one or more classes (or tranches). In general, CLOs are backed by a variety of assets, including whole commercial loans, revolving credit facilities, letters of credit, and bankers' acceptances;
- 5) *commercial mortgage-backed securities (CMBS)*: Exclude securities that have been issued or guaranteed by the Federal National Mortgage Association (FNMA) or the Federal Home Loan Mortgage Corporation (FHLMC) or guaranteed by the Government National Mortgage Association (GNMA). Report these securities as "Agency MBS" (above);
- 6) *common stock (equity)*;
- 7) *auto asset-backed securities (ABS)*: ABS collateralized by auto loans;
- 8) *credit card ABS*: ABS collateralized by credit card loans;
- 9) *student loan ABS*: ABS collateralized by student loans;
- 10) *other ABS (excluding home equity loan ABS)*: all other ABS that cannot properly be reported as auto ABS, credit card ABS, student loan ABS or home equity loan ABS;
- 11) *corporate bonds*: corporate bonds are debt obligations issued by corporations and may be secured or unsecured;
- 12) *covered bonds*: securities generally classified as "covered bonds" that feature recourse to cash flows of a pool of mortgages or public-sector loans on the balance sheet of an issuing financial institution;

- 13) *domestic non-government agency residential mortgage-backed securities (RMBS, includes home equity loan ABS)*: RMBS, including securities backed by home equity loans that are issued by domestic non-government agency entities. Such as Alt-A (option ARM), Alt-A FRM, Alt-A ARM, closed-end second, HELOC, Scratch & Dent, Subprime, Prime Fixed, and Prime ARM securities;
- 14) *foreign RMBS*: RMBS of foreign issuers;
- 15) *municipal bonds*: bonds issued by U.S. states, cities, counties, and other governmental entities at or below the state level. Include bonds issued by Canadian provinces or other local government entities and bonds issued by other non-US local government entities;
- 16) *mutual funds*: investments in mutual funds, including money market mutual funds and mutual funds that invest solely in U.S. government securities;
- 17) *preferred stock (equity)*: refer to the FR Y-9C Glossary entry for "Preferred Stock";
- 18) *sovereign bonds*: bonds issued by the central governments of foreign countries. Also, include in this category obligations of foreign country central banks, foreign central government units or agencies, fully government-guaranteed obligations of municipal or state-owned enterprises; and obligations of supranational organizations such as the International Bank for Reconstruction and Development (World Bank), Inter-American Development Bank, and Asian Development Bank;
- 19) *U.S. Treasuries & other government agency non-mortgage-backed securities*: U.S. government agency obligations issued by U.S. government agencies and U.S. government-sponsored agencies, including but not limited to, Small Business Administration "Guaranteed Loan Pool Certificates," U.S. Maritime Administration obligations, and Export-Import Bank participation certificates. Include obligations (other than mortgage-backed securities) issued by the Farm Credit System, the Federal Home Loan Bank System, the Federal Home Loan Mortgage Corporation, the Federal National Mortgage Association, the Financing Corporation, Resolution Funding Corporation, the Student Loan Marketing Association, and FDIC Structured Sale Guaranteed Notes and NCUA Guaranteed Notes; and
- 20) *other securities* (for "other" AFS and HTM securities, please provide the security type in row 22, currently labeled "Other", adding extra rows below as necessary): all securities that cannot properly be reported in the categories above.

In circumstances whereby the BHC holds securities in both AFS and HTM categories within a given asset class, separate each security into separate rows. If using additional rows, BHCs should ensure that the totals sum appropriately) as defined in the FR Y-14Q, Schedule B, Securities. All BHCs should estimate results using the conditions specified in the macroeconomic scenario. Securities should correspond with where the reporter has classified the asset on the balance sheet of the FR Y-9C.

A.3.a—Projected OTTI for AFS Securities and HTM by Security

For each individual security that incurred a loss in P&L, state the identifier value (CUSIP or ISIN) and the amount of loss projected (over the entire forecast horizon). Generally, securities should always be reported with a public identifier, if available, such as a valid CUSIP, ISIN, or SEDOL. If a valid CUSIP, ISIN or SEDOL identifier exists for the security, please report the value of the chosen identifier (the CUSIP, ISIN, or SEDOL code) and indicate the identifier type as “CUSIP”, “ISIN”, or “SEDOL”. If a CUSIP, ISIN, or SEDOL identifier is not available for a given security, please report an alternative public identifier value, if available, and report the identifier type. If only a private or internal identifier is available, please indicate “INTERNAL.” Create a separate line item for each position. Total projected losses should reconcile to the total sum of projected losses (across all quarters) provided in the Projected OTTI for AFS and HTM Securities by Portfolio Schedule (A.3.c).

In circumstances whereby the BHC holds securities in both AFS and HTM categories within a given asset class, separate each security into separate line items.

A.3.b—High-Level OTTI Methodology and Assumptions for AFS and HTM Securities by Portfolio

Complete the unshaded cells in the table provided. In the “Threshold for Determining OTTI” column, report either the price-based threshold, the ratings-based threshold, the cash flow model-based threshold, or other threshold. Report the aggregate cumulative lifetime loss on underlying collateral (% original balance) as the total undiscounted loss amount (including both historical and projected losses) for the underlying collateral as a percentage of original principal balance of the securities aggregated by portfolio. In the “discount rate methodology” column, state whether a market-based or accounting-based (e.g., book /purchase price) discount is used. In the final three columns: provide the name(s) of any vendor(s) and any vendor models that are used, indicate whether all securities were reviewed for potential OTTI for stress testing and provide the macro-economic and financial variables used in loss estimation.

A.3.c—Projected OTTI for AFS and HTM Securities by Portfolio

Provide the credit loss portion and non-credit loss portion of projected OTTI (for relevant portfolios) for the quarters detailed in the tables provided. Values should be quarterly, not cumulative.

For the Actual Amortized Cost column, BHCs should estimate and provide fair values of AFS securities based on a re-pricing of the CCAR as-of date positions held on the reporting date.

OTTI related to the security’s credit loss is recognized in earnings, whereas the OTTI related to other factors (defined as the non-credit loss portion) is included as part of a separate component of other comprehensive income (OCI). For only those securities determined to be other-than-temporarily impaired, BHCs should provide both projected losses that would be recognized in earnings and any projected losses that would be captured in OCI. Amortized Cost should represent all Securities held, regardless of if they are impaired or not and should be reconciled to amortized cost submitted on the FR Y-14Q, Schedule B.2. Only securities projected to experience an other-than-temporary impairment loss in the P&L should be reported in the "Credit Loss Portion" and "Non-Credit Loss Portion" columns. OTTI values should be stated as positive values.

A.3.d— Projected OCI and Fair Value for AFS and Impaired HTM Securities

This Schedule must be completed for all BHCs regardless of subjectivity to the advanced approaches rule.

The “Total Actual Fair Market Value” column is the end-of-quarter fair value of the portfolio assets for the reporting quarter. Amortized cost and fair market value for the as-of date should reconcile to balances submitted on the FR Y-14Q, Schedule B.2.

The “Beginning Fair Market Value” in each column for the projected quarters represents the beginning-of-quarter fair value of the AFS and impaired HTM portfolio assets evaluated during the projected quarter. For avoidance of doubt, Securities purchased in the middle of the quarter should be accounted for in the Beginning Fair Market Value of the subsequent quarter.

The “Fair Value Rate of Change” is the weighted average percent change in fair value over the quarter for assets projected to be held at the beginning and end of the relevant quarter. (The “Fair Value Rate of Change” is **not** a ratio of projected OCI to Beginning Fair Market Value). The Fair Value Rate of Change should represent the change in price of the assets whereby the change in fair value does not include amortizations or paydowns. Reinvested assets should be included if the securities were held at the beginning and end of the relevant quarter.

The “Projected OCI” in each column represents the pre-tax incremental change in Accumulated Other Comprehensive Income during the period due to changes in the fair value of the securities in the portfolio and may also reflect changes in amortized cost, including changes due to amortization and accretion, or any other anticipated factors affecting the amortized cost amounts of AFS and impaired HTM holdings. Future OCI may include fair value gains and losses on new instruments if re-investments are anticipated. These columns, including the “Total Projected OCI in all Quarters”, may be affected by changes in a securities' amortized cost due to a projected experience of OTTI and estimate of OTTI write-down for a given quarter.

A.3.e—Actual AFS and HTM Fair Market Value Sources by Portfolio

Provide information on the sources of actual fair market values as of the reporting date. In the “Principal Market Value Source” column, state whether a vendor or proprietary model is used. If using a third party vendor, provide the name of the vendor. BHCs should also indicate how often securities are normally marked to market (e.g., daily, weekly, quarterly, etc.).

Supporting documentation:

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

4. Trading

Only the BHCs subject to the market shock scenario are required to complete this sub-schedule.

The Trading sub-schedule collects firm-wide trading profit and loss (P/L) results decomposed into the various categories listed (e.g., Equities, FX, Rates) as of a date specified by the Federal Reserve or another recent reporting date prior to the supplied as-of date as appropriate (see When to Report section of the General Instructions for additional detail). These categories are not meant to denote lines of business or desks, but rather firm-wide totals by risk. The decomposition of losses into risk areas should sum to equal the total trading mark-to-market (MTM) loss reported on the income statement. Report total P/L for the entire scenario horizon. When reporting P/L numbers, report profits as positive numbers and losses as negative numbers.

Column Instructions

Column A Firmwide Trading Total

Report firm-wide total trading profit and loss for the entire scenario horizon. Do not include P/L related to CVA hedges in this column.

Column B Contributions from Higher-Order Risks

Report contributions to P/L included in Column A from higher-order risks. Higher order risks are those inter-asset risks attributable to terms not represented in the FR Y-14Q. The highest order term represented in the FR Y-14Q will vary based on the specific asset class. For example, the commodity spot vol grids do not capture risks attributable to the co-movement of multiple underlying commodities.

Column C Firmwide CVA Hedges Total

Report firm-wide total P/L related to the Credit Value Adjustment (CVA) hedges.

Line item Instructions

The categories are not meant to denote lines of business or desks, but rather firmwide totals by risk. Categorization matches that on the FR Y-14Q. See FR Y-14Q Trading Schedule instructions for additional detail.

Line item 1 Equity

Report the contribution to P/L from exposures associated with firmwide Equity risk.

Line item 2 FX

Report the contribution to P/L from exposures associated with firmwide FX risk.

Line item 3 Rates

Report the contribution to P/L from exposures associated with firmwide Rates risk.

Line item 4 Commodities

Report the contribution to P/L from exposures associated with firmwide Commodities risk.

Line item 5 Securitized Products

Report the contribution to P/L from exposures detailed on the Securitized Products and Agencies sub-schedules of the FR Y-14Q Trading Schedule. For Agency products, the P/L related to interest rates risk should be reported in the Rates section (Line 3), while the P/L associated with OAS/credit risk elements should be reported in this line item.

Line item 6 Other Credit

Report the contribution to P/L from all credit products other than those specified on the Securitized Products or Agencies sub-schedules of the FR Y-14Q Trading Schedule. For Muni products, the P/L related to interest rates risk should be reported in the Rates section (Line 3), while the P/L associated with credit risk elements should be reported in this line item.

Line item 7 Private Equity

Report the contribution to P/L from exposures detailed on the Private Equity Sub-schedule of the FR Y-14Q Trading Schedule.

Line item 8 Other Fair Value Assets

Report the contribution to P/L from exposures detailed on the Other Fair Value Assets Sub-schedule of the FR Y-14Q Trading Schedule.

Line item 9 Cross-Asset Terms

Report the contribution to P/L from intra-asset risks attributable to the co-movement of multiple asset classes. For example, an equity option paying off in a foreign currency would have both Equity and FX risk. The P/L due to this co-dependence would be entered into line 9 and should not be divided among the individual categories listed in Lines 1-8.

Line item 10 Total

Report the total of lines 1 through 9. This total must equal line 58, Trading mark-to-market (MTM) loss, reported on the Income Statement sub-schedule of this Schedule.

Supporting Documentation

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

5. Counterparty Credit Risk (CCR)

The CCR sub-schedule collects projected counterparty credit losses as of a date specified by the Federal Reserve. Losses should be reported as positive values and gains should be reported as negative values..

Line item 1 Issuer Default Losses (Trading book)

Report losses arising from potential default of the issuers of securities held in the trading book.

Line item 1a Issuer Default losses from securitized products (Trading book)

Report losses arising from potential default of the issuers of securitized products, including RMBS, CMBS, and other securitized products as specified on the Securitized Products Sub-schedule of the FR Y-14Q Trading Schedule.

Line item 1b Issuer Default losses from other credit sensitive instruments (Trading book)

Report losses arising from potential default of the issuers of all other credit sensitive instruments (i.e., all products considered in Trading IDR losses other than securitized products), such as sovereigns, advanced economy corporate credits, and emerging market corporate credits.

Line item 2 Counterparty Credit MTM Losses (CVA Losses)

Report Counterparty Credit MTM Losses. Report total losses as equivalent to the BHC's calculation of aggregate stressed CVA less unstressed CVA for each scenario. This figure, the sum of items 2a and 2b should correspond to the difference between aggregate stressed CVA and aggregate unstressed CVA, as reported in Schedule F – Counterpart Credit Risk, Sub-schedule 1.e, for all scenarios.

Line item 2a Counterparty CVA losses

Report Counterparty CVA losses.

Line item 2b Other CVA Losses

Report CVA losses that result from offline/additional CVA reserve.

Line item 3 Counterparty Default Losses

Report losses arising from potential default of one or more counterparties.

Line item 3a Impact of Counterparty Default Hedges

Report the reduction to Counterparty Default losses reported in item 3 due to the gains from single name CDS hedges (as defined in Schedule L of the FR Y-14Q) of defaulting counterparties.

Supporting Documentation

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

6. BHC Operational Risk Scenario Inputs and Projections

Operational risk losses are defined in the Revised Capital Framework as losses arising from inadequate or failed internal processes, people and systems, or from external events. Operational risk losses include legal losses but exclude boundary events. Boundary events are operational losses that could also be classified as credit event losses. The Interagency Final Rule further defines an operational loss as a financial loss (excluding insurance or tax effects) resulting from an operational loss event and includes all expenses associated with an operational loss event except for opportunity costs, forgone revenue, and costs related to risk management and control enhancements implemented to prevent future operational losses. An operational loss event is defined as a financial loss that results from a risk exposure to the firm. Some examples of operational loss events that BHCs may consider are losses related to improper business practices (including class action lawsuits), execution errors, cyber security breaches, natural disasters, and fraud. Operational risk loss projections should be included in the PPNR Projections sub-schedule in line 29, Operational Risk Expense.

See Schedule E – Operational Risk for additional operational risk reporting requirements.

Definitions

Refer to the following definitions when completing the Operational Risk Scenario Inputs and Projections sub-schedule, and the BHC Operational Risk Historical Capital sub-schedule:

1. Type of Data:

- a) **External data:** Historical operational losses that have been experienced by other BHCs.
- b) **Internal data:** Historical operational losses that have been experienced by the BHC.
- c) **Operational Risk Scenario Analysis:** A systematic process of obtaining expert opinions from business managers and risk management experts to derive reasoned assessments of the likelihood and loss impact of plausible high severity operational losses
- d) **Business Environment and Internal Control Factors (BEICFs):** Risk and control assessments, key risk indicators, and other factors useful in identifying the level of risk within an organization.
- e) **Model Output:** Output generated by an internal or external model, such as a factor model
- f) **Other:** Data types unique to an organization's operational risk framework

2. **Brief Description:** Description of operational loss event or other factor considered.

3. **Risk Segment:** The level at which the BHC's methodology or quantification model generates a separate estimate for potential operational losses.

4. **Dollar Contribution to Operational Loss Estimate:** For each risk segment, report the projected operational loss amount. The total of all risk segments for each CCAR Scenario should agree to the projected "Operational risk expense" amount included in Line 29 in the Scenario's PPNR Projections sub-schedule.

Sub-schedule Instructions

The BHC Operational Risk Scenario Inputs and Projections sub-schedule collects information about the composition of the operational risk loss projections. Each reporting institution should identify the operational risks to which it is exposed, develop and define the risk segments that represent the firm's risks,

and project operational losses using relevant data. Data can include external data, internal data, scenario analysis, risk assessment, etc. As appropriate, quantitative methodologies may be used to convert relevant data into loss projections. Each risk segment should produce an input to the overall loss projection. Reporting institutions are expected to provide the type of data, a brief description of the loss event, how it was categorized (risk segment), and the contribution the data made to the loss projection.

Loss Projections based on Legal Reserves and Settlements

As part of the overall Operational Risk loss projections, BHCs should report the potential impact of losses resulting from a firm's actions to prevent or mitigate an operational loss settlement with clients, or to prevent future legal action. Each of the Operational Risk loss projections in each of the required CCAR Scenarios should include all projected settlements, make-whole payments, payouts that satisfy adverse legal rulings, and other legal losses if they are not covered on the PPNR Projections Sub-schedule under items 14N and 30 (Provisions to Repurchase Reserve / Liability for Residential Mortgage Representations and Warranties). If specifically linked to operational risk, BHCs should include all legal consultation fees, retainer fees, and provisions to the legal reserve within the Operational Risk loss projections.

Unrelated Professional Services

The cost of outside consulting, routine "business as usual" legal expenses, external audit, and other professional services that are unrelated to operational risk should be included in item 31 (Professional and Outside Services Expenses) on the PPNR Projections Sub-schedule.

Supporting documentation:

Please refer to Appendix A: Supporting Documentation.

7. Pre-Provision Net Revenue (PPNR)

A. General Technical Details

This section provides general guidance and data definitions for the three PPNR sub-schedules included in the Summary Schedule: PPNR Projections sub-schedule, PPNR Net Interest Income (NII) sub-schedule, and PPNR Metrics sub-schedule. The three sub-schedules are described in detail below.

Certain commonly used terms and abbreviations, including PPNR, are defined at the end of this section. Other definitions are embedded in the Schedule. Undefined terms should be assumed to follow FR Y-9C definitions. In cases where FR Y-9C guidance is unavailable, BHCs should use internal definitions and include information about the definitions used in the Supporting Documentation Instructions for FR Y-14A projections.

All line item definitions and identification numbers are consistent between the FR Y-14A and FR Y-14Q and data should be reported accordingly. Where specific FR Y-14 PPNR and/or FR Y-9C guidance exists for business line and/or other items, provide both historical and projections data consistently throughout time in accordance with the instructions. If a BHC has not done so in prior filings, restate and resubmit. If a BHC is unable to consistently adhere to definitions, it can request an exemption.

All quarterly figures should be reported on a quarterly basis (not on a year-to-date basis).

Provide data for all non-shaded cells, except where the data requested is optional. The BHC is not required to populate cells shaded gray.

If there are no data for certain numerical fields, then populate the fields with a zero (0). If the fields are optional and a BHC chooses not to report data, leave the fields blank. For numerical fields requesting information in percent (e.g. average rates earned), use standard format where .01 = 1%. Do not use non numerical characters in numerical fields.

If there is no information for certain descriptive fields, then populate the fields with "N/A." Do not leave descriptive fields blank.

The BHCs need to ensure that (a) revenues and expenses reported always reconcile on a net basis to FR Y-9C, Schedule HI, item 3 plus item 5.m minus 7.e plus item 7.c.(1) minus item 40 of PPNR Projections sub-schedule (note that this does not include losses resulting from the trading shock exercise), (b) Net Interest Income is equal between the PPNR Projections and PPNR Net Interest Income sub-schedules, and that (c) Average balances reported for the purposes of the PPNR Net Interest Income sub-schedule equal FR Y-9C, Schedule HC-K, item 5 for average assets and an average of FR Y-9C, Schedule HC, item 21 for average liabilities. BHCs should follow the same guidance when restating data to correct any errors either internally identified or identified by the Federal Reserve.

Materiality Thresholds

BHCs for which deposits comprise less than 25 percent of total liabilities for any period reported in any of the four most recent FR Y-14Q should complete the PPNR Projections sub-schedule as

well as the Metrics by Business Segment/Line and “Firm-Wide Metrics: PPNR Projections Sub-schedule” sections of the PPNR Metrics sub-schedule. The Net Interest Income sub-schedule is optional for these BHCs. All other BHCs should complete all three sub-schedules, including the Net Interest Income sub-schedule and the Net Interest Income sub-schedule section of the PPNR Metrics sub-schedule.

Report data for all quarters for a given business segment in the PPNR Projections and PPNR Metrics sub-schedules if the total revenue of that business segment (calculated as the sum of net interest income and noninterest income for that segment), relative to total revenue of the BHC exceeded 5 percent in any of the most recent four actual quarters as provided by the BHC in the FR Y-14Q.

If international revenue exceeded 5 percent of total revenue in any of the most recent four actual quarters as provided by the BHC in the FR Y-14Q, provide regional breakouts (PPNR Metrics sub-schedule, items 45A-45D) for all quarters in the PPNR Metrics sub-schedule.

If International Retail and Small Business revenues exceeded 5 percent of Total Retail and Small Business Segment revenue and Total Retail and Small Business Segment revenues were material based on an applicable 5 percent threshold in any of the most recent four actual quarters as provided by the BHC in the FR Y-14Q, provide related metrics data for all quarters (PPNR Metrics sub-schedule, item 10).

Net Interest Income: Primary and Supplementary Designation

BHCs are expected to report all line items for all sub-schedules subject to applicable thresholds as detailed in the instructions. In addition, for all BHCs that are required to complete the *PPNR Net Interest Income* sub-schedule, the PPNR Net Interest Income sub-schedule should be designated as “Primary Net Interest Income.” The PPNR Projections Sub-schedule for such BHCs will be “Supplementary Net Interest Income” by default. For BHCs that are not required to complete the PPNR Net Interest Income sub-schedule the PPNR Projections Sub-schedule should be designated as “Primary Net Interest Income.” PPNR Net Interest Income Sub-schedule will be “Supplementary Net Interest Income” for such BHCs by default, but is optional. Note that this designation would refer only to the net interest income portion of the sub-schedules.

B. Commonly Used Terms and Abbreviations

Credit cards: Unless specified otherwise, use the same definitions as provided in the FR Y-14M Credit Card schedule

Domestic Revenues: Revenues from the US and Puerto Rico only. Note that this differs from the definition of domestic on the FR Y-9C.

International Revenues: International Revenues should be those generated from transactions with clients that are domiciled outside the U.S. and Puerto Rico.

Pre-provision Net Revenue (PPNR): Sum of net interest income and noninterest income net of noninterest expense, with components expected to reconcile with those reported in the FR Y-9C when adjusted for certain items. As presented on the PPNR schedules, the adjustments include

exclusions of Valuation Adjustment for BHC's debt under fair value option (FVO), goodwill impairment, loss resulting from trading shock exercise (if applicable), as well as adjustments related to operational risk expense required for PPNR purposes. For the related items, reference the PPNR Projections sub-schedule and related instructions for the items 29, 40-42. Gains and losses on AFS and HTM securities, including other than temporary impairments (OTTI) estimates, are not a component of PPNR. All revenue and expenses related to mortgage servicing rights (MSRs) are components of PPNR to be reported in the associated noninterest income and noninterest expense line items on the PPNR schedules. Total Loans Held for Sale and Loans Accounted for under the Fair Value Option (item 57 of the Income Statement sub-schedule) are excluded only if they are a result of a market shock exercise. Other Losses (item 66) are excluded as applicable and are expected to be infrequent.

Revenues: Sum of net interest income and noninterest income adjusted for selected exclusions, as reported on line item 27 of the PPNR Projections sub-schedule.

Run-Off or Liquidating Businesses: operations that do not meet an accounting definition of "discontinued operations" but which the BHC intends to exit. In order to facilitate the calculation of the proper net interest income on the *Net Interest Income sub-schedule*, report total balances related to discontinued operations as a negative number in "Other" in items 15 and 38 and the corresponding average rates earned in items 31 and 46. BHCs should provide a detailed listing of the type (by corresponding line item on the *Net Interest Income sub-schedule*) of such balances reported as negative items in "Other" and the corresponding rates in the submission documentation.

A.7.a—PPNR Projections Sub-schedule

The PPNR Projections sub-schedule is based on standardized reporting of each component of PPNR, using business segment/line views as discussed below. If there is a difference between the FR Y-14 standardized reporting requirements and the BHCs' internal view used for internal capital planning purposes, the BHCs should report data in the PPNR sub-schedules only per the standardized FR Y-14 requirements. The BHCs are encouraged to provide data consistent with their own internal view in supporting documentation, accompanying the FR Y-14A Projections and discuss data differences. If the BHCs are unable to comply with the requirements, they can request a temporary exemption. This guidance applies to PPNR Submission/Projections and PPNR Net Interest Income sub-schedules. Please see guidance for PPNR Metrics in the PPNR Metrics section of the instructions.

Revenue Components

Revenue items are divided into net interest income and noninterest income, with totals expected to reconcile with what would be reported in the FR Y-9C when adjusted for Valuation Adjustment for firm's own debt under fair value option (FVO), loss resulting from trading shock exercise (if applicable), and operational risk expense adjustments required for PPNR purposes. For related items, reference PPNR Projections sub-schedule and related instructions for line items 29, 40, and 42. In the documentation supporting the FR Y-14A PPNR submission, BHCs are encouraged to discuss operational risk losses reported as contra-revenues for FR Y-9C purposes and their reallocation to Operational Risk expense in accordance with the PPNR instructions. Do not report gains and losses on AFS and HTM securities, including other than temporary impairments (OTTI) estimates, as a component of PPNR.

Report all items either in the segments that generated them and/or segments that they were allocated to through funds transfer pricing (FTP). Net interest income allocation to the defined segments should be based on the cost of funds applicable to those segments as determined by the BHC. Supporting Documentation instructions regarding methodology used should be provided in the memo required with the FR Y-14A Projections. Business segments and related sub-components do not have to correspond to but may include certain line items on the FR Y-9C schedule. The Business segment structure of the sub-schedule is defined by product/service (e.g., credit cards, investment banking) and client type (e.g., retail, medium size businesses); it is not defined by client relationship.

BHCs are encouraged to note which line items contain Debit Valuation Adjustments (DVA) and/or Credit Valuation Adjustments (CVA) (note: these are different from fair value adjustment on the BHC's own debt under the Fair Value Option (FVO) which is excluded from PPNR by definition), including amounts if available, and whether these are generated with the purpose to generate profit.

All revenue and expenses related to mortgage servicing rights (MSRs) and the associated noninterest income and noninterest expense line items should be evolved over the nine quarter projection horizons, and reported in the pre-provision net revenue (PPNR) schedules.

Gains or losses on loans held for sale and loans accounted for under the fair value option (HFS/FVO loans) should be reported in the relevant items on the PPNR Projections Sub-schedule in accordance with the BHC's normal accounting procedures. Starting in January 2014, all BHCs

should project gains or losses on HFS/FVO loans for all nine quarters using only the macroeconomic scenario without reference to the global market shock.

Business Segment Definitions

Subject to applicable thresholds, reporting of net interest income and noninterest income items is requested based on a business segment/line view, with business segments/lines defined as follows:

- As general guidance, small business clients are those with annual sales of less than \$10 million. Business, government, not-for-profit, and other institutional entities of medium size are those with annual sales between \$10 million and \$2 billion. Large business and institutional entities are those with annual sales of more than \$2 billion. If a BHC's internal reporting for these client segments deviates from this general guidance, continue to report according to internal definitions and describe how the BHC defined these or similar client segments and the scope of related business segments/lines (internal and those defined in the FR Y-14 PPNR sub-schedules) in the memo supporting the FR Y-14A submission.
- A BHC may include public funds in the segment reporting based on the type of the relationship that exists between the public funds and the BHC. For example, if the BHC acts in a custodial or administrative capacity, the BHC may report public funds in Investor Services. If a BHC is involved in the management of funds, the BHC may report the public funds in Investment Management.

Net Interest Income by Business Segment (unless specified otherwise, all numbers are global).

Line item 1 Retail and Small Business

This item is a shaded cell and is derived, per column, from the sum of items 1A and 1G. For items 1A through 1F, domestic includes U.S. and Puerto Rico only.

Report in the appropriate sub-item all net interest income related to retail and small business banking and lending, including both ongoing as well as run-off and liquidating businesses¹¹. Exclude any revenues related to Wealth Management/Private Banking (WM/PB) clients even if they are internally classified as retail. BHCs may include such revenues in WM/PB line items instead. In case of WM/PB mortgage repurchase contra-revenues, if any, report them as outlined in the PPNR Projection sub-schedule.

Line item 1A Domestic

This item is a shaded cell and is derived, per column, from the sum of items 1B through 1F.

Line item 1B Credit and Charge Cards

Report net interest income from domestic BHC issued credit and charge cards to retail customers including those that result from partnership agreements. May include revenue that is generated on domestic accounts due to foreign exchange transactions. Exclude the following:

- other unsecured borrowing and debit cards;

¹¹ See "Commonly Used Terms and Abbreviations" for the definition.

- small business cards (report in Other Retail and Small Business Lending, item 1F);
- wholesale and commercial cards (report in Treasury Services, item 8).
- Cards to Wealth Management/Private Banking clients (report in Wealth Management/Private Banking, line 19B)

Line item 1C Mortgages

Report net interest income from domestic residential mortgage loans offered to retail customers.

Line item 1D Home Equity

Report net interest income from domestic home equity loans and lines of credit (HELOANs/HELOCs) provided to retail customers.

Line item 1E Retail and Small Business Deposits

Report net interest income from domestic branch banking and deposit-related products and services provided to retail and small business customers. Include debit card revenues in this line. May include revenue that is generated on domestic accounts due to foreign exchange transactions. This item does not include any lending revenues.

Line item 1F Other Retail and Small Business Lending

Report net interest income from other domestic retail and small business lending products and services. These include, but are not limited to, small business cards, loans, auto loans, student loans, or personal unsecured credit. All domestic lending revenues not captured in Credit Cards, Mortgages, and Home Equity should be reported here.

Line item 1G International Retail and Small Business

Report net interest income from retail and small business generated outside of the U.S. and Puerto Rico. Includes, but is not limited to, all international revenues from credit/charge/debit cards, mortgages, home equity, branch and deposit services, auto, student, and small business loans.

Line item 2 Commercial Lending

Report net interest income from lending products and services provided to business, government, not-for-profit, and other institutional entities of medium size, as well as to commercial real estate investors and owners. Exclude treasury, deposit, and investment banking services.

Line item 3 Investment Banking

Report in the appropriate sub-item all net interest income generated from investment banking services provided to business and institutional entities of both medium and large size. Include revenues from new issue securitizations for third parties. Business lines are defined as follows:

- Advisory: Corporate strategy and financial advisory, such as services provided for mergers and acquisitions (M&A), restructuring, financial risk management, among others.
- Equity Capital Markets: Equity investment banking services (e.g., IPOs or secondary offerings).
- Debt Capital Markets: Generally non-loan debt investment banking services.
- Syndicated/Corporate Lending: Lending commitments to larger corporate clients, including event or transaction-driven lending (e.g., to finance M&A, leveraged buyouts, bridge loans). Generally, all syndicated lending origination activity should be included here (not in Commercial Lending).

Line item 4 Merchant Banking/ Private Equity

Report net interest income from private equity (PE), real estate, infrastructure, and principal investments in hedge funds. May include principal investment related to merchant banking activities.

Line item 5 Sales and Trading

This item is a shaded cell and is derived, per column, from the sum of items 5A and 5B.

Report in the appropriate sub-item all net interest income generated from sales and trading activities. Any interest income from carry should be included in Sales & Trading net interest income. May include short-term trading made for positioning or profit generation related to the Sales & Trading activities in this line item.

Line item 5A Prime Brokerage

Report net interest income generated from securities financing, securities lending, custody, clearing, settlement, and other services for hedge funds and other prime brokerage clients. Include all prime brokerage revenues in this line and not in any other business segments/lines.

Line item 5B Other

Report net interest income from all other Sales & Trading activities. These include, but are not limited to:

- Equities: Commissions, fees, dividends, and trading gains and losses on equity products. Exclude prime brokerage services.
- Fixed Income: Commissions, fees, and trading gains and losses on rates, credit, and other fixed income products. Exclude prime brokerage services.
 - Rates: Generally U.S. Treasury, investment grade sovereign, U.S. agency bonds, and interest rate swaps. Rates revenues related to trading activities outside of the Sales & Trading division need not be included into the Rates trading in this section, but describe where they are allocated in the BHC's documentation supporting the FR Y-14A submission.
 - Credit: Generally corporate bonds, loans, ABS, muni, emerging markets, CDS. If a BHC classifies some of the credit related trading (such as distressed debt) in segments other than "Sales & Trading," it can continue to report it as in its internal financial reports but indicate where they are reported in the documentation supporting FR Y-14A submission.
 - Other: e.g., FX/Currencies if not included above.
- Commodities: Commissions, fees, and trading gains and losses on commodity products. Exclude prime brokerage services.

Line item 6 Investment Management

Report all net interest income generated from investment management activities. Business lines are defined as follows:

- Asset Management: Professional management of mutual funds and institutional accounts. Institutional clients may include endowments, not-for-profit entities, governments, and others.
- Wealth Management/Private Banking (WM/PB): Professional portfolio management and advisory services for individuals. Individual clients may be defined as mass market, affluent, and high net worth. Activities may also include tax planning, savings, inheritance, and wealth planning, among others. May include deposit and lending services to WM/PB clients here and retail brokerage services for both WM/PB and non WM/PB clients.

Line item 7 Investment Services

Report all net interest income generated from investment servicing. Exclude prime brokerage revenues. Business lines are defined as follows:

- Asset Servicing: Custody, fund services, securities lending, liquidity services, collateral management; and other asset servicing. Include record keeping services for 401K and employee benefit plans, but exclude funding or guarantee products offered to such clients.
- Issuer Services: Corporate trust, shareowner services, depository receipts, and other issuer services.
- Other Investment Services: Clearing and other investment services.

Line item 8 Treasury Services

Report all net interest income from cash management, global payments, working capital solutions, deposit services, and trade finance from business and institutional entities of both medium and large size. Include wholesale/corporate and commercial cards.

Line item 9 Insurance Services

Report all net interest income from insurance activities including, but not limited to, individual (e.g., life, health), auto and home (property and casualty), title insurance and surety insurance, and employee benefits insurance.

Line item 10 Retirement/Corporate Benefit Products

Report premiums, fees, and other net interest income generated from retirement and corporate benefit funding products, such as annuities, guaranteed interest products, and separate account contracts. The fees/revenues that may be recorded here are generally generated as a result of the BHC accepting risks related to actuarial assumptions or the estimation of market returns where guarantees of future income streams have been made to clients.

Line item 11 Corporate/Other

Report net interest income associated with:

- Capital and asset-liability management (ALM) activities. Among other items, may include investment securities portfolios (but not gains and losses on AFS and HTM securities, including OTTI, as these are excluded from PPNR by definition). Also may include principal investment supporting the corporate treasury function to manage firm-wide capital, liquidity, or structural risks.
- Run-off or liquidating businesses¹² (but exclude retail and small business run-off/liquidating businesses, per Retail and Small Business segment definition)
- Non-financial businesses (e.g., publishing, travel services)
- Corporate support functions (e.g., Human Resources, IT)
- Other non-core revenues not included in other segments (e.g., intersegment eliminations).

Line item 12 Optional Immaterial Business Segments

BHCs have the option to report less material business segment revenue in Optional Immaterial Business Segments. The reported total optional immaterial business segment revenue relative to total revenue cannot exceed 10 percent. If the total immaterial business segment revenue relative

¹² See “Commonly Used Terms and Abbreviations” for the definition.

to total revenue would be greater than 10 percent in any of the most recent four actual quarters as provided by the BHC in the FR Y-14Q, report data for the largest business segment among the immaterial business segments for all quarters in the PPNR Projections and PPNR Metrics sub-schedules such that the amount reported in the Optional Immaterial Business segments line items does not exceed 10 percent. BHCs should provide comprehensive information in the Supporting Documentation Instructions on which business segments are included in the Optional Immaterial Business segments line items in both FR Y-14Q and FR Y-14A schedules, their relative contribution to the totals reported in both schedules and the manner in which the revenues were projected for FR Y-14A purposes. List segments included in this line item in Footnote 7.

Line item 13 Total Net Interest Income

This item is a shaded cell and is derived, per column, from the sum of items 1, 2 through 5, and 6 through 12. Line item 13, per column, should equal item 49 on PPNR NII Sub-schedule, if completed.

Noninterest Income by Business Segment (unless specified otherwise, all numbers are global).

Line item 14 Retail and Small Business

This item is a shaded cell and is derived, per column, from the sum of items 14A and 14T.

Line item 14A Domestic

This item is a shaded cell and is derived, per column, from the sum of items 14B, 14E, 14O, and 14S.

Report in the appropriate sub-item all domestic revenues related to retail and small business banking and lending, including both ongoing as well as run-off and liquidating businesses¹³. Exclude any revenues related to Wealth Management/Private Banking (WM/PB) clients even if they are internally classified as retail. BHCs may include such revenues in WM/PB line items instead. In case of WM/PB mortgage repurchase contra-revenues, if any, report them as outlined in the PPNR Projection sub-schedule.

Line item 14B Credit and Charge Cards

This item is a shaded cell and is derived, per column, from the sum of items 14C and 14D. Report in the appropriate sub-item all noninterest income generated from domestic BHC issued credit and charge cards to retail customers including those that result from a partnership agreements. May include revenue that is generated on domestic accounts due to foreign exchange transactions and corporate cards. Exclude the following:

- other unsecured borrowing and debit cards;
- small business cards (report in Other Retail and Small Business Lending, item 1F);
- wholesale and commercial cards (report in Treasury Services, item 8);
- Cards to Wealth Management/Private Banking clients (report in Wealth Management/Private Banking, line 19B)

Line item 14C Credit and Charge Card Interchange Revenues - Gross

Report interchange revenues from all domestic BHC issued credit and charge cards including those that result from a partnership agreement. Report before any contra-revenues (e.g.,

¹³ See “Commonly Used Terms and Abbreviations” for the definition.

rewards, etc.).

Line item 14D Other

Report all other fee income and revenue earned from credit and charge cards not captured in item 14C.

Line item 14E Mortgage and Home Equity

This item is a shaded cell and is derived, per column, from the sum of items 14F, 14I and 14N. Report in the appropriate sub-item noninterest income generated from domestic residential mortgage loans offered to retail customers and domestic home equity loans and lines of credit (HELOANs/HELOCs) provided to retail customers.

Line item 14F Production

This item is a shaded cell and is derived, per column, from the sum of items 14G and 14H.

Line item 14G Gains/Losses on Sale

Report gains/(losses) from the sale of domestic mortgages and home equity originated through all production channels (retail, broker, correspondent, etc.) with the intent to sell. Such gains/losses should include deferred fees and costs that are reported as adjustments to the carrying balance of the sold loan, fair value changes on loan commitments with rate locks that are accounted for as derivatives, fair value changes on mortgage loans held-for-sale designated for fair value treatment, lower-of-cost or market adjustments on mortgage loans held-for-sale not designated for fair value treatment, fair value changes on derivative instruments used to hedge loan commitments and held-of-sale mortgages, and value associated with the initial capitalization of the MSR upon sale of the loan.

Line item 14H Other

Report all other fee income and revenue earned from mortgage production not captured in item 14G.

Line item 14I Servicing

This item is a shaded cell and is derived, per column, from the sum of items 14J, 14K, 14L, and 14M.

Line item 14J Servicing & Ancillary Fees

Report fees received from activities relating to the servicing of mortgage loans, including (but not limited to) the collection principal, interest, and escrow payments from borrowers; payment of taxes and insurance from escrowed funds; monitoring of delinquencies; execution of foreclosures; temporary investment of funds pending distribution; remittance of fees to guarantors, trustees, and others providing services; and accounting for and remittance of principal and interest payments to the holders of beneficial interests in the financial assets.

Line item 14K MSR Amortization

Include economic amortization or scheduled and unscheduled payments, net of defaults under both FV and LOCOM accounting methods.

Line item 14L MSR Value Changes due to Changes in Assumptions/Model Inputs/Other Net of Hedge Performance

Report changes in the MSR value here and not in any other items. Report changes in the MSR hedges here and not in any other items. Include MSR changes under both FV and LOCOM accounting methods.

Line item 14M Other

Report all other revenue earned from servicing activities not captured in lines 14J through 14L.

Line item 14N Provisions to Repurchase Reserve/Liability for Residential Mortgage Representations and Warranties (contra-revenue)

Report provisions to build any non-litigation reserves/accrued liabilities that have been established for losses related to sold or government-insured residential mortgage loans (first or second lien). Do not report such provisions in any other items; report them only in line items 14N or 30, as applicable. Exclude all provisions to litigation reserves/liability for claims related to sold residential mortgages (report in item 29).

Line item 14O Retail and Small Business Deposits

This item is a shaded cell and is derived, per column, from the sum of items 14P, 14Q and 14R. Report in the appropriate sub-item noninterest income from domestic branch banking and deposit-related products and services provided to retail and small business customers. Include debit card revenues in this line. May include revenue that is generated on domestic accounts due to foreign exchange transactions.

Line item 14P Non-Sufficient Funds/Overdraft Fees – Gross

Report noninterest income from fees earned from insufficient fund deposit balances and overdrawn client deposit accounts. Report before any contra-revenues (e.g., waivers, etc.).

Line item 14Q Debit Interchange – Gross

Report noninterest income from interchange fees earned on debit cards. Report before any contra-revenues (e.g., rewards, etc.).

Line item 14R Other

Among items included here are debit card contra-revenues and overdraft waivers, as applicable.

Line item 14S Other Retail and Small Business Lending

Report noninterest income from other domestic retail and small business lending products and services. These include, but are not limited to, small business cards, other small business loans, auto loans, student loans, or personal unsecured credit.

Line item 14T International Retail and Small Business

Report noninterest income from retail and small business generated outside of the US and Puerto Rico. Includes, but is not limited to, all revenues from credit/charge/debit cards, mortgages, home equity, branch and deposit services, auto, student, and small business loans.

Line item 15 Commercial Lending

Report noninterest income from lending products and services provided to business, government, not-for-profit, and other institutional entities of medium size, as well as to commercial real estate investors and owners. Exclude treasury, deposit, and investment banking services provided to

commercial lending clients.

Line item 16 Investment Banking

This item is a shaded cell and is derived, per column, from the sum of items 16A through 16D. Report in the appropriate sub-item noninterest income generated from investment banking services provided to business and institutional entities of both medium and large size. Include revenues from new issue securitizations for third parties.

Line item 16A Advisory

Corporate strategy and financial advisory, such as services provided for mergers and acquisitions (M&A), restructuring, financial risk management, among others.

Line item 16B Equity Capital Markets

Equity investment banking services (e.g., IPOs or secondary offerings).

Line item 16C Debt Capital Markets

Generally non-loan debt investment banking services.

Line item 16D Syndicated/Corporate Lending

Lending commitments to larger corporate clients, including event or transaction-driven lending (e.g., to finance M&A, leveraged buyouts, bridge loans). Generally, all syndicated lending origination activity should be included here (not in Commercial Lending).

Line item 17 Merchant Banking/ Private Equity

This item is a shaded cell and is derived, per column, from the sum of items 17A through 17C.

Report in the appropriate sub-item revenues from the sponsorship of, management of, or from investing in, distinct long-term investment vehicles, such as real estate funds, private equity funds, hedge funds or similar vehicles. Also include direct long-term investments in securities and assets made primarily for capital appreciation, or investments where the BHC is likely to participate directly in corporate governance. Do not include revenues from sales & trading operations, corporate lending outside of a fund structure, investing in a HTM or AFS securities portfolio, brokerage or mutual fund operations.

Line item 17A Net Investment Mark-to-Market

Report the net gain or loss from sale or from the periodic marking to market of Merchant Banking/Private Equity investments.

Line item 17B Management Fees

Report fees and commissions paid by third parties to the BHC in connection with sale, placement or the management of above described investment activities.

Line item 17C Other

Report any noninterest income items not included in items 17A and 17B. Also include the BHC's proportionate share of the income or other adjustments from its investments in equity method investees.

Line item 18 Sales and Trading

This item is a shaded cell and is derived, per column, from the sum of items 18A, 18D, 18H, and 18K. Report in the appropriate sub-item noninterest income generated from sales and trading activities. Any interest income from carry should be included in Sales & Trading under net interest income. May include short-term trading made for positioning or profit generation related to the Sales & Trading activities in this line item.

Line item 18A Equities

This item is a shaded cell and is derived, per column, from the sum of items 18B and 18C.

Line item 18B Commission and Fees

Report commissions, fees, and dividends on equity products. Exclude prime brokerage services.

Line item 18C Other

Report all noninterest income for equities sales and trading, excluding prime brokerage (to be reported as a separate line item) and excluding commissions and fees. This includes trading profits and other noninterest non-commission income.

Line item 18D Fixed Income

This item is a shaded cell and is derived, per column, from the sum of items 18E, 18F, and 18G. Report in the appropriate sub-item commissions, fees, and trading gains and losses on rates, credit, and other fixed income products. Exclude prime brokerage services.

Line item 18E Rates

Generally U.S. Treasury, investment grade sovereign, U.S. agency bonds, and interest rate swaps. Rates revenues related to trading activities outside of the Sales & Trading division need not be included into the Rates trading in this section, but describe where they are allocated in the BHC's documentation supporting the FR Y-14A submission.

Line item 18F Credit

Generally corporate bonds, loans, ABS, muni, emerging markets, CDS. If a BHC classifies some of the credit related trading (such as distressed debt) in segments other than "Sales & Trading," it can continue to report it as in its internal financial reports but indicate where they are reported in the documentation supporting FR Y-14A submission.

Line item 18G Other

Report other fixed income products if not included above (e.g., FX/Currencies).

Line item 18H Commodities

This item is a shaded cell and is derived, per column, from the sum of items 18I and 18J.

Line item 18I Commission and Fees

Report commissions, fees, and trading gains and losses on commodity products. Exclude prime brokerage services.

Line item 18J Other

Report other noninterest income generated from commodity products, excluding prime brokerage

services.

Line item 18K Prime Brokerage

This item is a shaded cell and is derived, per column, from the sum of items 18L and 18M. Report in the appropriate sub-item noninterest income from securities financing, securities lending, custody, clearing, settlement, and other services for hedge funds and other prime brokerage clients. Include all prime brokerage revenues in this line and not in any other business segments/lines.

Line item 18L Commission and Fees

Report commissions and fees on prime brokerage services.

Line item 18M Other

Report other noninterest income generated from prime brokerage services.

Line item 19 Investment Management

This item is a shaded cell and is derived, per column, from the sum of items 19A and 19B. Report in the appropriate sub-item all noninterest income generated from investment management activities.

Line item 19A Asset Management

Professional management of mutual funds and institutional accounts. Institutional clients may include endowments, not-for-profit entities, governments, and others.

Line item 19B Wealth Management/Private Banking (WM/PB)

Professional portfolio management and advisory services for individuals. Individual clients may be defined as mass market, affluent, and high net worth. Activities may also include tax planning, savings, inheritance, and wealth planning, among others. May include deposit and lending services to WM/PB clients here and retail brokerage services for both WM/PB and non WM/PB clients.

Line item 20 Investment Services

This item is a shaded cell and is derived, per column, from the sum of items 20A, 20D, and 20E. Report in the appropriate sub-item all noninterest income generated from investment servicing. Exclude prime brokerage revenues.

Line item 20A Asset Servicing

This item is a shaded cell and is derived, per column, from the sum of items 20B and 20C. Report in the appropriate sub-item all noninterest income from custody, fund services, securities lending, liquidity services, collateral management, and other asset servicing. Include record keeping services for 401K and employee benefit plans, but exclude funding or guarantee products offered to such clients.

Line item 20B Securities Lending

Report noninterest income generated from securities lending.

Line item 20C Other

Report all other noninterest income asset servicing, excluding securities lending.

Line item 20D Issuer Services

Corporate trust, shareowner services, depository receipts, and other issuer services.

Line item 20E Other

Report noninterest income from clearing and other investment services not included above.

Line item 21 Treasury Services

Report cash management, global payments, working capital solutions, deposit services, and trade finance from business and institutional entities of both medium and large size. Include wholesale and commercial cards.

Line item 22 Insurance Services

Report all noninterest income from insurance activities including, but not limited to, individual (e.g., life, health), auto and home (property and casualty), title insurance and surety insurance, and employee benefits insurance.

Line item 23 Retirement/Corporate Benefit Products

Report premiums, fees, and other noninterest income generated from retirement and corporate benefit funding products, such as annuities, guaranteed interest products, and separate account contracts. The fees/revenues that may be recorded here are generally generated as a result of the BHC accepting risks related to actuarial assumptions or the estimation of market returns where guarantees of future income streams have been made to clients.

Line item 24 Corporate/Other

Report noninterest income associated with:

- Capital and asset-liability management (ALM) activities. Among other items, may include investment securities portfolios (but not gains and losses on AFS and HTM securities, including OTTI, as these are excluded from PPNR by definition). Also may include principal investment supporting the corporate treasury function to manage firm-wide capital, liquidity, or structural risks.
- Run-off or liquidating businesses¹² (but exclude retail and small business run-off/liquidating businesses, per Retail and Small Business segment definition)
- Non-financial businesses (e.g., publishing, travel services)
- Corporate support functions (e.g., Human Resources, IT)
- Other non-core revenues not included in other segments (e.g., intersegment eliminations).

Line item 25 Optional Immaterial Business Segment

BHCs have the option to report less material business segment revenue in separate line items "Optional Immaterial Business Segments". The reported total optional immaterial business segment revenue relative to total revenue cannot exceed 10 percent. If the total immaterial business segment revenue relative to total revenue would be greater than 10 percent in any of the most recent four actual quarters as provided by the BHC in the FR Y-14Q, report data for the largest business segment among the immaterial business segments for all quarters in the PPNR Projections and PPNR Metrics sub-schedules such that the amount reported in the Optional Immaterial Business segments line items does not exceed 10 percent. BHCs should provide comprehensive information in the Supportig Documendation on which business segments are included in the Optional Immaterial Business segments line items in both FR Y-14Q and FR Y-14A schedules, their relative contribution to the totals reported in both schedules and the manner in which the

revenues were projected for FR Y-14A purposes. List segments included in this line item in Footnote 7.

Line item 26 Total Noninterest Income

This item is a shaded cell and is derived, per column, from the sum of items 14, 15, 16, 17, 18, 19, 20, and 21 through 25. Excludes Valuation Adjustment for firm's own debt under fair value option (FVO) reported in item 40 and the result of trading shock exercise (where applicable), as it is reported in item 42.

Line item 27 Total Revenues

This item is a shaded cell and is derived, per column, from the sum of items 13 and 26.

Noninterest Expense Components

Noninterest Expense figures are to be broken out as detailed on the sub-schedule. The total is expected to reconcile with what would be reported in the FR Y-9C when adjusted for certain items. As presented on the PPNR sub-schedules, the adjustments include exclusions of goodwill impairment and adjustments related to operational risk expense required for PPNR purposes. For the related items, reference PPNR Projections sub-schedule and related instructions for the line items 29 and 41.

Expense data on the PPNR Submission sub-schedule are only intended to be reported as firm-wide BHC expenses, with exception of line item 34A, i.e. Marketing Expense for Domestic Credit Cards. This line item is for Domestic Credit Cards business line only. See the description of the Domestic Credit Card business line in the Business Segment Definitions section of the document.

If the Worker's Compensation expense is an expected item, or is regularly budgeted and paid out similar to an insurance premium or accrual of agreed-upon expenses, then a BHC would report it as Compensation expense or line item 28. If the Worker's Compensation results from a legal settlement, or is part of a large payout to prevent litigation, solve a complaint, or satisfy a penalty or fine, then a BHC would report it in line item 29 with Operational Risk Expenses.

Line item 28 Compensation Expense

This item is a shaded cell and is derived, per column, from the sum of items 28A through 28E.

Line item 28A Salary

Exclude stock based and cash variable pay compensation and report in items 28D and 28E, respectively.

Line item 28B Benefits

Exclude stock based and cash variable pay compensation and report in items 28D and 28E, respectively.

Line item 28C Commissions.

Report commissions only in "Commissions" line item 28C; do not report commissions in any other compensation line items.

Line item 28D Stock Based Compensation

Report all expenses related to stock based compensation as defined by ASC Topic 718, Compensation-Stock Compensation (formerly FASB Statement No. 123(R), *Shared-Based Payment*).

Line item 28E Cash Variable Pay

Report expenses related to all discretionary variable compensation paid (or to be paid) in the form of cash. Include deferred variable compensation plans not associated with BHC stock.

Line item 29 Operational Risk Expense

This item is a shaded cell and is derived, per column, from the item on the OpRisk Projected Losses Sub-schedule. All operational loss items, including operational losses that are contra revenue amounts or cannot be separately identified, should be reported in the operational risk expense. Any legal consultation or retainer fees specifically linked to an operational risk event should be included in the Operational Risk Expense. Include all provisions to litigation reserves/liability for claims related to sold residential mortgages and all litigation settlements and penalties in this line item and not in any other line item. The reporting of the operational risk expense item will not necessarily be consistent with FR Y-9C reporting.

Line item 30 Provisions to Repurchase Reserve/Liability for Residential Mortgage Representations and Warranties

Provisions to build any non-litigation reserves/accrued liabilities that have been established for losses related to sold or government-insured residential mortgage loans (first or second lien). Do not report such provisions in any other items; report them only in line items 14N or 30, as applicable. Exclude all provisions to litigation reserves/liability for claims related to sold residential mortgages (report in item 29).

Line item 31 Professional and Outside Services Expenses

Among items included are routine legal expenses (i.e., legal expenses not related to operational losses), audit and consulting fees, and other fees for professional services.

Line item 32 Expenses of Premises and Fixed Assets

Report expenses of premises and fixed assets, as defined in the FR Y-9C, Schedule HI, item 7.b.

Line item 33 Amortization Expense and Impairment Losses for Other Intangible Assets

Report amortization expense and impairment losses for other intangible assets, as defined in the FR Y-9C, Schedule HI, item 7.c.(2).

Line item 34 Marketing Expense

This item is a shaded cell and is derived, per column, from the sum of items 34A and 34B.

Line item 34A Domestic Credit and Charge Card Marketing Expense

Include domestic BHC issued credit and charge cards, as defined in item 1B, including those that result from a partnership agreement. Include both direct and allocated expenses. Report any expenses that are made to expand the company's card member and/or merchant base, facilitate greater segment penetration, enhance the perception of the company's credit card brand, and/or increase the utilization of the existing card member base across the spectrum of marketing and advertising mediums.

Line item 34B Other

Report all marketing expenses not related to domestic credit and charge cards captured in line 34A.

Line item 35 Other Real Estate Owned Expense

All expenses associated with other real estate owned that would normally be reported in the FR Y-9C, Schedule HI, item 7.d., "Other noninterest expense".

Line item 36 Provision for Unfunded Off-Balance Sheet Credit Exposures (to build/decrease item 139 (BHCKB557) in Balance Sheet)

Report the provision for credit losses on off-balance sheet credit exposures normally reported as one of the items in FR Y-9C, Schedule HI, item 7.d.

Line item 37 Other Noninterest Expense

Provide a further break out of significant items included in Other Noninterest Expense in footnote 4, such that no more than 5% of Noninterest Expense are reported without further breakout.

Report the line item breakout for the combined 9 quarters of projected "Other noninterest expense" (line item 37). A quarterly breakout of these data should be included in the Supporting Documentation.

Line item 38 Total Noninterest Expense

This item is a shaded cell and is derived, per column, from the sum of items 28, 29 through 34, and 35 through 37. Excludes Goodwill Impairment included in item 41.

Line item 39 Projected PPNR

This item is a shaded cell and is derived, per column, from item 27 less 38. By definition, PPNR will calculate as net interest income plus noninterest income less noninterest expense, excluding items broken out in items 40 and 41.

Line item 40 Valuation Adjustment for Firm's Own Debt Under Fair Value Option (FVO)

List segments from which item was excluded in Footnote 9. In footnote 27, list FR Y-9C, Schedule HI items in which this amount is normally reported and has been excluded from in this reporting view.

Line item 41 Goodwill Impairment

Report impairment losses for goodwill, as defined in the FR Y-9C, Schedule HI, item 7.c.(1). Under GAAP (ASC 350-20-35-30), "Goodwill of a reporting unit shall be tested for impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount." However, it is acceptable for purposes of this exercise to provide annual estimates as long as the resulting quarterly capital projections would not differ materially from those generated using quarterly impairment projections.

Line item 42 Loss Resulting from Trading Shock Exercise (if applicable)

This item is a shaded cell and is derived, per column, from the sum of items 58 through 62 on the Sub-schedule 1.a, Income Statement. BHCs should not report changes in value of the MSR asset or hedges within the trading book. List segments from which item was excluded in Footnote 25.

A.7.b—PPNR Net Interest Income (NII) Sub-schedule

BHCs for which deposits comprise 25 percent or more of total liabilities for any period reported in any of the four most recent FR Y-14Q are required to submit the Net Interest Income sub-schedule. BHCs should complete non-shaded cells only; all shaded cells with embedded formulas will self-populate.

This sub-schedule requires BHCs to provide average asset and liability balances and average yields to calculate net interest income. The total net interest income calculated should equal the total net interest income reported using a business segment/line view in the PPNR Projections sub-schedule.

The average balances and rates are meant to reflect the average over each quarter as best as possible. The Federal Reserve understands that because of changes in balances over the period, the simple multiplication of average loan rates and balances may not yield the actual interest income. In these cases, the BHCs may report the average loan rate so that it equals a weighted average rate over the period and the interest income total for each quarter reflects historical results or the BHC's projection, as applicable. If the average rates are materially impacted by large shifts in balances over the period, highlight this in documentation supporting the FR Y-14A submission.

Rates on this sub-schedule are intended to provide a product level view exclusive of transfer pricing activity and should be reported on a gross basis. The reporting of net interest income on the PPNR Projections and PPNR Submission Sub-schedules provide a business line view and should be reported net of transfer pricing adjustments.

Average Assets

BHCs should reference FR Y-9C and other definitions provided in the PPNR Net Interest Income sub-schedule when completing this section. Align the asset categories definitions, where no FR Y9C code is provided, with those on the Balance Sheet sub-schedule of the FR Y-14A Summary Schedule. The FR Y-9C code references are intended only to provide guidance for the types of items to be included or excluded; but NOT the type of balance to be provided. All requested balance items are averages.

In the case of loans, align definitions with the “total loans” section of the Balance Sheet sub-schedule. Include purchased credit impaired loans PCI loan balances and the interest income recognized on these loans. However, report the aggregate of all nonaccrual loans as line item 9, rather than including them in each loan type. Although nonaccrual loans are reported in aggregate for reporting purposes, BHCs are encouraged to provide details on the nonaccrual loans by Balance Sheet sub-schedule definition, if available, in the documentation supporting their FR Y-14A submission.

Balance sheet forecasts are intended to be reported in a manner consistent with how the BHC reports such balances on the FR-Y9C based on the BHCK references in the notes column of the balance sheet sub-schedule, or otherwise in accordance with FR Y-14A reporting instructions where no references are provided. Such balances should then be reported consistently on the PPNR Net II Sub-schedule (in both FR Y-14A and FR Y-14Q schedules). If this reporting results in

recording certain non-earning assets in the average trading assets line on the PPNR Net II sub-schedule (or any other line item with an associated rate), a BHC should simply reduce the weighted average rate applied to that balance to ensure that income forecasts are calculated appropriately.

Average balances on the PPNR Net Interest Income sub-schedules (both on FR Y-14Q and FR Y-14A) are intended to be reported in a manner consistent with items on the Balance Sheet sub-schedule of FR Y-14A schedule. As such, average asset balances on PPNR Net Interest Income sub-schedule are to reconcile to average of asset balances based on FR Y-9C BHCK2170 (which reflects fair value of AFS securities).

Line item 1 First Lien Residential Mortgages (in domestic offices)

Report the average balance of first lien residential mortgages in domestic offices (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a), column B).

Line item 2 Second/Junior Lien Residential Mortgages (in domestic offices)

This item is a shaded cell and is derived, per column, from the sum of items 2A and 2B.

Line item 2A Closed-End Junior Liens

Report the average balance of second/junior lien residential mortgages in domestic offices (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b), column B).

Line item 2B Home Equity Lines of Credit (HELOCs)

Report the average balance of home equity lines of credit in domestic offices (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1), column B).

Line item 3 C&I Loans

Report the average balance of C&I Graded, Small Business (Scored/Delinquency Managed), Corporate Card, and Business Card loans.

Line item 4 CRE Loans (in domestic offices)

Report the average balance of CRE loans in domestic offices as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1), and 1.e.(2), column B.

Line item 5 Credit Cards

Report the average balance of credit cards (as defined in the FR Y-9C, Schedule HC-C, item 6.a, column A).

Line item 6 Other Consumer

This item is a shaded cell and is derived, per column, from the sum of items 6A through 6C.

Line item 6A Auto Loans

Report the average balance of auto loans as defined in the FR Y-9C, Schedule HC-C, item 6.c, column A.

Line item 6B Student Loans

Report the average balance of student loans.

Line item 6C Other (including loans backed by securities (non-purpose lending))

Report the average balance of other loans.

Line item 7 Real Estate Loans (not in domestic offices)

This item is a shaded cell and is derived, per column, from sum of items 7A and 7B. (Also, defined as FR Y-9C, Schedule HC-C, item 1, column A, less above items 1, 2, 5, and FR Y-9C, Schedule HC-C, item 1.b, column B.)

Line item 7A Residential Mortgages (first and second lien)

Report the average balance of first and second lien residential mortgages not in domestic offices.

Line item 7B Other

Report the average balance of other real estate loans not in domestic offices.

Line item 8 Other Loans and Leases

Report the average balance of other loans and leases. Include loans secured by farmland as defined in FR Y-9C, Schedule HC-C, item 1.b, column B, and other loans not accounted for in the above categories. If total net interest income does not reconcile to FR Y-9C total per PPNR definition using fair value average balances for AFS securities, use "Other" balances (line items 15 and 38) and corresponding rates (line items 31 and 46) to offset the difference.

Line item 9 Nonaccrual Loans

Report the average balance of nonaccrual loans, as defined in the FR Y-9C, Schedule HC-N, item 10 (Column C) less Schedule HC-N, item 9 (Column C). Institutions are to provide additional details within the supporting documentation; the composition of the non-accrual loans by key loan type over the reported time periods for each of the scenarios.

Line item 10 Securities (AFS and HTM) – Treasuries and Agency Debentures

Report the average balance of AFS/HTM balances in Treasury and Agency debentures, as defined in the FR Y-9C, Schedule HC-B, items 1, 2.a and 2.b, columns A and D.

Line item 11 Securities (AFS and HTM) – Agency RMBS (both CMOs and pass-throughs)

Report the average balance of AFS/HTM balances in Agency RMBS, as defined in the FR Y-9C, Schedule HC-B, items 4.a.(1), 4.a.(2), 4.b.(1) and 4.b.(2), columns A and D.

Line item 12 Securities (AFS and HTM) - Other

Report the average balance of all AFS/HTM investments not reported in items 10 and 11, defined in the FR Y-9C, Schedule HC, items 2.a and 2.b less Net II Sub-schedule items 10 & 11.

Line item 13 Trading Assets.

Report the average balance of trading assets as defined in the FR Y-9C, Schedule HC-K, item 4.a.

Line item 14 Deposits with Banks and Other

Report the average balance of deposits with banks.

Line item 15 Other Interest/Dividend-Bearing Assets

Report the average balance of other interest/dividend-bearing asset not accounted for in the above

categories (e.g. Fed Funds Sold, Repos, etc.). In Footnote 2, breakout and explain nature of significant items included in other average interest-bearing asset balances such that no more 5% of total average interest-bearing asset balances are reported without a further breakout.

Line item 16 Other Assets

Report the average balance of all non-interest bearing assets. Line 16 of the Net Interest Income Sub-schedule is intended for a BHC to report noninterest bearing assets, and accordingly is excluded from the calculation of interest income.

Line item 17 Total Average Asset Balances

This item is a shaded cell and is derived, per column, from sum of items 1, 2, 3 through 6, 7, and 8 through 16, as defined in the FR Y-9C, Schedule HC-K, item 5.

Average Rates Earned

All rates are annualized.

Line item 18 First Lien Residential Mortgages (in domestic offices)

Report the earned average rate of first lien residential mortgages in domestic offices as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a), column B.

Line item 19 Second/Junior Lien Residential Mortgages (in domestic offices)

This item is a shaded cell and is derived, per column, from sum of items 19A and 19B.

Line item 19A Closed-End Junior Liens

Report the earned average rate of second/junior lien residential mortgages in domestic offices as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b), column B.

Line item 19B Home Equity Lines of Credit (HELOCs)

Report the earned average rate of home equity lines of credit in domestic offices as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1), column B.

Line item 20 C&I Loans (excluding small business (scored/delinquency managed))

Report earned average rate of large commercial credits and small business (graded) loans. Note that the definitions for Large Commercial Credits and Small Business (Graded) are aligned with Balance Sheet definitions (e.g., in the current reports, consistent with CCAR 2012 Balance Sheet sub-schedule).

Line item 21 CRE Loans (in domestic offices)

Report the earned average rate of CRE loans in domestic offices as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1), and 1.e.(2), column B.

Line item 22 Credit Cards

Report earned average rate of credit cards as defined in the FR Y-9C, Schedule HC-C, item 6.a, column A.

Line item 23 Other Consumer

This item is a shaded cell and is derived, per column, from the sum of items 23A through 23C.

Line item 23A Auto Loans

Report earned average rate of auto loans as defined in the FR Y-9C, Schedule HC-C, item 6.c, column A.

Line item 23B Student Loans

Report earned average rate of student loans.

Line item 23C Other, incl. loans backed by securities (non-purpose lending)

Report earned average rate of other loans.

Line item 24 Real Estate Loans (not in domestic offices)

Item 24 is a shaded cell and is derived, per column, from sum of items 24A and 24B. (Also, defined as FR Y-9C, Schedule HC-C, item 1, column A, less above items 18, 19, 21, and FR Y-9C, Schedule HC-C, item 1.b, column B.)

Line item 24A Residential Mortgages (first and second lien)

Report the earned average rate of first and second lien residential mortgages not in domestic offices.

Line item 24B Other

Report the earned average rate of other real estate loans not in domestic offices.

Line item 25 Other Loans and Leases

Report the earned average rate of other loans and leases. Include loans secured by farmland as defined in Schedule HC-C, FR Y-9C, Schedule HC-C, item 1.b, column B, and other loans not accounted for in the above categories. If total net interest income does not reconcile to FR Y-9C total per PPNR definition using fair value average balances for AFS securities, use "Other" balances (line items 15 and 38) and corresponding rates (line items 27 and 43) to offset the difference.

Line item 26 Nonaccrual Loans

Report the earned average rate of nonaccrual loans. Interest income earned on nonaccrual balances is generally expected to be small.

Line item 27 Securities (AFS and HTM) – Treasuries and Agency Debentures

Report the earned average rate earned on AFS/HTM balances in Treasury and Agency debentures.

Line item 28 Securities (AFS and HTM) – Agency RMBS (both CMOs and pass-throughs)

Report the earned average rate earned on AFS/HTM balances in Agency RMBS.

Line item 29 Securities (AFS and HTM) - Other

Report the earned average rate earned on all other AFS/HTM balances.

Line item 30 Trading Assets

Report the earned average rate of trading assets as defined in the FR Y-9C, Schedule HC-K, item 4.a.

Line item 31 Deposits with Banks and Other

Report the earned average rate of deposits with banks.

Line item 32 Other Interest/Dividend-Bearing Assets

Report the earned average rate of other interest/dividend-bearing asset not accounted for in the above categories.

Line item 33 Total Interest Income

This item is a shaded cell and is derived, per column, from sum of the products of items 1 and 18, 2 and 19, 2A and 19A, 2B and 19B, 3 and 20, 4 and 21, 5 and 22, 6A and 23A, 6B and 23B, 6C and 23C, 7A and 24A, 7B and 24B, 8 and 25, 9 and 26, 10 and 27, 11 and 28, 12 and 29, 13 and 30, 14 and 31, & 15 and 32 annualized.

Average Liability Balances

For the classification of domestic and foreign deposit liabilities, BHCs should report based on internal definitions (those deemed to best represent the behavior characteristics of deposits). For all other liabilities, BHC should reference FR Y-9C and other definitions provided in the PPNR Net interest Income sub-schedule when completing this section.

Line item 34 Deposits-Domestic

This item is a shaded cell and is derived, per column, from sum of items 34A through 34E.

A sum of average domestic and foreign deposits should be equal to a sum of average FR Y-9C, Schedule HC, items 13.a.(1), 13.a.(2), 13.b.(1), and 13.b.(2).

Line item 34A Noninterest-bearing Demand

Report balances using internal definitions.

Line item 34B Money Market Accounts

Report balances using internal definitions.

Line item 34C Savings

Report balances using internal definitions.

Line item 34D Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other Transaction Accounts

Report balances using internal definitions.

Line item 34E Time Deposits

Report balances using internal definitions.

Line item 35 Deposits-Foreign

This item is a shaded cell and is derived, per column, from the sum of items 35A and 35B.

A sum of average domestic and foreign deposits should be equal to a sum of average FR Y-9C, Schedule HC, items 13.a.(1), 13.a.(2), 13.b.(1), and 13.b.(2).

Line item 35A Foreign Deposits

Report balances using internal definitions.

Line item 35B Foreign Deposits-Time

Report balances using internal definitions.

Line item 36 Fed Funds, Repos, & Other Short Term Borrowing

This item is a shaded cell and is derived, per column, from the sum of items 36A through 36C.

Line item 36A Fed Funds

Report the average balance of Fed Funds purchased in domestic offices as defined in the FR Y-9C, Schedule HC, item 14.a.

Line item 36B Repos

Report the average balance of Securities sold under agreement to repurchase as defined in the FR Y-9C, Schedule HC, item 14.b.

Line item 36C Other Short Term Borrowing

Report the average balance of liabilities reported as other borrowed money and subordinated notes and debentures (as defined in the FR Y-9C, Schedule HC, items 16 and items 19.a. which the firm would define as short term borrowings).

A sum of line items 36C (“other short term borrowing”) and 39 (“other interest bearing liabilities”) equals a sum of average BHCK3190, average BHCK4062, and average interest-bearing liabilities reported in BHCK2750; line item 40 (“other liabilities”) captures average non-interest bearing liabilities in BHCK2750.

Line item 37 Trading Liabilities

Report the average balance of Trading Liabilities as defined in the FR Y-9C, Schedule HC, item 15.

Line item 38 Subordinated Notes Payable to Unconsolidated Trusts Issuing Trust Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities

Report the average balance of Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities as defined in the FR Y-9C, Schedule HC, item 19b.

Line item 39 Other Interest-Bearing Liabilities

Report the average balance of liabilities reported as Other Borrowed Money and Subordinated Notes and Debentures as defined in the FR Y-9C, Schedule HC, items 16 and items 19a which are not already reported in line item 35c Other Short Term Borrowing. This includes all long-term debt not included in line item 38 above. A sum of line items 36C (“other short term borrowing”) and 39 (“other interest bearing liabilities”) equals a sum of average BHCK3190, average BHCK4062, and average interest-bearing liabilities reported in BHCK2750; line item 40 (“other liabilities”) captures average non-interest bearing liabilities in BHCK2750.

Line item 40 Other Liabilities

Report the average balance of liabilities reported as Other Liabilities as defined in the FR Y-9C, Schedule HC, item 20. A sum of line items 36C (“other short term borrowing”) and 39 (“other

interest bearing liabilities”) equals a sum of average BHCK3190, average BHCK4062, and average interest-bearing liabilities reported in BHCK2750; line item 40 (“other liabilities”) captures average non-interest bearing liabilities in BHCK2750.

Line item 41 Total Average Liability Balances

This item is a shaded cell and is derived, per column, from sum of items 34, 35, 36, and 37 to 40.

Average Liability Rates

All rates are annualized.

Line item 42 Deposits—Domestic

This item is a shaded cell and is derived, per column, from sum of items 42A through 42E.

Line item 42A Noninterest-bearing Demand

This item is a shaded cell; rates are equal to zero by definition.

Line item 42B Money Market Accounts

Report the earned average rate of Money Market Accounts reported in item 34B.

Line item 42C Savings

Report the earned average rate of Savings Accounts reported in item 34C.

Line item 42D Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other Transaction Accounts

Report the earned average rate of Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other Transaction Accounts reported in item 34D.

Line item 42E Time Deposits

Report the earned average rate of Time Deposits reported in item 34E.

Line item 43 Deposits-Foreign

This item is a shaded cell and is derived, per column, from the sum of items 43A and 43B.

Line item 43A Foreign Deposits

Report the earned average rate of Foreign Deposits reported in item 35A.

Line item 43B Foreign Deposits-Time

Report the earned average rate of Foreign Deposits—Time reported in item 35B.

Line item 44 Fed Funds, Repos, & Other Short Term Borrowing

This item is a shaded cell and is derived, per column, from the sum of items 44A through 44C.

Line item 44A Fed Funds

Report the average rate paid for Fed Funds purchased in domestic offices as defined in the FR Y-9C, Schedule HC, item 14a.

Line item 44B Repos

Report the average rate paid for Securities Sold under agreements to repurchase as defined in the FR Y-9C, Schedule HC, item 14b.

Line item 44C Other Short Term Borrowing

Report the average rate paid on liabilities reported as other borrowed money and subordinated notes and debentures as defined in the FR Y-9C, Schedule HC, items 16 and items 19a which the firm defined as short term borrowings.

Line item 45 Trading Liabilities

Report the average rate of Trading Liabilities as defined in the FR Y-9C, Schedule HC, item 15.

Line item 46 Subordinated Notes Payable to Unconsolidated Trusts Issuing Trust Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities

Report the average rate of Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities as defined in the FR Y-9C, Schedule HC, item 19b.

Line item 47 Other Interest-Bearing Liabilities

Report the average rate paid on the liabilities reported as other borrowed money and subordinated notes and debentures as defined in the FR Y-9C, Schedule HC, items 16 and 19a which the firm defined as Other Interest Bearing Liabilities.

Line item 48 Total Interest Expense

This item is a shaded cell and is derived, per column, from sum of the products of items 34A and 42A, 34B and 42B, 34C and 42C, 34D and 42D, 34E and 42E, 35A and 43A, 35B and 43B, 36A and 44A, 36B and 44B, 36C and 44C, 37 and 45, 38 and 46, and 39 and 47, annualized.

Line item 49 Total Net Interest Income

This item is a shaded cell and is derived, per column, from item 33 minus item 48. Amount should equal Sub-schedule 7.a, PPNR Submission Sub-schedule, item 13.

A.7.c—PPNR Metrics

The PPNR Metrics sub-schedule requests information on certain metrics relevant for the assessment of various components of PPNR. Elements in Section C of the PPNR Metrics sub-schedule (line items 53 through 87 and either 884A or 88B&C) are required only for BHCs that must complete the Net Interest Income sub-schedule. All other metrics are required of all BHCs, subject to applicable thresholds.

Metrics in Section A, "Metrics by Business Segment/Line," correspond to Business Segments/Lines on PPNR Submission sub-schedule. In contrast, Sections B and C are both for firm-wide metrics.

In providing industry market size information, BHCs can use third party data and are not required to independently derive these metrics. Any supporting information should be described in detail, including the data source, and corresponding data should be provided in the sub-schedule. A BHC, if relying upon third party data for building projections, should still be cognizant of how their estimates would be appropriate across the range of assumed macro-economic conditions in various scenarios or if some adjustment may be appropriate. BHCs should use internal definitions of proprietary trading and clearly describe the covered activities and transactions in methodology narratives.

If a BHC is unable to provide a metric on the PPNR Metrics sub-schedule, it should offer a data series for alternative metrics that are considered by the BHC in projecting the relevant component(s) of PPNR and include in the Supporting Documentation required with the FR-14A Projections a discussion of why the standard metric could not be provided.

Where applicable, respondents are encouraged to report actual utilized betas per the scenario.

Section A. Metrics by Business Segment/Line (unless specified otherwise, all numbers are global).

"Metrics by Business Segment/Line" correspond to Business Segments/Lines on the PPNR Submission Sub-schedule. This means that each metric is reflective of revenues reported on the PPNR Submission sub-schedule for a given business segment/line, unless explicitly stated otherwise.

Retail and Small Business Segment

Domestic

For line items 1 through 9, domestic includes U.S. and Puerto Rico only.

Credit and Charge Cards

Line item 1 Total Open Accounts – End of Period

Report number of total open accounts at the end of period for credit and charge cards.

Line item 2 Credit and Charge Card Purchase Volume

Report credit and charge card purchase volume, net of returns. Exclude cash and balance transfer volumes.

Line item 3 Credit and Charge Card Rewards/Partner Sharing Expense

Report credit card rewards/partner sharing expense for credit and charge cards.

In Footnote 23, list which line item(s) on PPNR Submission Sub-schedule contain(s) the Cards Rewards/Partner Sharing contra-revenues and/or expenses.

Note if this item includes any contra-revenues other than Rewards/Partner Sharing (e.g. Marketing Expense Amortization) in footnote 34.

Mortgages and Home Equity

Line item 4 Average Third-Party Residential Mortgages Serviced

Report the average outstanding principal balance for residential mortgage loans the BHC services for others.

Line item 5 Residential Mortgage Originations Industry Market Size – Volume

Report total volume of domestic mortgages that originated during the quarter. A BHC would provide US industry-wide origination volume (\$millions) for closed-end loans secured by first liens on 1 to 4 family residential properties during a given quarter. This would not include any home equity loans or lines of credit.

Line item 6 Mortgages and Home Equity Sold During the Quarter

Report first and junior lien mortgages and home equity loans sold during the quarter as defined in FR Y-9C, Schedule HC-P, items 3.a, 3.b, 3.c.(1), 3.c.(2). FR Y-9C name is "Residential Mortgages Sold During the Quarter"; this metric need not be limited to Mortgages and Home Equity business line.

Line item 7 Servicing Expenses

Report expenses for servicing first and junior lien mortgages and home equity loans. Include both direct and allocated expenses.

Retail and Small Business Deposits

Line item 8 Total Open Checking and Money Market Accounts – End of Period

Report only the number of checking and money market accounts that are deposit accounts under FR Y-9C guidance and are consistent with the definitions provided for "Retail and small business banking and lending services" segment and "Retail and small business deposits" business line within this segment in the PPNR instructions.

Line item 9 Debit Card Purchase Transactions

Report number of transactions (not dollar value).

International Retail and Small Business

International retail and small business located in regions outside the U.S. and Puerto Rico.

Line item 10 Credit and Charge Card Revenues

Provide metrics data for all quarters, but only if international retail and small business segment revenues exceeded 5% of total retail and small business segment and total retail and small business revenue exceeded 5% of total revenues in any of the last four actual quarters requested in the PPNR schedule.

Investment Banking Segment

Line item 11 Number of Employees

Report the number of full-time equivalent employees at end of current period as defined in the FR Y-9C, Schedule HI, Memorandum item 5, for investment banking segment.

Line item 12 Compensation - Total

Include both direct and allocated expenses for investment banking segment.

Line item 13 Stock Based Compensation and Cash Variable Pay

Include both direct and allocated expenses for investment banking segment.

Advisory

Line item 14 Deal Volume

Report the global dollar volume of all completed deals for the reporting BHC.

Line item 15 Industry Market Size - Fees

Report global fees earned by all relevant industry participants in this area.

Line item 16 Industry Market Size - Completed Deal Volume

Report the global dollar volume of completed deals for all relevant industry participants.

Line item 17 Backlog

A global backlog should be based on probability weighted fees. The data should be consistent with historical internal reporting, not by market measurement. The last quarter should be the BHC's latest backlog estimate. Backlog reporting is not required on a projections basis.

Equity Capital Markets

Line item 18 Deal Volume

Report the global dollar volume of all deals for the reporting BHC.

Line item 19 Industry Market Size - Fees

Report global fees earned by all relevant industry participants in this area.

Line item 20 Industry Market Size - Volume

Report global dollar volume of completed deals for all relevant industry participants.

Debt Capital Markets

Line item 21 Deal Volume

Report the global dollar volume of all deals for the reporting BHC.

Line item 22 Industry Market Size - Fees

Report global fees earned by all relevant industry participants in this area.

Line item 23 Industry Market Size - Volume

Report the global dollar volume of completed deals for all relevant industry participants.

Syndicated Lending

Line item 24 Deal Volume

Report the global dollar volume of all deals for the reporting BHC.

Line item 25 Industry Market Size - Fees

Report global fees earned by all relevant industry participants in this area.

Line item 26 Industry Market Size - Volume

Report the global dollar volume of completed deals for all relevant industry participants.

Merchant Banking/Private Equity

Line item 27 Assets Under Management (AUM)

Report total assets under management for this division.

Sales and Trading Segment

Line item 28 Number of Employees

Report the number of full-time equivalent employees at end of current period as defined in the FR Y-9C, Schedule HI, Memorandum item 5, for sales and trading segment.

Line item 29 Total Proprietary Trading Revenue

Report total proprietary trading revenue.

Line item 30 Compensation - Total

Include both direct and allocated expenses for sales and trading segment.

Line item 31 Stock Based Compensation and Cash Variable Pay

Include both direct and allocated expenses for sales and trading segment.

Equities

Line item 32 Average Asset Balance

Report average asset balance for the quarter of all mark-to-market assets associated directly with the equity sales and trading businesses.

Fixed Income

Line item 33 Average Asset Balance

Report average asset balance for the quarter of all mark-to-market assets associated directly with the fixed income sales and trading businesses.

Commodities

Line item 34 Average Asset Balance

Report average asset balance for the quarter of all mark-to-market assets associated directly with the commodities sales and trading businesses.

Prime Brokerage

Line item 35 Average Client Balances

Report the grossed up "interest balances" that result from prime brokerage activities.

Line item 36 Transaction Volume

Report total dollar volume of all transactions during the quarter.

Investment Management Segment

Asset Management

Line item 37 AUM - Total

This item is a shaded cell and is derived, per column, from the sum of items 37A through 37C.

Line item 37A AUM - Equities

Report total assets under management for which the investment mandate/strategy is primarily equities.

Line item 37B AUM - Fixed Income

Report total assets under management for which the investment mandate/strategy is primarily

fixed income.

Line item 37C AUM – Other

Report total assets under management for which the investment mandate/strategy cannot be classified as either Equities or fixed income. For example, include alternative investments, currency products, etc.

Line item 38 Net Inflows/Outflow

Report impact of net inflows/outflows on assets under management.

Wealth Management/Private Banking

Line item 39 AUM – Total

This item is a shaded cell and is derived, per column, from the sum of items 39A through 39C.

Line item 39A AUM – Equities

Report total assets under management for which the investment mandate/strategy is primarily equities.

Line item 39B AUM – Fixed Income

Report total assets under management for which the investment mandate/strategy is primarily fixed income.

Line item 39C AUM – Other

Report total assets under management for which the investment mandate/strategy cannot be classified as either Equities or fixed income. For example, include alternative investments, currency products, etc.

Line item 40 Net Inflows/Outflow

Report impact of net inflows/outflows on assets under management.

Line item 41 Number of Financial Advisors

Provide a relevant headcount number (e.g. financial advisors, portfolio managers) to facilitate the assessment of revenue productivity in the Wealth Management/Private Banking business line.

Investment Services Segment

Asset Servicing

Line item 42 Assets under Custody and Administration

Report total assets under custody and administration as of the end of the quarter.

Issuer Services

Line item 43 Corporate Trust Deals Administered

Report total number of deals administered during the quarter.

Section B. Firm Wide Metrics: PPNR Projections Sub-schedule

Line item 44 Number of Employees

Report the number of full-time equivalent employees at end of current period as defined in the FR Y-9C, Schedule HI, Memorandum item 5.

Line item 45 Revenues – International

This item is a shaded cell and is derived, per column, from the sum of items 45A through 45D. These items are based on holding company consolidated reporting and not on legal-entity basis.

Line item 45A Revenues - APAC

Provide Asia and Pacific (includes South Asia, Australia, and New Zealand) region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule. For specific country assignments, use internal definitions.

Line item 45B Revenues - EMEA

Provide Europe, Middle East, and Africa region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule. For specific country assignments, use internal definitions.

Line item 45C Revenues - LatAm

Provide Latin America, including Mexico region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule. For specific country assignments, use internal definitions.

Line item 45D Revenues - Canada

Provide Canada region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule.

Line item 46 Revenues – Domestic

This item is a shaded cell and is derived, per column, from PPNR Submission Sub-schedule item 27 less item 45. The item will capture all revenues so long as international revenues do not exceed 5% of total revenue in any of the last four actual quarters requested in the PPNR schedule.

Line item 47 Severance Costs

In Footnote 14, list items on PPNR Submission sub-schedule that include this item if any.

Line item 48 Collateral Underlying Operating Leases for Which the Bank is the Lessor

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 126.

Refers to the balance sheet carrying amount of any equipment or other asset rented to others under operating leases, net of accumulated depreciation. This item should correspond to the amount provided in the FR Y-9C, Schedule HC-F item 6 (see item 13 in the instructions). The amount included should only reflect collateral rented under operating leases and not include collateral subject to capital/ financing type leases.

Line item 48A Auto

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 127.

Line item 48B Other

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 128.

Line item 49 OREO Balance

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 122, as defined in the FR Y-9C, Schedule HC, item 7. Reporting of OREO items on FR Y-14Q PPNR Metrics is expected to be consistent with reporting of OREO items on FR Y-14A PPNR Metrics sub-schedule which sources the data directly from FR Y-14A Balance Sheet sub-schedule. Thus, reporting of OREO items on FR Y-14Q PPNR Metrics sub-schedule is consistent with reporting of OREO items on FR Y-14A Balance Sheet sub-schedule.

Line item 49A Commercial

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 123.

Line item 49B Residential

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 124.

Line item 49C Farmland

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 125.

Line item 50 Non-Recurring PPNR Items

Report the total income statement impact of all material non-recurring and infrequent items. Examples of such items include gains or losses on sales of business lines, gains or losses on extinguishment of debt, gains or losses on mergers / joint ventures, etc. Break out and explain these excluded items in footnote 32.

Line item 51 Trading Revenue

Report trading revenue as defined in the FR Y-9C, Schedule HI, item 5.c.

Line item 52 Net Gains/(Losses) on Sales of Other Real Estate Owned

Report trading revenue as defined in the FR Y-9C, Schedule HI, item 5.j.

In Footnote 19, list business segments reported on PPNR Submission Sub-schedule that include this item, if any.

Section C. Firm Wide Metrics: Net Interest Income Sub-schedule (Required only for BHCs that were required to complete the Net Interest Income Sub-schedule)

Line item 53 Carrying Value of Purchased Credit Impaired (PCI) Loans

Report trading revenue as defined in the FR Y-9C, Schedule HC-C, memorandum item M.5.b.

Line item 54 Net Accretion of discount on PCI Loans included in interest Revenues

Report the net accretion of discount on PCI loans included in net interest income as included on the PPNR Submission Sub-schedule and Net Interest Income Sub-schedule.

Line item 55 Loans Held for Sale – First Lien Residential Liens in Domestic Offices (Average Balances)

Report average balance of first lien residential loans held for sale as included in the Net Interest Income Sub-schedule.

Line item 56 Average Rate on Loans Held for Sale – First Lien Residential Liens in Domestic Offices

Report average rate paid on first lien residential loans held for sale as included in the Net Interest Income Sub-schedule.

Quarter End Weighted Average Life of Assets

The Weighted Average Life (WAL) should reflect the current position, the impact of new business activity, as well as the impact of behavioral assumptions such as prepayments or defaults, based on the expected remaining lives, inclusive of behavioral assumptions. It should reflect the weighted average of time to principal actual repayment (as modeled) for all positions in that portfolio, rounded to the nearest monthly term. For revolving products, the WAL should reflect the underlying repayment behavior assumptions assumed by the institution, which would include contractual repayments, any assumed excess payments or prepayments, and defaults. The WAL for the FR Y-14Q disclosures should reflect the spot balance sheet position for each time period. The WAL should be reflective of the timing assumed by the institutions for those assets/liabilities trading portfolios to be held on the balance sheet and not at the individual position level. For the FR Y-14A, given that it covers forecasted time periods, the WAL should be forward-looking which incorporates the changes to the projected WAL, including new business activity. Reference the PPNR Net Interest Income sub-schedule for product definitions.

Line item 57 First Lien Residential Mortgages (in Domestic Offices)

Report the quarter end weighted average life of domestic first lien residential mortgages (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a), column B).

Line item 58 Closed-End Junior Residential Liens (in Domestic Offices)

Report the quarter end weighted average life of domestic closed-end junior residential liens (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b), column B).

Line item 59 Home Equity Lines Of Credit (HELOCs)

Report the quarter end weighted average life of domestic home equity lines of credit (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1), column B).

Line item 60 C&I Loans

Report the quarter end weighted average life of C&I Graded, Small Business (Scored/Delinquency Managed), Corporate Card, and Business Card loans.

Line item 61 CRE Loans (in Domestic Offices)

Report the quarter end weighted average life of domestic CRE loans (as defined in the FR Y-9C, Schedule HC-C, the sum of items 1.a.(1), 1.a.(2), 1.d., 1.e.(1) 1.e.(2)), Column B.

Line item 62 Credit Cards

Report the quarter end weighted average life of credit cards (as defined in the FR Y-9C, Schedule HC-C, item 6.a., column A).

Line item 63 Auto Loans

Report the quarter end weighted average life of auto loans (as defined in the FR Y-9C, Schedule HC-C, item 6.c., column A).

Line item 64 Student Loans

Report the quarter end weighted average life of student loans.

Line item 65 Other, incl. loans backed by securities (non-purpose lending)

Report the quarter end weighted average life of Other Consumer Loans, incl. loans backed by securities (non-purpose lending).

Line item 66 Residential Mortgages (First and Second Lien, Not in Domestic Offices)

Report the quarter end weighted average life of all residential mortgages (first and second lien) not in domestic offices.

Line item 67 Other Real Estate Loans (Not in Domestic Offices)

Report the quarter end weighted average life of other real estate loans not in domestic offices.

Line item 68 Other Loans & Leases

Report the quarter end weighted average life of other loans and leases. Include loans secured by farmland (as defined in the FR Y-9C, Schedule HC-C, item 1.b, column B), and other loans not accounted for in the above categories.

Line item 69 Securities (AFS and HTM) - Treasuries and Agency Debentures

Report the quarter end weighted average life of AFS/HTM balances in Treasury and Agency Debentures (as defined in the FR Y-9C, Schedule HC-B, items 1, 2.a and 2.b, columns A and D). The WAL reporting items (items 69-71) on PPNR Metrics within the Summary Schedule is intended to reflect the weight average remaining life for the reported period. The number is to reflect both the weighted average life of the current positions as well as the impact of assumed new business.

Line item 70 Securities (AFS and HTM) - Agency RMBS (both CMOs and pass-throughs)

Report the quarter end weighted average life of AFS/HTM balances in Agency RMBS (as defined in the FR Y-9C, Schedule HC-B, items 4.a.(1), 4.a.(2), 4.b.(1) and 4.b.(2), columns A and D). The WAL reporting items (items 69-71) on PPNR Metrics within the Summary Schedule is intended to reflect the weight average remaining life for the reported period. The number is to reflect both the

weighted average life of the current positions as well as the impact of assumed new business.

Line item 71 Securities (AFS and HTM) - Other

Report the quarter end weighted average life of all other AFS/HTM (defined in the FR Y-9C, Schedule HC, as items 2.a and 2.b less PPNR Metrics Sub-schedule line items 69 & 70). The WAL reporting items (items 69-71) on PPNR Metrics within the Summary Schedule is intended to reflect the weight average remaining life for the reported period. The number is to reflect both the weighted average life of the current positions as well as the impact of assumed new business.

Line item 72 Trading Assets

Report the quarter end weighted average life of trading assets (as defined in the FR Y-9C, Schedule HC-K, item 4.a.). For trading assets, WAL should be reflective of the timing assumed by the institutions for those assets to be held on the balance sheet and not necessarily the duration of the underlying positions.

Line item 73 All Other Earning Assets

Report the quarter end weighted average life of all other interest-bearing assets not accounted for in the above categories.

Quarter End Weighted Average Life of Liabilities

The Weighted Average Life (WAL) should reflect the current position, the impact of new business activity, as well as the impact of behavioral assumptions such as prepayments or defaults, based on the expected remaining lives, inclusive of behavioral assumptions. It should reflect the weighted average of time to principal actual repayment (as modeled) for all positions in that portfolio, rounded to the nearest monthly term. For revolving products, the WAL should reflect the underlying repayment behavior assumptions assumed by the institution, which would include contractual repayments, any assumed excess payments or prepayments, and defaults. The WAL for the FR Y-14Q disclosures should reflect the spot balance sheet position for each time period. For the FR Y-14A, given that it covers forecasted time periods, the WAL should be forward-looking which incorporates the changes to the projected WAL, including new business activity. Reference PPNR Net Interest Income sub-schedule for product definitions.

Line item 74 Domestic Deposits - Time

Report the quarter end weighted average life for Domestic Time Deposits (using internal definitions).

Line item 75 Foreign Deposits - Time

Report the quarter end weighted average life of Foreign Time Deposits (using internal definitions).

Line item 76 Fed Funds

Report the quarter end weighted average life of Fed Funds purchased in domestic offices (as defined in the FR Y-9C, Schedule HC, item 14.a.).

Line item 77 Repos

Report the quarter end weighted average life of Securities sold under agreement to repurchase (as defined in the FR Y-9C, Schedule HC, item 14.b.).

Line item 78 Other Short Term Borrowing

Report the quarter end weighted average life of liabilities reported as other borrowed money and subordinated notes and debentures (as defined in the FR Y-9C, Schedule HC, items 16. and 19.a., of which the firm would define as short term borrowings).

Line item 79 Trading Liabilities

Report the weighted average life of Trading Liabilities (as defined in the FR Y-9C, Schedule HC, item 15). For trading liabilities, WAL should be reflective of the timing assumed by the institutions for those assets to be held on the balance sheet and not necessarily the duration of the underlying positions.

Line item 80 Subordinated Notes Payable to Unconsolidated Trusts Issuing TruPS and TruPS Issued by Consolidated Special Purpose Entities

Report the quarter end weighted average life of Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities (as defined in the FR Y-9C, Schedule HC, item 19.b.).

Line item 81 All Other Interest Bearing Liabilities

Report the quarter end weighted average life of all long-term debt not included in line item 80 above.

Average Domestic Deposit Repricing Beta in a in a “Normal Environment”

Domestic deposit repricing is rate movement in an environment where the repricing assumption assumed by each of the major deposit products is not restricted by a cap, floor, or zero. Beta should be reported as a balance-weighted average of the betas of the line items that contribute to the roll up point requested. The as of date of the balance weights must be equal to the reporting date for all applicable scenarios.

For the balance-weighted average beta, each deposit category should be reported using a blend of brokered and retail deposits. Beta refers to the average repricing response rate the firm projects for each of the deposit products relative to movements in interest rates.

The betas for line items 82 through 85 should be reported in basis points (bp) movement in the yield curve, either up or down in relationship to an assumed 100 bps movement and specific to each scenario, if applicable. For beta-related line items 82 to 87 on the PPNR Metrics template, a negative number can be reported in the downward rate movements. However, a negative would be indicating that the firm is projecting an “increase” in the beta when rates movements are down.

Line item 82 Money Market Accounts

Report (in decimal form basis points) the balance-weighted average beta of domestic money market accounts (using internal definitions for this product).

Line item 83 Savings

Report (in basis points) the balance-weighted average beta of domestic savings accounts (using internal definitions for this product).

Line item 84 NOW, ATS, and other Transaction Accounts

Report (in basis points) the balance-weighted average beta of Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other transaction accounts (using internal definitions for these products).

Line item 85 Time Deposits

Report (in basis points) the balance-weighted average beta of time deposits (using internal definitions for this product).

Average Foreign Deposit Repricing Beta in a in a “Normal Environment”

Foreign deposit repricing is rate movement in an environment where the repricing assumption assumed by each of the major deposit products is not restricted by a cap, floor, or zero. Beta should be reported as a balance-weighted average of the betas of the line items that contribute to the roll up point requested. The as of date of the balance weights must be equal to the reporting date for all applicable scenarios.

For the balance-weighted average beta, each deposit category should be reported using a blend of brokered and retail deposits. Beta refers to the average repricing response rate the firm projects for each of the deposit products relative to movements in interest rates.

The beta ratios for line items 86 through 88C should be reported in basis points (bp) movement in the yield curve, either up or down in relationship to an assumed 100 bps movement and specific to each scenario, if applicable.

Line item 86 Foreign Deposits

Report (in basis points) the balance-weighted average beta of foreign deposits (using internal definitions for this product).

Line item 87 Foreign Deposits-Time

Report (in basis points) the balance-weighted average beta of foreign time deposits (using internal definitions for this product). It is appropriate to report this item as a “balance-weighted average beta of foreign time deposits.

Line item 88 New Domestic Business Pricing for Time Deposits

New business pricing for time deposits refers to the anticipated average rate on newly issued time deposits, including renewals. Given that time deposits have a stated maturity, all time deposits issued for that time period are considered new business. The sub-schedule is requesting re-pricing beta under normal rate scenarios for both an upward and downward rate movement.

Line item 88A Curve (if multiple terms assumed)

Report the primary reference curve used by the firm for pricing time deposits.

If more than one curve for the pricing of time deposits is used, the curve used to price the majority of the time deposits should be noted on the schedule and additional pricing information should be provided in the supplementary information. If the institution only assumes a single maturity term

for new issuance, then the institution should provide the relative index (line item 88B) and spread used to estimate new business pricing in lieu of the curve (line item 88C).

The term “curve” refers to the reference rate used to price time deposits. Given that the pricing of time deposits is dependent on the term, the institution should provide the overall curve used to price time deposits.

Line item 88B Index Rate (if single term assumed)

Report the index (e.g., 30 day LIBOR) used to price time deposits when a single maturity term for new issuances is assumed. The index should be the one to which the beta in line item 85 is applied.

Line item 88C Spread (Relative to the Index Rate)

Report the weighted average spread used to price time deposits above the index rate when a single maturity term for new issuances is assumed.

Schedule B—Scenario

These instructions provide guidance for reporting the variables used in the firm-defined macroeconomic scenarios underlying the projections of losses, revenue, and capital. These scenarios include the supervisory baseline scenario, supervisory adverse scenario, supervisory severely adverse, BHC baseline scenario, and BHC stress scenario, as well as, any additional scenarios generated by the firm or supplied by the Federal Reserve. (Additional Scenario #1; Additional Scenario #2; etc.)

The template consists of three sub-schedules that each BHC must complete. Additional sub-schedules are provided if the BHC generated additional variables for the supervisory scenarios or reported additional scenarios beyond the BHC baseline and BHC stress scenarios. The sub-schedules in the template are:

Scenario Variable Definitions: This sub-schedule should be used to list and define the variables included in the BHC baseline and BHC stress scenarios, as well as, any additional BHC scenarios reported.

- The sub-schedule provides space for the supervisory baseline scenario, supervisory adverse scenario, supervisory severely adverse scenario, BHC baseline scenario, and BHC stress scenario, as well as, space for an additional scenario. The sections for the BHC baseline and BHC stress scenarios must be completed. If no additional scenarios are provided, then this section of the sub-schedule may be left blank. If one or more additional scenarios are provided, then a section should be created for each additional scenario and labeled accordingly (Additional Scenario #1; Additional Scenario #2; etc.)
- For each scenario, list the variables included in the scenario in the column titled "Variable Name."
- Variable definitions should be provided in the column titled "Variable Definition." Variable definitions should include a description of the variable and the denomination and/or frequency of the variable (e.g., "Billions of 2005 dollars" or "in percent, average of monthly values").
- The forecasts and historical data for all the scenario variables are constructed on the same basis. Thus, if a variable is, over history, constructed as an average, its forecast should be interpreted as an average as well. For reference, below are the definitions (i.e. period-average or period-end) of the financial market variables in the scenario:
 - U.S. 3-month Treasury yield: Quarterly average of 3-month Treasury bill secondary market rate discount basis.
 - U.S. 10-year Treasury yield: Quarterly average of the yield on 10-year U.S. Treasury bonds.
 - U.S. BBB corporate yield: Quarterly average of the yield on 10-year BBB-rated corporate bonds.
 - U.S. mortgage rate: Quarterly average of weekly series of Freddie Mac data.
 - U.S. Dow Jones Total Stock Market Index: End of quarter value, Dow Jones.
 - U.S. Market Volatility Index (VIX): Chicago Board Options Exchange converted to quarterly by using the maximum value in any quarter.
- For convenience, the sub-schedule provides space for 10 variables per scenario, but any number of variables may be reported, depending on the variables actually used in the scenario. Extra

lines may be created as needed. The same variables do not necessarily have to be included in each scenario.

- Firms should include all economic and financial market variables that were important in projecting results, including those that affect only a subset of portfolios or positions. For example, if asset prices had a meaningful impact, the assumed level of the equity market and interest rates should be included, or if bankruptcy filings affect credit card loss estimates, then the assumed levels of these should be reported.
- For additional variables generated for the supervisory adverse scenario or supervisory severely adverse scenario, BHCs should set the paths to be as consistent as possible with the paths of the variables already specified in the scenario.
- Firms should also include any variables capturing regional or local economic or asset value conditions, such as regional unemployment rates or housing prices, if these were used in the projections.
- Firms should include historical data, as well as projections, for any macroeconomic, regional, local, or financial market variables that are not generally available. Historical data for these variables can be included in a separate sub-schedule.

B.1—Supervisory Baseline Scenario

This sub-schedule should be used to report the values of any additional variables generated for the supervisory baseline scenario.

B.2—Supervisory Adverse Scenario

This sub-schedule should be used to report the values of any additional variables generated for the supervisory adverse scenario.

B.3—Supervisory Severely Adverse Scenario

This sub-schedule should be used to report the values of any additional variables generated for the supervisory severely adverse scenario.

B.4—BHC Baseline Scenario

This sub-schedule should be used to report the values of the variables included in the BHC baseline scenario.

B.5—BHC Adverse Scenario

This sub-schedule should be used to report the values of the variables included in the BHC stress scenario.

B.6+ —Additional Scenario #1/#2/etc.

These sub-schedules should be used to report the values of the variables included in any additional scenarios.

Please create a separate sub-schedule (tab) for each additional scenario. Name the sub-schedules “Additional Scenario #1;” “Additional Scenario #2;” etc.

All Scenarios: The following applies to all of the Scenario tabs:

- The variables should be the same (and have the same names) as the variables listed

in the corresponding sections of the *Scenario Variable Definitions* Sub-schedule.

- List quarterly values for the variables starting with the last realized value through the end of the forecast horizon.
- If a BHC needs to infer a monthly (instead of quarterly) progression of variables, it should smooth or prorate the variables, rather than holding the quarterly value constant over the quarter months.
- Please enter all variables as levels rather than as changes or growth rates (for instance, the dollar value of real GDP rather than the GDP growth rate).

Schedule C—Regulatory Capital Instruments

General guidance

The Regulatory Capital Instruments annual (FR Y-14A) schedule collects actual (historical) data and projections over the nine quarter horizon of BHCs' balances of the funded instruments that are included in regulatory capital. The schedule collects data on the historical balances and projected balances of funded regulatory capital instruments by instrument type, in addition to projections for issuances and redemptions that contribute to changes in balances under the BHC baseline scenario.

This schedule collects the total balances of capital instruments and planned redemptions and issuances at an aggregate instrument-type level (e.g., common stock, non-cumulative perpetual preferred, subordinated debt, etc.).

The instructions for the sub-schedule should be read in conjunction with the regulatory capital guidelines issued by the Federal Reserve, the FR Y-9C report and instructions and the revised regulatory capital rule (see generally 12 CFR 217).

BHCs must report information on both a notional basis and on the basis of the dollar amount included in regulatory capital. For "Notional Amount" report the total notional amount of each instrument. BHCs must provide the "Notional Amount" regardless of whether there is an associated amount recognized in regulatory capital. For example, 100% of subordinated debt nearing maturity with limited or no recognition in regulatory capital should be included. For "Amount Recognized in Regulatory Capital" report the portion of the notional amount that is recognized in regulatory capital.

BHCs should use the "Comments" field to provide identification of individual instruments that have changed in value. Respondents should also include any other characteristics that impact the investment value. BHCs must provide a page reference in their Capital Plan in which the stated activities are captured in the "Page Reference in the Capital Plan" fields for field for any line item with "Comments"; this information is not required for the capital balance sections of the schedule. If page references are not available for the entries in the 'Quarterly Activity - Other than Issuances, Repurchases, or Redemptions' section, then the BHC is required to provide detailed comments explaining the entry in the "Comments" field. All BHCs must report quarter ending balances under the "Actual As of Date" and projected balances under Projection Quarters PQ1, PQ2, PQ3, PQ4, PQ5, PQ6, PQ7, PQ8, and PQ9 for both the "Notional Amount" and the "Amount recognized in regulatory capital".

For any instrument type the BHC has not issued and does not project to issue, BHCs must leave the field blank.

For both the "Notional amount" and "Amount recognized in regulatory capital" within the "Revised regulatory capital treatment section," BHCs must provide the actual and projected aggregate dollar amounts (\$Millions) for each line item under the revised regulatory capital rule. Submissions must reflect the necessary transition provisions for non-qualifying capital instruments with their quarter ending actual balances reported.

For “Quarterly Redemption/Repurchase Activity,” report the actual and projected aggregate dollar amount (\$Millions) of planned redemptions and repurchases to be conducted in each quarter for each type of capital instrument. All redemptions and repurchases must be reported as negative values. “Quarterly Redemption/Repurchase Activity” must include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation.

For “Quarterly Issuance Activity,” report the actual and projected aggregate dollar amount (\$Millions) of planned issuances to be conducted in each quarter for each instrument type. “Quarterly Issuance Activity” must include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation.

Conversion of preferred stock to common stock should be reported as a redemption of preferred stock and an issuance of common stock in the same quarter.

For “Quarterly Activity – Other than Issuances, Repurchases, or Redemptions,” report the actual and projected aggregate dollar amount (\$Millions) of planned changes in regulatory capital instruments that are not the direct result of issuances, repurchases, or redemptions, including but not limited to: (1) Maturities of capital instruments; and (2) Equity contributions from a parent that do not involve the issuance of common stock.

For “Capital Balances,” report the actual aggregate balances (\$Millions) of each type of capital instrument for the as-of quarter end date, reflecting the impact of planned capital actions. “Capital Balances” “Notional Amount” the actual must be completed, even if the instrument is not recognized in regulatory capital. Projection quarters are calculated based on the activity reported in the “Quarterly Redemption/Repurchase Activity”, “Quarterly Issuance Activity”, and “Quarterly Activity – Other than issuances and repurchases” and the reported “Actual”.

Quarterly Redemption/Repurchase Activity

Line Item 1 Common Stock (CS) (Revised regulatory capital rule treatment – Common Equity Tier 1)

(1) "Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the revised regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;

(2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;

(3) LESS: "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c); and

(4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b).

Line 1 should exclude amounts reported in line 2 as described below.

Line Item 2 Common Stock (CS) - Employee Stock Compensation (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report the carrying amount of common stock as defined in the FR Y-9C, Schedule HC, line item 24 issued as part of an employee stock ownership plan (ESOP) and included in equity capital on the balance sheet. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for employee stock for employee stock compensation.

Line Item 3 CS Warrants (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

Line Item 4 CS USG Investment (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b).

Line Item 5 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4. To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

Line Item 6 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report all other Common Equity Tier 1 instruments issued that are not included in the FR Y-9C, Schedule HC-R, Part I, line items 1, 2, 4 and 5.

Line Item 7 Non-Cumulative Perpetual Preferred (NCPP) (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 8 NCPP Convertible (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of NCPP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 9 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 10 MCP USG Preferred (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3, and Schedule HC-M, line item 24(a).

Item 11 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

Line Item 12 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of all other capital instruments, other than those included in line items 7 through 11 that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 13 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 14 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 15 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 16 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 17 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 18 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 19 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of all other capital instruments other than those include in line items 14 through 18 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 20 Subordinated Debt (Revised regulatory capital rule treatment – Tier 2)

Report subordinated debt instruments that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve's general risk-based capital rules.

Line Item 21 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Tier 2)

Report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

Line Item 22 Other Tier 2 Instruments (Revised regulatory capital rule treatment – Tier 2)

Report all other capital instruments, other than those included in line items 20 and 21, that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27.

In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For items 23 through 29, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the revised regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in the FR Y-9C, Schedule HC-R, line item 21.

Line Item 23 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 24 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 25 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 26 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 27 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 28 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 29 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of all capital instruments other than the ones included in line items 23 through 28 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Quarterly Issuance Activity

Line Item 30 Common Stock (CS) (Revised regulatory capital rule treatment - Common Equity Tier 1)

Report (1) "Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the revised regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;

(2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;

(3) LESS: "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c); and

(4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b).

Line 30 should exclude amounts reported in line 31 as described below.

Line Item 31 Common Stock (CS) - Employee Stock Compensation (Revised regulatory capital rule treatment - Common Equity Tier 1)

Report the carrying amount of common stock as defined in the FR Y-9C, Schedule HC, line item 24 issued as part of an employee stock ownership plan (ESOP) and included in equity capital on the balance sheet. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for employee stock for employee stock compensation.

Line Item 32 CS Warrants (Revised regulatory capital rule treatment - Common Equity Tier 1)

Report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

Line Item 33 CS USG Investment (Revised regulatory capital rule treatment - Common Equity Tier 1)

Report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b).

Line Item 34 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4. To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

Line Item 35 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report as defined in the revised regulatory capital rule (July 2013).

Line Item 36 Non-Cumulative Perpetual Preferred (NCP) (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 37 NCP Convertible (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of NCP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 38 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 39 MCP USG Preferred (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3 and Schedule HC-M, line item 24(a).

Line Item 40 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

Line Item 41 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of all other capital instruments, other than those included in line items 36 through 40 that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 42 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 43 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 44 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 45 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 46 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 47 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 48 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of all other capital instruments other than those include in line items 42 through 47 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 49 Subordinated Debt (Revised regulatory capital rule treatment – Tier 2)

Report subordinated debt instruments that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve's general risk-based capital rules.

Line Item 50 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Tier 2)

Report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

Line Item 51 Other Tier 2 Instruments (Revised regulatory capital rule treatment - Tier 2)

Report all other capital instruments, other than those included in line items 49 and 50, that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For items 52 through 58, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the revised regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in Schedule HC-R, item 21.

Line Item 52 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 53 CPP TARP Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 54 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 55 MCP USG Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 56 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 57 USG Preferred TRUPS (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 58 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

Report the amount of all capital instruments other than the ones included in line items 52 through 57 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Quarterly Activity - Other than issuances or repurchases

Line Item 59 Common Stock (CS) (Revised regulatory capital rule treatment - Common Equity Tier 1)

Report (1) "Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the revised regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;

(2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;

(3) LESS: "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c); and

(4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b).

Line 59 should exclude amounts reported in line 60 as described below.

Line Item 60 Common Stock (CS) - Employee Stock Compensation (Revised regulatory capital rule treatment - Tier 1)

Report the carrying amount of common stock as defined in the FR Y-9C, Schedule HC, line item 24 issued as part of an employee stock ownership plan (ESOP) and included in equity capital on the balance sheet. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for employee stock for employee stock compensation.

Line Item 61 CS Warrants (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

Line Item 62 CS USG Investment (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b)

Line Item 63 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4. To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

Line Item 64 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment – Common Equity Tier 1)

Report as defined in the revised regulatory capital rule (July 2013).

Line Item 65 Non-Cumulative Perpetual Preferred (NCP) (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 66 NCP Convertible (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of NCP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 67 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 68 MCP USG Preferred (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c)

of the revised regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3 and Schedule HC-M, line item 24(a).

Line Item 69 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

Line Item 70 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment – Additional Tier 1)

Report the amount of all other capital instruments, other than those included in line items 65 through 69 that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

Line Item 71 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 72 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 73 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 74 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 75 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 76 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 77 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

Report the amount of all other capital instruments other than those included in line items 71 through 76 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 78 Subordinated Debt (Revised regulatory capital rule treatment – Tier 2)

Report subordinated debt instruments that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve’s general risk-based capital rules.

Line Item 79 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Tier 2)

Report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

Line Item 80 Other Tier 2 Instruments (Revised regulatory capital rule treatment – Tier 2)

Report all other capital instruments, other than those included in line items 78 and 79, that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27.

In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For items 81 through 87, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the revised regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in Schedule HC-R, item 21.

Line Item 81 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 82 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 83 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 84 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 85 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 86 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Line Item 87 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

Report the amount of all capital instruments other than the ones included in items 81 through 86 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

Capital Balances

Line Item 88 Common Stock (CS) (Revised regulatory capital rule treatment – Common Equity Tier 1)

For the actual as-of date, report

(1) "Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the revised regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;

(2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;

(3) LESS: "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c); and

(4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b). Line 88 should exclude amounts reported in line 89 as described below.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 1, 2, 30, 31, 59, 60 and actual as-of date item 88. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 1, 2, 30, 31, 59, 60 and the prior projection period's item 88.

Line Item 89 CS Warrants (Revised regulatory capital rule treatment – Common Equity Tier 1)

For the actual as-of date, report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 3, 32, 61 and actual as-of date item 89. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 3, 32, 61 and the prior projection period's item 89.

Line Item 90 CS USG Investment (Revised regulatory capital rule treatment – Common Equity Tier 1)

For the actual as-of date, report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b).

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 4, 33, 62, and actual as-of date item 90. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 4, 33, 62 and the prior projection period's item 90

Line Item 91 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Common Equity Tier 1)

For the actual as-of date, report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4). To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 5, 34, 63 and actual as-of date item 91. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 5, 34, 63 and the prior projection period's item 91.

Line Item 92 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment – Common Equity Tier 1)

For the actual as-of date, report as defined in the revised regulatory capital rule (July 2013).

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 6, 35, 64 and actual as-of date item 92. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 6, 35, 64 and the prior projection period's item 92.

Line Item 93 Non-Cumulative Perpetual Preferred (NCP) (Revised regulatory capital rule treatment – Additional Tier 1)

For the actual as-of date, report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 7, 36, 65 and actual as-of date item 93. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 7, 36, 65 and the prior projection period's item 93.

Line Item 94 NCP Convertible (Revised regulatory capital rule treatment – Additional Tier 1)

For the actual as-of date, report the amount of NCP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 8, 37, 66 and actual as-of date item 94. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 8, 37, 66 and the prior projection period's item 94.

Line Item 95 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Additional Tier 1)

For the actual as-of date, report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 9, 38, 67 and actual as-of date item 95. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 9, 38, 67 and the prior projection period's item 95.

Line Item 96 MCP USG Preferred (Revised regulatory capital rule treatment – Additional Tier 1)

For the actual as-of date, report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3 and Schedule HC-M, line item 24(a).

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 10, 39, 68 and actual as-of date item 96. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 10, 39, 68 and the prior projection period's item 96.

Line Item 97 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Additional Tier 1)

For the actual as-of date, report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 11, 40, 69 and actual as-of date item 97. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 11, 40, 69 and the prior projection period's item 97.

Line Item 98 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment – Additional Tier 1)

For the actual as-of date, report the amount of all other capital instruments, other than those included in line items 93 through 97, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the revised regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 12, 41, 70 and actual as-of date item 98. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 12, 41, 70 and the prior projection period's item 98.

Line Item 99 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

For the actual as-of date, report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 13, 42, 71 and actual as-of date item 99. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 13, 42, 71 and the prior projection period's item 99.

Line Item 100 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

For the actual as-of date, report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 14, 43, 72 and actual as-of date item 100. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 14, 43, 72 and the prior projection period's item 100.

Line Item 101 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)

For the actual as-of date, report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 15, 44, 73 and actual as-of date item 101. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 15, 44, 73 and the prior projection period's item 101.

Line Item 102 MCP USG Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)

For the actual as-of date, report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 16, 45, 74 and actual as-of date item 102. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 16, 45, 74 and the prior projection period's item 102.

Line Item 103 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)

For the actual as-of date, report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 17, 46, 75 and actual as-of date item 103. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 17, 46, 75 and the prior projection period's item 103.

Line Item 104 USG Preferred TRUPS (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)

For the actual as-of date, report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 18, 47, 76 and actual as-of date item 104. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 18, 47, 76 and the prior projection period's item 104.

Line Item 105 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)

For the actual as-of date, report the amount of all other capital instruments other than those included in line items 99 through 104 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 19, 48, 77 and actual as-of date item 105. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 19, 48, 77 and the prior projection period's item 105.

Line Item 106 Subordinated Debt (Revised regulatory capital rule treatment - Tier 2)

For the actual as-of date, report subordinated debt instruments that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve's general risk-based capital rules.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 20, 49, 78 and actual as-of date item 106. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 20, 49, 78 and the prior projection period's item 106.

Line Item 107 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Tier 2)

For the actual as-of date, report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 21, 50, 79 and actual as-of date item 107. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 21, 50, 79 and the prior projection period's item 107.

Line Item 108 Other Tier 2 Instruments (Revised regulatory capital rule treatment - Tier 2)

For the actual as-of date, report all other capital instruments, other than those included in line items 106 and 107, that satisfy all eligibility criteria under the revised regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27.

In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 22, 51, 80 and actual as-of date item 108. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 22, 51, 80 and the prior projection period's item 108

For items 109 through 115, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the revised regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in Schedule HC-R, item 21.

Line Item 109 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

For the actual as-of date, report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 23, 52, 81 and actual as-of date item 109. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 23, 52, 81 and the prior projection period's item 109.

Line Item 110 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

For the actual as-of date, report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 24, 53, 82 and actual as-of date item 110. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 24, 53, 82 and the prior projection period's item 110.

Line Item 111 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

For the actual as-of date, report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 25, 54, 83 and actual as-of date item 111. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 25, 54, 83 and the prior projection period's item 111.

Line Item 112 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

For the actual as-of date, report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 26, 55, 84 and actual as-of date item 112. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 26, 55, 84 and the prior projection period's item 112.

Line Item 113 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

For the actual as-of date, report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 27, 56, 85 and actual as-of date item 113. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 27, 56, 85 and the prior projection period's item 113.

Line Item 114 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)

For the actual as-of date, report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 28, 57, 86 and actual as-of date item 114. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 28, 57, 86 and the prior projection period's item 114.

Line Item 115 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)

For the actual as-of date, report the amount of all capital instruments other than the ones included in line items 109 through 114 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 29, 58, 87 and actual as-of date item 115. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 29, 58, 87 and the prior projection period's item 115.

Schedule D—Regulatory Capital Transitions

For the purposes of the Regulatory Capital Transitions Schedule, BHCs must reflect the revised regulatory capital rules on a fully phased-in basis (e.g., BHCs should apply 100% of all capital deductions, not assuming the transition provisions for implementation of changes to the capital composition as in the revised regulatory capital rule). Where applicable, BHCs should also reference the methodology descriptions outlined within the FR Y-9C, HC-R, Part IB (final) and part II (draft). Please note, however, that numbers do not need to tie to the FR Y-9C reports, given that the FR Y-14 Transitions schedule requires calculations on a fully phased-in basis.

The Regulatory Capital Transitions FR Y-14A annual schedule collects actual (historical) data for the as-of date and projected fourth quarter data for five years. All projections in the FR Y-14A Regulatory Capital Transitions schedule should be based under the Supervisory Baseline scenario through the end of Projected Year 5 on a year-to-date basis (unless otherwise specified). BHCs should report planned capital actions as included under the Supervisory Baseline scenario. For reporting periods beyond the quarters projected in the BHC's FR-Y-14A Summary schedule, BHCs should adopt assumptions necessary to make reasonable projections of capital ratios, including forecasts of macroeconomic factors and potential earnings through projected year 6. All forecasts must be well-developed and well-documented, consistent with the relevant baseline scenario, and internally consistent with the BHC's planned capital actions.

BHCs should provide projections of capital composition, exceptions bucket calculation, risk-weighted assets, and leverage exposures through projected year 5 even if the BHC anticipates complying with the proposed fully phased-in 7% Common Equity Tier 1, 8.5% Tier 1 capital, 4% Tier 1 leverage, and 3% supplementary leverage target ratios (inclusive the capital conservation buffer, where applicable) plus any applicable surcharge for systemically important financial institutions (SIFI surcharge) by an earlier date.

Each CCAR Capital Plan must include management's best estimate of a BHC's likely SIFI surcharge. In the process of assessing a BHC's transition path toward compliance with the Revised Capital Framework, supervisors will evaluate the methodology and assumptions used by BHCs in determining the SIFI surcharge, and may adjust such estimates as necessary when evaluating the transition path. See Appendix A: Supporting Documentation for more details about the associated information that must be submitted in addition to this report template.

In the event that a capital plan resubmission prompts a BHC has to submit the FR Y-14A Regulatory Capital Transitions schedule with a date other than the as-of date, the BHC should treat all columns labeled "Actual in \$Millions as of date" as being as-of the date dictated by the capital plan resubmission. The PY1 column should be the projection 1 year from the capital plan resubmission as-of date, PY2 should be the projection 2 years from the capital plan resubmission as-of date, and so forth.

Relevant References

All BHCs are required to follow the methodologies outlined in the revised regulatory capital rule (78 Federal Register 62018, July October 11, 2013), the updated market risk capital rule (78 Federal Register 76521, December 18, 2013), and the supplementary final rule (September 2014) for purposes of completing the Regulatory Capital Transitions schedules for the *entire* forecast

period. BHCs should reflect the revised regulatory capital framework on a fully phased-in basis.

Links to these reference documents are listed below:

- Basel global systemically important banks: updated assessment methodology and the higher loss absorbency requirement (July 2013): <http://www.bis.org/publ/bcbs255.pdf>
- Revised Regulatory Capital Rule (78 Federal Register 62018, October 11, 2013): <http://www.gpo.gov/fdsys/pkg/FR-2013-10-11/pdf/2013-21653.pdf>
- Supplementary Leverage Final Rule (September 2014): <http://www.federalreserve.gov/newsevents/press/bcreg/bcreg20140903b1.pdf>
- Updated Market Risk Rule (December 2013): <http://www.gpo.gov/fdsys/pkg/FR-2013-12-18/pdf/2013-29785.pdf>

Completing the Schedule

All data should be provided in the non-shaded cells in all sub-schedules; grey shaded cells include embedded formulas and will be automatically populated.

All BHCs, including advanced approaches BHCs and non-advanced approaches BHCs must complete the “Standardized RWA” sub-schedule for all reporting periods. For the purpose of completing the “Standardized RWA” sub-schedule, BHCs are required to report credit risk-weighted assets using the methodologies under the standardized approach of the revised regulatory capital rule. Advanced approaches BHCs, including the BHCs that are considered mandatory advanced approaches institutions or that have opted-in voluntarily as an advanced approaches institution, are also required to complete the “Advanced RWA” sub-schedule for all reporting periods. Note that all data must be completed on a fully phased-in basis.

Note that for purposes of completing the FR Y-14A Regulatory Capital Transitions schedule, **BHCs should not assume future model approval in the RWA projections for positions and models that have not yet been approved.** BHCs that have received comprehensive risk model approval should base their projections on the comprehensive risk measure plus the surcharge for the entire planning horizon. BHCs should not assume that the surcharge will be replaced by the floor approach in the schedule or as part of planned actions.

If a BHC does not have an exposure relevant to any particular line item in the sub-schedules (except for the Planned Action sub-schedule); it should enter zero (0) in those cells. In order for the embedded formulas to automatically populate the shaded cells in the schedule with calculated numbers, BHCs must complete all unshaded cells in the schedule with a value. In addition, BHCs should ensure that the version of Microsoft Excel they use to complete the schedule is set to automatically calculate formulas. This is achieved by setting “Calculation Options” (under the Formulas function) to “Automatic” within Microsoft Excel.

D.1—Capital Composition

The “Capital Composition” sub-schedule and the “Exceptions Bucket Calculator” sub-schedule collect the data necessary to calculate the composition of capital under the guidelines set forth by the Revised Regulatory Capital Rule. Please provide all data on a fully phased-in basis (i.e., not

assuming any transitional or phase- out arrangements included in the revised regulatory capital rule.

Common Equity Tier 1

Line item 1 AOCI opt-out election

Non-advanced approaches BHCs have the option to select either 1 for opt-out, or 0 for opt-in. Note that there are no transition provisions applied

Common equity tier 1 capital

Line item 2 Common stock and related surplus (net of treasury stock and unearned employee stock ownership plan (ESOP) shares

Report common shares and the related surplus issued by BHCs that meet the criteria of the final rules. This should be net of treasury stock and other investments in own shares to the extent that these are already not recognized on the balance sheet under the relevant accounting standards. This line item should reflect the impact of share repurchases or issuances projected in the CCAR forecast horizon. This line should also reflect the netting of any treasury stock, unearned ESOP shares, and any other contra-equity components.

Line item 3 Retained earnings

Retained earnings reported by BHCs. This should reflect the impact of dividend pay-outs projected in the CCAR forecast horizon.

Line item 4 Accumulated other comprehensive income (AOCI)

Report the amount of AOCI as reported under generally accepted accounting principles (GAAP) in the U.S. that is consistent with the definitions included in Schedule HC-R, Part I.B., item 3, with no transition provisions.

Line item 5 Common equity tier 1 minority interest includable in common equity tier 1 capital (report this on a fully phased-in basis)

Report the aggregate amount of common equity tier 1 minority interest that is consistent with the definitions provided in Schedule HC-R, Part I.B., item 4, with no transition provisions. Common equity tier 1 minority interest means the common equity tier 1 capital of a depository institution or foreign bank that is a consolidated subsidiary of the holding company and that is not owned by the holding company. In addition, the capital instruments issued by the subsidiary must meet all of the criteria for common equity tier 1 capital (qualifying common equity tier 1 capital).

Line item 6 Common equity tier 1 capital before adjustments and deductions

This captures the sum of line items 2 through 5.

Common equity tier 1 capital: adjustments and deductions

Line item 7 Goodwill net of associated deferred tax liabilities (DTLs)

Report the amount of goodwill that is consistent with the definitions provided in Schedule HC-R, Part I.B., item 6, with no transition provisions.

If a holding company has significant investments in the capital of unconsolidated financial institutions in the form of common stock, the holding company should report in this item goodwill embedded in the valuation of a significant investment in the capital of an unconsolidated financial institution in the form of common stock (embedded goodwill). Such deduction of embedded goodwill would apply to investments accounted for under the equity method. Under GAAP, if there is a difference between the initial cost basis of the investment and the amount of underlying equity in the net assets of the investee, the resulting difference should be accounted for as if the investee were a consolidated subsidiary (which may include imputed goodwill).

Line item 8 Intangible assets (other than goodwill and mortgage servicing assets (MSAs)), net of associated DTLs

Report all intangible assets (other than goodwill and MSAs) net of associated DTLs, included in Schedule HC-M, items 12.b and 12.c, that do not qualify for inclusion in common equity tier 1 capital under the regulatory capital rules. Generally, all purchased credit card relationships (PCCRs) and non-mortgage servicing rights, reported in Schedule HC-M, item 12.b, and all other identifiable intangibles, reported in Schedule HC-M, item 12.c, do not qualify for inclusion in common equity tier 1 capital and should be included in this item.

Further, if the holding company has a DTL that is specifically related to an intangible asset (other than servicing assets and PCCRs) acquired in a nontaxable purchase business combination that it chooses to net against the intangible asset for regulatory capital purposes, the amount of disallowed intangibles to be reported in this item should be reduced by the amount of the associated DTL. However, a DTL that the holding company chooses to net against the related intangible reported in this item may not also be netted against DTAs when the holding company determines the amount of DTAs that are dependent upon future taxable income and calculates the maximum allowable amount of such DTAs for regulatory capital purposes.

Line item 9 Deferred Tax Assets (DTAs) that arise from net operating loss and tax credit carryforwards, net of any related valuation allowances and net of DTLs

Report the amount of DTAs that arise from net operating loss and tax credit carryforwards, net of any related valuation allowances and net of DTLs.

AOCI-related adjustments

If Item 1 is “1” for “Yes”, complete items 10 through 14 only for AOCI related adjustments.

Line item 10 Net unrealized gains (losses) on available-for-sale securities

Report the amount of net unrealized holding gains (losses) on available-for-sale securities, net of applicable taxes, that is consistent with the definitions provided in Schedule HC-R, Schedule I.B., item 9a, “Accumulated other comprehensive income,” With no transition provisions. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

Line item 11 Net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures

Report as a positive value net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures, consistent with the definition that is included in Schedule HC-R, Schedule I.B., item 9b, with no transition provisions. i

Line item 12 Accumulated net gains (losses) on cash flow hedges

Report the amount of accumulated net gains (losses) on cash flow hedges, consistent with the definitions that is included in Schedule HC-R, Schedule I.B., item 9c, "Accumulated other comprehensive income," With no transition provisions. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

Line item 13 Amounts recorded in AOCI attributed to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans

Report the amounts recorded in AOCI and is consistent with the definitions included in Schedule HC-R, Schedule I.B., item 9d, "Accumulated other comprehensive income," with no transition provisions, resulting from the initial and subsequent application of ASC Subtopic 715-20 (formerly FASB Statement No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans") to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans.

Line item 14 Net unrealized gains (losses) on held-to-maturity securities that are included in AOCI

Report the amount of net unrealized gains (losses) that are not credit-related on held-to-maturity securities and are included in AOCI, consistent with the definitions as reported in Schedule HC-R, Schedule I.B., item 9e, "Accumulated other comprehensive income," with no transition provisions. If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

If Item 1 is "0" for "No", complete item 15 only for AOCI related adjustments.

Line item 15 Accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects, that relate to the hedging of items that are not recognized at fair value on the balance sheet.

Report the amount of accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects that relate to the hedging of items not recognized at fair value on the balance sheet. If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

Other deductions from (additions to) common equity tier 1 capital before threshold-based deductions:

Line item 16 Unrealized net gain (loss) related to changes in the fair value of liabilities that are due to changes in own credit risk

Report the amount of unrealized net gain (loss) related to changes in the fair value of liabilities that are due to changes in the holding company's own credit risk. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

Advanced approaches holding companies only: include the credit spread premium over the risk free rate for derivatives that are liabilities.

Line item 17 All other deductions from (additions to) common equity tier 1 capital before threshold-based deductions

Report the amount of other deductions from (additions to) common equity tier 1 capital that are not included in items 1 through 15, as described below:

(1) After-tax gain-on-sale in connection with a securitization exposure

Include any after-tax gain-on-sale in connection with a securitization exposure. Gain-on-sale means an increase in the equity capital of a holding company resulting from a securitization (other than an increase in equity capital resulting from the holding company's receipt of cash in connection with the securitization or reporting of a mortgage servicing asset on Schedule HC).

(2) Defined benefit pension fund assets, net of associated DTLs

A BHC must deduct defined benefit pension fund assets, net of associated DTLs, held by a holding company. With the prior approval of the Federal Reserve, this deduction is not required for any defined benefit pension fund net asset to the extent the holding company has unrestricted and unfettered access to the assets in that fund.

(3) Investments in the holding company's own shares to the extent not excluded as part of treasury stock.

Include the BHC's investments in (including any contractual obligation to purchase) its own common stock instruments, including direct, indirect, and synthetic exposures to such instruments (as defined in the revised regulatory capital rules), to the extent such instruments are not excluded as part of treasury stock.

For example, if a BHC already deducts its investment in its own shares (for example, treasury stock) from its common equity tier 1 capital elements, it does not need to make such deduction twice.

A holding company may deduct gross long positions net of short positions in the same underlying instrument only if the short positions involve no counterparty credit risk.

The holding company must look through any holdings of index securities to deduct investments in its own capital instruments.

In addition:

- (i) Gross long positions in investments in a holding company's own regulatory capital instruments resulting from holdings of index securities may be netted against short

- positions in the same underlying index;
- (ii) Short positions in index securities that are hedging long cash or synthetic positions may be decomposed to recognize the hedge; and
 - (iii) The portion of the index that is composed of the same underlying exposure that is being hedged may be used to offset the long position if both the exposure being hedged and the short position in the index are covered positions under the market risk capital rule, and the hedge is deemed effective by the holding company's internal control processes which would have been assessed by the Federal Reserve.

(4) Reciprocal cross-holdings in the capital of financial institutions in the form of common stock

Include investments in the capital of other financial institutions (in the form of common stock) that the holding company holds reciprocally (this is the corresponding deduction approach). Such reciprocal crossholdings may result from a formal or informal arrangement to swap, exchange, or otherwise intend to hold each other's capital instruments.

(5) Equity investments in financial subsidiaries

A BHC must deduct the aggregate amount of its outstanding equity investment, including retained earnings, in its financial subsidiaries (as defined in 12 CFR 208.77) and may not consolidate the assets and liabilities of a financial subsidiary with those of the parent institution. No other deduction is required for these investments in the capital instruments of financial subsidiaries.

(6) Amount of expected credit loss that exceeds its eligible credit reserves (Advanced approaches institutions that exit parallel run only)

Include the amount of expected credit loss that exceeds the eligible credit reserves.

Line item 18 Non-significant investments in the capital of unconsolidated financial institutions in the form of common stock that exceed the 10 percent threshold for non-significant investments

A BHC has a non-significant investment in the capital of an unconsolidated financial institution (as defined in the revised regulatory capital rules) if it owns 10 percent or less of the issued and outstanding common shares of that institution.

Report the amount of non-significant investments in the capital of unconsolidated financial institutions in the form of common stock that, in the aggregate, exceed the 10 percent threshold for non-significant investments, calculated as described below. The BHC may apply associated DTLs to this deduction.

Line item 19 Subtotal

This item is a shaded cell and is derived from other items in the schedule; no input required. This is the total of common equity tier 1 prior to adjustments less all of the regulatory adjustments and deductions.

Line item 20 Significant investments in the capital of unconsolidated financial institutions in the form of common stock, net of DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 21 MSAs, net of associated DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 22 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 23 Amount of significant investments in the capital of unconsolidated financial institutions in the form of common stock; MSAs, net of associated DTLs; and DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs; that exceeds the 15 percent common equity tier 1 capital deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 24 Deductions applied to common equity tier 1 capital due to insufficient amounts of additional tier 1 capital and tier 2 capital to cover deductions

Report the total amount of deductions related to reciprocal cross holdings, non-significant investments in the capital of unconsolidated financial institutions, and non-common stock significant investments in the capital of unconsolidated financial institutions if the holding company does not have a sufficient amount of additional tier 1 capital and tier 2 capital to cover these deductions.

Line item 25 Total adjustments and deductions for common equity tier 1 capital

This is the sum of line item 20 through 24.

Line item 26 Common Equity Tier 1

This is the subtotal of line item 19 minus line item 25.

Line item 27 Additional tier 1 capital instruments plus related surplus

Report the portion of noncumulative perpetual preferred stock and related surplus as defined by Schedule HC-R, Part I.B., item 20, with zero transition provisions, that satisfy all the criteria for additional tier 1 capital in the revised regulatory capital rules of the Federal Reserve.

Include instruments that were (i) issued under the Small Business Job's Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 1 capital under the Federal Reserve's general risk-based capital rules (12 CFR part 225, appendix A, and, if applicable, appendix E) (for example, tier 1 instruments issued under the TARP program that are grandfathered permanently). Also include additional tier 1 capital instruments issued as part of an ESOP, provided that the repurchase of such instruments is required solely by virtue of ERISA for a banking organization that is not publicly-traded.

Line item 28 Tier 1 minority interest not included in common equity tier 1 capital (report on a fully phased-in basis)

Similar to item 5, this captures all qualifying tier 1 minority interest includable under additional tier 1 capital.

Line item 29 Additional tier 1 capital before deductions

This is the sum of line items 27 and 28.

Line item 30 Additional tier 1 capital deductions

Report additional tier 1 capital deductions as the sum of the following elements:

(1) Investments in own additional tier 1 capital instruments:

Report the holding company's investments in (including any contractual obligation to purchase) its own additional tier 1 instruments, whether held directly or indirectly.

A holding company may deduct gross long positions net of short positions in the same underlying instrument only if the short positions involve no counterparty risk.

The holding company must look through any holdings of index securities to deduct investments in its own capital instruments. In addition:

- (i) Gross long positions in investments in a holding company's own regulatory capital instruments resulting from holdings of index securities may be netted against short positions in the same index;
- (ii) Short positions in index securities that are hedging long cash or synthetic positions can be decomposed to recognize the hedge; and
- (iii) The portion of the index that is composed of the same underlying exposure that is being hedged may be used to offset the long position if both the exposure being hedged and the short position in the index are covered positions under the market risk capital rule, and the hedge is deemed effective by the holding company's internal control processes.

(2) Reciprocal cross-holdings in the capital of financial institutions.

Include investments in the additional tier 1 capital instruments of other financial institutions that the holding company holds reciprocally, where such reciprocal crossholdings result from a formal or informal arrangement to swap, exchange, or otherwise intend to hold each other's capital instruments. If the holding company does not have a sufficient amount of a specific component of capital to effect the required deduction, the shortfall must be deducted from the next higher (that is, more subordinated) component of regulatory capital.

For example, if a holding company is required to deduct a certain amount from additional tier 1 capital and it does not have additional tier 1 capital, then the deduction should be from common equity tier 1 capital.

(3) Non-significant investments in additional tier 1 capital of unconsolidated financial institutions that exceed the 10 percent threshold for non-significant investments.

Calculate this amount as follows:

- (i) Determine the aggregate amount of non-significant investments in the capital of unconsolidated financial institutions in the form of common stock, additional tier 1, and tier 2 capital.
 - (ii) Determine the amount of non-significant investments in the capital of unconsolidated financial institutions in the form of additional tier 1 capital.
 - (iii) If the amount in (i) is greater than the 10 percent threshold for non-significant investments then multiply the difference by the ratio of (ii) over (i).
 - (iv) If the amount in (i) is less than the 10 percent threshold for non-significant investments, report zero.
- (4) Significant investments in the capital of unconsolidated financial institutions not in the form of common stock to be deducted from additional tier 1 capital.

Report the total amount of significant investments in the capital of unconsolidated financial institutions in the form of additional tier 1 capital.

- (5) Other adjustments and deductions.

Include adjustments and deductions applied to additional tier 1 capital due to insufficient tier 2 capital to cover deductions (related to reciprocal cross holdings, non-significant investments in the tier 2 capital of unconsolidated financial institutions, and significant investments in the tier 2 capital of unconsolidated financial institutions).

Line item 31 Additional tier 1 capital (greater of item 29 minus item 30 or zero)

This item is a shaded cell and is derived from other items in the schedule. This provides the total of additional tier 1 capital.

Tier 1 Capital

Line item 32 Tier 1 capital (sum of items 26 and 31)

This item is a shaded cell and is derived from other items in the schedule. This provides the total amount of tier 1 capital.

Other (reflect all items on a year-to-date basis)

Line item 33 Issuance of Common Stock (Including Conversion of Common Stock)

Captures the total issuance of common stock and related surplus in the reporting period on a calendar year-to-date basis. This figure for PY 1 and PY2 should equal the sum of "Total issuance of common stock" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

Line item 34 Repurchases of Common Stock

Captures the total repurchases of common stock in the reporting period on a calendar year-to-date

basis. This figure for PY1 and PY2 should equal the sum of "Total share repurchases" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

Line item 35 Net Income (Loss) Attributable to Bank Holding Company

Refer to FR Y-9C instructions for Schedule HI-A, item 4 and report on a calendar year-to-date basis. Report losses as a negative value. This figure for PY1 and PY2 should equal the sum of "Net income (loss) attributable to BHC" reported in the FR Y-14A Summary Schedule, Income Statement sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

Line item 36 Cash Dividends Declared on Preferred Stock

Refer to FR Y-9C instructions for Schedule HI-A, item 10 and report on a calendar year-to-date basis. This figure for PY1 and PY2 should equal the sum of "Cash dividends declared on preferred stock" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

Line item 37 Cash Dividends Declared on Common Stock

Refer to FR Y-9C instructions for Schedule HI-A, item 11 and report on a calendar year-to-date basis. This figure for PY1 and PY2 should equal the sum of "Cash dividends declared on common stock" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

Line item 38 Previously Issued Tier 1 Capital Instruments (Excluding Minority Interest) that would No Longer Qualify (please report 100% value)

Report 100% of the value of previously issued Tier 1 capital instruments that will no longer qualify as Tier 1 capital as per the revised regulatory capital rule (including perpetual preferred stock and trust preferred securities subject to phase-out arrangements). Report balances in full, without reflecting any phase-out arrangements included in the revised regulatory capital rule.

Line item 39 Previously Issued Tier 1 Minority Interest that Would No Longer Qualify (Please Report 100% Value)

Report 100% of the value of previously issued tier 1 minority interest that will no longer qualify as tier 1 capital as per the revised regulatory capital rule. Report balances in full, without reflecting any phase-out arrangements included in the revised regulatory capital rule.

Line item 40 Data Completeness Check

If "No", please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable.

D.2—Exception Bucket Calculator

The Exception Bucket Calculator sub-schedule collects the data necessary to calculate the items that may receive limited recognition in Common Equity Tier 1 (i.e., significant investments in the common shares of unconsolidated financial institutions, mortgage servicing assets and deferred tax assets arising from temporary differences). These items may be recognized in Common Equity Tier 1 up to 10% of the BHC's common equity on an individual basis and 15% on an aggregated basis after application of all regulatory adjustments.

Significant investments in the capital of unconsolidated financial institutions in the form of common stock

Line item 1 Gross significant investments in the capital of unconsolidated financial institutions in the form of common stock

Aggregate holdings of capital instruments relevant to significant investments in the capital of unconsolidated financial entities, including direct, indirect and synthetic holdings in both the banking book and trading book.

Line item 2 Permitted offsetting short positions in relation to the specific gross holdings included above

Offsetting positions in the same underlying exposure where the maturity of the short position either matches the maturity of the long position or has a residual maturity of at least one year.

Line item 3 Significant investments in the capital of unconsolidated financial institutions in the form of common stock net of short positions

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 4 10 percent common equity tier 1 deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 5 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Mortgage servicing assets

Line item 6 Total mortgage servicing assets classified as intangible

Mortgage servicing assets may receive limited recognition when calculating common equity tier 1, with recognition typically capped at 10% of the bank's common equity (after the application of all regulatory adjustments).

Line item 7 Associated deferred tax liabilities which would be extinguished if the intangible becomes impaired or derecognized under the relevant accounting standards

The amount of mortgage servicing assets to be deducted from common equity tier 1 is to be offset by

any associated deferred tax liabilities, with recognition capped at 10% of the bank's common equity tier 1 (after the application of all regulatory adjustments). If the bank chooses to net its deferred tax liabilities associated with mortgage servicing assets against deferred tax assets (in Line 17 of the Capital Composition sub-schedule), those deferred tax liabilities should not be deducted again here.

Line item 8 Mortgage servicing assets net of related deferred tax liabilities

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 9 10 percent common equity tier 1 deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 10 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Deferred tax assets due to temporary differences

Line item 11 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs

Net deferred tax assets arising from temporary differences may receive limited recognition in common equity tier 1, with recognition capped at 10% of the bank's common equity (after the application of all regulatory adjustments).

Line item 12 10 percent common equity tier 1 deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 13 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Aggregate of items subject to the 15% limit (significant investments, mortgage servicing assets and deferred tax assets arising from temporary differences)

Line item 14 Sum of items 3, 8, and 11

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 15 15 percent common equity tier 1 deduction threshold (item 19 in the Capital Composition tab minus item 14, multiplied by 17.65 percent)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 16 Sum of items 5, 10, and 15

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 17 Item 14 minus item 16

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 18 Amount to be deducted from common equity tier 1 due to 15 percent deduction threshold

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 19 Data Completeness Check

If "No", please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable.

D.3—Advanced Risk-Weighted Assets

Advanced approaches BHCs, including BHCs that are considered as mandatory advanced approaches institutions or that have opted-in voluntarily as an advanced approaches institution, are required to complete the “Advanced RWA” sub-schedule. All BHCs, including advanced approaches BHCs and non-advanced approaches BHCs must complete the “Standardized RWA” sub-schedule.

In the “Advanced RWA” sub-schedule, BHCs should provide risk-weighted asset estimates reflecting the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013) and the updated market risk capital rule (78 Federal Register 76521, December 18, 2013) released by the U.S. banking agencies.

BHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. However, if a BHC projects to meet the trading activity threshold that would require it to be subject to the market risk capital requirements during the forecast period, then the BHC should complete the market risk-weighted asset section within the sub-schedule. Please refer to the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013) and the updated market risk capital rule (78 Federal Register 76521, December 18, 2013) released by the U.S. banking agencies for details of the requirements.

Advanced approaches BHCs that are unable to provide advanced approaches risk weighted asset estimates should send formal written notification to the Federal Reserve and specify the affected portfolios, current limitations that preclude the BHC from providing advanced approaches RWA estimates as well as management's plan for addressing those limitations. The notification should be sent to info@CCAR.frb.org.

MDRM codes have been included in the sub-schedule (column C) and correspond to the definitions for the FFIEC 101 line items where applicable.

Advanced Approaches Credit Risk (Including CCR and non-trading credit risk), with 1.06 scaling factor where applicable – Applicable to Advanced Approaches Banking Organizations
Risk-weighted assets should reflect the 1.06 scaling factor to the Internal Rating-Based Approach (IRB) credit risk-weighted assets where relevant, unless noted otherwise.

Line item 1 Credit RWA

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 2 through 30 Various

Definition of the BHC's projections should correspond to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report per the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013).

Line item 31 Credit Valuation Adjustment (CVA) Capital Charge (Risk-Weighted Asset Equivalent)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 32 Advanced Credit Valuation Adjustment (CVA) Approach

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 33 Credit Valuation Adjustment (CVA) capital charge (Risk-Weighted Asset Equivalent); Advanced CVA Approach: Unstressed Value at Risk (VaR) with Multipliers

Stand-alone 10-day value-at-risk (VaR) calculated on the set of credit valuation adjustments (CVAs) for all Over-the-counter (OTC) derivatives counterparties together with eligible credit valuation adjustment (CVA) hedges. The reported value-at-risk should consist of both general and specific credit spread risks and is restricted to changes in the counterparties credit spreads. The bank must multiply the reported value-at-risk by three times, consistent with the approach used in calculating market risk capital charge (three-time multiplier). The 1.06 scaling factor does not apply.

BHC should report 0 if it does not use the advanced credit value adjustment (CVA) approach.

Line item 34 Credit Valuation Adjustment (CVA) Capital Charge (Risk-Weighted Asset Equivalent); Advanced CVA Approach: Stressed Value at Risk (VaR) with multipliers

Stand-alone 10-day stressed Value-at-risk (VaR) calculated on the set of credit valuation adjustments (CVAs) for all over-the-counter (OTC) derivatives counterparties together with eligible credit valuation adjustments (CVA) hedges. The reported value-at-risk should consist of both general and specific credit spread risks and is restricted to changes in the counterparties credit spreads. It should reflect three-times multiplier. The 1.06 scaling factor does not apply. BHC should report 0 if it does not use the advanced credit valuation adjustments (CVA) approach.

Line item 35 Credit Valuation Adjustment (CVA) Capital Charge (Risk-Weighted Asset Equivalent): Simple CVA Approach

Risk-weighted asset (RWA) equivalent using the simple credit valuation adjustment (CVA) approach.

Advanced Approaches Operational Risk

Line item 36 Operational RWA

Definition of the BHC's projections should correspond to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report per the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013).

Market Risk

If a BHC does not have a particular portfolio or no trading book at all, risk-weighted assets should be reported as 0.

Line item 37 Market RWA

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 38 Value at Risk (VaR) with Multipliers (general and specific risk)

Report the greater of previous day's VaR-based measure or average of daily VaR-based measure for each of the preceding 60 business days with applicable multiplication factor. VaR-based measure should be inclusive of all sources of risks that are included in the VaR calculation.

Line item 39 Stressed Value-at-Risk (VaR) with Multipliers (general and specific risk)

Report the greater of most recent stressed VaR-based measure or average of stressed VaR-based measures for the preceding 12 weeks with applicable multiplication factor. Stressed VaR-based measure should be inclusive of all sources of risks that are included in the stressed VaR calculation.

Line item 40 Incremental Risk Capital Charge (IRC)

Report the greater of most recent increment risk measure or average of incremental risk measures for the preceding 12 weeks.

Line item 41 Correlation Trading

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 42 Correlation Trading: Comprehensive Risk Measurement (CRM), Before Application of Surcharge

Risk-weighted asset equivalent for exposures in the correlation trading portfolio which are subject to the comprehensive risk measurement, before the application of the 8% surcharge based on the standardized measurement method. Report the greater of most recent comprehensive risk measure or average of comprehensive risk measures for the preceding 12 weeks.

Line item 43 Correlation Trading: Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 44 Correlation Trading: Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM) - Net long

100% of the risk-weighted asset (RWA) equivalent according to the standardized measurement method for net long exposures in the correlation trading portfolio which are subject to the comprehensive risk measurement.

Line item 45 Correlation Trading; Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM) - Net Short

100% of the risk-weighted asset equivalent according to the standardized measurement method for net short exposures in the correlation trading portfolio which are subject to the comprehensive risk measurement.

Line item 46 Non-modeled Securitization

This item is a shaded cell and is derived from other items in the schedule; no input required.

Formula embedded in the schedule; no input required. The capital charge (or risk-weighted asset equivalent) for non-modeled traded securitization, including securitization positions that are not correlation trading positions and non-modeled correlation trading positions, is the larger of the net long and net short positions. For purposes of CCAR submission, traded securitization exposures subject to a dollar for dollar capital requirement (e.g. 1250% risk weight or the equivalent of a deduction) should be captured here by including values in lines 47 and 48.

Line item 47 Non-modeled Securitization: Net Long

Risk-weighted asset equivalent according to the standardized measurement method for net long non-modeled securitization exposures including nth-to-default credit derivatives. For

purposes of CCAR submission, traded securitization exposures subject to a dollar for dollar capital requirement (e.g. 1250% risk weight or the equivalent of a deduction) should be included here.

Line item 48 Non-modeled Securitization: Net Short

Risk-weighted asset equivalent according to the standardized measurement method for net short non- modeled securitization exposures including nth-to- default credit derivatives. For purposes of CCAR submission, traded securitization exposures subject to a dollar for dollar capital requirement (e.g. 1250% risk weight or the equivalent of a deduction) should be included here.

Line item 49 Standardized Specific Risk (excluding securitization and correlation)

This item is a shaded cell and is derived from other items in the schedule; no input required. Risk-weighted asset equivalent for specific risk based on the standardized measurement method as applicable. This should not include the risk-weighted assets according to the standardized measurement method for exposures included in the correlation trading portfolio or the standardized approach for other non- correlation related traded securitization exposures.

Line item 50 Sovereign debt positions

Report specific risk add-ons for sovereign debt positions for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 51 Government sponsored entity (GSE) debt positions

Report specific risk add-ons for GSE debt positions for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 52 Depository institution, foreign bank, and credit union debt positions

Report specific risk add-ons for depository institutions, foreign banking organization, and credit union debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 53 Public sector entity (PSE) debt positions

Report total specific risk add-on for PSE debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 54 Corporate debt positions

Report Specific risk add-on for corporate debt positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 55 Equity

Report specific risk add-on for equity positions, for which the BHC's VaR-based measure does not capture all material aspects of specific risk.

Line item 56 Other Market Risk

If the BHC is unable to assign market risk-weighted assets to one of the above categories, they should be reported in this line. If no such requirements exist, 0 should be entered.

Other

Line item 57 Assets subject to the general risk-based capital requirements

Definition of the BHC's projections should correspond to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report per the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013).

Line item 58 Other RWA

If the BHC is unable to assign RWA to one of the above categories, even on a best-efforts basis, they should be reported in this line.

Line item 59 Excess eligible credit reserves not included in tier 2 capital

Include excess eligible credit reserves not included in tier 2 capital, consistent with the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013). Definition of the BHC's projections should correspond to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report.

Line item 60 Total Risk-Weighted Assets

This item is a shaded cell and is derived from other items in the schedule, no input required.

Line item 61 Data Completeness Check

This item is a shaded cell and to check that all nonshaded cells have been completed. If "No" appears, please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable. Please ensure that "Yes" appears across all cells.

D.4—Standardized Risk-Weighted Assets

All BHCs, including advanced approaches BHCs and non-advanced approaches BHCs must complete “Standardized RWA” sub-schedule. In addition, advanced approaches BHCs are required to complete “Advanced RWA ” sub-schedule due to the floor requirement per the Collins Amendment under Section 171 of the DFA.

For the purpose of completing the “Standardized RWA” sub-schedule, BHCs are required to report credit risk-weighted assets using the methodologies in the standardized approach of the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013). BHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. However, if a BHC projects to meet the trading activity threshold that would require it to be subject to the market risk capital requirements during the forecast period, then the BHC should complete the market risk-weighted asset section within the sub-schedule. Please refer to the revised regulatory capital rule (78 Federal Register 62018, October 11, 2013) and the updated market risk capital rule (78 Federal Register 76521, December 18, 2013) for details of the requirements.

Where possible, please reference the definitions on Standardized RWA that is provided in the draft version of the HC-R, Part II, on a fully phased-in basis.

Standardized Approach Credit Risk

Line item 1 Credit RWA

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 2 Balance Sheet Asset Category RWA

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 3 Cash and balances due from depository institutions

Report the total risk-weighted asset amount of cash and balances due from depository institutions.

Line item 4 Federal funds sold and securities purchased under agreements to resell

Report the total risk-weighted asset amount of federal funds sold and securities purchased under agreements to resell, including reverse repurchase agreements.

Securities (Excluding securitization)

Line item 5 Held-to-maturity

Report the total risk-weighted asset amount of amortized cost of held-to-maturity (HTM) securities excluding those securities that qualify as securitization exposures as defined in §.2 of the revised regulatory capital rules.

Line item 6 Available-for-sale

Report the total risk-weighted fair value of available-for-sale (AFS) securities, excluding those securities that qualify as securitization exposures as defined in §.2 of the regulatory capital rules.

Loans and leases on held for sale**Line item 7 Residential Mortgage exposures**

Report the total risk-weighted asset amount of the carrying value of loans and leases held for sale (HFS) composed of items related to residential mortgage exposures.

Line item 8 High Volatility Commercial Real Estate

Report the total risk-weighted asset amount of the carrying value of loans and leases held for sale (HFS) related to high volatility commercial real estate exposures (HVCRE), as defined in §.2 of the revised regulatory capital rules, including HVCRE exposures that are 90 days or more past due or on non-accrual status.

Line item 9 Past due exposures

Report the total risk-weighted asset amount of the carrying value of loans and leases held for sale (HFS) that are 90 days or more past due or on non-accrual status according to the requirements set forth in §.32(k) of the revised regulatory capital rules. Do not include exposures to sovereigns or residential real estate, as described in §.32(a) and §.32(g) respectively, that are past due or on non-accrual status. Also do not include HVCRE exposures that are past due or on non-accrual status.

Line item 10 All other exposures

Report the total risk-weighted asset amount of the carrying value of loans and leases held for sale (HFS) that are not reported in items 7 through 9.

Loans and leases, net of unearned income**Line item 11 Residential mortgage exposures**

Report the total risk-weighted asset amount of loans and leases, net of unearned income, composed of items related to residential mortgage exposures, including the carrying value of the guaranteed portion of FHA and VA mortgage loans, loans secured by 1-4 family residential properties and by multifamily residential properties, as well as loans that meet the definition of statutory multifamily mortgage according to §.2 of the revised regulatory capital rules.

Line item 12 High Volatility Commercial Real Estate

Report the total risk-weighted asset amount of loans and leases, net of unearned income that are related to high volatility commercial real estate exposures (HVCRE), including HVCRE exposures that are 90 days or more past due or on non-accrual status.

Line item 13 Past due exposures

Report the total risk-weighted asset amount of loans and leases, net of unearned income, that are 90 days or more past due or on non-accrual status according to the requirements set forth in §.32(k) of the revised regulatory capital rules. Do not include exposures to sovereigns or residential real estate, as described in §.32(a) and §.32(g) respectively, that are past due or on non-accrual status. Also do not include HVCRE exposures that are past due or on non-accrual status.

Line item 14 All other exposures

Report the total risk-weighted asset amount of loans and leases, net of unearned income that are not reported in items 11 through 13.

Line item 15 Trading assets (excluding securitizations that receive standardized charges)

If the BHC is subject to the market risk capital rules, report the total risk-weighted fair value of trading assets that do not meet the definition of a covered position per the market risk capital rules, excluding those trading assets that do not meet the definition of a covered position per the market risk capital that are securitization exposures as defined in §.2 of the regulatory capital rules.

If the BHC is not subject to the market risk capital rules, report the total risk-weighted fair value of trading assets, excluding those trading assets that are securitization exposures as defined in §.2 of the regulatory capital rules.

Line item 16 All other assets

Include total risk-weighted amounts of items such as "Premises and fixed assets," "Other real estate owned," "Investments in unconsolidated subsidiaries and associated companies," "Direct and indirect investments in real estate ventures," "Goodwill," "Other intangible assets," and "Other assets," excluding those trading assets that are securitization exposures as defined in §.2 of the regulatory capital rules. Also include the total risk-weighted amount of default fund contributions made by the banking organization to central counterparties (CCP) and collateral provided by the banking organization to CCPs that is not bankruptcy remote as described in §.35 of the regulatory capital rules.

Securitization exposures**Line item 17 Held-to-maturity**

Report the total risk-weighted asset amount of amortized cost of held-to-maturity (HTM) securities that are securitization exposures.

Line item 18 Available-for-sale

Report the total risk-weighted asset amount of available-for-sale (AFS) securities that are securitization exposures.

Line item 19 Trading assets that are securitization exposures that receive standardized charges

If the BHC is subject to the market risk capital rules, report the total risk-weighted fair value of the portion of trading assets reported that are securitization exposures that do not meet the definition of a covered position per the market risk capital rules.

If the BHC is not subject to the market risk capital rules, report the total risk-weighted fair value of trading assets that are securitization exposures.

Line item 20 All other on-balance sheet securitization exposures

Report the total risk-weighted amount of any qualifying on-balance sheet securitization exposures which are not included above.

Line item 21 Off-balance sheet securitization exposures

Consistent with the draft HC-R, part II instructions, report the total risk-weighted amount of all off-balance sheet items included in Schedule HC-L or HC-S that qualify as securitization exposures.

Derivatives and Off-Balance Sheet Items**Line item 22 Derivatives and Off-Balance Sheet Items RWA**

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 23 Financial standby letters of credit

Report the total risk-weighted amount of all financial standby letters of credit that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules.

Line item 24 Performance standby letters of credit and transaction related contingent items

Report the total risk-weighted amount of transaction related contingent items, which includes the face amount of performance standby letters of credit and any other transaction related contingent items that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules.

Line item 25 Commercial and similar letters of credit

Report the the total risk-weighted amounts of commercial and similar letters of credit, including self-liquidating, trade-related contingent items that arise from the movement of goods, with an original maturity of one year or less that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules.

Line item 26 Retained recourse on small business obligations sold with recourse

Report the total risk-weighted amount of retained recourse on small business obligations that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules. Under Section 208 of the Riegle Community Development and Regulatory Improvement Act of 1994, a "qualifying institution"¹⁴ that transfers small business loans and leases on personal property (small business obligations) with recourse in a transaction that qualifies as a sale under generally accepted accounting principles (GAAP) must maintain risk-based capital only against the amount of recourse retained, provided the institution establishes a recourse liability account that is sufficient under GAAP. Only loans and leases to businesses that meet the criteria for a small business concern established by the Small Business Administration under Section 3(c) of the Small Business Act (12 U.S.C. 631) are eligible for this favorable risk-based capital treatment.

¹⁴ In general, a "qualifying institution" is one that is well capitalized without regard to the Section 208 provisions. If a bank ceases to be a qualifying institution or exceeds the retained recourse limit set forth in banking agency regulations implementing Section 208, all new transfers of small business obligations with recourse would not be treated as sales. However, the reporting and risk-based capital treatment described above will continue to apply to any transfers of small business obligations with recourse that were consummated during the time the bank was a "qualifying institution" and did not exceed the limit.

Line item 27 Repo-style transactions (excluding reverse repos)

Report the total risk-weighted amount of repo-style transactions, which is composed of the sum of the amount of securities lent, the amount of securities borrowed, and the amount of securities sold under agreements to repurchase that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules. Exclude the amount of securities purchased under agreements to resell (i.e., reverse repos).

Line item 28 All other off-balance sheet liabilities

Report the total risk-weighted amount of all other off-balance sheet liabilities that are covered by the regulatory capital rules as well as the amount of those credit derivatives that are covered by the regulatory capital rules, but do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules, and have not been included in any of the preceding items in the Derivatives and Off-Balance Sheet section.

Unused commitments**Line item 29 Original maturity of one year or less, excluding ABCP conduits**

Report the total risk-weighted amount of the unused portion of an eligible liquidity facility with an original maturity of one year or less, excluding ABCP facilities that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules. The unused portion of commitments (facilities) that are unconditionally cancelable (without cause) at any time by the holding company have a zero percent credit conversion factor. The unused portion of such commitments should be excluded from this item and included in line item 32.

Note that “original maturity” is defined as the length of time between the date a commitment is issued and the date of maturity, or the earliest date on which the banking organization: (1) is scheduled to, and as a normal practice actually does, review the facility to determine whether or not it should be extended and; (2) can unconditionally cancel the commitment.

Line item 30 Original maturity of one year or less to ABCP

Report the total risk-weighted amount of the unused portion of an eligible liquidity facility with an original maturity of one year or less to ABCP facilities that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules. Under the regulatory capital rules, the unused portion of commitments (facilities) which are unconditionally cancelable (without cause) at any time by the banking organization have a zero percent conversion factor. The unused portion of such commitments should be excluded from this item and included in line item 32.

Line item 31 Unused commitments: Original maturity exceeding one year

Report the total risk-weighted amount of the unused portion of the eligible liquidity facility with an original maturity exceeding one year, are subject to the risk-based capital rules, and do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules. Under the regulatory capital rules, the unused portion of commitments (facilities) which are unconditionally

cancelable (without cause) at any time by the banking organization have a zero percent conversion factor. The unused portion of such commitments should be excluded from this item and included in line item 32.

Line item 32 Unconditionally cancelable commitment

Report the total risk-weighted amount unconditionally cancelable commitments that are subject to the regulatory capital rules that do not meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules. The unused portion of commitments (facilities) that are unconditionally cancelable (without cause) at any time by the banking organization have a zero percent conversion factor. The unused portion of such commitments should be reported in this item.

Line item 33 Over-the-counter derivatives

Report the total risk-weighted credit equivalent amount of over-the-counter derivative contracts covered by the regulatory capital rules. Include over-the-counter credit derivative contracts held for trading purposes and subject to the market risk capital rules. Do not include centrally cleared derivative contracts. Do not include over-the-counter credit derivative contracts that meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules.

Line item 34 Centrally cleared derivatives

Report the total risk-weighted credit equivalent amount of centrally cleared derivative contracts covered by the regulatory capital rules. Include centrally cleared credit derivative contracts held for trading purposes and subject to the market risk capital rules. Do not include over-the-counter derivative contracts. Do not include centrally cleared derivative contracts that meet the definition of a securitization exposure as described in §.2 of the regulatory capital rules.

Market Risk

If a BHC does not have a particular portfolio or no trading book at all, risk-weighted assets should be reported as 0.

For items 35 to 54, refer to instructions for items 37 to 56, respectively, for market risk under Advanced Risk Weighted Assets.

Other

Line item 55 Excess allowance for loan and lease losses

Report the amount (report as positive value), if any, by which the banking organization's allowance for loan and lease losses exceeds 1.25% of the banking organization's gross risk-weighted assets.

Line item 56 Allocated transfer risk reserve

Report the entire amount (report as positive value) of any allocated transfer risk serve (ATRR) the reporting banking organization is required to establish and maintain as specified in Section 905(a) of the International Lending Supervision Act of 1983, in the agency regulations implementing the

Act (Subpart D of Federal Reserve Regulation K, Part 347 of the FDIC's Rules and Regulations, and 12 CFR Part 28, Subpart C (OCC)), and in any guidelines, letters, or instructions issued by the agencies. The entire amount of the ATRR equals the ATRR related to loans and leases held for investment (which is reported in Schedule RI-B, part II, Memorandum item 1) plus the ATRR for assets other than loans and leases held for investment.

Line item 57 Total Risk-Weighted Assets

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 58 Data Completeness Check

This item is a shaded cell and to check that all nonshaded cells have been completed. If "No" appears, please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable. Please ensure that "Yes" appears across all cells.

D.5—Leverage Exposure

All BHCs must complete the portion of the sub-schedule relevant to “Leverage Exposure for Tier 1 Leverage Ratio” (lines 1 - 4). Advanced approaches BHCs must also complete the portion of the sub-schedule relevant to “Leverage Exposure for Supplementary Leverage Ratio” (lines 5 - 24).

The exposure measure for the tier 1 leverage ratio is based upon methodology in the revised regulatory capital rule. The exposure measure for the supplementary leverage ratio has been revised from the 2014 CCAR instructions to reflect the changes to the definition of leverage exposure, per the final rule on the Supplementary Leverage Ratio issued by the banking agencies on September 3, 2014 (final rule).¹⁵ The final rule modifies the definition of “total leverage exposure,” which is the denominator in the supplementary leverage ratio, in a manner consistent with the recent changes agreed to by the Basel Committee on Banking Supervision in January 2014. The revisions in the final rule would apply to all advanced approaches banking organizations.

Consistent with the final rule, an advanced approaches banking organization should calculate its supplementary leverage ratio as the ratio of its tier 1 capital to total leverage exposure. The proposed rule would have required banking organizations to use daily averages to calculate both on- and off-balance sheet items in total leverage exposure. However, under the final rule, institutions are required to calculate total leverage exposure as the mean of the on-balance sheet assets calculated as of each day of the reporting quarter, plus the mean of the off-balance sheet exposures calculated as of the last day of each of the most recent three months, minus the applicable deductions under the 2013 revised capital rule. For purposes of calculating projections for the supplementary leverage ratio denominator, BHCs that are unable to calculate averages based on the averages of daily or monthly data may report exposures as of the quarter end.

Leverage Exposure for Tier 1 Leverage Ratio (applicable to all BHCs)

Line item 1 Average total consolidated assets

Report average total on-balance sheet assets as reported in the FR Y-9C, Schedule HC-K, item 5.

Line item 2 LESS: Deductions from Common Equity Tier 1 and Additional Tier 1 Capital (report as a positive number)

Regulatory deductions from common equity tier 1 and additional tier 1 capital. Deductions should be calculated as defined in the FR Y-9C, Schedule HC-R, Part I.B., item 37.

Line item 3 LESS: Other Deductions from (Additions to) Assets for Leverage Ratio Purposes (report as a positive number if a net deduction or a negative value if a net addition)

Other deductions from or additions to assets for purposes of the leverage ratio as defined in the FR Y-9C, Schedule HC-R, Part I.B., item 38.

Line item 4 Total Assets for the Leverage Ratio (item 1 less the sum of items 2 and 3)

This item is a shaded cell and is derived from other items in the schedule; no input required

¹⁵ See <http://www.federalreserve.gov/newsevents/press/bcreg/bcreg20140903b1.pdf>.

Leverage Exposure for Supplementary Leverage Ratio (applicable to advanced approaches BHCs only)

Refer to section 217.10 (c)(4)(ii) (A) of the final rule.

Line item 5 On-Balance Sheet Assets (excluding on-balance sheet assets for repo-style transactions and derivative exposures, but including cash collateral received in derivative transactions)

On-balance sheet assets (excluding on-balance sheet assets for repo-style transactions and derivative exposures, but including for the qualifying cash collateral received in derivative transactions, in accordance with *section 217.10 (c)(4)(ii)(C)*).

Line item 6 LESS: Deductions from common equity tier 1 capital and additional tier 1 capital (report as a positive number)

Regulatory deductions from common equity tier 1 and additional tier 1 capital, as applicable to advanced-approaches BHCs per the revised capital rules under section 217.22(a),(c), and (d). .

Line item 7 Total On-Balance Sheet Exposures (excluding on-balance sheet assets for repo-style transactions and derivative exposures, but including cash collateral received in derivative transactions) (item 5 less item 6)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Derivative exposures

Refer to sections 217.10 (c)(4)(ii) (B), (C), (D), or (I) of the final rule as appropriate.

Line item 8 Replacement cost for derivative exposures (net of qualifying cash variation margin).

Report the total amount of the replacement cost for all derivative exposures, generally consistent with the US GAAP balance sheet numbers for derivative assets, and adjusted for cash variation margin that does not meet the criteria described in section 217.10 (c)(4)(ii)(C) of the final rule.

Line item 9 Add-on amounts for potential future exposure (PFE) for derivatives exposures

Report the total amount of PFE for each derivative contract, including for cleared transactions except as provided in section 217.10 (c)(4)(ii)(I) of the final rule, to which the banking organization is a counterparty (or each single-product netting set of such transactions), as described in section 34 of the revised regulatory capital rule, but without regard to section 217.34(b). Specifically, a banking organization may not use cash variation margin to reduce the net current credit exposure or the gross current credit exposure in calculation of the net-to-gross ratio.

Line item 10 Gross-up for cash collateral posted if deducted from the on-balance sheet assets, except for cash variation margin

Report cash collateral posted to a counterparty in a derivative transaction if a banking organization offsets a negative mark-to-fair value of a derivative contract by the amount of cash collateral posted

to the counterparty and does not include such cash collateral in its on-balance sheet assets (as permitted under the GAAP offset option), but the posted cash collateral does not meet the final rule's requirements for cash variation margin in section 217.10 (c)(4)(ii)(C).

Line item 11 LESS: Deductions of receivable assets for cash variation margin posted in derivatives transactions, if included in on-balance sheet assets (report as a positive value)

Report the value of cash collateral that is posted to a counterparty to a derivative contract and that has been included on the banking organization's balance sheet as a receivable if the posted cash collateral satisfies the requirements described in section 217.10 (c)(4)(ii)(C) of the final rule. If not applicable, report zero.

Line item 12 LESS: Exempted CCP leg of client-cleared transactions (report as a positive value)

A clearing member banking organization that does not guarantee the performance of a CCP with respect to a transaction cleared on behalf of a clearing member client may exclude its exposure to the CCP for purposes of determining its total leverage exposure (if such exposure is included in the on-balance sheet items).

A clearing member banking organization that guarantees the performance of a CCP with respect to a transaction cleared on behalf of a clearing member client must treat its exposure to the CCP as a derivative contract for purposes of determining its total leverage exposure.

Line item 13 Effective notional principal amount of sold credit protection

The effective notional principal amount (that is, the apparent or stated notional principal amount multiplied by any multiplier in the derivative contract) of a credit derivative, or other similar instrument, through which the banking organization provides credit protection (for example, credit default swaps or total return swaps that reference instruments with credit risk, such as a bond).

Line item 14 LESS: Effective notional principal amount offsets and PFE adjustments for sold credit protection (report as a positive value)

A banking organization may reduce the effective notional principal amount of sold credit protection by a reduction in the mark-to-fair value of the sold credit protection if the reduction is recognized in common equity tier 1 capital.

A banking organization may further reduce the effective notional principal amount of sold credit protection by the effective notional principal amount of a credit derivative or similar instrument through which the banking organization has purchased credit protection from a third party (purchased credit protection) if the requirements of section 217.10 (c)(4)(ii)(D) of the final rule are satisfied. When a banking organization reduces the effective notional principal amount of sold credit protection by purchased credit protection in accordance with section 217.10 (c)(4)(ii)(D)(1), the banking organization must reduce the effective notional principal amount of purchased credit protection by the amount of any increase in the mark-to-fair value of the purchased credit protection that is recognized in common equity tier 1 capital.

If a banking organization purchases credit protection through a total return swap and records the net payments received as net income but does not record offsetting deterioration in the mark-to-fair value of the sold credit protection on the reference exposure (either through reductions in fair value or by additions to reserves) in common equity tier 1 capital, the banking organization may

not reduce the effective notional principal amount of the sold credit protection.

A banking organization may also adjust PFE for sold credit protection as described in section 217.10 (c)(4)(ii)(B) of the final rule, to avoid double-counting of the notional amounts of these exposures.

Line item 15 Total derivative exposures (sum of items 8, 9, 10, and 13, minus items 11, 12, and 14)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Repo-style transactions

Refer to sections (c)(4)(ii) (E), (F), or (G) of the final rule as appropriate.

Line item 16 On-balance sheet assets for repo-style transactions

Report the on-balance sheet assets for repo-style transactions, except include the gross value of receivables for reverse repurchase transactions. Exclude from this item the value of securities received in a security-for-security repo-style transaction where the securities lender has not sold or re-hypothecated the securities received. Include in this item the value of securities sold under a repo-style arrangement.

Line item 17 LESS: Reduction of the gross value of receivables in reverse repurchase transactions by cash payables in repurchase transactions under netting agreements (report as a positive value)

Where a banking organization acting as a principal has more than one repo-style transaction with the same counterparty and has applied the GAAP offset for repo-style transactions, report the reduction of the gross value of receivables in reverse repurchase transactions if the criteria in section 217.10(c)(4)(ii)(E), (1) through (3) of the final rule are satisfied.

Line item 18 Counterparty credit risk for all repo-style transactions

To determine the counterparty exposure for a repo-style transaction, including a transaction in which a banking organization acts as an agent for a customer and indemnifies the customer against loss, the banking organization would subtract the fair value of the instruments, gold, and cash received from a counterparty from the fair value of any instruments, gold and cash lent to the counterparty. If the resulting amount is greater than zero, it would be included in total leverage exposure. For repo-style transactions that are not subject to a qualifying master netting agreement or that are not cleared transactions, the counterparty exposure measure must be calculated on a transaction-by-transaction basis. However, if a qualifying master netting agreement is in place, or the transaction is a cleared transaction, the banking organization could net the total fair value of instruments, gold, and cash lent to a counterparty against the total fair value of instruments, gold and cash received from the counterparty for those transactions.

Line item 19 Exposure for repo-style transactions where a banking organization acts as an agent

Where a banking organization acts as agent for a repo-style transaction and provides a guarantee (indemnity) to a customer with regard to the performance of the customer's counterparty that is greater than the difference between the fair value of the security or cash lent and the fair value of the security or cash borrowed, the banking organization must include the amount of the guarantee

that is greater than this difference.

Line item 20 Total exposures for repo-style transactions (sum of items 16, 18, and 19 minus item 17)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Other off-balance sheet exposures

Refer to section (c)(4)(ii) (H) of the final rule.

Line item 21 Off-balance sheet exposures at gross notional amounts

The notional amount of all off-balance sheet exposures (excluding off-balance sheet exposures associated with securities lending, securities borrowing, reverse repurchase transactions, and derivatives).

Line item 22 LESS: Adjustments for conversion to credit equivalent amounts (report as a positive value)

The final rule retains the 10 percent CCF for unconditionally cancellable commitments, but it would replace the uniform 100 percent CCF for other off-balance sheet items with the CCFs applicable under the standardized approach for risk-weighted assets in section 217.33 of the revised regulatory capital rule.

Line item 23 Off-balance sheet exposures (item 21 less item 22)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Line item 24 Total Leverage Exposure (sum of items 7, 15, 20 and 23)

This item is a shaded cell and is derived from other items in the schedule; no input required.

Data Completeness Check

Line item 25 Leverage Exposure for Tier 1 Leverage Ratio (applicable to all BHCs)

Check to ensure sub-schedule is complete. Please ensure that "Yes" appears across all cells.

Line item 26 Leverage Exposure for Supplementary Leverage Ratio (applicable to advanced approaches institutions only)

This item is a shaded cell and to check that all nonshaded cells have been completed. If "No" appears, please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable. Please ensure that "Yes" appears across all cells.

D.6—Planned Actions

The FR Y-14A Planned Action sub-schedule collects information on all material planned actions that management intends to pursue to address the revised regulatory capital rule. BHCs are required to factor the combined quantitative impact of all planned actions into the projections reported on all other relevant sub-schedules of the Regulatory Capital Transitions submission. Such actions might include, but are not limited to, the roll-off or sale of an existing portfolio; development/implementation of risk-weighting models; data remediation to facilitate the use of lower risk weights for existing exposures; the issuance of regulatory capital instruments; or other strategic corporate actions. Planned actions should be attributable to a specific strategy or portfolio; BHCs are not expected to cite period-over-period changes in the balances of exposures as a planned action unless those changes are attributable to a specific and identifiable strategy (e.g., citing “reduction in credit risk-weighted assets” would not be considered a valid planned action, but citing sale or runoff of a particular portfolio (which would have the effect of reducing credit risk-weighted assets) would be a valid planned action).

For each reporting period, BHCs should report the incremental quantitative impact of each action on:

- Common equity tier 1 capital
- Tier 1 capital
- RWA_Standardized
- RWA_Advanced
- Average Total Assets for Leverage Capital Purposes (relevant to the tier 1 leverage ratio; to be completed by all BHCs)
- Total Leverage Exposure for the Supplementary Leverage Ratio (to be completed by advanced approaches BHCs only); and
- Balance sheet.

The quantitative impact of planned actions submitted by BHCs should represent the stand-alone, incremental immediate impact of the action relevant to the time period in which it is planned to be executed. For example, if a planned action were forecasted to reduce the BHC’s risk-weighted assets by \$200 million as of Q4 in the current year and an additional \$100 million as of Q4 of the following year (for a total reduction of \$300 million), the BHC should report “(200)” for PY1, “(100)” for PY2, and “0” for subsequent periods. BHCs are required to factor the combined quantitative impact of all planned actions into the projections reported on all other relevant sub-schedules of the Regulatory Capital Transitions submission.

Additional Information Required for Each Planned Action

In addition to the information provided within the Planned Action sub-schedule, BHCs are also required to submit additional details of each of its planned actions. This information should be provided in a separate attachment.

Column Instructions

Note that certain columns include an option of “other” in the drop down list that can be used if the listed action cannot be described using the listed selections.

Column B Description

Brief description of the planned action.

Column C Action Type

Select from a list of available actions provided in the schedule. BHCs should select the type of action that best describes the planned action.

Column D Exposure Type

Select from a list of available exposure types provided in the schedule. BHCs should select the type of exposure that is most impacted by the planned action.

Column E RWA Type

Selection from a list of available RWA exposure types provided in the schedule. For planned actions that have an impact on RWAs, the BHC should report the type of RWA (i.e., Counterparty Credit, Other Credit, Market, or Operational) that is most impacted by the planned action.

Columns F-AU Projected impact (for periods PY 1 through PY 6) on:

- **Common Equity Tier 1**
- **Tier 1**
- **Standardized Risk-Weighted Assets (RWA) (impact on the RWA projections shown on Standardized RWA sub-schedule)**
- **Advanced RWA (impact on the RWA projections shown on Advanced RWA sub-schedule)**
- **Average Total Assets for Leverage Capital Purposes**
- **Total Leverage Exposure for Supplementary Leverage Ratio**
- **Balance Sheet**

Projected incremental impact year-over-year on the BHC's common equity tier 1 capital, Tier 1 capital, risk-weighted assets, leverage exposures and balance sheet in \$Millions as of year-end. For PY 1 only, report the incremental impact projected between the as of date and fourth quarter period corresponding to PY 1.

Columns F-L PY1

Report the projected impact at year-end (PY 1) for each of the seven capital and balance sheet items listed above.

Columns M-S PY2

Report the projected impact at year-end (PY 2) for each of the seven capital and balance sheet items listed above.

Columns T-Z PY3

Report the projected impact at year-end (PY 3) for each of the seven capital and balance sheet items listed above.

Columns AA-AG PY4

Report the projected impact at year-end (PY 4) for each of the seven capital and balance sheet items listed above.

Columns AH-AN PY5

Report the projected impact at year-end (PY 5) for each of the seven capital and balance sheet items listed above.

Columns AO-AU Total

These are shaded cells, no input is required. These items capture the projected cumulative impact of for each of the seven capital and balance sheet items listed above.

Column AV

Enter the file name and page number of the separate document in which a detailed description is provided for each planned action.

Please note:

Total impact of planned actions is provided at the bottom of the sub-schedule. This is auto-calculated and is the summation of each individual column aligned with the applicable category impact for the relevant reporting period.

Reported changes from prior period is the last row on the sub-schedule. This field captures the change between each reporting period on the change in impact for the applicable category (e.g., "Common Equity Tier 1," "Tier 1 capital," etc).

Schedule E—Operational Risk

E.1—BHC Operational Risk Historical Capital (BHC Baseline Scenario Only)

The BHC Operational Risk Historical Capital sub-schedule must be completed by respondents that are subject to the advanced approaches rule or that elect to apply the advanced approaches rule. BHCs subject to the Board’s advanced approaches risk-based capital rules (12 CFR part 225, Appendix, G) must submit the Operational Risk Historical Capital sub-schedule of the FR Y-14A Operational Risk Schedule. Institutions that are required to complete the Historical sub-schedule must also complete the Operational Risk Scenario Inputs and Projections Sub-schedule within the Summary Schedule. When completing the Historical sub-schedule, refer to the definitions section of the Summary Schedule Instructions for Operational Risk. The institution should report the BHC’s operational risk capital by unit-of-measure (undiversified basis) from Q4 of the previous year to Q3 of the reporting year. The unit-of-measure is the level at which the BHC’s quantification model generates a separate distribution for estimating potential operational losses (e.g., organizational unit, operational loss event type, risk category, etc.). The institution must complete this sub-schedule for the BHC Baseline Scenario only.

E.2—BHC Legal Reserves Reporting

The BHC Legal Reserves Reporting sub-schedule must be completed by all institutions. For each year, report the total dollar values of the institution’s legal reserve balance, representing the total legal reserve balance that was included on the institution’s financial statements for the as-of date. The BHC’s submission should contain annual legal reserve balances for at least five years through to the reporting quarter .

On a voluntary basis, report the total dollar value of the institution’s legal reserves pertaining to repurchase litigation which was included on the institution’s financial statements as part of the total legal reserve on the as-of date. Also please indicate the subset of this amount which is related only to contractual Representation and Warranty (R&W) claims (excluding any amounts set aside for damages, penalties, fees, etc).

Schedule F – Business Plan Changes

This schedule is used to estimate the effect of a material change in business plan on a BHC's asset, liability, and capital projections.¹⁶ Examples of a material change in business plan could include a planned merger, change in a key business strategy, a significant investment, or a divestiture, provided that the divestiture has been completed or contractually agreed to prior to the submission deadline of FR Y-14A, Schedule A.

BHCs that include a material business plan change in their capital plan must report this schedule. Respondents should refer to the CCAR instructions for a given year for requirements of materiality. Schedule F should **only** be used to report material business plan changes that derive from contractual agreements with another party. Overall projections of balances, liabilities, and capital, which include the assumed effects of run-off, growth, and contractual agreements, should be reported in the FR Y-14A Summary schedule.

Unless instructed otherwise, firms with material business plan changes are only required to complete Schedule F for the supervisory baseline, supervisory adverse, and supervisory severely adverse scenarios.

Schedule F mirrors the structure of the FR Y-14A Summary schedule. Using that structure, for a given supervisory scenario, report the dollar amount of the effect of a material change in business plan on the balance sheet, income statement, RWA, retail balance and loss projections, and capital worksheet items of the Y-14A Summary schedule. In quarters in which no change in business plan occurs, report zero for all of those fields. Separately report this information for each of the supervisory scenarios (Baseline, Adverse, and Severely Adverse). In addition, the following items on the Y-14A summary schedule should be reported on the Business Plan Changes schedule:

Summary, Income Statement (Schedule A.1.a)

- Item 63, Other Losses: Goodwill Impairment
- Item 64, Other Losses: Valuation Adjustment for firm's own debt under fair value option (FVO)
- Item 68, Allowance for Loan and Lease Losses: ALLL Prior Quarter
- Item 117, Pre-provision net revenue: Net interest income
- Item 118, Pre-provision net revenue: Noninterest income
- Item 119, Pre-provision net revenue: Noninterest expense
- Item 120, Pre-provision net revenue: Pre-provision net revenue
- Item 126, Condensed income statement: Realized gains (losses) on available-for-sale securities, including OTTI
- Item 127, Condensed income statement: Realized gains (losses) on held-to-maturity securities, including OTTI
- Item 136, Repurchase Reserve/Liability for Mortgage Reps and Warranties: Reserve, prior

¹⁶ A BHC is required include in its capital plan a discussion of any expected changes to the BHC's business plan that are likely to have a material impact on the BHC's capital adequacy or liquidity. See 12 CFR 225.8(e)(2)(iv). In this discussion, the BHC should consider not just the impacts of these expected changes, but also the potential adverse consequences should the actions not result in the planned changes—e.g., a merger plan falls through, a change in business strategy is not achieved, or there is a loss on the planned significant investment.

- quarter
- Item 137, Repurchase reserve/liability for mortgage reps and warranties: Provisions during the quarter
- Item 138, Repurchase reserve/liability for mortgage reps and warranties: Net charges during the quarter

Summary, Capital (Schedule A.1.d.1)

- Item 1, Schedule HI-A—Changes in Bank Holding Company Equity Capital: Total bank holding company equity capital most recently reported for the end of previous QUARTER

BHCs should provide supporting documentation that includes any information relating to portfolio risk characteristics that has been collected during the BHC's due diligence process.

Example of What to Report: Suppose that, as of 4Q15 (the data as of date for CCAR 2016), a BHC has a US first lien mortgage portfolio of \$100 million which is projected to grow by \$5 million per quarter over the planning horizon. In the first quarter of the planning horizon (1Q16 for CCAR 2016) the BHC completes a divestiture of a \$20 million portfolio and enters an agreement to acquire a \$40 million portfolio, estimated to close in the fourth quarter of the planning horizon (4Q16 for CCAR 2016). Further suppose that all of the projections mentioned above correspond to projections under the Supervisory Severely Adverse scenario.

On its Y-14A Summary schedule for the Supervisory Severely Adverse scenario, the BHC would report the projected balances of its US first lien mortgage portfolio on Item 1 of the Retail Balance and Loss Projections worksheet (RBLP) (MDRM number CPSRP381). These balances would correspond to column in Exhibit 1, below.

The BHC would also be required to submit a Y-14A Business Plan Changes schedule for the supervisory scenarios. In that submission, for the Supervisory Severely Adverse scenario, the BHC would report the dollar amount of the effect that the merger and divestiture would have on the projected balances of its US first lien mortgage portfolio on Item 1 of the RBLP (MDRM number CBPRP381). These balances would correspond to column (4) in Exhibit 1, below.

(1)	(2)	(3)	(4)	
Projection Quarter	Y-14A Summary RBLP, Line 1	Portfolio Growth	FR Y-14A BPC RBLP, Line 1	
4Q15	100			
1Q16	85	5	-20	<- Divestiture
2Q16	90	5	0	
3Q16	95	5	0	
4Q16	140	5	40	<- Acquisition
1Q17	145	5	0	
2Q17	150	5	0	
3Q17	155	5	0	
4Q17	160	5	0	
1Q18	165	5	0	

Note: Column (3) of exhibit 1 is not explicitly reported in either the Y-14 Summary or Business Plan Changes schedules. It is included in exhibit 1 for illustration only.

Appendix A: Supporting Documentation

This appendix sets forth requirements and supervisory expectations related to supporting documentation for all BHCs subject to the Y-14 reporting requirements. This document is primarily focused on helping to ensure that BHCs subject to Y-14 reporting requirements provide accurate and comprehensive information for their Y-14 reports. In certain cases, this document describes additional expectations for certain capital planning practices to help support BHCs' Y-14 reporting. However, this document is not intended to describe the full set of expectations for capital planning. The full set of capital planning expectations have been consolidated in two Federal Reserve two supervisory letters, SR Letters 15-18 and 15-19, issued in December 2015. Importantly, those two SR letters clarify that the capital planning expectations for LISCC and Large and Complex Firms (as defined in those letters) are higher than the expectations for Large and Noncomplex Firms (as defined in those letters).¹⁷ A BHC should refer to SR Letter 15-18 or SR Letter 15-19, as applicable, for the capital planning expectations applicable to that BHC (depending on the BHC's size and complexity), as this document applies to all BHCs subject to Y-14 reporting and does not differentiate between Large and Complex vs Large and Noncomplex Firms. To the extent that this appendix references expectations that may not be applicable to a Large and Noncomplex Firm pursuant to SR Letter 15-19, a Large and Noncomplex will not be held to those expectations but should instead refer to the expectations in SR Letter 15-19.

Schedule A – Summary

For each part of the Summary Schedule, BHCs must submit supporting documentation that clearly describes the methodology used to produce the BHC's projections. The supporting documentation should include the following:

Policies and Procedures

BHCs should submit all policies and procedures related to the capital adequacy process, including the BHC's model risk-management policies. The model risk management policies should provide the BHC's general framework for model development, implementation and use; model validation, and governance policies and controls (consistent with supervisory guidance on model risk management), including oversight by specifying criteria and controls across various stages of the model lifecycle (Identification; Inventory/ Tracking; Development and Documentation; Independent Validation; Approval for Implementation; Ongoing monitoring; Model Retirement).

Documentation of Risk Measurement Practices

Capital plan submissions should include documentation of key risk identification and measurement practices supporting the BHC-wide stress testing required in the capital plans. BHC submissions should also include internal documentation describing the BHC's framework for development, calibration, estimation, validation, oversight, and escalation of key risk identification and

¹⁷ SR Letter 15-18 sets forth capital planning expectations for BHCs that are subject to the Federal Reserve's Large Institution Supervisory Coordinating Committee (LISCC) framework and BHCs with total consolidated assets with total consolidated assets of \$250 billion or more or consolidated total on-balance sheet exposure of \$10 billion or more (defined as a Large and Complex Firm). SR Letter 15-19 sets forth capital planning expectations for BHCs that have total consolidated assets of at least \$50 billion but less than \$250 billion, have consolidated total on-balance sheet exposure of less than \$10 billion, and are not otherwise subject to the LISCC framework (defined as a Large and Noncomplex Firm).

measurement practices. As noted above, an assessment of the robustness of these practices is a critical aspect of the supervisory assessment of capital planning processes as outlined in SR 15-18 and 15-19.

Model and Methodology Inventory Mapping to FR Y-14A

BHCs should submit an inventory of all models and methodologies used to estimate losses, revenues, expenses, balances, and risk-weighted assets (RWAs) and the status of validation/independent review for each. The inventory should include mapping that clearly conveys the methodology used for each FR Y-14A product line under each stress scenario.

Methodology Documentation

BHCs should include in their capital plan submissions thorough documentation that describes and makes transparent key methodologies and assumptions for performing stress testing on their portfolios. This documentation should describe how the BHC translated the macroeconomic factors (or market shock for the Trading and Counterparty Risk sections) associated with the scenario into the BHC's projections and technical details of any underlying statistical methods used, including information on model validation and independent review. Where judgment is an essential part of the projection, the methodology documentation should demonstrate the rationale and magnitude, as well as the process involved to ensure consistency of projections with scenario conditions. Methodology documentation should include, at a minimum, the following documents:

- **Methodology and Process Overview**

BHCs should provide documentation that describes key methodologies, processes, and assumptions for performing stress testing on the BHC's portfolios, business, and performance drivers. Documentation should clearly describe the model-development process, the derivation of outcomes, and validation procedures, as well as assumptions concerning the evolution of balance sheet and RWAs under the scenarios, changing business strategies, and other impacts to a BHC's risk profile. Supporting documentation should clearly describe any known model weaknesses and how such information is factored into the capital plan.

- **Model Technical Documents**

BHCs should submit model technical documentation for key models used to performing stress testing on the BHC's portfolios. The documentation should include:

- A description of the model methodology;
- An explanation of the theory, logic, and design underlying the model methodology and support from published research and sound industry practice;
- A discussion of historical data set construction, including data sources, adjustments to the data set, and documentation validating the use of any external data;
- The rationale for portfolio segmentation and a discussion on how a particular methodology and model captures the key characteristics and the unique risk drivers of each portfolio segment;
- A description of model selection and specification, variable choice, and estimation methodology, including the statistical results used to arrive at the selected model;
- An analysis of the model output, including the congruence of inputs with the assumed economic scenario, the justification of any qualitative adjustment, along with the statistical analysis used to support the model output; and

- A model inventory log specifying, at a minimum, the model's version, the date of model approval, the date of its last revision, its intended use, the name of its model owner and developer, the model's priority, the date of the model's last independent validation, and the date of the model's next expected independent validation.

If third-party models are used, the documentation should describe how the model was constructed, validated, and any known limitations of the model. Documentation should clearly describe assumptions concerning new growth and changes to credit policy. Supporting documentation should transparently describe internal governance around the development of comprehensive capital plans. Documentation should demonstrate that senior management has provided the board of directors with sufficient information to facilitate the board's full understanding of the stress testing used by the firm for capital planning purposes.

- **Model Validation and Independent Review**

Models employed by BHCs (either developed internally or supplied by a vendor) should be independently validated or otherwise reviewed in line with model risk management expectations presented in existing supervisory guidance, including Supervisory Letter SR 11-7. Institutions should provide model validation documentation on the following elements: conceptual soundness, inputs, transparency, implementation, reporting, model robustness and limitations, use of expert judgment, exception reports, outcomes analysis (back testing and/or benchmarking) and qualitative adjustments.

Validation documentation should include the BHC's assessment of the vulnerability of their models to error, an understanding of any of their other limitations, and consideration of the risk to the BHC should estimates based on those models prove materially inaccurate. Specifically, validation reviews should examine the efficacy of model use in both base case and stress scenarios. While the use of existing risk measurement models and processes provides a useful reference point for considering stress scenario potential loss estimates, validation efforts should consider whether these processes generate outputs that are relevant in a stressful scenario or if the use of models should be supplemented with other data elements and alternative methodologies. To the extent available, the above items should also be provided for any vendor supplied models used by the BHC, along with any third party validation documentation available for the vendor supplied model.

- **Audit Reports**

BHCs should submit audit reports from their internal audit of the capital adequacy process including reviews of the models and methodologies used in the process. (See "*Capital Planning at Large Bank Holding Companies: Supervisory Expectations and Current Range of Practice*").

- **Results Finalization and Challenge Materials**

BHCs should ensure that they have sound processes for review, challenge and aggregation of estimates used in their capital planning processes. BHCs should submit documentation providing transparency into the review, challenge, and aggregation processes and the finalization of results.

Within this methodology documentation, BHCs should provide credible support for all assumptions used to derive loss estimates, including assumptions related to the components of loss, severity of loss, and any known weaknesses in the translation of assumptions into loss estimates. BHCs should demonstrate that these assumptions are clearly conditioned on the stated macroeconomic scenario, are consistent with stated business strategies, and reflect the competitive environment of each business line. If firm-specific assumptions (other than broad macroeconomic assumptions) are used, also describe these assumptions and how they relate to reported projections. If the BHC models rely upon historical relationships, provide the historical data and clearly describe why these relationships are expected to be maintained in each scenario. The impact of assumptions concerning new growth or changes to credit policy on forecasted loss estimates relative to historical performance should be clearly documented.

While judgment is an essential part of risk measurement and risk management, including for loss forecasting, BHCs should not be over-reliant on judgment to prepare their loss estimations without providing documentation or evidence of transparency and discipline around the process. BHCs should adequately support their judgments and should ensure that judgments are in line with scenario conditions. BHCs should be consistently conservative in the assumptions they make to arrive at loss rates. Where appropriate, documentation should quantify the impact of qualitative adjustments from modeled output.

Furthermore, within this methodology documentation, BHCs should include a thorough discussion of any material deviations from the instructions and how the materiality of such deviations was decided upon.

Additional information to be included in the methodology documentation is described in more detail in sections A.2 – A.10 below.

Consolidated Pro Forma Financials Methodology

BHCs should submit documentation that describes (1) how the various balance sheet and income statement line items were developed and reported, (2) the specific assumptions used to calculate regulatory capital, including a discussion of any proposed capital distributions, and (3) any other information necessary to understand the BHC's capital calculations (e.g., calculations related to the projections of the deferred tax asset or servicing assets that may be disallowed for regulatory capital purposes). *Additional information to be provided as part of this documentation is outlined in section A.1 below for the FR Y-14A Income Statement, Balance Sheet, and Capital sub-schedules.*

Governance

BHCs should include in their submission supporting documentation that transparently describes internal governance around the development of stress testing models and methodologies, and discuss how the stress testing methodologies have been implemented in the BHC's existing firm-wide risk management practices. Furthermore, documentation should include a discussion of the stress testing outcomes in terms of the nature of the portfolio and the modeled scenario. The BHC should demonstrate that senior management provided the board of directors with sufficient information to facilitate the board's full understanding of the stress testing used by the firm for capital planning purposes and allow for the appropriate level of challenge of assumptions and outcomes.

A.1 – Income Statement, Balance Sheet, and Capital

Income Statement, Balance Sheet, and Capital Sub-schedules

HCs should submit supporting documentation that clearly describes the methodologies used to make the loss, reserve change, and revenue projections that underlie the pro forma projections of equity capital. BHCs may submit separate documents for different models/methodologies. Each BHC should include in its supporting documentation a clear description of how the various balance sheet and income statement line items were reported.

Provide information on the specific assumptions used to calculate regulatory capital, including a discussion of any proposed capital distributions. When appropriate, clearly state assumptions related to the corporate tax rate and the evolution of the deferred tax assets. In situations where the BHC chooses not to project components of the balance sheet, those components should be held constant at the last current level and the BHC should explain why the zero delta assumption is appropriate in the given scenario.

BHCs should submit any other information and documentation necessary to support or understand its capital calculations. For example, a BHC could show the calculations related to the projections of the deferred tax asset or servicing assets that may be disallowed for regulatory capital purposes. Where applicable, BHCs should link the additional supporting documentation to the Summary Memo of Capital Methodology and Assumptions and the Capital sub-schedule.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as follows using the metadata tags provided:

Supporting Materials → Consolidated Pro Forma Financials Methodology → General

If a BHC submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.2 – Retail

HCs should submit separate documentation for their Retail-related projections. A BHC may submit separate documents for different models and/or methodologies. Documentation should be submitted for all aspects of the retail portfolio, including purchased credit impaired loans and mortgage repurchase risk. Mortgage repurchase documentation should include descriptions of all important assumptions made in each scenario, including, but not limited to, assumptions about legal process outcomes and counterparty behavior. All retail documentation should include documentation of assumptions, governance, validation and independent review as outlined in the Supporting Documentation section of the Overview.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Retail

Supporting Materials → Methodology Technical Document → Retail

Supporting Materials → Model Validation → Retail

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.3 – Wholesale

BHCs should submit separate documentation for their Wholesale (Corporate and CRE) loan balances and loss projections. A BHC may submit separate documents for different models and/or methodologies. BHCs should include supporting documentation that describes the key methodologies and assumptions for performing stress testing on each wholesale portfolio. Documentation should include an index of documents submitted, a general overview document providing a broad summary of the stress testing methodologies utilized, and detailed supporting documentation that clearly describe the model development process, the derivation of outcomes, and validation procedures as outlined below. The methodologies' formulaic specification, assumptions, numerical techniques, and approximations should be explained in detail with particular attention to both their merits and limitations.

Specifically, documentation should include:

- Discussion of historical data set construction, including data sources, adjustments to the data set, and documentation validating the use of any external data.
- Time period of model calibration.
- Rationale for portfolio segmentation and a discussion on how a particular methodology and model captures the key characteristics and the unique risk drivers of each portfolio segment.
- A description of how the loss estimates appropriately capture the severity of the macroeconomic scenario, reflecting both industry and borrower characteristics. Documentation should include a justification for explanatory variables selected, including coefficients from statistical models, measures of their statistical significance, and qualitative assessments where appropriate. Where relevant, descriptive statistics, including their mean, median, minimum, maximum, and standard deviation should be outlined.
- Step-by-step examples of loss calculation, including a transparent breakdown of all components of forecasted loss (i.e., probability of default, severity of loss, exposure at default) and how each component is adjusted for the given macroeconomic scenario.
- Discussion of how losses were distributed to each quarter in the forecasted period as it relates to changes in the macroeconomic factors within the modeled scenario.
- Qualitative or quantitative adjustment to main model output. Firms should perform pre-adjustment/post-adjustment loss analysis and supply that analysis for material disparity.

Where the current total balances in the wholesale line items do not tie directly to the corresponding category on the FR Y-9C, BHCs should provide a reconciliation which accounts for all wholesale

balances. To the extent that loss projection line items include the consolidation of various loan portfolios which have different risk characteristics, supporting documentation should break out the relevant sub- portfolio losses. Furthermore, BHCs should provide supporting documentation and forecasts for any wholesale loan portfolios acquired after the beginning quarter of the stress scenario and/or for loans covered by loss sharing agreements with the FDIC.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Wholesale

Supporting Materials → Methodology Technical Document → Wholesale

Supporting Materials → Model Validation → Wholesale

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.4 - Loans Held for Sale and Loans Accounted for Under the Fair Value Option

BHCs should submit separate documentation for their Fair Value Option and Held for Sale retail and wholesale loans. A respondent may submit separate documents for different models and/or methodologies. The documentation should include:

- Total loss and outstanding fair market value balances segmented by Commercial/Wholesale, Commercial Real Estate and Retail along with explanation as to the main drivers of loss for each category noted above.
- Please document the amount of funded and non-funded commitments for wholesale loans and for retail loans please include the average amount of loans that had been rejected or were in not in conformance with agency standards.
- An attestation to completeness: describe the process and governance & oversight for ensuring the full set of positions were accounted for and included,
- Documentation should clearly make note of instances where different methodologies were used across different business lines with like assets,
- Documentation should make note where judgment was used in defining and allocating exposure,
- Where shocks were used that differed from prescribed shocks,
- Document approach and asset coverage under these approaches,
- Describe any additional broadening or simplification of the scenario done to get the requisite amount of granularity needed to run to scenario,
- Scenario design and choice for BHC scenario and method of application compared to the FRB scenario.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Wholesale or Retail

Supporting Materials → Methodology Technical Document → Wholesale or Retail

Supporting Materials → Model Validation → Wholesale or Retail

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.5 – AFS/HTM Securities

Supporting documentation should clearly address the OTTI and OCI methodologies used by BHCs to complete the FR Y-14A Summary schedule. The documentation should, at a minimum, address the questions outlined below by major product/portfolio type (e.g., non-agency residential mortgage-backed securities (RMBS), commercial mortgage-backed securities (CMBS), auto asset-backed securities (ABS), corporate bonds, etc.).

Projected OTTI for AFS Securities and HTM Securities by CUSIP

OTTI Methodology

- Describe the model/methodology used to develop stressed OTTI losses. Please state whether a vendor or proprietary model was used.
- If a vendor model was used, please provide the name of the vendor model. If a vendor model was used, has the BHC performed an independent review of the vendor model?
- What data source(s) was used to estimate the model?
- What were the key inputs/variables and how were these determined? (e.g., how were default, severity, and other elements determined? What were the key inputs in determining default, severity, and other elements? What were the key assumptions and how were these assumptions determined?)
- If using a cash flow model, was a vendor or proprietary model used? If using a vendor model, please provide the name of the vendor and model.
- How did the model/methodology (whether vendor or proprietary) incorporate macroeconomic assumptions?
- If relevant, how were macroeconomic assumptions (as prescribed under the supervisory stress scenario) used to determine projected collateral default and severity?
- Were all securities reviewed for impairment? If not, describe the rationale, decision rule, or filtering process.
- If the threshold for determining OTTI on structured products was based on a loss coverage multiple, describe the multiple used.
- If OTTI was estimated for multiple quarters, describe the process for determining OTTI in each period of the forecast time horizon.
- Is the BHC using shortcuts or rules of thumb to recognize the OTTI charges for this analysis or going through the BHC's normal process for recognizing OTTI charges? If using shortcuts or rules of thumb, state how this process differs from the normal process for recognizing OTTI charges.

Fair Market Value Determination

- If more than one third-party vendor is used as the principal pricing source for a given security, what are the criteria for determining the final price? (e.g., is a mean, median, weighting scheme or high/low price taken?) Is there a hierarchy of sources? If appropriate, describe responses by major product or portfolio type (e.g., non-agency RMBS, CMBS, Consumer ABS).
- If an internal model is used as the principal pricing source for a given security, are prices (from an internally created model) compared with third party vendor prices? If so, which vendors are used? If prices are not compared with third party vendors, state the reason. If appropriate, describe responses by major product/portfolio type (e.g., non-agency RMBS, CMBS, Consumer ABS.).
- Describe any additional adjustments made to prices determined by internal model(s) and/or third parties. How is the ultimate price determined?
- If an internal model is used as the principal pricing source for a given security, what are the primary market pricing variables used for fair value estimation?
- Describe briefly the BHC's price validation and verification process. Provide readily available documentation related to the BHC's price validation and verification process.

Projected OCI and Fair Market Value for AFS Securities

- Describe the model/methodology used to develop stressed OCI losses. If appropriate, describe responses by major product or portfolio type (e.g., non-agency RMBS, CMBS, Consumer ABS). State whether the same model was used to derive OTTI losses. If not, detail the specific model/methodology and rationale for utilizing a different model.
- Detail if a vendor or proprietary model was used. If a vendor model was used, provide the name of the vendor model. If a vendor model was used, has the BHC performed an independent review of the vendor model?
- What data source(s) was used to estimate the model?
- What were the key inputs/variables and how were these determined? (e.g., how were fair value losses, and other elements determined?) What were the key inputs in determining OCI loss and how were they determined?
- If using a cash flow model, was a vendor or proprietary model used? If using a vendor model, please provide the name of the vendor and model.
- How did the model/methodology (whether vendor or proprietary) incorporate macroeconomic assumptions? How were macroeconomic assumptions (as prescribed under the supervisory stress scenario) used to determine projected OCI?
- Were all securities reviewed for OCI? If not, describe the rationale, decision rule, or filtering process. If OCI was estimated for multiple quarters, describe the process for determining OCI in each period of the forecast time horizon.
- Is the BHC using shortcuts or rules of thumb to recognize the OCI charges for this analysis or going through the BHC's normal process for recognizing OCI charges? If using shortcuts or rules of thumb, state how this process differs from the normal process for recognizing OCI charges.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Securities

Supporting Materials → Methodology Technical Document → Securities

Supporting Materials → Model Validation → Securities

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.6 - Trading

- Documentation should include supporting details explaining the main drivers and attribution of loss for the overall trading and MTM loss estimate, and for each respective primary risk/business unit area details on the loss attribution by the primary risk factors.
- Documentation should provide a complete and technical definition of second and higher order risk factors (cross gamma, vanna, etc.) and describe the methods undertaken by the firm to estimate the cross gamma and higher order effects.
 - Estimate the contribution to total losses from higher-order risks.
- Describe the evolution of risk per each risk area two weeks before and after the submission date, i.e. make note of positions that may expire or terminate within this time frame that significantly alters a risk profile.
- Describe the process and governance & oversight for ensuring the full set of positions were accounted for and included and also please make note of differences in the products and/or exposures included in the FR Y-14Q vs. the FR Y-14A.
- A detailed and technical description of modeling methods (including pricing models) used,
 - Documentation should clearly make note of instances where different methodologies were used across different business lines with like assets.
 - Document approach (full revaluation vs. grid based approach, e.g.) and asset coverage under these approaches,
 - Please identify those products or exposures where the firm used models or systems that were outside of the normal routine stress testing framework for the FRB stress scenario and indicate if they were reviewed or validated by an independent Model Review function.
- The decision-making used for allocating exposures according to risk area. Documentation should make note where judgment was used in defining and allocating exposure per each risk area.
- Where shocks were used that differed from prescribed shock
- Describe any additional broadening or simplification of the scenario done to get the requisite amount of granularity needed to run to scenario,
- Scenario design and choice for BHC scenario and method of application compared to the FRB scenario.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Trading

Supporting Materials → Methodology Technical Document → Trading

Supporting Materials → Model Validation → Trading

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.7 – Counterparty Credit Risk

The documentation should include a detailed description of the methodologies used to estimate Trading IDR, CVA, and CCR IDR losses under the stress scenario as well as methodologies used to produce the data in the FR_Y-14A_CCR schedule. All information relevant for supervisors to understand the approach should be included. Any differences between the BHC and the FR scenarios in methodology, position capture, or other material elements of the loss modeling approach should be clearly described.

As part of the detailed methodology document, BHCs should provide an Executive Summary that gives an overview of each model and answers each of the questions below. If one of the questions below is not fully addressed in the Executive Summary, cite the page number(s) of the methodology document that fully addresses the question.

In addition to the Executive Summary, there should be a section of the methodology document devoted to any divergence from the instructions to the Counterparty Risk Sub-schedule or the FR_Y-14A Schedule. Use this section to explain any data that is missing or not provided as requested. This section should also be used to describe where and how judgment was used to interpret an instruction.

1. Data and systems

- a. What product types are included and excluded? Specifically, comment on whether equities are excluded and what types of securitized products, if any, are excluded. Comment on the materiality of any exclusions.
- b. Are there any issuer type exclusions? Comment on the materiality of any exclusions.
- c. Are there any exposure measurement or trade capture limitations impacting the Trading IDR loss estimate in Item 1 on the Counterparty Risk Sub-schedule in the SUMMARY_SCHEDULE or the data provided in Sub-schedules Corporate Credit-Advanced, Corporate Credit-EM, Sovereign Credit, Credit Correlation, IDR-Corporate Credit, or IDR-Jump To Default in the FR_Y-14Q_TRADING Schedule? If so, make sure to elaborate in the documentation, particularly where these limitations understate losses.
- d. Are there any discrepancies in position capture between the MV and Notionals reported in Sub-schedules Corporate Credit-Advanced, Corporate Credit-EM, Sovereign Credit, Credit Correlation, or IDR-Corporate Credit in the FR_Y-14Q_TRADING Schedule? If so, elaborate on the discrepancies in the documentation.

- e. Are any index or structured exposures decomposed/unbundled into single name exposures on the IDR Corp Credit or IDR Jump to Default Sub-schedules in the FR_Y-14Q_TRADING Schedule? If so, provide a description of the exposures that are decomposed and the methodology used.
 - f. What types of CVA hedges are included in the FR_Y-14Q_TRADING Schedule and Item 10 on the Trading Sub-schedule of the SUMMARY_SCHEDULE (e.g., market risk hedges, counterparty risk hedges)? Which, if any, of these hedges are excluded from the Trading IDR loss estimates (Item 1 on the Counterparty Risk Sub-schedule of the SUMMARY_SCHEDULE)? Confirm that hedges modeled in Trading IDR are excluded from CCR IDR.
2. PD methodology
 - a. How is the severity of default risk treated? Is a stressed expected PD used, or is it an outcome in the tail of the default distribution? If an outcome in the tail is used, what is the tail percentile?
 - b. How is default risk represented over the horizon of the stress test? Is a cumulative two- year PD or a one-year PD used as a model input? How is migration risk captured?
 - c. What data sources and related time periods are used to generate the assumptions on stressed expected PD or the default distribution? In the documentation, provide a breakdown of PDs (e.g., by rating, asset category). Provide stressed PDs if a stressed PD is used, or provide PD inputs if an outcome in the tail is used.
 3. Correlation assumptions
 - a. What correlation assumptions are used in the Trading IDR models?
 4. LGD methodology
 - b. Do the models assume a static LGD or a stochastic LGD with a non-zero recovery rate volatility?
 - i. If a static LGD is used, were the mean LGDs stressed? What data sources and related time periods were used to determine the LGDs? In the methodology documentation, provide the relevant breakdown of LGDs used in the model (e.g., by ratings, asset category).
 - ii. If a stochastic LGD is used, elaborate on the assumptions generating the stochastic LGD in the documentation, including assumptions on the LGD mean and volatility and rationale for modeling choices.
 5. Liquidity horizon
 - a. What liquidity horizon assumptions are used?
 6. Exposure at default (EAD)
 - a. What Exposure at Default (EAD) is used for Trading IDR? For example, is the calculation based on actual issuer exposures, stressed exposures, a mix of both, or something else? If exposures are stressed, please explain how the exposures were stressed.
 7. Treatment of gains
 - a. Are any gains being reflected in the Trading IDR calculations? If so, elaborate in the documentation how gains are treated.

CVA

1. Divergence from instructions
 - a. In the FR_Y-14A_CCR or Summary Schedules, is liability-side CVA (i.e., DVA) included in any element of the submission? If so, elaborate in the documentation.

- b. In the FR_Y-14A_CCR or Summary Schedules, is bilateral CVA included in any element of the submission (i.e., CVA where the counterparty default probabilities are conditional on the survival of the BHC)? If so, elaborate in the documentation.
 - c. Is there any place where CVA data is reported net of hedges on the FR_Y_14A_CCR Schedule or Item 2 on the Counterparty Risk Sub-schedule in the SUMMARY_SCHEDULE?
 - d. In calculating Stressed Net CE in Sub-schedules 1a, 1b, 1c, 1d, and 1e in FR_Y-14A_CCR, are there any occasions where it is assumed additional collateral has been collected after the shock? If so, elaborate in the documentation.
 - e. Are there any counterparties for which your firm did not fully implement the FR specification for the EE profiles on Sub-schedules 2a and 2b in the FR_Y-14A_CCR? If so, elaborate in the documentation.
2. Data and systems: In the documentation, clearly identify, describe, and comment on the materiality of any exclusions that prevent 100% capture of counterparties or trades. At a minimum, address the questions below and elaborate in the documentation where appropriate.
- a. Are any counterparties on Sub-schedule 1a of FR_Y-14A_CCR excluded from Sub-schedule 2a? Where specific counterparties are reported as top 200 counterparties on one Sub-schedule of the Schedule, but are not listed on other top 200 Sub-schedules, list these counterparties in the documentation by name and provide a reason for their exclusion.
 - b. Are any counterparties excluded from the unstressed or stressed aggregate data reported in Sub-schedules 1e, 2b, or 3b of FR_Y-14A_CCR or the losses reported in the SUMMARY_SCHEDULE SUMMARY_SCHEDULE (Item 2 in the Counterparty Risk Sub-schedule)? In the documentation, elaborate on the nature, materiality, and rationale for these exclusions.
 - c. Do the expected exposure (EE) profiles, CDS spreads, PDs, LGDs, discount factors, as provided on FR_Y-14A_CCR Schedule (Sub-schedules 2a and 2b), come from the same systems as that used for the calculation of CVA losses as provided in the SUMMARY_SCHEDULE (Item 2 in the Counterparty Risk Sub-schedule)? If not, elaborate in the documentation.
 - d. For unstressed and stressed CVA reported in the FR_Y-14A_CCR Schedule, which counterparties, counterparty types, or trade types are calculated offline or using separate methodologies? Why are they calculated offline or with a different methodology? Elaborate in the documentation.
 - e. Are any add-ons used to calculate stressed CVA in the FR_Y-14A_CCR Schedule? Elaborate regarding the nature and rationale for each type of add-on in the documentation.
 - f. Are there any additional/ offline CVA reserves are reported in Sub-schedule 1e in the FR_Y-14A_CCR Schedule? If so, elaborate about the nature of these reserves in the documentation. Explain what counterparties, counterparty types, or trade types are included, why are they calculated as reserves, and how they are stressed.
 - g. Are there any exposure measurement or product capture limitations impacting the loss estimate in Item 2 on the Counterparty Risk Sub-schedule in the SUMMARY_SCHEDULE? If so, make sure to elaborate in the documentation, particularly where these limitations understate losses.

- h. Does the firm conduct a reconciliation between the sum of items 15(a) in Schedule HC-L of the FRY-9C and the aggregate unstressed Gross CE on Sub-schedule 1e of the FRY-14A_CCR Schedule? Note that the figures in the FRY-9C are called "net current credit exposure", as the "net" refers to counterparty netting.
 - i. In calculating CVA losses for both FR Scenarios, if there are large discrepancies between what is reported in FR Y-14Q schedules L.1a-1d and schedule L.2, provide a quantitative and qualitative explanation for the differences.
 - j. Are all sensitivities/ slides provided as requested? If slides are not provided as requested in the FR_Y-14A_CCR Schedule, elaborate in the documentation why they are missing or not provided correctly.
 - k. Are the sensitivities/ slides provided in Sub-schedule 4 of FR_Y-14A_CCR sourced from the same calculation engine and systems as used for the firm's loss estimates (Item 2 in the Counterparty Risk Sub-schedule in the SUMMARY_SCHEDULE)? If not, elaborate in the documentation.
 - l. Elaborate on how sensitivities/ slides in Sub-schedule 4 of FR_Y-14A_CCR were determined to be material. What qualifies a risk factor as immaterial?
3. LGD methodology
- a. For the LGD used to calculate PD, are market implied recovery rates used? If not, elaborate on the source of the LGD assumption in the methodology documentation.
 - b. Is the same recovery/LGD used in the CVA calculation as is used to calculate PDs from the CDS spread? If not, in the documentation provide a detailed rationale and backup data to support the use of a different LGD, and provide the source of the LGD used to calculate CVA.
4. Exposure at default (EAD)
- a. What Margin Period of Risk (MPOR) assumptions are used for unstressed and stressed CVA?
 - b. Are collateral values stressed in the numbers reported in the FR_Y_14A_CCR Schedule or Items 2 or 3 on the Counterparty Risk Sub-schedule in the SUMMARY_SCHEDULE? If so, elaborate on the stress assumptions applied.
 - c. In the FR_Y-14A_CCR on Sub-schedules 2a and 2b, for the BHC specification, are downgrade triggers modeled in the exposure profiles?
5. Application of shocks
- a. Are the shocks applied to CVA (for calculating Item 2 in the Counterparty Risk Sub-schedule in the SUMMARY_SCHEDULE as well as the Stressed figures reported in FR_Y-14A_CCR) the same as those applied to the Trading Book (Item 10 in the Trading Sub-schedule in the SUMMARY_SCHEDULE)? Where they are different, or where shocks applied diverge from the FR shock scenario, elaborate in the documentation.
 - b. Have the models for CVA been validated? If not, elaborate on the review process, if any.

CCR IDR

1. Data and systems

- a. Are there any exposure measurement or product capture limitations impacting the loss estimate in Item 3 on the Counterparty Risk Sub-schedule in the SUMMARY_SCHEDULE? If so, make sure to elaborate in the documentation,

- particularly where these limitations understate losses.
- b. What types of CVA hedges are included in CCR IDR? Confirm that hedges modeled in CCR IDR were excluded from Trading IDR.
2. PD methodology
 - a. How is the severity of default risk treated? Is a stressed expected PD used, or is it an outcome in the tail of the default distribution? If an outcome in the tail is used, what is the tail percentile?
 - b. How is default risk represented over the horizon of the stress test? Is a cumulative two- year PD or a one-year PD used as a model input? How is migration risk captured?
 - c. What data sources and related time periods are used to generate the assumptions on stressed expected PD or the default distribution? In the documentation, provide a breakdown of PDs (e.g., by rating, counterparty type). Provide stressed PDs if a stressed PD is used, or provide PD inputs if an outcome in the tail is used.
 3. Correlation assumptions
 - a. What correlation assumptions are used in the CCR IDR models?
 4. LGD methodology
 - a. Do the models assume a static LGD or a stochastic LGD with a non-zero recovery rate volatility?
 - b. If a static LGD is used, are the mean LGDs stressed? What data sources and related time periods are used to determine the LGDs? In the methodology documentation, provide the relevant breakdown of LGDs used in the model (e.g., by ratings, counterparty type).
 - c. If a stochastic LGD is used, elaborate on the assumptions generating the stochastic LGD in the documentation, including assumptions on the LGD mean and volatility and rationale for modeling choices.
 5. Liquidity horizon
 - a. What liquidity horizon assumptions are used?
 6. Exposure at default (EAD)
 - a. Provide an overview of how EAD is modeled for CCR IDR.
 - b. Are any downgrade triggers assumed in the CCR IDR model? If so, elaborate in the documentation.
 - c. What Margin Period of Risk (MPOR) assumptions are modeled in CCR IDR?
 7. Treatment of gains
 - a. Are any gains being reflected in the CCR IDR calculations? If so, elaborate in the documentation how gains are treated.
 - 8.

Other CCR Losses

- a. Data and Systems
 - a. What types of CCR losses are included in the "Other CCR Losses" Counterparty Risk Sub-schedule of the SUMMARY_SCHEDULE? What are the loss amounts for each major category of "Other CCR Losses"? For any material losses, discuss the methodology and rationale in the documentation.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Counterparty

Supporting Materials → Methodology Technical Document → Counterparty

Supporting Materials → Model Validation → Counterparty

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.8 – Operational Risk

The reporting institution should provide any supporting information including statistical results, data, summary tables, and additional descriptions in a separate document and cross reference the document to the respective question/item. BHCs may submit separate documents for different models and/or methodologies.

Documentation

Generally, a BHC should have robust internal controls governing its operational risk loss projection methodology and process components, including sufficient documentation, model validation and independent review. Supporting documentation should cover all models, loss and resource forecasting methodologies and processes. Adequate documentation includes comprehensive and clear policies and procedures. For models, adequate documentation includes specific delineation of all key assumptions for projecting operational losses under each scenario, a description of the underlying operational risk data used to determine projected losses and the approach for translating the data into loss projections. If a budgeting process was used, the BHC should describe the budgeting process and provide specific detail on how operational losses are estimated. Adequate documentation includes articulating the models' vulnerability to error, and estimates of an error's impact should parameter specifications prove inaccurate. Documentation of all models should clearly identify the exact statistical process employed by the BHC including:

1. How the current set of explanatory factors was chosen, what variables were tested and then discarded, and how often the set of possible explanatory factors is reviewed and, if appropriate, revised;
2. If applicable, description of work the BHC has done to assess relationships between macroeconomic factors and operational risk losses, including relationships that were found to have the highest level of dependency, a summary of statistical results, and how these results were incorporated in the estimates;
3. A discussion of how pending litigation and reserves for litigation were incorporated into operational loss projections for all requested scenarios;
4. A detailed, transparent, and credible description of the foundation, approach, and process for making management adjustments to modeled results;
5. A description of the methodology for allocating an operational loss amount to a particular quarter;
6. An explanation summarizing the reasonableness of results, how they differ from

- expectations, and what the BHC does when the results are deemed "unreasonable";
7. A description of internal controls that ensure the integrity of reported results and that all material changes to the process and its components are appropriately reviewed and approved. BHCs should ensure that change control principles apply to forecasting models used in the stress scenario analysis program, including processes that rely on management judgment;
 8. An assessment of how effective or accurate the model is;
 9. Identification of possible drawbacks and limitations of the selected approach.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Operational Risk

Supporting Materials → Methodology Technical Document → Operational Risk

Supporting Materials → Model Validation → Operational Risk

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

A.9 – Pre-Provision Net Revenue (PPNR)

Each methodological memo should clearly describe how a BHC approached the PPNR projection process and translated macro-economic factors into the reported projections. Separate documents may be submitted for different models and/or methodologies.

Projected Outcomes

- 1) Provide an explanation summarizing the reasonableness of projected outcomes relative to the stated macroeconomic scenario, business profile, as well as regulatory and competitive environment. Especially in the more adverse scenario(s), include substantial supporting evidence for PPNR estimates materially exceeding recently realized values.
- 2) BHCs should discuss linkages between PPNR projections and the balance sheet as well as other exposure assumptions used for related loss projections.
- 3) Include discussion of PPNR outcomes by component (i.e. Net Interest Income, Non Interest Income, and Non Interest Expense) and by major source of each component (e.g. by major balance/rate category, type of revenue/expense, and/or business activity).
- 4) Consideration should be given to how changes in regulation will impact the BHC's revenues and expenses over the projection period. The memo should include a section that addresses how recent or pending regulatory changes have impacted projected figures and business strategies and in which line items these adjustments are reflected.

Models and Methodology

- 1) The documentation should include a full list of all models and parameters used to generate projections of PPNR components for CCAR purposes and whether these models

are also used as part of other existing processes (e.g. the business-as-usual budgeting and forecasting process). Where existing processes are leveraged, discuss how these are deemed appropriate for stress testing purposes, including any modifications that were necessary to fit a stressful scenario.

Also discuss those items that are particularly challenging to project and identify limitations and weaknesses in the process.

- 2) Thorough discussion of use of management/expert judgment, including information about rationale and process involved in translation of macroeconomic scenario variables into projections of various PPNR components should be provided. Where a combination of a modeled approach and management judgment was used to project an item, quantify the impact of qualitative adjustments to modeled output.
- 3) Provide support for all key assumptions used to derive PPNR estimates, with a focus on the link of these assumptions to projected outcomes and whether the assumptions are consistent with the stated macroeconomic scenario, regulatory and competitive environment as well as business strategies for each of major business activities. Document the impact of assumptions concerning new growth, divestitures or other substantial changes in business profile on PPNR estimates. In cases where there is a high degree of uncertainty surrounding assumptions, discuss and reference sensitivity of projections to these assumptions. Also ensure that all relevant macro-economic factors used for PPNR projections are also reported on the firm submitted Scenario Schedule.
- 4) In addition to broad macro-economic assumptions that will guide the exercise, it is expected that more specific assumptions will be used by BHCs in projections of PPNR, including macro-economic factors other than those provided by the Federal Reserve System as well as BHC specific assumptions. Such assumptions and their link to reported figures, standardized and/or BHC business segments and lines should be discussed in the methodology memo.
- 5) Where historical relationships are relied upon (e.g. ratios of compensation expense to total revenues), BHCs are expected to document the historical data used and describe why these relationships are expected to hold true in each scenario, particularly under adverse conditions.
- 6) Projecting future business outcomes inevitably relies on the identification of key relationships between business metrics and other explanatory variables. Key limitations and difficulties encountered by the BHC in the process to model these relationships should be identified and discussed in the memo.
- 7) Highlight changes in various aspects of BHC's PPNR forecasting models and methodology, primarily focusing on the changes that occurred since the last CCAR submission.

Projections Governance and Data

- 1) BHCs are asked to describe governance aspects for the PPNR projections development. This includes but is not limited to a description of:
 - a. The roles of various business lines and management teams involved in the process
 - b. How the projections are generated. Particular attention should be given to how the BHC ensures that assumptions are consistent across different business line projections, how assumptions are translated into projections of revenue and expenses, and the process of aggregating and reporting the results.

- c. Senior management's involvement of the process and the process in which the assumptions are vetted and challenged.

Also note whether established policies and procedures are in place related to this process.

- 2) Also include a separate section devoted to any divergence from the instructions in completing the PPNR sub-schedules in the FR Y-14A and FR Y-14Q Schedules. Use this section to explain any data that is missing or not provided as requested. Use this section to discuss major instances where judgment was used to interpret PPNR instructions.
- 3) Discuss general data validation and reconciliation practices here as they pertain to FR Y-14Q/A submissions. PPNR is defined as the sum of net interest income and non-interest income net of non-interest expense, with components expected to reconcile with those reported in the FR Y-9C when adjusted for certain items (see "Commonly Used Terms and Abbreviations" section of FR Y14-Q/A PPNR instructions for guidance for such items). BHCs are encouraged to include information allowing confirmation that the data were reported per the PPNR definition. Documentation should discuss consistency of a given schedule with the BHC's external reporting and internal reporting and forecasting. Provide a description of broadly-defined types of business models currently used (e.g. Asset/Liability, Relationship, Business Product/Services/Activity as defined or named by the BHC). Provide reconciliation between BHC reporting used to manage and forecast operations and a standardized business segment/line view required for FR Y-14A reporting. Note if allocation methodologies were used when providing data for PPNR sub-schedules in FR Y-14A/Q Schedules.
- 4) Highlight changes in various aspects of BHC's PPNR forecasting governance and data, primarily focusing on the changes that occurred since the last CCAR submission.

Other

- 1) BHCs are also expected to address items requested in the Supporting Documentation portion of the Overview section (beginning on page 4) as applicable to PPNR if not already addressed per PPNR documentations guidance as stated above.
- 2) Other sections of the FR Y-14A and FR Y-14Q PPNR Instructions request additional information and supporting documentation. Please ensure that these items are also referenced and described in this memo. For example, include a discussion of small/medium/large business segmentation, as noted in section "B. PPNR Projections Sub-schedule."
- 3) BHCs are encouraged to submit any other information and documentation (including data series) that would support of the BHC's PPNR projections. One example of such information would be identification and discussion of major deviations of BHC historical performance from forecasted figures, focusing on the last four quarters and noting items that the BHC regards as non-recurring and/or non-core. Where applicable, it would be useful to reference this additional supporting information in the memo outlined above.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → PPNR/Balance Sheet

Supporting Materials → Methodology Technical Document → PPNR/Balance Sheet

Supporting Materials → Model Validation → PPNR/Balance Sheet

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology as one of the following types in the Comment field:

1. Net interest income and banking book balances,
2. Trading and investment banking revenue and related balances, and
3. All other non-interest income, non-interest expense, and other balances.

A.10 – MSR Projection Documentation

Supporting documentation should address the questions outlined below.

1. Models and Methodologies

- Describe the models and related submodels that were used to complete the submission, and please state whether the model is a third-party vendor or proprietary model.
 - o Income/Expense/Valuation Engine
 - o Prepayment Model
 - o Default Model
 - o Delinquency Model
 - o Hedging Simulation
- If a vendor model was used, please provide the name of the vendor model. If a vendor model was used, has the BHC performed an independent review of the vendor model?
- Has the model undergone rigorous model validation, with results reviewed independently of the business line?
- Has any performance testing been conducted on the model? If so, what type of performance testing has been conducted?
- What data sources were used to calibrate each model?
- What were the key inputs/variables and how were these determined?
- How did the model (whether vendor or proprietary) incorporate macroeconomic assumptions?

2. Assumptions

- For each quarter, what new loan capitalizations and amortizations are assumed over both the baseline and supervisory stress scenarios?
 - How were the new loan capitalization forecast assumptions developed?
 - What excess spread assumptions were made with respect to new loan capitalizations in each scenario and how was this assumption derived (e.g., historical buy-up/buy-down grids, etc.)?
 - How were HARP assumptions, if any, estimated?
 - What market share is assumed, and does this change within the stress scenario?

- Does the submission include any MSR sales or purchases under the supervisory stress? If yes, please provide detail.
- What is the composition of the underlying portfolio of loans serviced for others with respect to the following, and how does this composition change (if at all) during the supervisory stress scenario?
 - i. Loan type
 - ii. Geographical region
 - iii. FICO score
- How were macroeconomic assumptions as prescribed under the supervisory baseline and stress scenarios used to determine the respective projected loan prepayment, delinquency, and default experience for each quarter?
- How were macroeconomic assumptions that were not prescribed under the supervisory baseline and stress scenarios (for example, interest rate volatility, option adjusted spreads, primary to secondary spreads) used to determine the respective projected loan prepayment, delinquency, and default experience for each quarter?
- What are the voluntary prepayment speeds (e.g., conditional prepayment rates (CPRs) associated with refinancing) assumed for each quarter in the respective baseline and supervisory stress scenarios? Do not include constant default rates (CDRs).
- What are the factors that drive or explain the level and trend in prepayment speeds through the nine quarters over the baseline and supervisory stress scenarios?
- What are the default rates assumed for each quarter in the respective baseline and supervisory stress scenarios?
- What are the factors that drive or explain the level and trend in default rates through the nine quarters over the baseline and supervisory stress scenarios?
- How were the assumptions regarding cost of service with respect to both the baseline and stressed scenarios derived?
- Was inflation incorporated into the projection?
- What is the servicing cost structure on a per loan basis on a base and incremental basis for each level of delinquency? What are the foreclosure costs per loan?
- Does the cost structure per loan stay the same throughout the nine quarters with the number of delinquent loans changing, or do both change?
- What foreclosure time frames are used in the baseline scenario? Do these lengthen or contract in the supervisory stress?
- Is late fee income included in the submission?
 - If so, what is the BHC's actual late fee income structure, as well as waiver policy if applicable?
 - What is the late fee income assumed in the baseline and stress scenarios?
 - Is it assumed that late fees are 100% collectable in the stress scenario?
- Are earnings on escrow and other balances included in the submission?
 - If yes, how are the balances forecasted, and what is the crediting rate?
- Is cost to finance advances to investors relating to delinquent loans incorporated in the submission?
 - If yes, how is the borrowing rate determined?

3. Hedging and Rebalancing

- Are MSR hedges assumed to be rebalanced or rolled-over at any time during the nine quarter CCAR horizon? How often are hedges assumed to be rebalanced or rolled-over? What is the timing of such rebalancing or roll-over trades?

- What are the hedge rebalancing and/or roll-over rules applied during the baseline and stress scenarios?
- Are the hedge rebalancing and/or roll-over rules applied in the baseline and stress scenarios consistent with the firm’s risk appetite statement and Board/management approved limit structure?
- To what degree does hedge effectiveness decline in the stress scenarios? How was this estimated?
- How is the impact of hedging instrument bid-ask spreads captured in the submission? To what degree does the bid-ask spread widen in the stress scenario? How was this estimated?
- How does the firm account for the liquidity risk from concentrated hedge positions?
- What is assumed regarding collateral requirements?
- What are the current risk tolerance limits with respect to MSR hedging

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → PPNR/Balance Sheet

Supporting Materials → Methodology Technical Document → PPNR/Balance Sheet

Supporting Materials → Model Validation → PPNR/Balance Sheet

In the Comment field, please identify the document as “MSR”.

A.11 Documenting Consideration of Certain Off-Balance Sheet Risks

Supporting documentation should clearly highlight how each institution (i) identified unconsolidated entities and sponsored products to which the Firm has potential exposure, (ii) evaluated those entities / sponsored products under stressed scenario conditions, and (iii) projected and reported any associated financial losses – whether in the form of non-contractual support or reflected elsewhere in PPNR (e.g., foregone revenue).

1. *Identification:* The submission should include a complete inventory of all off-balance sheet entities and sponsored products. Those assessed collectively may be aggregated for the purposes of reporting the information requested below, except that all investment management products that seek to maintain a stable net asset value (NAV) should be listed separately. Please include, at a minimum, the following information related to unconsolidated entities / sponsored products:
 - Product category. For example, Asset-Backed Commercial Paper conduits, Real Estate Investment Trusts, Hedge Funds, SEC-registered mutual funds, Collective Investment Funds, etc.
 - Total assets by product or category (for those that are aggregated).
 - Revenues earned by product or category for the most recent four quarters and a description of the nature of such revenues.
 - Product name and/or unique identifier for those listed separately
 - For stable NAV funds only, the regulatory framework by which each product is offered. For example, Investment Company Act of 1940, Rule 12 CFR 9.18, etc.

Each firm should also include a brief description of the process utilized to develop the inventory.

2. *Evaluation Methodology*: Clearly describe the methodology that was applied to the inventory in order to determine the unconsolidated entities / sponsored products for which there is a potential for non-contractual support, for example based on client expectations. This should include even those entities / sponsored products which the firm may choose not to support but such a decision could lead to lost revenues and/or other costs. Indicate the resulting decision for each product or category.
3. *Determination of Related Losses*: For each unconsolidated entity / sponsored product for which it was determined that a client expectation of non-contractual support may exist:
 - a) Describe the expected impact of macroeconomic and/or idiosyncratic stress factors to these entities / sponsored products.
 - This might include, but is not limited to, market value shocks, increased redemption activity, rollover risk, counterparty-default-related losses, etc.
 - Critical assumptions such as assumed counterparty LGD rates, velocity of redemptions amid stress, and nature of market shocks should be highlighted.
 - b) Describe the decision framework applied in determining whether non-contractual support would be provided and include a discussion of the identified costs/benefits related to each decision by major category and/or product.
 - c) Quantify and provide calculations of any related financial losses expected to be borne by the firm either in the form of non-contractual support or lost revenues and legal/operational costs and provide related calculations of those losses.
 - This should include both direct impacts (e.g., product closure and/or potential litigation costs) and indirect (i.e., second-order) impacts, such as lost revenue in other products that results from client attrition, where a decision to not support has been applied.
 - d) Clearly indicate the line items within the Y-14A summary schedule where such projected financial losses have been recorded.

Schedule B – Scenario

No supporting documentation is required for this schedule.

Schedule C – Regulatory Capital Instruments

No supporting documentation is required for this schedule.

Schedule D – Regulatory Capital Transitions

Additional Information Required for SIFI Surcharge

In November 2011, the Basel Committee on Banking Supervision (BCBS) published its methodology for assessing an additional loss absorbency requirement for global systemically important banks (SIFI surcharge) that effectively serves as an extension of the capital conservation buffer. **As part of the FR Y-14A filing, each BHC must submit a separate document that includes management’s best estimate of the likely SIFI surcharge that would be assessed under this**

methodology, along with an explanation of assumption used when determining the estimate.

Any BHC not currently designated as a global systemically important financial institution (G-SIFI) should include a SIFI surcharge assessment if management expects changes to its business model that would potentially lead to the BHC’s designation as a G-SIFI. Supervisors will evaluate the methodology and assumptions used by BHCs in determining the SIFI surcharge, and may adjust such estimates as necessary when evaluating the Revised Capital Framework transition path.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Regulatory Capital

Supporting Materials → Methodology Technical Document → Regulatory Capital

Supporting Materials → Model Validation → Regulatory Capital

In the Comment field, please identify the document as “SIFI surcharge”.

Note that if this information is already included the BHC’s CCAR Capital Plan, then the BHC has the option of simply including text that clearly describes location of this information (e.g. file name, document page number, section title, etc.). If the BHC uses this option, the document should still use the naming convention described above.

Additional Information Required for Each Planned Action (Tied to Sub-schedule 6) for FR Y-14A submission

BHCs are required to provide a detailed description of each planned action in a separate attachment(s). The description of each planned action should include:

- Discussion of how each planned action aligns with the BHC’s long term business strategy and risk appetite on a going concerns basis;
- Assessment of each planned action’s impact on the BHC’s capital and funding needs, earnings, and overall risk profile;
- Assessment of market conditions and market capacity around each planned action (e.g., planned sale size and the availability and appetite of buyers and other potential sellers);
- Assessment of any potential execution risks to each planned action (e.g., contractual, accounting or structural limitations). The estimation of execution risk should be well documented for each planned action that are to occur;
- Discussion of any recent transactions conducted either by the BHC or by other institutions that would demonstrate or support the BHC’s ability to execute each planned action at the level of impact projected.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as follows using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Regulatory Capital

In the Comment field, please identify the document as “Planned Capital Action” and include the appropriate “Action #” in column A of the Planned Actions Sub-schedule.

Included below are examples of other supporting documentation which should be included along with the description of each planned action:

- Detailed information on planned sales such as risk profile and size of the positions, indicative term sheets and contracts; potential buyer information; current marked to market (MTM), support for the execution price; potential associated loans, financing, or liquidity credit support arrangements; potential buy back commitments; and impact on any offsetting positions. If similar recent transactions have taken place, BHCs should provide information as a point of reference. BHCs should also describe any challenges that may be encountered in executing the sale.
- Detailed information on planned unwinds, such as risk profile and size of the positions, profit and loss (P&L) impact at execution or in the future; funding implications; impact on any offsetting positions; and trigger of consolidation or on-boarding of the underlying assets.
- Detailed information on planned run-offs, such as risk profile and size of the positions, impact on any offsetting positions; details on trades; and maturity dates.
- Detailed information on planned hedging, such as indicative term sheets and contracts; P&L impact at execution or during life of the hedges; and impact on counterparty credit RWA.
- Detailed information on changes to risk-weighted assets calculation methodologies, such as which data or parameters would be changed, whether the firm has submitted model application to its supervisors, and remaining work to be completed and expected completion date.
- Detailed information on expanded use of clearing houses, such as types of products to be cleared and central counterparties to be used.

BHCs should also provide detailed information on any alternative Regulatory Capital Transitions action plans in the event the firm falls short of the targets outlined in the Capital Plan, and trigger events that would result in a need to pursue any alternative action plans.

IntraLinks Instructions: When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as follows using the metadata tags provided:

Supporting Materials → Methodology and Process Overview → Regulatory Capital

In the Comment field, please identify the document as “Regulatory Capital Transitions action plan”.

Schedule E - Operational Risk

No supporting documentation is required for this schedule.